[
  {
    "conteudo":"CLINICAL PRACTICE GUIDELINE FOR NUTRITION IN"
  },
  {
    "conteudo":"CHRONIC KIDNEY DISEASE: 2019 UPDATE"
  },
  {
    "conteudo":"Public Review DRAFT"
  },
  {
    "conteudo":"October 2019"
  },
  {
    "conteudo":"Page 1"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE"
  },
  {
    "conteudo":"This Clinical Practice Guideline document is based upon the best information available as of"
  },
  {
    "conteudo":"April 2017*. It is designed to provide information and assist decision making. It is not intended"
  },
  {
    "conteudo":"to define a standard of care, and should not be construed as one, nor should it be interpreted as"
  },
  {
    "conteudo":"prescribing an exclusive course of management. Variations in practice will inevitably and"
  },
  {
    "conteudo":"appropriately occur when clinicians take into account the needs of individual patients, available"
  },
  {
    "conteudo":"resources, and limitations unique to an institution or type of practice. Every health-care"
  },
  {
    "conteudo":"professional making use of these recommendations is responsible for evaluating the"
  },
  {
    "conteudo":"appropriateness of applying them in the setting of any particular clinical situation. The"
  },
  {
    "conteudo":"recommendations for research contained within this document are general and do not imply a"
  },
  {
    "conteudo":"specific protocol."
  },
  {
    "conteudo":"*Commissioned evidence review included articles published through April 2017. Consensus"
  },
  {
    "conteudo":"opinion statements use literature published though August 2018."
  },
  {
    "conteudo":"SECTION II: DISCLOSURE"
  },
  {
    "conteudo":"Kidney Disease Outcomes Quality Initiative (KDOQI) and American Academy of Nutrition and"
  },
  {
    "conteudo":"Dietetics (AND) make every effort to avoid any actual or reasonably perceived conflicts of"
  },
  {
    "conteudo":"interest that may arise as a result of an outside relationship or a personal, professional, or"
  },
  {
    "conteudo":"business interest of a member of the Work Group. All members of the Work Group are required to"
  },
  {
    "conteudo":"complete, sign, and submit a disclosure and attestation form showing all such relationships that"
  },
  {
    "conteudo":"might be perceived or actual conflicts of interest. All reported information will be printed"
  },
  {
    "conteudo":"in the final publication and are on file at the National Kidney Foundation (NKF)."
  },
  {
    "conteudo":"Page 2"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"TABLE OF CONTENTS"
  },
  {
    "conteudo":"Table of Tables……………………………………………………………………………………….……. 4"
  },
  {
    "conteudo":"Table of Figures………………………………………………………………………………………….… 4"
  },
  {
    "conteudo":"Abbreviations and Acronyms……………………………………………………………………………… 5"
  },
  {
    "conteudo":"Work Group Membership…………………………………………………………………………………. 8"
  },
  {
    "conteudo":"Organization Leadership……………………………………………………………..……………………. 9"
  },
  {
    "conteudo":"Abstract……………………………………………………………………………………………………. NA"
  },
  {
    "conteudo":"Foreword…………………………………………………………………………………………………… NA"
  },
  {
    "conteudo":"Methods……................................................................................................................................................. 10"
  },
  {
    "conteudo":"Summary of Guideline Statements............................................................................................................... 25"
  },
  {
    "conteudo":"Guideline 1: Assessment……………………………………………………………..……………...…… 36"
  },
  {
    "conteudo":"1.0 Usual Care Statements 36"
  },
  {
    "conteudo":"…1.1… T…ech…ni…ca…l D…ev…ic…es …& …An…th…ro…po…me…tri…c M…e…asu…re…m…ent…s t…o M…e…as…ure… B…od…y C…o mposition …………… 36"
  },
  {
    "conteudo":"1.2 Laboratory Measures of Body Composition ………………………………………………………. 50"
  },
  {
    "conteudo":"1.3 Handgrip Strength …………………………………………………………………………………. 57"
  },
  {
    "conteudo":"1.4 Methods to Assess Energy Requirements …………………………………………………………. 59"
  },
  {
    "conteudo":"1.5 Composite Nutritional Indices to Measure Nutritional Status in CKD Patients …………………... 62"
  },
  {
    "conteudo":"1.6 Tools\/Methods Used to Assess Protein Intake and Calorie Intake ………………….……………... 71"
  },
  {
    "conteudo":"Guideline 2: Medical Nutrition Therapy……………………………………………...………………… 74"
  },
  {
    "conteudo":"Guideline 3: Dietary Protein and Energy Intake……………………….………………………………. 82"
  },
  {
    "conteudo":"3.0 Energy Intake ………………………………………………………………………………………. 82"
  },
  {
    "conteudo":"3.1 Protein Amount ………….………………………………………………………………………... 82"
  },
  {
    "conteudo":"3.2 Protein Type ………………………………………………………………………………………. 94"
  },
  {
    "conteudo":"3.3 Dietary patterns (Fruits and Vegetables; Mediterranean) …………….……………………………. 98"
  },
  {
    "conteudo":"Guideline 4: Nutritional Supplementation ………………………………………..…………………… 103"
  },
  {
    "conteudo":"4.1 Nutrition Supplementation - Oral, Enteral, and Parental Nutrition ……………………… 103"
  },
  {
    "conteudo":"…4.2… N…ut…riti…on… Su…pp…le…me…nt…ati…on. .- Dialysate………………………………………..…….…… 115"
  },
  {
    "conteudo":"4.3 Long Chain Omega-3 Polyunsaturated Fatty Acids ....………………………….............. 119"
  },
  {
    "conteudo":"Guideline 5: Micronutrients.……………………………………………………….…………. 128"
  },
  {
    "conteudo":"5.0 General Guidance ……………………………………………………………………….. 128"
  },
  {
    "conteudo":"5.1 Folic acid (with and without other B Vitamins) ……..…………………………………….............. 132"
  },
  {
    "conteudo":"5.2 Vitamin C ………………………………………………………………………………….............. 137"
  },
  {
    "conteudo":"5.3 Vitamin D ………………………………………………………………………………….............. 142"
  },
  {
    "conteudo":"5.4 Vitamin E and A ……………………………………………..…………………………….............. 148"
  },
  {
    "conteudo":"5.5 Vitamin K ………………………………………………………………………………….............. 155"
  },
  {
    "conteudo":"5.6 Selenium and Zinc………………………………………………………………………………….. 159"
  },
  {
    "conteudo":"Guideline 6: Electrolytes.………………………………………………………………………….……. 164"
  },
  {
    "conteudo":"6.1 Acid-Base ………………………………………………………………………………….............. 164"
  },
  {
    "conteudo":"6.2 Calcium ………………………………………………………………..……………………............ 171"
  },
  {
    "conteudo":"6.3 Phosphorus …………………………………………………………...…………………….............. 175"
  },
  {
    "conteudo":"6.4 Potassium ……………………………………………………………….………………….............. 184"
  },
  {
    "conteudo":"6.5 Sodium …………………………………………………………….……………………….............. 188"
  },
  {
    "conteudo":"Biographic and Disclosure Information…………………………………………………………………. 196"
  },
  {
    "conteudo":"References…………………………………………………………………………………………………. 206"
  },
  {
    "conteudo":"Page 3"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"TABLES"
  },
  {
    "conteudo":"Table 1. Key Questions for Evidence Review …………………………………………………. 16"
  },
  {
    "conteudo":"Table 2. Evidence Review Inclusion and Exclusion Criteria …………………………………... 18"
  },
  {
    "conteudo":"Table 3. Quality of Evidence Grades …………………………………………………………… 24"
  },
  {
    "conteudo":"Table 4. Implications of strong and weak recommendations for different users of guidelines …. 25"
  },
  {
    "conteudo":"FIGURES"
  },
  {
    "conteudo":"Figure 1. Flow diagram of identified studies for Assessment questions ………………..……….. 21"
  },
  {
    "conteudo":"Figure 2. Flow diagram of identified studies for Intervention questions ……………….…..…… 22"
  },
  {
    "conteudo":"Page 4"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"ABBREVIATIONS AND ACRONYMS"
  },
  {
    "conteudo":"ACE Angiotensin converting enzyme inhibitors"
  },
  {
    "conteudo":"APD Animal-based Protein Diet"
  },
  {
    "conteudo":"AND Academy of Nutrition and Dietetics"
  },
  {
    "conteudo":"ARB Angiotensin II receptor blocker"
  },
  {
    "conteudo":"BF Body fat"
  },
  {
    "conteudo":"BIA Bio-electrical impedance analysis"
  },
  {
    "conteudo":"BMI Body mass index"
  },
  {
    "conteudo":"BP Blood pressure"
  },
  {
    "conteudo":"BPI Body protein index"
  },
  {
    "conteudo":"CAPD Continuous ambulatory peritoneal dialysis"
  },
  {
    "conteudo":"CIMT Constraint induced movement therapy"
  },
  {
    "conteudo":"CK Creatinine kinase"
  },
  {
    "conteudo":"CKD Chronic kidney disease"
  },
  {
    "conteudo":"CRP C-reactive protein"
  },
  {
    "conteudo":"CVD Cardiovascular disease"
  },
  {
    "conteudo":"DBP Diastolic blood pressure"
  },
  {
    "conteudo":"DEXA Dual-energy X-ray absorptiometry"
  },
  {
    "conteudo":"eGFR Estimated glomerular filtration rate"
  },
  {
    "conteudo":"EAAs Essential amino acids"
  },
  {
    "conteudo":"ESRD End-stage renal disease"
  },
  {
    "conteudo":"FM Fat mass"
  },
  {
    "conteudo":"FFM Fat free mass"
  },
  {
    "conteudo":"FSA Four-site skinfold anthropometry"
  },
  {
    "conteudo":"GFR Glomerular filtration rate"
  },
  {
    "conteudo":"GNRI Geriatric Nutrition Risk Index"
  },
  {
    "conteudo":"GRADE Grades of Recommendation Assessment, Development, and Evaluation"
  },
  {
    "conteudo":"HD Hemodialysis"
  },
  {
    "conteudo":"HDL-C High-density lipoprotein cholesterol"
  },
  {
    "conteudo":"HGS Handgrip Strength"
  },
  {
    "conteudo":"HOMA-IR Homeostatic Model Assessment of Insulin Resistance"
  },
  {
    "conteudo":"HR Hazard ratio"
  },
  {
    "conteudo":"hsCRP High sensitivity C-reactive protein"
  },
  {
    "conteudo":"IBW Ideal body weight"
  },
  {
    "conteudo":"IDPN Intradialytic parenteral nutrition"
  },
  {
    "conteudo":"IL-6 Interleukin"
  },
  {
    "conteudo":"IMT Intima media thickening"
  },
  {
    "conteudo":"IV Intravenous"
  },
  {
    "conteudo":"Page 5"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"KA Ketoacid"
  },
  {
    "conteudo":"KAA Ketoacid analogue"
  },
  {
    "conteudo":"KDIGO Kidney Disease: Improving Global Outcomes"
  },
  {
    "conteudo":"KDQOL-SF Kidney disease quality of life short form"
  },
  {
    "conteudo":"KDOQI Kidney Disease Outcomes Quality Initiative"
  },
  {
    "conteudo":"KQ Key question"
  },
  {
    "conteudo":"LBM Lean body mass"
  },
  {
    "conteudo":"LDL-C Low-density lipoprotein cholesterol"
  },
  {
    "conteudo":"LPD Low protein diet"
  },
  {
    "conteudo":"MAMC Mid-arm muscle circumference"
  },
  {
    "conteudo":"MF-BIA Multi-frequency-bio-electrical impedance analysis"
  },
  {
    "conteudo":"MGP Matrix Gla protein"
  },
  {
    "conteudo":"MHD Maintenance hemodialysis"
  },
  {
    "conteudo":"MHDE Maintenance Hemodialysis Equation"
  },
  {
    "conteudo":"MIS Malnutrition Inflammation Score"
  },
  {
    "conteudo":"MNA Mini-nutrition assessment"
  },
  {
    "conteudo":"MNA-SF Mini-Nutrition Assessment-Short Form"
  },
  {
    "conteudo":"MST Malnutrition Screening Tool"
  },
  {
    "conteudo":"MUST Malnutrition Universal Screening Tool"
  },
  {
    "conteudo":"NEAAs Non-essential amino acids"
  },
  {
    "conteudo":"NEAP Net endogenous acid production"
  },
  {
    "conteudo":"NHANES National Health and Nutrition Examination Survey"
  },
  {
    "conteudo":"NIS Nutrition Impact Symptoms NKF"
  },
  {
    "conteudo":"National Kidney Foundation"
  },
  {
    "conteudo":"NRCT Non-randomized controlled trial"
  },
  {
    "conteudo":"nPCR Normalized protein catabolic rate"
  },
  {
    "conteudo":"nPNA Normalized protein nitrogen appearance"
  },
  {
    "conteudo":"NST Nutrition Screening Tool"
  },
  {
    "conteudo":"ONS Oral nutritional supplements"
  },
  {
    "conteudo":"PCR Protein catabolic diet"
  },
  {
    "conteudo":"PD Peritoneal dialysis"
  },
  {
    "conteudo":"PEW Protein energy wasting"
  },
  {
    "conteudo":"PNA Protein nitrogen appearance"
  },
  {
    "conteudo":"PNI Protein Nutrition Index"
  },
  {
    "conteudo":"RCTs Randomized controlled trials"
  },
  {
    "conteudo":"RDN Registered dietitian nutritionist"
  },
  {
    "conteudo":"REE Resting energy expenditure"
  },
  {
    "conteudo":"R-NST Renal-Nutrition Screening Tool"
  },
  {
    "conteudo":"RRT Renal Replacement Therapy"
  },
  {
    "conteudo":"Page 6"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"SBP Systolic blood pressure"
  },
  {
    "conteudo":"SGA Subjective Global Assessment"
  },
  {
    "conteudo":"SKF Skinfold thickness"
  },
  {
    "conteudo":"SR Systematic review"
  },
  {
    "conteudo":"TBF Total body fat"
  },
  {
    "conteudo":"TG Triglycerides"
  },
  {
    "conteudo":"TNF-a Tumor Necrosis Factor alpha"
  },
  {
    "conteudo":"TSF Triceps skinfold thickness"
  },
  {
    "conteudo":"VPD Vegetable proteindiet"
  },
  {
    "conteudo":"VLPD Very low protein diet"
  },
  {
    "conteudo":"vs. Versus"
  },
  {
    "conteudo":"Page 7"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"WORK GROUP MEMBERSHIP"
  },
  {
    "conteudo":"Work Group Co-Chairs"
  },
  {
    "conteudo":"T. Alp Ikizler, MD Lilian Cuppari, PhD"
  },
  {
    "conteudo":"Vanderbilt University Medical Center Oswaldo Ramos Foundation-Hrim"
  },
  {
    "conteudo":"Nashville, TN, USA Federal University of Sao Paulo"
  },
  {
    "conteudo":"São Paulo, Brazil"
  },
  {
    "conteudo":"Work Group"
  },
  {
    "conteudo":"Jerrilynn Burrowes, PhD, RD, CDN Laura Byham-Gray, PhD, RD, CDN"
  },
  {
    "conteudo":"Long Island University Brookville, Rutgers University"
  },
  {
    "conteudo":"NY, USA Newark, NJ, USA"
  },
  {
    "conteudo":"Katrina Campbell, PhD Juan Jesus Carrero, Pharm, PhD Pharm, PhD Med"
  },
  {
    "conteudo":"Bond University Karolinska Institutet"
  },
  {
    "conteudo":"Robina, Queensland, Australia Stockholm, Sweden"
  },
  {
    "conteudo":"Winnie Chan, PhD, RD Denis Fouque, MD, PhD"
  },
  {
    "conteudo":"Queen Elizabeth Hospital Birmingham University Claude Bernard Lyon"
  },
  {
    "conteudo":"Birmingham, United Kingdom Lyon, France"
  },
  {
    "conteudo":"Allon Friedman, MD, FASN Sana Ghaddar, PhD, RDN"
  },
  {
    "conteudo":"Indiana University Carmel, DaVita"
  },
  {
    "conteudo":"Indianapolis, IN, USA San Francisco, CA, USA"
  },
  {
    "conteudo":"Jordi Goldstein-Fuchs, DSc, APRN-C, RD George Kaysen, MD, PhD"
  },
  {
    "conteudo":"Sierra Nevada Nephrology Consultants University of California-Davis,"
  },
  {
    "conteudo":"Reno, NV, USA Davis, CA, USA"
  },
  {
    "conteudo":"Joel Kopple, MD Daniel Teta, MD, PhD"
  },
  {
    "conteudo":"Lundquist Institute for Biomedical Innovation at Lausanne University"
  },
  {
    "conteudo":"Harbor-UCLA Medical Center and UCLA Lausanne, Switzerland"
  },
  {
    "conteudo":"Torrance, CA, USA"
  },
  {
    "conteudo":"Angela Yee-Moon Wang, MD, PhD"
  },
  {
    "conteudo":"University of Hong Kong"
  },
  {
    "conteudo":"Hong Kong"
  },
  {
    "conteudo":"Evidence Review Team"
  },
  {
    "conteudo":"Deepa Handu, PhD, RD, LDN Mary Rozga, PhD, RDN"
  },
  {
    "conteudo":"Academy of Nutrition and Dietetics Academy of Nutrition and Dietetics"
  },
  {
    "conteudo":"Chicago, IL, USA"
  },
  {
    "conteudo":"Chicago, IL, USA"
  },
  {
    "conteudo":"Page 8"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"KDOQI and Academy Guideline Development Staff"
  },
  {
    "conteudo":"Kerry Willis, PhD Jessica Joseph, MBA"
  },
  {
    "conteudo":"National Kidney Foundation National Kidney Foundation"
  },
  {
    "conteudo":"New York, NY New York, NY"
  },
  {
    "conteudo":"Laura Brereton, MSc Tom Manley, RN, BSN"
  },
  {
    "conteudo":"National Kidney Foundation National Kidney Foundation"
  },
  {
    "conteudo":"New York, NY New York, NY"
  },
  {
    "conteudo":"Alison Steiber, PhD, RDN Mary Rozga, PhD, RDN"
  },
  {
    "conteudo":"Academy of Nutrition and Dietetics Academy of Nutrition and Dietetics"
  },
  {
    "conteudo":"Chicago, IL, USA Chicago, IL, USA"
  },
  {
    "conteudo":"Deepa Handu, PhD, RDN, LDN"
  },
  {
    "conteudo":"Academy of Nutrition and Dietetics"
  },
  {
    "conteudo":"Chicago, IL, USA"
  },
  {
    "conteudo":"Organizational Leadership"
  },
  {
    "conteudo":"Academy of Nutrition and Dietetics KDOQI"
  },
  {
    "conteudo":"Alison Steiber, PhD, RDN Michael Rocco, MD, MSCE"
  },
  {
    "conteudo":"Chief Science Officer KDOQI Chair"
  },
  {
    "conteudo":"Holly Kramer, MD"
  },
  {
    "conteudo":"Vice Chair, Research"
  },
  {
    "conteudo":"President, National Kidney Foundation"
  },
  {
    "conteudo":"Bernard Jaar, MD MPH"
  },
  {
    "conteudo":"Vice Chair, Education"
  },
  {
    "conteudo":"Michael J. Choi, MD"
  },
  {
    "conteudo":"Vice Chair, Policy"
  },
  {
    "conteudo":"Past President, National Kidney Foundation"
  },
  {
    "conteudo":"Page 9"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"METHODS"
  },
  {
    "conteudo":"The Guideline Development Process"
  },
  {
    "conteudo":"According to the Institute of Medicine (National Academy of Sciences), “Clinical practice"
  },
  {
    "conteudo":"guidelines are statements that include recommendations intended to optimize patient care that"
  },
  {
    "conteudo":"are informed by a systematic review of evidence and an assessment of the benefits and harms"
  },
  {
    "conteudo":"of alternative care options”. This chapter describes the process and methods used to conduct"
  },
  {
    "conteudo":"comprehensives systematic reviews and how the findings from these systematic reviews were"
  },
  {
    "conteudo":"used to develop clinical practice nutrition guidelines for patients with chronic kidney disease."
  },
  {
    "conteudo":"These guidelines were developed according to the Standards for Developing Trustworthy"
  },
  {
    "conteudo":"Clinical Practice Guidelines as stated by Institute of Medicine."
  },
  {
    "conteudo":"Development of these guidelines was a collaborative process between National Kidney"
  },
  {
    "conteudo":"Foundation (NKF) and the Academy of Nutrition and Dietetics (Academy). Nutrition and its"
  },
  {
    "conteudo":"management are an integral aspect of care for patients with kidney disease. Due to recent"
  },
  {
    "conteudo":"developments in the literature regarding treatment and assessment of CKD, the Academy and"
  },
  {
    "conteudo":"NKF collaborated to merge, update and expand the current 2010 Evidence Analysis Library®"
  },
  {
    "conteudo":"(EAL®) CKD guidelines and the Kidney Disease Outcomes Quality Initiative (KDOQI)"
  },
  {
    "conteudo":"Nutrition Guidelines. Hence, the objective of this initiative is to provide medical nutrition"
  },
  {
    "conteudo":"therapy (MNT) guidelines for patients with chronic kidney disease (CKD) to assess, prevent"
  },
  {
    "conteudo":"and treat protein-energy wasting, mineral and electrolyte disorders, and other metabolic co-"
  },
  {
    "conteudo":"morbidities associated with CKD."
  },
  {
    "conteudo":"Overview of the guideline development process: Guideline development is a detailed and"
  },
  {
    "conteudo":"comprehensive process. The steps followed to develop this guideline are below (some steps"
  },
  {
    "conteudo":"were completed concurrently):"
  },
  {
    "conteudo":"1. Select the Work group or expert panel that works with the evidence review team."
  },
  {
    "conteudo":"2. Orient the work group the 5-step systematic review process of the Academy of"
  },
  {
    "conteudo":"Nutrition and Dietetics’ Evidence Analysis Center."
  },
  {
    "conteudo":"3. Develop research questions, inclusion and exclusion criteria and a detailed search plan"
  },
  {
    "conteudo":"as well as identify interventions and outcomes of interest."
  },
  {
    "conteudo":"Page 10"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"4. Search multiple databases based on search plan."
  },
  {
    "conteudo":"5. Screen abstracts and full text articles based on a priori eligibility criteria."
  },
  {
    "conteudo":"6. Extract data and critically assess the quality of included studies (risk of bias of studies)"
  },
  {
    "conteudo":"7. Synthesize evidence narratively (evidence summary and conclusion statements) and in"
  },
  {
    "conteudo":"table format (Study characteristics and findings table). Grade the quality of evidence for"
  },
  {
    "conteudo":"each outcome and provide GRADE tables."
  },
  {
    "conteudo":"8. Develop recommendation statements based on the findings of the systematic review"
  },
  {
    "conteudo":"and other important considerations and assign “strength of recommendation”."
  },
  {
    "conteudo":"9. Write a guideline manuscript."
  },
  {
    "conteudo":"10. Conduct internal, external, and public review of the guideline."
  },
  {
    "conteudo":"11. Respond to reviewer comments and update the guideline before publication."
  },
  {
    "conteudo":"Work group selection process: The Academy of Nutrition and Dietetics led the process of work"
  },
  {
    "conteudo":"group member recruitment. To assure appropriate expertise and limit bias, the Evidence Based"
  },
  {
    "conteudo":"Practice Committee Work Group Selection sub-committee followed a transparent process of"
  },
  {
    "conteudo":"selecting work group members. An open recruitment message with a link to online application"
  },
  {
    "conteudo":"was circulated via stakeholders for experts in the topic area of chronic kidney disease."
  },
  {
    "conteudo":"Interested candidates provided: signed Disclosure and Conflict of Interest From, curriculum"
  },
  {
    "conteudo":"vitae, and personal statements indicating interest and qualifications that related to the topic."
  },
  {
    "conteudo":"The workgroup selection committee then evaluated each candidate based on set criteria."
  },
  {
    "conteudo":"Higher scoring candidates were considered for position of workgroup chair \/co-chair. A total"
  },
  {
    "conteudo":"of 15 workgroup members were selected to develop these guidelines. Two co-chairs were"
  },
  {
    "conteudo":"appointed, and the work group consisted of physicians, registered dietitians or nutritionists,"
  },
  {
    "conteudo":"researchers, and methodologists with expertise in the renal nutrition field. The selected"
  },
  {
    "conteudo":"members, according to their experiences and skill sets, were assigned to corresponding"
  },
  {
    "conteudo":"subtopics. The work group participated in all steps of systematic review process, which"
  },
  {
    "conteudo":"included developing research questions, agreeing on inclusion and exclusive criteria,"
  },
  {
    "conteudo":"developing the search plan, evaluating the evidence, and approving and grading the evidence"
  },
  {
    "conteudo":"and developing recommendation statements. All workgroup members and the evidence review"
  },
  {
    "conteudo":"team (ERT) met twice for 2-day face to face meetings as well as a teleconference calls once a"
  },
  {
    "conteudo":"month for the duration of the project."
  },
  {
    "conteudo":"Page 11"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Guideline focus: During the first meeting the work group defined the scope for the guideline."
  },
  {
    "conteudo":"The co-chairs developed the first draft of the scope which was discussed and refined by the"
  },
  {
    "conteudo":"work group members. It was determined that the guideline would focus on Nutrition in all"
  },
  {
    "conteudo":"stages of CKD in adults and would cover the subtopics of macronutrient, micronutrient, and"
  },
  {
    "conteudo":"electrolyte management in CKD. Both assessment and intervention question under these"
  },
  {
    "conteudo":"subtopics were proposed. Three workgroups were developed, with five members assigned to"
  },
  {
    "conteudo":"each workgroup and a Chair appointed to help lead the workgroup."
  },
  {
    "conteudo":"Systematic review process: Question development, literature search and study selection This"
  },
  {
    "conteudo":"guideline followed the Academy of Nutrition and Dietetics systematic review methodology."
  },
  {
    "conteudo":"An analytical framework was developed by the ERT and refined by the work group"
  },
  {
    "conteudo":"members to help guide question development. During the initial teleconference calls and"
  },
  {
    "conteudo":"first face to face meeting, the workgroup developed a list of questions that were deemed"
  },
  {
    "conteudo":"important for clinicians and patients (Table 1). The workgroup developed the a priori inclusion"
  },
  {
    "conteudo":"and exclusion criteria as listed in Table 2."
  },
  {
    "conteudo":"A comprehensive search of literature was conducted using PubMed, MEDLINE, EMBASE,"
  },
  {
    "conteudo":"and CINAHL search engines. A first literature search was conducted to identify studies"
  },
  {
    "conteudo":"addressing assessment questions and a second search was conducted to identify studies"
  },
  {
    "conteudo":"addressing intervention questions in order to identify studies that answered more than one"
  },
  {
    "conteudo":"question. Inclusion criteria included in the search plan included: human adults with CKD aged"
  },
  {
    "conteudo":"19 years and older published between 1985 and December 2016. hu Search terms included"
  },
  {
    "conteudo":"terms to identify relevant nutrition interventions assessment tools in adult CKD patients."
  },
  {
    "conteudo":"The first literature search focused on assessment questions identified 4,857 potential studies."
  },
  {
    "conteudo":"The PRISMA diagram illustrating the study selection process are presented in Figure 1. The"
  },
  {
    "conteudo":"second comprehensive search to answer all the intervention questions in order identified"
  },
  {
    "conteudo":"11,017 potential studies. The PRISMA diagram illustrating study selection process for"
  },
  {
    "conteudo":"intervention questions is in Figure 2."
  },
  {
    "conteudo":"Page 12"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"After the search was completed, studies were systematically screened based additional a priori"
  },
  {
    "conteudo":"inclusion\/exclusion criteria. For intervention questions, only randomized controlled trials that"
  },
  {
    "conteudo":"had at least 6 individuals per arm were included. Included studies investigated an intervention"
  },
  {
    "conteudo":"of interest (e.g. protein restrictions, phosphorus intake, sodium intake etc.) in comparison with"
  },
  {
    "conteudo":"no intervention or minimal intervention. For assessment questions, only studies that tested the"
  },
  {
    "conteudo":"validity, reliability or relationship of an assessment tool against a comparative tool (reference"
  },
  {
    "conteudo":"standard) or mortality were included in this review."
  },
  {
    "conteudo":"The list of titles and abstracts were independently reviewed and marked for inclusion or"
  },
  {
    "conteudo":"exclusion (along with the reason) and any differences were resolved by discussion with a third"
  },
  {
    "conteudo":"reviewer. Full texts of articles meeting inclusion criteria were ordered and reviewed for"
  },
  {
    "conteudo":"inclusion. 225 studies met the inclusion criteria for Intervention questions and 125 for"
  },
  {
    "conteudo":"assessment articles. A list of excluded articles with reason for exclusion was also created to"
  },
  {
    "conteudo":"maintain transparency (available of Academy of Nutrition and Dietetics Evidence Analysis"
  },
  {
    "conteudo":"Center website)."
  },
  {
    "conteudo":"Data extraction and study quality assessment: Relevant data was extracted from the included"
  },
  {
    "conteudo":"articles using a standardized online data extraction tool. Key information extracted from each"
  },
  {
    "conteudo":"study included: Authors information; year of publication; type of study design; details of"
  },
  {
    "conteudo":"intervention: type of intervention, duration of the intervention, who delivered the intervention,"
  },
  {
    "conteudo":"setting, number of centers; Participants: sample size, mean age, age range, gender, study"
  },
  {
    "conteudo":"inclusion and exclusion criteria, comorbidities; Interventions: intervention details, comparison"
  },
  {
    "conteudo":"group details, medication use; Outcomes: reported primary and secondary outcomes, time"
  },
  {
    "conteudo":"points of reported outcomes; other details such as funding source."
  },
  {
    "conteudo":"All included studies were critically appraised for risk of bias. Two independent reviewers"
  },
  {
    "conteudo":"assessed the quality or studies using the Academy’s online risk of bias tool, the Quality Criteria"
  },
  {
    "conteudo":"Checklist (QCC). The questions of the QCC are based on quality constructs and risk of bias"
  },
  {
    "conteudo":"domains identified by the Cochrane Collaboration and the Agency for Healthcare Research ad"
  },
  {
    "conteudo":"Quality (AHRQ). Questions examine sampling bias, performance bias, detection bias, attrition"
  },
  {
    "conteudo":"Page 13"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"bias, and reporting bias. Any discrepancies between the two reviewers were resolved by"
  },
  {
    "conteudo":"consensus or by a third reviewer."
  },
  {
    "conteudo":"Data synthesis and grading the evidence: Descriptive synthesis of evidence was conducted for"
  },
  {
    "conteudo":"all identified outcomes for which there were included studies. When possible, meta-analysis"
  },
  {
    "conteudo":"was conducted using random-effects model. For continuous data, results were summarized as"
  },
  {
    "conteudo":"mean difference (MD) between treatment groups (intervention v\/s control\/placebo) with 95%"
  },
  {
    "conteudo":"confidence interval (CI) or standardized mean differences (SMD). Dichotomous outcomes"
  },
  {
    "conteudo":"were reported as odds ratio (OR) or risk ratios (RR) with 95% CI. The I2 statistic was used to"
  },
  {
    "conteudo":"determine the degree of heterogeneity in the calculated effect size, and 25%, 50%, and 75%"
  },
  {
    "conteudo":"were considered low, moderate, high, respectively. Sub-group analysis was conducted as"
  },
  {
    "conteudo":"appropriate to manage clinical heterogeneity."
  },
  {
    "conteudo":"After completion of the data extraction and data synthesis, the ERT provided the systematic"
  },
  {
    "conteudo":"review results in the following formats for the workgroup to review, edit, and approve: 1)"
  },
  {
    "conteudo":"Evidence summary: a narrative summary of all included trials for each identified outcome was"
  },
  {
    "conteudo":"drafted for each research question in the systematic review. A conclusion statement was"
  },
  {
    "conteudo":"developed for each proposed question \/outcome. The conclusion statement is a clear, simple"
  },
  {
    "conteudo":"and to the point answer to the proposed questions.; 2) Study characteristics table: provided"
  },
  {
    "conteudo":"information regarding study characteristics, sample size, population, intervention details and"
  },
  {
    "conteudo":"quality of each included study; 3) Quality of evidence (strength of evidence): Each of the"
  },
  {
    "conteudo":"conclusion statements were assigned a GRADE (reference) to reflect the quality of studies,"
  },
  {
    "conteudo":"inconsistency of results, imprecision, indirectness of the evidence, and publication bias. Using"
  },
  {
    "conteudo":"this method, the evidence for each outcome of interest was graded as A (high), B (moderate), C"
  },
  {
    "conteudo":"(low), or D (very low). A GRADE table was generated using GradePro and demonstrated how"
  },
  {
    "conteudo":"the strength of evidence (GRADE) was derived for each outcome of interest."
  },
  {
    "conteudo":"Guideline development: The workgroup members drafted comprehensive recommendations for"
  },
  {
    "conteudo":"nutrition care for adults with CKD. During this phase, the role of the work group member was"
  },
  {
    "conteudo":"to translate the available evidence into action statements that were clear, concise, and ready to"
  },
  {
    "conteudo":"Page 14"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"be implemented by practitioners. The workgroup and ERT used the GRADE method for"
  },
  {
    "conteudo":"development of recommendations. The GRADE method involves two major components: a"
  },
  {
    "conteudo":"rating for quality of evidence (described above) and rating the strength of recommendations."
  },
  {
    "conteudo":"The evidence grades are reported at the end of the recommendation statements (e.g. A, B, C, or"
  },
  {
    "conteudo":"D) and reflect the confidence in the estimated effects (Table 3)."
  },
  {
    "conteudo":"The second component is rating the strength of the recommendation statement. This rating"
  },
  {
    "conteudo":"reflects the extent to which one is confident that desirable effects of an intervention outweigh"
  },
  {
    "conteudo":"undesirable effects. The grade for strength of the recommendation can be assigned Level 1 or"
  },
  {
    "conteudo":"Level 2. Table 4 shows the implication of each level for practitioners, clinicians, and policy"
  },
  {
    "conteudo":"makers. Level 1 recommendations use the terminology “We recommend”, which means that"
  },
  {
    "conteudo":"this course of action should be applied to most people and practitioners can have confidence"
  },
  {
    "conteudo":"that implementing this recommendation has more benefit than risk. Level 2 recommendations"
  },
  {
    "conteudo":"use the terminology “We suggest”."
  },
  {
    "conteudo":"When providing the level for the strength of the recommendation, a number of factors besides"
  },
  {
    "conteudo":"the quality of evidence are taken into consideration, including patient values and preferences,"
  },
  {
    "conteudo":"quality of evidence, benefits and harms, cost\/resources to implement the recommendation,"
  },
  {
    "conteudo":"acceptability, feasibility, and health equity. In addition to evidence-based recommendations, in"
  },
  {
    "conteudo":"certain scenarios “Opinion” statements were developed. These statements were developed"
  },
  {
    "conteudo":"when there was not enough evidence or evidence had too low of quality to write a graded"
  },
  {
    "conteudo":"recommendation, but the workgroup determined it was important to provide some guidance to"
  },
  {
    "conteudo":"patients and practitioners. These recommendations are ungraded, and usually refer to general"
  },
  {
    "conteudo":"or routine practice."
  },
  {
    "conteudo":"Once the full draft of recommendation statements was ready, it was reviewed and edited"
  },
  {
    "conteudo":"multiple times by all the workgroup members and the ERT. The workgroup participated in a"
  },
  {
    "conteudo":"final blinded vote of recommendation statements, and a majority of votes approving the"
  },
  {
    "conteudo":"statement was necessary for each statement to be accepted into the final guideline."
  },
  {
    "conteudo":"Page 15"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Draft report with supporting rationale: Once the recommendation statements were developed,"
  },
  {
    "conteudo":"the work group members drafted a guideline manuscript that included the supporting materials"
  },
  {
    "conteudo":"for each topic, including rationale, detailed justification (evidence summary), special"
  },
  {
    "conteudo":"discussions, implementation considerations, risks and harms, costs, and need for future"
  },
  {
    "conteudo":"research. In these sections the work group members also cited additional references important"
  },
  {
    "conteudo":"to the respective topic, including discussion of studies published after our search dates or other"
  },
  {
    "conteudo":"systematic reviews on the topic."
  },
  {
    "conteudo":"Peer review process: These guidelines underwent a systematic peer review process. The first"
  },
  {
    "conteudo":"phase of review was an internal review conducted by KDOQI leadership and the National"
  },
  {
    "conteudo":"Kidney Foundation Scientific Advisory Board. Feedback from this internal review were"
  },
  {
    "conteudo":"reviewed and incorporated in the guideline as appropriate. The second phase of the review was"
  },
  {
    "conteudo":"an external review conducted by 12 experts in this field. The AGREE II tool (Appraisal of"
  },
  {
    "conteudo":"Guidelines for Research and Evaluation) criteria was used to assess the quality of guideline"
  },
  {
    "conteudo":"reporting. The third phase was an open, public review phase. Reviewer comments from all"
  },
  {
    "conteudo":"phases were collated by staff and sent to workgroup members for discussion and possible edits."
  },
  {
    "conteudo":"Work group chairs coordinated the final revision of the guideline document based on review"
  },
  {
    "conteudo":"comments and the final guideline manuscript will be submitted for publication."
  },
  {
    "conteudo":"Table 1. Key Questions for Evidence Review"
  },
  {
    "conteudo":"Topics Questions"
  },
  {
    "conteudo":"Assessment: What composite nutritional indices should be used to assess nutritional"
  },
  {
    "conteudo":"Nutritional status status, and\/or protein-energy wasting in adults with CKD 1-5D, non-"
  },
  {
    "conteudo":"dialysis and transplant?"
  },
  {
    "conteudo":"What technical devices and anthropometric measures should be used to"
  },
  {
    "conteudo":"assess body composition in adults with CKD 1-5D, non-dialyzed and"
  },
  {
    "conteudo":"transplant?"
  },
  {
    "conteudo":"What laboratory measures should be used to assess nutritional status in"
  },
  {
    "conteudo":"adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"Is there evidence to support the use of hand-grip strength for assessing"
  },
  {
    "conteudo":"nutritional status in adults with CKD 1-5D, non-dialyzed and transplant?"
  },
  {
    "conteudo":"Assessment: What methods should be used to assess dietary intake of energy and"
  },
  {
    "conteudo":"Macronutrients protein in adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"What methods should be used assess energy and protein requirements in"
  },
  {
    "conteudo":"adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"Page 16"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Assessment: What methods should be used to assess micronutrient intake in adults"
  },
  {
    "conteudo":"Micronutrients with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"What methods should be used to assess micronutrient needs in adults"
  },
  {
    "conteudo":"with CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"What methods should be to assess micronutrient status in adults with"
  },
  {
    "conteudo":"CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"Assessment: What are the methods should be used to assess dietary electrolyte intake"
  },
  {
    "conteudo":"Electrolytes in adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"What methods should be used to assess electrolyte needs in adults with"
  },
  {
    "conteudo":"CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"3. What methods should be used to assess electrolyte status in adults"
  },
  {
    "conteudo":"with CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"Medical Nutrition What is the effect of MNT provided by a registered dietitian or"
  },
  {
    "conteudo":"Therapy international equivalent on outcomes in adult patients with CKD 1-5D,"
  },
  {
    "conteudo":"non-dialysis and transplant?"
  },
  {
    "conteudo":"Macronutrient: What is the effect of protein restriction, with or without ketoanalogues of"
  },
  {
    "conteudo":"Protein restriction amino acids, intake on outcomes in adults with CKD 1-5D, non-dialysis"
  },
  {
    "conteudo":"and type and transplant?"
  },
  {
    "conteudo":"What is the effect of protein type (animal vs plant) intake on outcomes in"
  },
  {
    "conteudo":"adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"Macronutrient: What is the effect of specific dietary patterns on outcomes in patients"
  },
  {
    "conteudo":"Dietary patterns with CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"Macronutrient: What is the effect of omega 3 supplementation on outcomes in adults"
  },
  {
    "conteudo":"Omega-3 with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"supplementation"
  },
  {
    "conteudo":"Macronutrient: Oral What is the effect of oral nutritional supplementation on outcomes in"
  },
  {
    "conteudo":"Nutrition adults with CKD 1-5, non-dialysis and transplant?"
  },
  {
    "conteudo":"supplements"
  },
  {
    "conteudo":"Macronutrient: What is the effect of nutritional supplementation via dialysate on"
  },
  {
    "conteudo":"Dialysate outcomes in adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"supplements"
  },
  {
    "conteudo":"Macronutrient: What is the effect of nutritional supplementation via IDPN on outcomes"
  },
  {
    "conteudo":"IDPN supplements in adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"Micronutrients: What is the effect of micronutrient intake (B vitamins, vitamins C, D, E"
  },
  {
    "conteudo":"intervention and K and selenium and zinc) on outcomes in adults with CKD 1-5D,"
  },
  {
    "conteudo":"questions non-dialysis and transplant?"
  },
  {
    "conteudo":"Electrolytes: What is the effect of dietary intake of (acid-base, calcium, phosphorus,"
  },
  {
    "conteudo":"intervention potassium, magnesium, sodium) on (electrolyte) biomarkers and other"
  },
  {
    "conteudo":"questions health outcomes in adults with CKD 1-5D, non-dialysis and transplant?"
  },
  {
    "conteudo":"Page 17"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Table 2. Evidence Review Inclusion and Exclusion Criteria"
  },
  {
    "conteudo":"Assessment Research Questions"
  },
  {
    "conteudo":"Inclusion Exclusion"
  },
  {
    "conteudo":"Age Adults (age 18 and older) Young adults ≤18 years of age, infants,"
  },
  {
    "conteudo":"children and adolescents."
  },
  {
    "conteudo":"Setting Clinical or outpatient Other than clinical or outpatient"
  },
  {
    "conteudo":"Health Status CKD of any stage, nephrotic Cancer or any other terminal"
  },
  {
    "conteudo":"syndrome, maintenance condition or serious condition"
  },
  {
    "conteudo":"hemodialysis chronic peritoneal"
  },
  {
    "conteudo":"dialysis, and kidney"
  },
  {
    "conteudo":"transplantation with different"
  },
  {
    "conteudo":"CKD stages, with or without"
  },
  {
    "conteudo":"dyslipidemia and diabetes;"
  },
  {
    "conteudo":"kidney transplant recipients"
  },
  {
    "conteudo":"Nutrition Related Chronic kidney disease None"
  },
  {
    "conteudo":"Problem\/Condition"
  },
  {
    "conteudo":"Study Design • Diagnostic, validity, • Review article; meta-analysis"
  },
  {
    "conteudo":"Preferences reliability studies, (Pertinent review articles will be"
  },
  {
    "conteudo":"prediction, and\/or hand searched)"
  },
  {
    "conteudo":"correlation studies • Not a research study: Poster"
  },
  {
    "conteudo":"session, commentary, letter to"
  },
  {
    "conteudo":"• Studies need to have a editor, “grey” literature:"
  },
  {
    "conteudo":"comparative tool\/method technical reports from"
  },
  {
    "conteudo":"included government agencies or"
  },
  {
    "conteudo":"scientific research groups,"
  },
  {
    "conteudo":"working papers from research"
  },
  {
    "conteudo":"groups or committees, white"
  },
  {
    "conteudo":"papers, position papers,"
  },
  {
    "conteudo":"abstracts, conference reports or"
  },
  {
    "conteudo":"preprints."
  },
  {
    "conteudo":"Outcomes • Evaluates validity, • No evaluation of validity,"
  },
  {
    "conteudo":"agreement and reliability of agreement or reliability of the"
  },
  {
    "conteudo":"the screening tool screening tool"
  },
  {
    "conteudo":"• Reports one or more of the • Does not report on at least one of"
  },
  {
    "conteudo":"following outcomes: the outcomes of interest."
  },
  {
    "conteudo":"• Validity [e.g., construct • Tools evaluated as predictors of"
  },
  {
    "conteudo":"(convergent, divergent) morbidity and mortality"
  },
  {
    "conteudo":"criterion (concurrent or outcomes."
  },
  {
    "conteudo":"predictive)]"
  },
  {
    "conteudo":"• Reliability (e.g., inter- or"
  },
  {
    "conteudo":"intra-rater)"
  },
  {
    "conteudo":"• Sensitivity \/ Specificity"
  },
  {
    "conteudo":"• Positive and\/or negative"
  },
  {
    "conteudo":"predictive value"
  },
  {
    "conteudo":"Page 18"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Agreement [kappa]."
  },
  {
    "conteudo":"Study Dropout 20% for studies <1 year and >20% for studies <1 year and"
  },
  {
    "conteudo":"rate 30% for studies > 1 year. >30% for studies >1 year"
  },
  {
    "conteudo":"Year Range 1985 to December 2016 Published prior to 1985"
  },
  {
    "conteudo":"Authorship • If an author is included on Studies by same author similar in"
  },
  {
    "conteudo":"more than one primary content."
  },
  {
    "conteudo":"research article that is"
  },
  {
    "conteudo":"similar in content, the most"
  },
  {
    "conteudo":"recent review or article will"
  },
  {
    "conteudo":"be accepted, and earlier"
  },
  {
    "conteudo":"versions will be rejected."
  },
  {
    "conteudo":"• If an author is included on"
  },
  {
    "conteudo":"more than one Review"
  },
  {
    "conteudo":"Article or primary research"
  },
  {
    "conteudo":"article and the content is"
  },
  {
    "conteudo":"different, then both reviews"
  },
  {
    "conteudo":"may be accepted."
  },
  {
    "conteudo":"Language Limited to articles in English Languages other than English"
  },
  {
    "conteudo":"Subjects Humans Animals"
  },
  {
    "conteudo":"Publication Published in peer-reviewed Not published in peer-reviewed"
  },
  {
    "conteudo":"journal. journal."
  },
  {
    "conteudo":"Intervention Research Questions"
  },
  {
    "conteudo":"Inclusion Exclusion"
  },
  {
    "conteudo":"Age Adults (age 18 and older) Young adults ≤18 years of age, infants,"
  },
  {
    "conteudo":"children and adolescents."
  },
  {
    "conteudo":"Setting Clinical or outpatient Other than clinical or outpatient"
  },
  {
    "conteudo":"Health Status CKD of any stage, nephrotic Cancer or any other terminal"
  },
  {
    "conteudo":"syndrome, maintenance condition or serious condition"
  },
  {
    "conteudo":"hemodialysis chronic peritoneal"
  },
  {
    "conteudo":"dialysis, and kidney"
  },
  {
    "conteudo":"transplantation with different"
  },
  {
    "conteudo":"CKD stages, with or without"
  },
  {
    "conteudo":"dyslipidemia and diabetes;"
  },
  {
    "conteudo":"kidney transplant recipients"
  },
  {
    "conteudo":"Nutrition Related Chronic kidney disease None"
  },
  {
    "conteudo":"Problem\/Condition"
  },
  {
    "conteudo":"Study Design RCT or Clinical Controlled • Observational studies"
  },
  {
    "conteudo":"Preferences Studies • Review article; meta-analysis"
  },
  {
    "conteudo":"(Pertinent review articles will be"
  },
  {
    "conteudo":"hand searched)"
  },
  {
    "conteudo":"• Not a research study: Poster"
  },
  {
    "conteudo":"session, commentary, letter to"
  },
  {
    "conteudo":"editor, “grey” literature: technical"
  },
  {
    "conteudo":"reports from government agencies"
  },
  {
    "conteudo":"or scientific research groups,"
  },
  {
    "conteudo":"working papers from research"
  },
  {
    "conteudo":"groups or committees, white"
  },
  {
    "conteudo":"papers, position papers, abstracts,"
  },
  {
    "conteudo":"conference reports or preprints."
  },
  {
    "conteudo":"Page 19"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Outcomes Mortality, renal replacement • Does not report on at least one of"
  },
  {
    "conteudo":"therapy, quality of life, the outcomes of interest."
  },
  {
    "conteudo":"nutritional status outcomes,"
  },
  {
    "conteudo":"dietary intake outcomes,"
  },
  {
    "conteudo":"inflammation outcomes,"
  },
  {
    "conteudo":"anthropometrics, micronutrient"
  },
  {
    "conteudo":"biomarkers, electrolyte"
  },
  {
    "conteudo":"biomarkers, CKD progression,"
  },
  {
    "conteudo":"comorbidity outcomes (lipid"
  },
  {
    "conteudo":"profile, blood pressure)"
  },
  {
    "conteudo":"Size of Study For controlled trials at least 6 • <6 individuals for each study"
  },
  {
    "conteudo":"Groups subjects in each arm group"
  },
  {
    "conteudo":"Study Dropout 20% for studies <1 year and >20% for studies <1 year and >30%"
  },
  {
    "conteudo":"rate 30% for studies > 1 year. for studies >1 year"
  },
  {
    "conteudo":"Year Range 1985 to December 2016 Published prior to 1985"
  },
  {
    "conteudo":"Authorship • If an author is included on Studies by same author similar in"
  },
  {
    "conteudo":"more than one primary content."
  },
  {
    "conteudo":"research article that is"
  },
  {
    "conteudo":"similar in content, the most"
  },
  {
    "conteudo":"recent review or article will"
  },
  {
    "conteudo":"be accepted, and earlier"
  },
  {
    "conteudo":"versions will be rejected."
  },
  {
    "conteudo":"• If an author is included on"
  },
  {
    "conteudo":"more than one Review"
  },
  {
    "conteudo":"Article or primary research"
  },
  {
    "conteudo":"article and the content is"
  },
  {
    "conteudo":"different, then both reviews"
  },
  {
    "conteudo":"may be accepted."
  },
  {
    "conteudo":"Language Limited to articles in English Languages other than English"
  },
  {
    "conteudo":"Subjects Humans Animals"
  },
  {
    "conteudo":"Publication Published in peer-reviewed Not published in peer-reviewed"
  },
  {
    "conteudo":"journal. journal."
  },
  {
    "conteudo":"Page 20"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Figure 1. Flow diagram of identified studies for assessment questions"
  },
  {
    "conteudo":"Records identified through Additional records identified"
  },
  {
    "conteudo":"database searching through other sources"
  },
  {
    "conteudo":"(n = 4,784) (n = 73)"
  },
  {
    "conteudo":"Records after duplicates removed"
  },
  {
    "conteudo":"(n = 3147)"
  },
  {
    "conteudo":"Records excluded"
  },
  {
    "conteudo":"Records screened"
  },
  {
    "conteudo":"(n = 2759)"
  },
  {
    "conteudo":"(n = 3147)"
  },
  {
    "conteudo":"Full-text articles assessed"
  },
  {
    "conteudo":"Full-text articles excluded,"
  },
  {
    "conteudo":"for eligibility"
  },
  {
    "conteudo":"with reasons"
  },
  {
    "conteudo":"(n = 388)"
  },
  {
    "conteudo":"(n = 263)"
  },
  {
    "conteudo":"Studies included in"
  },
  {
    "conteudo":"qualitative synthesis"
  },
  {
    "conteudo":"(n = 125)"
  },
  {
    "conteudo":"Page 21"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Figure 2. Flow diagram of identified studies for Intervention questions"
  },
  {
    "conteudo":"Records identified through Additional records identified"
  },
  {
    "conteudo":"database searching through other sources"
  },
  {
    "conteudo":"(n = 10,974) (n = 43)"
  },
  {
    "conteudo":"Records after duplicates removed"
  },
  {
    "conteudo":"(n = 10,309)"
  },
  {
    "conteudo":"Records excluded"
  },
  {
    "conteudo":"Records screened"
  },
  {
    "conteudo":"(n = 9508)"
  },
  {
    "conteudo":"(n = 10,309)"
  },
  {
    "conteudo":"Full-text articles assessed"
  },
  {
    "conteudo":"Full-text articles excluded,"
  },
  {
    "conteudo":"for eligibility"
  },
  {
    "conteudo":"with reasons"
  },
  {
    "conteudo":"(n = 801)"
  },
  {
    "conteudo":"(n = 247)"
  },
  {
    "conteudo":"Studies included in"
  },
  {
    "conteudo":"qualitative synthesis"
  },
  {
    "conteudo":"(n = 225)"
  },
  {
    "conteudo":"Studies included in"
  },
  {
    "conteudo":"quantitative analysis"
  },
  {
    "conteudo":"(n = 126)"
  },
  {
    "conteudo":"Page 22"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Table 3. Quality of Evidence Grades"
  },
  {
    "conteudo":"Grade Definition"
  },
  {
    "conteudo":"High (A) We are very confident that the true effect lies close to that of the"
  },
  {
    "conteudo":"estimate of the effect."
  },
  {
    "conteudo":"Moderate (B) We are moderately confident in the effect estimate: The true effect is"
  },
  {
    "conteudo":"likely to be close to the estimate of the effect, but there is a possibility"
  },
  {
    "conteudo":"that it is substantially different."
  },
  {
    "conteudo":"Low (C) Our confidence in the effect estimate is limited: The true effect may be"
  },
  {
    "conteudo":"substantially different from the estimate of the effect."
  },
  {
    "conteudo":"Very Low (D) We have very little confidence in the effect estimate: The true effect is"
  },
  {
    "conteudo":"likely to be substantially different from the estimate of effect."
  },
  {
    "conteudo":"Source: Reproduced with permission from the GRADE handbook1"
  },
  {
    "conteudo":"Page 23"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Table 4. Implications of strong and weak recommendations for different users of guidelines"
  },
  {
    "conteudo":"Strong Recommendation Weak Recommendation"
  },
  {
    "conteudo":"(Level 1 = We recommend) (Level 2 = We suggest)"
  },
  {
    "conteudo":"For patients Most individuals in this situation The majority of individuals in this"
  },
  {
    "conteudo":"would want the recommended situation would want the suggested"
  },
  {
    "conteudo":"course of action and only a small course of action, but many would not."
  },
  {
    "conteudo":"proportion would not."
  },
  {
    "conteudo":"For clinicians Most individuals should receive Recognize that different choices will"
  },
  {
    "conteudo":"the recommended course of be appropriate for different patients,"
  },
  {
    "conteudo":"action. Adherence to this and that you must help each patient"
  },
  {
    "conteudo":"recommendation according to arrive at a management decision"
  },
  {
    "conteudo":"the guideline could be used as a consistent with her or his values and"
  },
  {
    "conteudo":"quality criterion or performance preferences. Decision aids may well"
  },
  {
    "conteudo":"indicator. Formal decision aids be useful helping individuals making"
  },
  {
    "conteudo":"are not likely to be needed to decisions consistent with their values"
  },
  {
    "conteudo":"help individuals make decisions and preferences. Clinicians should"
  },
  {
    "conteudo":"consistent with their values and expect to spend more time with"
  },
  {
    "conteudo":"preferences. patients when working towards a"
  },
  {
    "conteudo":"decision."
  },
  {
    "conteudo":"For policy makers The recommendation can be Policy making will require substantial"
  },
  {
    "conteudo":"adapted as policy in most debates and involvement of many"
  },
  {
    "conteudo":"situations including for the use stakeholders. Policies are also more"
  },
  {
    "conteudo":"as performance indicators. likely to vary between regions."
  },
  {
    "conteudo":"Performance indicators would have"
  },
  {
    "conteudo":"to focus on the fact that adequate"
  },
  {
    "conteudo":"deliberation about the management"
  },
  {
    "conteudo":"options has taken place."
  },
  {
    "conteudo":"Source: Reproduced with permission from the GRADE handbook1"
  },
  {
    "conteudo":"Page 24"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"SUMMARY OF GUIDELINE STATEMENTS"
  },
  {
    "conteudo":"GUIDELINE 1: NUTRITION ASSESSMENT"
  },
  {
    "conteudo":"1.0 Usual Care Statements"
  },
  {
    "conteudo":"Routine Nutrition Screening"
  },
  {
    "conteudo":"1.0.1 In adults with CKD 3-5D and post-transplant, it is reasonable to consider"
  },
  {
    "conteudo":"routine nutrition screening at least biannually with the intent of identifying those at risk"
  },
  {
    "conteudo":"of protein-energy wasting (OPINION)."
  },
  {
    "conteudo":"Nutrition Screening Tools"
  },
  {
    "conteudo":"1.0.2 In adults with CKD 3-5D and post-transplant, there is limited evidence to"
  },
  {
    "conteudo":"suggest the use of one tool over others for identifying those at risk of protein-energy"
  },
  {
    "conteudo":"wasting (2D)."
  },
  {
    "conteudo":"Routine Nutrition Assessment"
  },
  {
    "conteudo":"1.0.3 In adults with CKD 3-5D and post-transplant, it is reasonable that a"
  },
  {
    "conteudo":"registered dietitian nutritionist (RDN) or an international equivalent conduct a"
  },
  {
    "conteudo":"comprehensive nutrition assessment (including but not limited to appetite, history of"
  },
  {
    "conteudo":"dietary intake, biochemical data, anthropometric measurements, and nutrition-"
  },
  {
    "conteudo":"focused physical findings) at least within the first 90 days of starting dialysis,"
  },
  {
    "conteudo":"annually, or when indicated by nutrition screening or provider referral (OPINION)."
  },
  {
    "conteudo":"1.1 Statement on Technical Devices & Anthropometric Measurements to Assess Body"
  },
  {
    "conteudo":"Composition"
  },
  {
    "conteudo":"Bioelectrical Impedance for Patients on Maintenance Hemodialysis (MHD)"
  },
  {
    "conteudo":"1.1.1 In adults with CKD on MHD, we suggest using bioimpedance and preferably"
  },
  {
    "conteudo":"multi-frequency bioelectrical impedance (MF-BIA) to assess body composition when"
  },
  {
    "conteudo":"available. Bioimpedance assessments should ideally be performed a minimum of 30"
  },
  {
    "conteudo":"minutes or more after the end of the hemodialysis session to allow for redistribution"
  },
  {
    "conteudo":"of body fluids (2C)."
  },
  {
    "conteudo":"Bioelectrical Impedance for Patients, Non-Dialyzed and on Peritoneal Dialysis (PD)"
  },
  {
    "conteudo":"1.1.2 In adults with CKD who are non-dialyzed or on PD, there is insufficient"
  },
  {
    "conteudo":"evidence to suggest using bioelectrical impedance to assess body composition (2D)."
  },
  {
    "conteudo":"DEXA for Body Composition Assessment"
  },
  {
    "conteudo":"1.1.3 In adults with CKD 1-5D and post-transplant, it is reasonable to use dual-"
  },
  {
    "conteudo":"energy x-ray absorptiometry (DEXA) when feasible as it remains the gold standard for"
  },
  {
    "conteudo":"measuring body composition despite being influenced by volume status (OPINION)."
  },
  {
    "conteudo":"Body Composition and Body Weight\/BMI"
  },
  {
    "conteudo":"1.1.4 In adults with CKD 1-5D and post-transplant, it reasonable to consider"
  },
  {
    "conteudo":"assessing body composition in combination with body weight\/BMI at the first visit"
  },
  {
    "conteudo":"and to monitor overall nutrition status periodically over time (OPINION)."
  },
  {
    "conteudo":"Page 25"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Frequency of Body Weight\/BMI and Body Composition Assessment"
  },
  {
    "conteudo":"1.1.5 In adults with CKD 1-5D and post-transplant who are clinically stable, it is"
  },
  {
    "conteudo":"reasonable measure body weight and BMI and to monitor for changes in body"
  },
  {
    "conteudo":"weight\/BMI and body composition as needed (OPINION)."
  },
  {
    "conteudo":"● At least Monthly in MHD and PD patients"
  },
  {
    "conteudo":"● At least Every 3 months in stages 4-5 and post-transplant patients"
  },
  {
    "conteudo":"● At least Every 6 months in stages 1-3 patients"
  },
  {
    "conteudo":"Assessment of Body Weight"
  },
  {
    "conteudo":"1.1.6 In adults with CKD 1-5D and post-transplant, it is reasonable for registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or an international equivalent or physicians to use clinical"
  },
  {
    "conteudo":"judgement to determine the method for measuring body weight (e.g. actual measured"
  },
  {
    "conteudo":"weight, history of weight changes, serial weight measurements, adjustments for"
  },
  {
    "conteudo":"suspected impact of edema, ascites and polycystic organs) due to absence of standard"
  },
  {
    "conteudo":"reference norms (OPINION)."
  },
  {
    "conteudo":"Body Mass Index (BMI) as a Predictor of Mortality"
  },
  {
    "conteudo":"1.1.7 In adults with CKD who are on PD, we suggest that underweight status (based"
  },
  {
    "conteudo":"on BMI) can be used as a predictor of higher mortality (2C)."
  },
  {
    "conteudo":"1.1.8 In adults with CKD who are on MHD, we suggest that overweight\/obese status"
  },
  {
    "conteudo":"(based on BMI) can be used as a predictor of lower mortality, whereas, underweight"
  },
  {
    "conteudo":"status and morbid obesity (based on BMI) can be used as a predictor of higher"
  },
  {
    "conteudo":"mortality (2B)."
  },
  {
    "conteudo":"1.1.9 In adults with CKD 1-5, it is reasonable to consider using underweight status"
  },
  {
    "conteudo":"(based on BMI) as a predictor of higher mortality, though the mortality risk associated"
  },
  {
    "conteudo":"with overweight or obesity status (based on BMI) is not clear (OPINION)."
  },
  {
    "conteudo":"1.1.10 In adults with CKD post-transplant, it is reasonable to consider using"
  },
  {
    "conteudo":"underweight and overweight\/obesity status (based on BMI) as a predictor of higher"
  },
  {
    "conteudo":"mortality (OPINION)."
  },
  {
    "conteudo":"BMI and Protein Energy Wasting"
  },
  {
    "conteudo":"1.1.11 In adults with CKD 1-5D and post-transplant, BMI alone is not sufficient to"
  },
  {
    "conteudo":"establish a diagnosis of PEW unless the BMI is very low (<18 kg\/m2) (OPINION)."
  },
  {
    "conteudo":"Skinfold Thickness"
  },
  {
    "conteudo":"1.1.12 In adults with CKD 1-5D (1B) and post-transplant (OPINION), in the"
  },
  {
    "conteudo":"absence of edema, we suggest using skinfold thickness measurements to assess body"
  },
  {
    "conteudo":"fat."
  },
  {
    "conteudo":"Waist Circumference"
  },
  {
    "conteudo":"1.1.13 In adults with CKD 5D, we suggest that waist circumference may be used to"
  },
  {
    "conteudo":"assess abdominal obesity, but its reliability in assessing changes over time is low (2C)."
  },
  {
    "conteudo":"Conicity Index"
  },
  {
    "conteudo":"Page 26"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.1.14 In adults with CKD on MHD, we suggest that the conicity index may be used to"
  },
  {
    "conteudo":"assess nutritional status and as a predictor of mortality (2C)."
  },
  {
    "conteudo":"Creatinine Kinetics"
  },
  {
    "conteudo":"1.1.15 In adults with CKD 5D, we suggest that creatinine kinetics may be used to"
  },
  {
    "conteudo":"estimate muscle mass, though very high or very low dietary intake of meat and\/or"
  },
  {
    "conteudo":"creatine supplements will influence accuracy of this measurement (2C)."
  },
  {
    "conteudo":"1.2 Statements on Assessment with Laboratory Measurements"
  },
  {
    "conteudo":"Single Biomarker Measurements"
  },
  {
    "conteudo":"1.2.1 In adults with CKD stages 1-5D and post-transplant, biomarkers such as"
  },
  {
    "conteudo":"normalized protein catabolic rate (nPCR), serum albumin and\/or serum prealbumin may"
  },
  {
    "conteudo":"be considered complementary tools to assess nutritional status. However, they should"
  },
  {
    "conteudo":"not be interpreted in isolation to assess nutritional status as they are influenced by non-"
  },
  {
    "conteudo":"nutritional factors (OPINION)."
  },
  {
    "conteudo":"Serum Albumin Levels"
  },
  {
    "conteudo":"1.2.2 In adults with CKD on maintenance dialysis, serum albumin"
  },
  {
    "conteudo":"may be used as a predictor of hospitalization and mortality, with lower levels associated"
  },
  {
    "conteudo":"with higher risk (1A)."
  },
  {
    "conteudo":"1.3 Statement on Handgrip Strength"
  },
  {
    "conteudo":"1.3.1 In adults with CKD 1-5D, we suggest that handgrip strength may be used as an"
  },
  {
    "conteudo":"indicator of protein-energy status and functional status when baseline data (prior"
  },
  {
    "conteudo":"measures) are available for comparison (2B)."
  },
  {
    "conteudo":"1.4 Statement on Methods to Assess Energy Requirements"
  },
  {
    "conteudo":"Assessment of Resting Energy Expenditure"
  },
  {
    "conteudo":"1.4.1 In adults with CKD 1-5D and post-transplant, it is reasonable to use indirect"
  },
  {
    "conteudo":"calorimetry to measure resting energy expenditure when feasible and indicated, as it"
  },
  {
    "conteudo":"remains the gold standard for determining resting energy expenditure (OPINION)."
  },
  {
    "conteudo":"Resting Energy Expenditure Equations"
  },
  {
    "conteudo":"1.4.2 In adults with CKD 5D who are metabolically stable, we suggest that in the"
  },
  {
    "conteudo":"absence of indirect calorimetry, disease-specific predictive energy equations may be"
  },
  {
    "conteudo":"used to estimate resting energy expenditure as they include factors that may influence"
  },
  {
    "conteudo":"the metabolic rate in this population (2C)."
  },
  {
    "conteudo":"1.5 Statement on Composite Nutritional Indices"
  },
  {
    "conteudo":"7-point Subjective Global Assessment (SGA)"
  },
  {
    "conteudo":"1.5.1 In adults with CKD 5D, we recommend the use of the 7-point Subjective Global"
  },
  {
    "conteudo":"Assessment as a valid and reliable tool for assessing nutritional status (1B)."
  },
  {
    "conteudo":"Page 27"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Malnutrition Inflammation Score (MIS)"
  },
  {
    "conteudo":"1.5.2 In adults with CKD on MHD and post-transplant, Malnutrition Inflammation"
  },
  {
    "conteudo":"Score may be used to assess nutritional status (2C)."
  },
  {
    "conteudo":"1.6 Statement on Tools\/Methods Used to Assess Protein and Calorie Intake"
  },
  {
    "conteudo":"Considerations when Assessing Dietary Intake"
  },
  {
    "conteudo":"1.6.1 In adults with CKD 3-5D and post-transplant, it is reasonable to assess factors"
  },
  {
    "conteudo":"beyond dietary intake (e.g. medication use, knowledge, beliefs, attitudes, behavior and"
  },
  {
    "conteudo":"access to food, depression, cognitive function etc.) to effectively plan nutrition"
  },
  {
    "conteudo":"interventions. (OPINION)."
  },
  {
    "conteudo":"3 Day Food Records to Assess Dietary Intake"
  },
  {
    "conteudo":"1.6.2 In adults with CKD 3-5D, we suggest the use of a 3-day food record, conducted"
  },
  {
    "conteudo":"during both dialysis and non-dialysis treatment days (when applicable), as a preferred"
  },
  {
    "conteudo":"method to assess dietary intake (2C)."
  },
  {
    "conteudo":"Alternative Methods of Assessing Dietary Intake"
  },
  {
    "conteudo":"1.6.3 In adults with CKD 3-5 (OPINION) and 5D (2D), 24-hour food recalls, food"
  },
  {
    "conteudo":"frequency questionnaires and normalized protein catabolic rate (nPCR)\/normalized"
  },
  {
    "conteudo":"protein catabolic rate (nPCR) may be considered as alternative methods of assessing"
  },
  {
    "conteudo":"dietary energy and protein intake (2D)."
  },
  {
    "conteudo":"GUIDELINE 2: MEDICAL NUTRITION THERAPY"
  },
  {
    "conteudo":"2.0 Statements on Medical Nutrition Therapy (MNT)"
  },
  {
    "conteudo":"MNT to Improve Outcomes"
  },
  {
    "conteudo":"2.1.1 In adults with CKD 1-5D, we recommend that a registered dietitian nutritionist"
  },
  {
    "conteudo":"(RDN, USA or international nutrition credential) in close collaboration with a"
  },
  {
    "conteudo":"physician, or other provider (nurse practitioner or physician assistant), provide medical"
  },
  {
    "conteudo":"nutrition therapy (MNT). Goals are to optimize nutritional status, and to minimize risks"
  },
  {
    "conteudo":"imposed by co-morbidities and alterations in metabolism on the progression of kidney"
  },
  {
    "conteudo":"disease (1C) and on adverse clinical outcomes (OPINION)."
  },
  {
    "conteudo":"MNT Content"
  },
  {
    "conteudo":"2.1.2 In adults with CKD 1-5D and post-transplant, it is reasonable to prescribe MNT"
  },
  {
    "conteudo":"that is tailored to the individuals’ needs, nutritional status and co-morbid conditions"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"MNT Monitoring and Evaluation"
  },
  {
    "conteudo":"2.1.3 In adults with CKD 3-5D and post-transplant, it is reasonable for the registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or an international equivalent to monitor and evaluate"
  },
  {
    "conteudo":"appetite, dietary intake, biochemical data, anthropometric measurements, and nutrition-"
  },
  {
    "conteudo":"focused physical findings to assess the effectiveness of medical nutrition therapy"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Page 28"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"GUIDELINE 3: PROTEIN AND ENERGY INTAKE"
  },
  {
    "conteudo":"3.0 Statement on Energy Intake"
  },
  {
    "conteudo":"3.0.1 In adults with CKD 1-5D (1C) and post-transplant (OPINION) who are metabolically"
  },
  {
    "conteudo":"stable, we recommend prescribing an energy intake of 25-35 kcal\/kg ideal body weight per day"
  },
  {
    "conteudo":"based on age, gender, level of physical activity, body composition, weight status goals, CKD"
  },
  {
    "conteudo":"stage, and concurrent illness or presence of inflammation to maintain normal nutritional status."
  },
  {
    "conteudo":"3.1 Statements on Protein Amount"
  },
  {
    "conteudo":"Protein Restriction, Non-Dialysis"
  },
  {
    "conteudo":"3.1.1 In adults with CKD 3-5 who are metabolically stable, we recommend protein"
  },
  {
    "conteudo":"restriction with or without keto acid analogs, to reduce risk for ESRD\/death (1A) and"
  },
  {
    "conteudo":"improve QoL (1C)."
  },
  {
    "conteudo":"● a low protein diet providing 0.55 to 0.60 g dietary protein\/kg ideal body"
  },
  {
    "conteudo":"weight\/day, OR"
  },
  {
    "conteudo":"● a very-low protein diet providing 0.28 to 0.43 g dietary protein\/kg ideal"
  },
  {
    "conteudo":"body weight\/day with additional keto acid analogs to meet protein"
  },
  {
    "conteudo":"requirements (0.55 to 0.60 g \/kg body weight\/day)"
  },
  {
    "conteudo":"Dietary Protein Intake, Maintenance Hemodialysis and Peritoneal Dialysis"
  },
  {
    "conteudo":"3.1.2 In adults with CKD on MHD (1C) and PD (OPINION) who are metabolically"
  },
  {
    "conteudo":"stable, we recommend prescribing a dietary protein intake of 1.0 -1.2 g \/kg ideal body"
  },
  {
    "conteudo":"weight per day to maintain a stable nutritional status."
  },
  {
    "conteudo":"Dietary Protein Intake, Diabetes Mellitus"
  },
  {
    "conteudo":"3.1.3 In the adult with CKD 3-5 and who have diabetes, it is reasonable to prescribe a"
  },
  {
    "conteudo":"dietary protein intake of 0.8 – 0.9 g \/kg ideal body weight per day to maintain a stable"
  },
  {
    "conteudo":"nutritional status and optimize glycemic control (OPINION)."
  },
  {
    "conteudo":"3.1.4 In adults with CKD on MHD and PD and who have diabetes, it is reasonable to"
  },
  {
    "conteudo":"prescribe a dietary protein intake of 1.0 -1.2 g \/kg ideal body weight per day to"
  },
  {
    "conteudo":"maintain a stable nutritional status. For patients at risk of hyper and\/or hypoglycemia,"
  },
  {
    "conteudo":"higher levels of dietary protein intake may need to be considered to maintain glycemic"
  },
  {
    "conteudo":"control (OPINION)."
  },
  {
    "conteudo":"3.2 Statement on Protein Type"
  },
  {
    "conteudo":"3.2.1 In adults with CKD 1-5D (1B) and post-transplant (OPINION), there is"
  },
  {
    "conteudo":"inadequate evidence to recommend a particular protein type (plant vs animal) in terms"
  },
  {
    "conteudo":"of the effects on nutritional status, calcium or phosphorus levels, or the blood lipid"
  },
  {
    "conteudo":"profile."
  },
  {
    "conteudo":"Page 29"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"3.3 Statements on Dietary Patterns"
  },
  {
    "conteudo":"Mediterranean Diet"
  },
  {
    "conteudo":"3.3.1 In adults with CKD 1-5 (non-dialysis) and post-transplant, with or without"
  },
  {
    "conteudo":"dyslipidemia, we suggest that prescribing a Mediterranean Diet may improve lipid"
  },
  {
    "conteudo":"profiles (2C)."
  },
  {
    "conteudo":"Fruits and Vegetables"
  },
  {
    "conteudo":"3.3.2 In adults with CKD 1-4, we suggest that prescribing increased fruit and vegetable"
  },
  {
    "conteudo":"intake may decrease body weight, blood pressure and net acid production (NEAP) (2C)."
  },
  {
    "conteudo":"GUIDELINE 4: NUTRITIONAL SUPPLEMENTATION"
  },
  {
    "conteudo":"4.1 Statements on Oral, Enteral and Intradialytic Parenteral Nutrition Supplementation"
  },
  {
    "conteudo":"Oral Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.1.1 In adults with CKD 3-5D (2D) and post-transplant (OPINION) at risk of or"
  },
  {
    "conteudo":"with protein-energy wasting, we suggest a minimum of a 3-month trial of oral"
  },
  {
    "conteudo":"nutritional supplements to improve nutritional status if dietary counselling alone does"
  },
  {
    "conteudo":"not achieve sufficient energy and protein intake to meet nutritional requirements."
  },
  {
    "conteudo":"Enteral Nutrition Supplementation"
  },
  {
    "conteudo":"4.1.2 In adults with CKD 1-5D, with chronically inadequate intake and whose protein"
  },
  {
    "conteudo":"and energy requirements cannot be attained by dietary counselling and oral nutritional"
  },
  {
    "conteudo":"supplements, it is reasonable to consider a trial of enteral tube feeding (OPINION)."
  },
  {
    "conteudo":"Total and Intradialytic Parenteral Nutrition (IDPN) Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.1.3 In adults with CKD on MHD with protein-energy wasting, we suggest a trial of"
  },
  {
    "conteudo":"IDPN for MHD patients, TPN for CKD patients and AA dialysate for PD patients to"
  },
  {
    "conteudo":"improve and maintain nutritional status if nutrition requirements cannot be met with"
  },
  {
    "conteudo":"existing oral and enteral intake (2C)"
  },
  {
    "conteudo":"4.2 Statement on Nutrition Supplementation – Dialysate"
  },
  {
    "conteudo":"Dialysate Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.2.1 In adults with CKD on peritoneal dialysis with protein-energy wasting, we"
  },
  {
    "conteudo":"suggest not substituting conventional dextrose dialysate with amino acid dialysate as a"
  },
  {
    "conteudo":"general strategy to improve nutritional status (2C), although in selected cases of"
  },
  {
    "conteudo":"protein-wasting when energy intake is adequate, 1.1% amino acid dialysate with alkali"
  },
  {
    "conteudo":"supplements may ameliorate protein deficits (OPINION)."
  },
  {
    "conteudo":"4.3 Statement on Long Chain Omega-3 Polyunsaturated Fatty Acids"
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Mortality and Cardiovascular disease"
  },
  {
    "conteudo":"Page 30"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"4.3.1 In adults with CKD on MHD or post-transplant, we suggest not routinely"
  },
  {
    "conteudo":"prescribing long-chain n-3 PUFA, including those derived from fish or flaxseed and"
  },
  {
    "conteudo":"other oils, to lower risk of mortality (2C) or cardiovascular events (2B)."
  },
  {
    "conteudo":"4.3.2 In adults with CKD on PD, it is reasonable to not routinely prescribe long-chain n-"
  },
  {
    "conteudo":"3 PUFA, including those derived from fish or flaxseed and other oils, to lower risk of"
  },
  {
    "conteudo":"mortality or cardiovascular events (OPINION)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Lipid Profile"
  },
  {
    "conteudo":"4.3.3 In adults with CKD on MHD, we suggest that 1.3-4 g\/d long-chain n-3 PUFA"
  },
  {
    "conteudo":"may be prescribed to reduce triglycerides and LDL cholesterol (2C) and raise HDL"
  },
  {
    "conteudo":"levels (2D)."
  },
  {
    "conteudo":"4.3.4 In adults with CKD on PD, it is reasonable to consider prescribing 1.3-4 g\/d long-"
  },
  {
    "conteudo":"chain n-3 PUFA to improve the lipid profile (OPINION)."
  },
  {
    "conteudo":"4.3.5 In adults with CKD 3-5, we suggest prescribing ~ 2g\/d long-chain n-3 PUFA to"
  },
  {
    "conteudo":"lower serum triglyceride levels (2C)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for AV Graft and Fistula Patency"
  },
  {
    "conteudo":"4.3.6 In adults with CKD on MHD, we suggest not routinely prescribing fish oil to"
  },
  {
    "conteudo":"improve primary patency rates in patients with AV grafts (2B) or fistulas (2A)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Kidney Allograft Survival"
  },
  {
    "conteudo":"4.3.7 In adults with CKD with kidney allograft, we suggest not routinely prescribing"
  },
  {
    "conteudo":"long-chain n-3 PUFA to reduce the number of rejection episodes or improve graft"
  },
  {
    "conteudo":"survival (2D)."
  },
  {
    "conteudo":"GUIDELINE 5: MICRONUTRIENTS"
  },
  {
    "conteudo":"5.0 Statements for General Guidance"
  },
  {
    "conteudo":"Dietary Micronutrient Intake"
  },
  {
    "conteudo":"5.0.1 In adults with CKD 3-5D and post-transplant, it is reasonable for the"
  },
  {
    "conteudo":"registered dietitian nutritionist (RDN) or international equivalent to encourage"
  },
  {
    "conteudo":"eating a diet that meets the recommended dietary allowance (RDA) for adequate"
  },
  {
    "conteudo":"intake for all vitamins and minerals (OPINION)."
  },
  {
    "conteudo":"Micronutrient Assessment and Supplementation"
  },
  {
    "conteudo":"5.0.2 In adults with CKD 3-5D and post-transplant, it is reasonable for the registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or international equivalent, in close collaboration with a"
  },
  {
    "conteudo":"physician or physician assistant, to assess dietary vitamin intake periodically and to"
  },
  {
    "conteudo":"consider multivitamin supplementation for individuals with inadequate vitamin intake"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Page 31"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Micronutrient Supplementation, Dialysis"
  },
  {
    "conteudo":"5.0.3 In adults with CKD 5D who exhibit inadequate dietary intake for sustained"
  },
  {
    "conteudo":"periods of time, it is reasonable to consider supplementation with multivitamins,"
  },
  {
    "conteudo":"including all the water-soluble vitamins, and essential trace elements to prevent or treat"
  },
  {
    "conteudo":"micronutrient deficiencies (OPINION)."
  },
  {
    "conteudo":"5.1 Statements on Folic Acid"
  },
  {
    "conteudo":"Folic Acid Supplementation for Hyperhomocysteinemia"
  },
  {
    "conteudo":"5.1.1 In adults with CKD 3-5D and post-transplant who have hyperhomocysteinemia"
  },
  {
    "conteudo":"associated with kidney disease, we recommend not to routinely supplement folate with"
  },
  {
    "conteudo":"or without B-complex since there is no evidence demonstrating reduction in"
  },
  {
    "conteudo":"cardiovascular outcomes (1A)."
  },
  {
    "conteudo":"Folic Acid Supplementation for Folic Acid Deficiency and Insufficiency"
  },
  {
    "conteudo":"5.1.2 In adults with CKD 1-5 D (2B) and post-transplant (OPINION), we suggest"
  },
  {
    "conteudo":"prescribing folate, Vit B12 and\/or B-complex supplement to correct for folate or"
  },
  {
    "conteudo":"Vitamin B12 deficiency\/insufficiency based on clinical signs and symptoms (2B)."
  },
  {
    "conteudo":"5.2 Statement on Vitamin C"
  },
  {
    "conteudo":"Vitamin C Supplementation Limit"
  },
  {
    "conteudo":"5.2.1 In adults with CKD 1-5D and post-transplant who are at risk of Vitamin C"
  },
  {
    "conteudo":"deficiency it is reasonable to consider supplementation to meet the recommended intake"
  },
  {
    "conteudo":"of at least 90 mg\/d for men and 75 mg\/d for women (OPINION)."
  },
  {
    "conteudo":"5.3 Statements on Vitamin D"
  },
  {
    "conteudo":"Vitamin D Supplementation for Vitamin D Deficiency and Insufficiency"
  },
  {
    "conteudo":"5.3.1 In adults with CKD 1-5 D (2C) and post-transplant (OPINION), we suggest"
  },
  {
    "conteudo":"prescribing vitamin D supplementation in the form of cholecalciferol or ergocalciferol"
  },
  {
    "conteudo":"to correct 25(OH)D deficiency\/insufficiency."
  },
  {
    "conteudo":"Vitamin D Supplementation with Proteinuria"
  },
  {
    "conteudo":"5.3.2 In adults with CKD with nephrotic range proteinuria, it is reasonable to"
  },
  {
    "conteudo":"consider supplementation of cholecalciferol, ergocalciferol or other safe and effective"
  },
  {
    "conteudo":"25(OH)D precursors (OPINION)."
  },
  {
    "conteudo":"5.4 Statement on Vitamins E and A"
  },
  {
    "conteudo":"Vitamins A and E Supplementation and Toxicity"
  },
  {
    "conteudo":"5.4.1 In adults with CKD on MHD or PD, it is reasonable to not routinely supplement"
  },
  {
    "conteudo":"vitamin A or E because of the potential for vitamin toxicity. However, if"
  },
  {
    "conteudo":"supplementation is warranted, patients should be monitored for toxicity (OPINION)."
  },
  {
    "conteudo":"Page 32"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"5.5 Statements on Vitamin K"
  },
  {
    "conteudo":"Anticoagulant Medication and Vitamin K Supplementation"
  },
  {
    "conteudo":"5.5.1 In adults with CKD 1-5D and post-transplant, it is reasonable that patients"
  },
  {
    "conteudo":"receiving anticoagulant medicines known to inhibit vitamin K activity (e.g., warfarin"
  },
  {
    "conteudo":"compounds) do not receive vitamin K supplements (OPINION)."
  },
  {
    "conteudo":"5.6 Statement on Trace Minerals – Selenium and Zinc"
  },
  {
    "conteudo":"Selenium and Zinc Supplementation"
  },
  {
    "conteudo":"5.6.1 In adults with CKD 1-5D, we suggest to not routinely supplement selenium or"
  },
  {
    "conteudo":"zinc since there is little evidence that it improves nutritional, inflammatory or"
  },
  {
    "conteudo":"micronutrient status (2C)."
  },
  {
    "conteudo":"GUIDELINE 6: ELECTROLYTES"
  },
  {
    "conteudo":"6.1 Statements: Acid Load"
  },
  {
    "conteudo":"Dietary Management of net acid production (NEAP)"
  },
  {
    "conteudo":"6.1.1 In adults with CKD 1-4, we suggest reducing net acid production (NEAP)"
  },
  {
    "conteudo":"through increased dietary intake of fruits and vegetables (2C) in order to reduce the rate"
  },
  {
    "conteudo":"of decline of residual kidney function."
  },
  {
    "conteudo":"Bicarbonate Maintenance"
  },
  {
    "conteudo":"6.1.2 In adults with CKD 3-5D, we recommend reducing net acid production (NEAP)"
  },
  {
    "conteudo":"through increased bicarbonate supplementation (1C) in order to reduce the rate of decline"
  },
  {
    "conteudo":"of residual kidney function."
  },
  {
    "conteudo":"6.1.3 In adults with CKD 3-5D, it is reasonable to maintain serum bicarbonate levels at"
  },
  {
    "conteudo":"24 - 26 mmol\/L (OPINION)."
  },
  {
    "conteudo":"6.2 Statement on Calcium"
  },
  {
    "conteudo":"Total Calcium Intake"
  },
  {
    "conteudo":"6.2.1 In adults with CKD 3-4 not taking active vitamin D analogs, we suggest that a"
  },
  {
    "conteudo":"total elemental calcium intake of 800-1,000 mg\/d (including dietary calcium, calcium"
  },
  {
    "conteudo":"supplementation and calcium-based phosphate binders) be prescribed to maintain a"
  },
  {
    "conteudo":"neutral calcium balance (2B)."
  },
  {
    "conteudo":"6.2.2 In adults with CKD 5D, it is reasonable to adjust calcium intake (dietary"
  },
  {
    "conteudo":"calcium, calcium supplements or calcium-based binders) with consideration of"
  },
  {
    "conteudo":"concurrent use of vitamin D analogs and calcimimetics in order to avoid"
  },
  {
    "conteudo":"hypercalcemia (OPINION)."
  },
  {
    "conteudo":"Page 33"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"6.3 Statements on Phosphorus"
  },
  {
    "conteudo":"Dietary Phosphorus Amount"
  },
  {
    "conteudo":"6.3.1 In adults with CKD 3-5 and on MHD, we recommend adjusting dietary"
  },
  {
    "conteudo":"phosphorus intake to maintain serum phosphate levels in the normal range (1B)."
  },
  {
    "conteudo":"Dietary Phosphorus Source"
  },
  {
    "conteudo":"6.3.2 In adults with CKD 1-5D and post-transplant, it is reasonable when making"
  },
  {
    "conteudo":"decisions about phosphorus restriction treatment to consider the bioavailability of"
  },
  {
    "conteudo":"phosphorus sources (e.g. animal, vegetable, additives) (OPINION)."
  },
  {
    "conteudo":"Phosphorus Intake with Hypophosphatemia"
  },
  {
    "conteudo":"6.3.3 For adult kidney transplant recipients with hypophosphatemia, it is reasonable"
  },
  {
    "conteudo":"to consider prescribing high-phosphorus intake (diet or supplements) in order to replete"
  },
  {
    "conteudo":"serum phosphate (OPINION)."
  },
  {
    "conteudo":"6.4 Statements on Potassium"
  },
  {
    "conteudo":"Dietary Potassium Amount"
  },
  {
    "conteudo":"6.4.1 In adults with CKD 3-5D and post- transplant, it is reasonable to adjust dietary"
  },
  {
    "conteudo":"potassium intake to maintain serum potassium within the normal range (OPINION)."
  },
  {
    "conteudo":"Dietary Potassium in Hyperkalemia"
  },
  {
    "conteudo":"6.4.2 In adults with CKD 3-5D and post-transplant who exhibit hyperkalemia, it is"
  },
  {
    "conteudo":"reasonable to consider lowering dietary potassium intake as a therapeutic strategy"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Potassium Intake for Hyperkalemia or Hypokalemia"
  },
  {
    "conteudo":"6.4.3 In adults with CKD 3-5 on MHD (2D) and post-transplant (OPINION) with"
  },
  {
    "conteudo":"either hyperkalemia or hypokalemia, we suggest that dietary or supplemental potassium"
  },
  {
    "conteudo":"intake be based on a patient’s individual needs and clinician judgment."
  },
  {
    "conteudo":"6.5 Statements on Sodium"
  },
  {
    "conteudo":"Sodium Intake and Blood Pressure"
  },
  {
    "conteudo":"6.5.1 In adults with CKD 3-5 (non-dialyzed) (1B), maintenance dialysis (1C), and"
  },
  {
    "conteudo":"post-transplant (1C), we recommend limiting sodium intake to less than 100"
  },
  {
    "conteudo":"mmol\/day (or <2.3 g\/day) to reduce blood pressure and improve volume control."
  },
  {
    "conteudo":"Sodium Intake and Proteinuria"
  },
  {
    "conteudo":"6.5.2 In adults with CKD 3-5 (non-dialyzed), we suggest that reduced sodium intake"
  },
  {
    "conteudo":"(100 mmol\/day or <2.3 g\/day) be prescribed to reduce proteinuria (2A)."
  },
  {
    "conteudo":"Sodium Intake and Dry Body Weight"
  },
  {
    "conteudo":"6.5.3 In adults with CKD 3-5D, we suggest reduced sodium intake as an adjunctive"
  },
  {
    "conteudo":"lifestyle modification strategy to achieve better volume control and a more desirable"
  },
  {
    "conteudo":"body weight (2B)."
  },
  {
    "conteudo":"Page 34"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"GUIDELINE 1: NUTRITIONAL ASSESSMENT"
  },
  {
    "conteudo":"1.0 Usual Care Statements"
  },
  {
    "conteudo":"Routine Nutrition Screening"
  },
  {
    "conteudo":"1.0.1 In adults with CKD 3-5D and post-transplant, it is reasonable to consider"
  },
  {
    "conteudo":"routine nutrition screening at least biannually with the intent of identifying those at"
  },
  {
    "conteudo":"risk of protein-energy wasting (OPINION)."
  },
  {
    "conteudo":"Nutrition Screening Tools"
  },
  {
    "conteudo":"1.0.2 In adults with CKD 3-5D and post-transplant, there is limited evidence to"
  },
  {
    "conteudo":"suggest the use of one tool over others for identifying those at risk of protein-"
  },
  {
    "conteudo":"energy wasting (2D)."
  },
  {
    "conteudo":"Routine Nutrition Assessment"
  },
  {
    "conteudo":"1.0.3 In adults with CKD 3-5D and post-transplant, it is reasonable that a"
  },
  {
    "conteudo":"registered dietitian nutritionist (RDN) or an international equivalent conduct a"
  },
  {
    "conteudo":"comprehensive nutrition assessment (including but not limited to appetite, history"
  },
  {
    "conteudo":"of dietary intake, biochemical data, anthropometric measurements, and nutrition-"
  },
  {
    "conteudo":"focused physical findings) at least within the first 90 days of starting dialysis,"
  },
  {
    "conteudo":"annually, or when indicated by nutrition screening or provider referral (OPINION)."
  },
  {
    "conteudo":"1.1 Statement on Technical Devices & Anthropometric Measurements to Assess Body"
  },
  {
    "conteudo":"Composition"
  },
  {
    "conteudo":"Bioelectrical Impedance for Patients on Maintenance Hemodialysis (MHD)"
  },
  {
    "conteudo":"1.1.1 In adults with CKD on MHD, we suggest using bioimpedance and preferably"
  },
  {
    "conteudo":"multi-frequency bioelectrical impedance (MF-BIA) to assess body composition"
  },
  {
    "conteudo":"when available. Bioimpedance assessments should ideally be performed a minimum"
  },
  {
    "conteudo":"of 30 minutes or more after the end of the hemodialysis session to allow for"
  },
  {
    "conteudo":"redistribution of body fluids (2C)."
  },
  {
    "conteudo":"Bioelectrical Impedance for Patients, Non-Dialyzed and on Peritoneal Dialysis (PD)"
  },
  {
    "conteudo":"1.1.2 In adults with CKD who are non-dialyzed or on PD, there is insufficient"
  },
  {
    "conteudo":"evidence to suggest using bioelectrical impedance to assess body composition"
  },
  {
    "conteudo":"(2D)."
  },
  {
    "conteudo":"DEXA for Body Composition Assessment"
  },
  {
    "conteudo":"1.1.3 In adults with CKD 1-5D and post-transplant, it is reasonable to use dual-"
  },
  {
    "conteudo":"energy x-ray absorptiometry (DEXA) when feasible as it remains the gold standard"
  },
  {
    "conteudo":"for measuring body composition despite being influenced by volume status"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Body Composition and Body Weight\/BMI"
  },
  {
    "conteudo":"1.1.4 In adults with CKD 1-5D and post-transplant, it reasonable to consider"
  },
  {
    "conteudo":"assessing body composition in combination with body weight\/BMI at the first visit"
  },
  {
    "conteudo":"and to monitor overall nutrition status periodically over time (OPINION)."
  },
  {
    "conteudo":"Page 35"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Frequency of Body Weight\/BMI and Body Composition Assessment"
  },
  {
    "conteudo":"1.1.5 In adults with CKD 1-5D and post-transplant who are clinically stable, it"
  },
  {
    "conteudo":"is reasonable measure body weight and BMI and to monitor for changes in body"
  },
  {
    "conteudo":"weight\/BMI and body composition as needed (OPINION)."
  },
  {
    "conteudo":"● At least Monthly in MHD and PD patients"
  },
  {
    "conteudo":"● At least every 3 months in stages 4-5 and post-transplant patients"
  },
  {
    "conteudo":"● At least every 6 months in stages 1-3 patients"
  },
  {
    "conteudo":"Assessment of Body Weight"
  },
  {
    "conteudo":"1.1.6 In adults with CKD 1-5D and post-transplant, it is reasonable for registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or an international equivalent or physicians to use"
  },
  {
    "conteudo":"clinical judgement to determine the method for measuring body weight (e.g. actual"
  },
  {
    "conteudo":"measured weight, history of weight changes, serial weight measurements,"
  },
  {
    "conteudo":"adjustments for suspected impact of edema, ascites and polycystic organs) due to"
  },
  {
    "conteudo":"absence of standard reference norms (OPINION)."
  },
  {
    "conteudo":"Body Mass Index (BMI) as a Predictor of Mortality"
  },
  {
    "conteudo":"1.1.7 In adults with CKD who are on PD, we suggest that underweight status"
  },
  {
    "conteudo":"(based on BMI) can be used as a predictor of higher mortality (2C)."
  },
  {
    "conteudo":"1.1.8 In adults with CKD who are on MHD, we suggest that overweight\/obese"
  },
  {
    "conteudo":"status (based on BMI) can be used as a predictor of lower mortality, whereas,"
  },
  {
    "conteudo":"underweight status and morbid obesity (based on BMI) can be used as a predictor of"
  },
  {
    "conteudo":"higher mortality (2B)."
  },
  {
    "conteudo":"1.1.9 In adults with CKD 1-5, it is reasonable to consider using underweight status"
  },
  {
    "conteudo":"(based on BMI) as a predictor of higher mortality, though the mortality risk"
  },
  {
    "conteudo":"associated with overweight or obesity status (based on BMI) is not clear"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"1.1.10 In adults with CKD post-transplant, it is reasonable to consider using"
  },
  {
    "conteudo":"underweight and overweight\/obesity status (based on BMI) as a predictor of higher"
  },
  {
    "conteudo":"mortality (OPINION)."
  },
  {
    "conteudo":"BMI and Protein Energy Wasting"
  },
  {
    "conteudo":"1.1.11 In adults with CKD 1-5D and post-transplant, BMI alone is not sufficient to"
  },
  {
    "conteudo":"establish a diagnosis of PEW unless the BMI is very low (<18 kg\/m2) (OPINION)."
  },
  {
    "conteudo":"Skinfold Thickness"
  },
  {
    "conteudo":"1.1.12 In adults with CKD 1-5D (1B) and post-transplant (OPINION), in the"
  },
  {
    "conteudo":"absence of edema, we suggest using skinfold thickness measurements to assess"
  },
  {
    "conteudo":"body fat."
  },
  {
    "conteudo":"Waist Circumference"
  },
  {
    "conteudo":"1.1.13 In adults with CKD 5D, we suggest that waist circumference may be used to"
  },
  {
    "conteudo":"assess abdominal obesity, but its reliability in assessing changes over time is low"
  },
  {
    "conteudo":"Page 36"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"(2C)."
  },
  {
    "conteudo":"Conicity Index"
  },
  {
    "conteudo":"1.1.14 In adults with CKD on MHD, we suggest that the conicity index may be used"
  },
  {
    "conteudo":"to assess nutritional status and as a predictor of mortality (2C)."
  },
  {
    "conteudo":"Creatinine Kinetics"
  },
  {
    "conteudo":"1.1.14 In adults with CKD 5D, we suggest that creatinine kinetics may be used"
  },
  {
    "conteudo":"to estimate muscle mass, though very high or very low dietary intake of meat"
  },
  {
    "conteudo":"and\/or creatine supplements will influence accuracy of this measurement (2C)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Methods of assessing body composition, including anthropometric measurements, are"
  },
  {
    "conteudo":"components of the nutrition assessment in CKD. Anthropometric measurements are"
  },
  {
    "conteudo":"practical, inexpensive and non-invasive techniques that describe body mass, size, shape, and"
  },
  {
    "conteudo":"levels of fatness and leanness; they are the most basic and indirect methods of assessing body"
  },
  {
    "conteudo":"composition. These include height, weight, skinfolds, circumferences, bioelectrical"
  },
  {
    "conteudo":"impedance analysis (BIA), creatinine kinetics and near infrared. Dual-energy X-ray"
  },
  {
    "conteudo":"absorptiometry (DXA) is a direct method that is considered the gold standard for assessing"
  },
  {
    "conteudo":"body composition in patients with CKD; however, this measure is labor intensive, invasive,"
  },
  {
    "conteudo":"expensive and can be influenced by a number of CKD related factors such as hydration"
  },
  {
    "conteudo":"status."
  },
  {
    "conteudo":"Timing of body composition assessments is important in CKD since assumptions of"
  },
  {
    "conteudo":"hydration are required for accurate interpretation of the results, and fluid\/electrolyte balance"
  },
  {
    "conteudo":"is likely to be altered significantly in CKD patients. For these reasons, in adults undergoing"
  },
  {
    "conteudo":"dialysis, assessments are best obtained after treatment when body fluid compartments levels"
  },
  {
    "conteudo":"are balanced.2, 3"
  },
  {
    "conteudo":"Regardless of the method selected to assess body composition, none are perfect, and the"
  },
  {
    "conteudo":"errors surrounding them should not be ignored. Errors may have clinical relevance,"
  },
  {
    "conteudo":"especially if the individual is treated and observed over time.3 Moreover, the results of the"
  },
  {
    "conteudo":"measures are only as useful as the availability of suitable reference data from a group of"
  },
  {
    "conteudo":"persons of at least the same age, race, gender and disease status."
  },
  {
    "conteudo":"Page 37"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Technical Devices to Measure Body Composition"
  },
  {
    "conteudo":"Multi-frequency bioelectrical impedance analysis (MF-BIA)"
  },
  {
    "conteudo":"Twelve studies reported on the use of MF-BIA to assess fat mass (FM) and fat free mass"
  },
  {
    "conteudo":"(FFM) in MHD, PD and pre-dialysis patients. Four of these studies were"
  },
  {
    "conteudo":"validity\/reliability studies: two in MHD patients;4, 5 one in PD patients;6 and one in pre-"
  },
  {
    "conteudo":"dialysis patients.7"
  },
  {
    "conteudo":"Three were prediction studies: two in MHD patients, and one in MHD and PD patients.8-10"
  },
  {
    "conteudo":"Eight were correlation studies; five in MHD patients;4, 6, 11-14one in PD patients; one in MHD"
  },
  {
    "conteudo":"and PD patients;15 and one in pre-dialysis patients.7"
  },
  {
    "conteudo":"MHD patients: FM and FFM measured by MF-BIA had good agreement with DEXA in two"
  },
  {
    "conteudo":"studies,4, 5 had high correlations with several markers of nutritional status in four studies,4, 13-"
  },
  {
    "conteudo":"15 and predicted hard outcomes in three studies.8-10 Furstenburg et al. concluded that MF-BIA"
  },
  {
    "conteudo":"was a more robust tool than DEXA for measuring body composition in MHD patients.5"
  },
  {
    "conteudo":"Donadio et al. found that MF-BIA yielded a smaller prediction error in MHD patients.4"
  },
  {
    "conteudo":"Body composition determined by MF-BIA was found to be predictive of hospitalization9"
  },
  {
    "conteudo":"and survival.8-10 In Rodriguez et al., BIA underestimated FM and overestimated FFM when"
  },
  {
    "conteudo":"compared with air displacement plethysmography in MHD patients.14 PEW determined by"
  },
  {
    "conteudo":"MF-BIA was positively related to BMI and negatively associated with serum albumin"
  },
  {
    "conteudo":"level.13 In Mancini et al., bioimpedance vector analysis was predicted by normalized protein"
  },
  {
    "conteudo":"catabolic rate (nPCR) and albumin in MHD patients with normal nutritional status, but the"
  },
  {
    "conteudo":"predictive effects were not accurate in undernourished patients.12 In MHD patients, a body"
  },
  {
    "conteudo":"protein index score calculated from MF-BIA protein mass and height significantly"
  },
  {
    "conteudo":"correlated with blood protein levels in men on MHD, but there was no relationship in"
  },
  {
    "conteudo":"women on MHD.15"
  },
  {
    "conteudo":"Page 38"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"PD patients: FM and FFM measured by MF-BIA showed wide limits of agreement with"
  },
  {
    "conteudo":"DEXA in 1 study, which was affected by hydration status,6 and was an independent risk"
  },
  {
    "conteudo":"factor for survival in another study.8 In CAPD patients, LBM measured by MF-BIA and"
  },
  {
    "conteudo":"creatinine kinetic method were highly correlated but there was no difference in LBM using"
  },
  {
    "conteudo":"BIA in patients with or without peritoneal dialysate.11 A body protein index score calculated"
  },
  {
    "conteudo":"from MF-BIA protein mass and height significantly correlated with blood protein levels in"
  },
  {
    "conteudo":"men on MHD, but there was no relationship in women on MHD or CAPD patients. The"
  },
  {
    "conteudo":"findings varied according to sex and dialysis treatment.15"
  },
  {
    "conteudo":"Pre-dialysis patients: In diabetic patients, % LBM measured by DEXA was greater than"
  },
  {
    "conteudo":"that predicted by BIA (p<0.05). Bland & Altman analysis demonstrated biases by BIA, but"
  },
  {
    "conteudo":"the mean of the results obtained by combined anthropometry and BIA demonstrated no bias"
  },
  {
    "conteudo":"from DEXA measurements.7"
  },
  {
    "conteudo":"Anthropometric and other measurements to measure body composition"
  },
  {
    "conteudo":"Skinfold measurements"
  },
  {
    "conteudo":"Ten studies reported on the use of skinfold measurements to assess body composition,"
  },
  {
    "conteudo":"including four agreement\/validity\/reliability studies,16-19 one prediction study20 and"
  },
  {
    "conteudo":"six correlation studies.17, 21-25"
  },
  {
    "conteudo":"MHD patients: Bross et al. used DEXA as the reference test and showed that, triceps"
  },
  {
    "conteudo":"skinfold thickness (TSF), BIA (Kushner), and near-infrared interactance were most accurate"
  },
  {
    "conteudo":"of the index tests in estimating total BF%, although the BIA (Segal) and BIA (Lukaski)"
  },
  {
    "conteudo":"equations overestimated total BF%.17 These results were not affected by skin color. In"
  },
  {
    "conteudo":"Bross et al., there were significant correlations (all p<0.001) between DEXA measurements"
  },
  {
    "conteudo":"and triceps skinfold measures of body fat in MHD participants.17 Kamimura et al. compared"
  },
  {
    "conteudo":"SKF with DEXA and BIA and found that body fat estimates using SKF and BIA were not"
  },
  {
    "conteudo":"significantly different from those obtained by DEXA in the total group.18 There were"
  },
  {
    "conteudo":"significant intra-class correlations between DEXA with SKF (r=0.94) and BIA (r=0.91)."
  },
  {
    "conteudo":"DEXA showed relatively good agreement with both SKF [0.47 ±2.8 (-5.0 to 6.0) kg] and"
  },
  {
    "conteudo":"BIA [0.39 ±3.3 (-6.9 to 6.1) kg] in the total group, but BIA showed greater mean prediction"
  },
  {
    "conteudo":"error for both men and women. This study indicated that SKF was preferable over BIA,"
  },
  {
    "conteudo":"Page 39"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"which showed gender-specific variability in the assessment of body fat."
  },
  {
    "conteudo":"A prediction study by Araujo et al. showed that TSF <90% was not associated with higher"
  },
  {
    "conteudo":"odds of mortality.20 Oe et al. in MHD patients found a significant correlation in LBM"
  },
  {
    "conteudo":"(r=0.69, p<0.025) between four skinfold anthropometry and BIA. BF-FSA was positively"
  },
  {
    "conteudo":"correlated with BF-BIA (r=0.65, p<0.005).24 Both techniques are comparable for LBM and"
  },
  {
    "conteudo":"BF measurements; however, four site skinfold anthropometry (FSA) is less affected by"
  },
  {
    "conteudo":"change in fluid status. Malnutrition score was significantly correlated with bicep skinfolds"
  },
  {
    "conteudo":"(r= -0.32) in MHD patients in a study by Kalantar-Zadeh et al.22 Aatif et al. showed that fat"
  },
  {
    "conteudo":"tissue index and TSF had a positive significant correlation (r=0.61, p<0.001).21 Kamimura et"
  },
  {
    "conteudo":"al. found a strong correlation between BIA and SKF (r=0.87) and near-infrared interactance"
  },
  {
    "conteudo":"and SKF (r=0.78).18 This study confirmed that the most simple, long-established, and"
  },
  {
    "conteudo":"inexpensive method of SFT is very useful for assessing body fat in patients on long-term"
  },
  {
    "conteudo":"MHD therapy."
  },
  {
    "conteudo":"PD patients: Stall et al. examined five different tools to assess BF%. BF% measurements"
  },
  {
    "conteudo":"were different between all methods (p<0.001), although there were differences according to"
  },
  {
    "conteudo":"sex.25For men, all techniques were significantly different from each other (p<0.05) except"
  },
  {
    "conteudo":"BIA and DEXA, as well as the Steinkamp method (SKF) and total body potassium. For"
  },
  {
    "conteudo":"women, all techniques were significantly different from each other (p<0.05) except DEXA"
  },
  {
    "conteudo":"and the two methods for measuring SKF (Durnin & Womersley and Steinkamp). Despite the"
  },
  {
    "conteudo":"differences between modalities, all techniques were found to correlate significantly with"
  },
  {
    "conteudo":"each other (p<0.01 or better for men and p<0.001 or better for women)."
  },
  {
    "conteudo":"HD and PD patients: Woodrow et al. compared SKF with DEXA and BIA.19 Bland & Altman"
  },
  {
    "conteudo":"analysis demonstrated no observed differences in 95% levels of agreement for percent total"
  },
  {
    "conteudo":"body fat (TBF) and FFM from SF-BIA or skinfold anthropometry (SFA)compared with"
  },
  {
    "conteudo":"DEXA (%TBF BIA-DEXA -13.7 to +8.3; %TBF SFA-DEXA -13.0 to +9.4%; FFM BIA-"
  },
  {
    "conteudo":"DEXA -5.1 to +9.6 kg; FFM SFA-DEXA -5.6 to +9.1 kg). There were considerable variations"
  },
  {
    "conteudo":"in agreement between the measures."
  },
  {
    "conteudo":"Pre-dialysis patients: Avesani et al. used a Bland-Altman plot analysis for body fat% and"
  },
  {
    "conteudo":"showed that the best agreement was between SKF and DEXA compared to other"
  },
  {
    "conteudo":"Page 40"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"measures.16 SKF also had significant intraclass correlations with body fat% and it"
  },
  {
    "conteudo":"significantly correlated with FFM as measured by DEXA (r=0.74, r=0.85) indicating"
  },
  {
    "conteudo":"moderate and good reproducibility, respectively. This study indicated that SKF may be a"
  },
  {
    "conteudo":"good method to determine body fat% in pre-dialysis, and mild to advanced CKD patients."
  },
  {
    "conteudo":"Serum Creatinine\/Creatinine Kinetics"
  },
  {
    "conteudo":"Seven studies examined the relationship between serum creatinine or creatinine kinetics"
  },
  {
    "conteudo":"and comparative measures of muscle mass in MHD, PD and pre-dialysis patients."
  },
  {
    "conteudo":"MHD patients: One study in MHD patients showed that creatinine kinetics correlated with"
  },
  {
    "conteudo":"creatinine levels, and other traditional measures of muscle mass (e.g. CT scan,"
  },
  {
    "conteudo":"anthropometric measurements).26 Another three studies in MHD patients showed that pre-"
  },
  {
    "conteudo":"dialysis, inter- dialytic change, and weekly creatinine clearance levels predicted mortality.26-"
  },
  {
    "conteudo":"28"
  },
  {
    "conteudo":"PD patients: In PD patients, creatinine kinetics was correlated with other body composition"
  },
  {
    "conteudo":"measurements in one study;29 however, significant differences existed between creatinine and"
  },
  {
    "conteudo":"anthropometric measures for LBM\/FFM in another.30 A study in PD examined creatinine"
  },
  {
    "conteudo":"clearance and relative risk of mortality.31 Evidence was limited in pre-dialysis patients to one"
  },
  {
    "conteudo":"study.16 CK was significantly correlated with BF% and FFM from DEXA (r=0.47 and"
  },
  {
    "conteudo":"r=0.57, respectively, indicating moderate reproducibility, though there were significant"
  },
  {
    "conteudo":"differences in adjusted means of BF% and FFM between CK and DEXA (p<0.05).16"
  },
  {
    "conteudo":"Waist circumference"
  },
  {
    "conteudo":"Two studies reported on the use of waist circumference to assess nutritional status in"
  },
  {
    "conteudo":"dialysis patients.32, 33"
  },
  {
    "conteudo":"MHD patients: Cordeiro et al. examined risk of PEW, inflammation and mortality according"
  },
  {
    "conteudo":"to waist circumference tertile in MHD patients. As waist circumference increased, indicating"
  },
  {
    "conteudo":"increased abdominal fat, patients had increased odds of PEW (assessed by SGA) and"
  },
  {
    "conteudo":"inflammation (assessed by IL-6). In the fully adjusted model, there was no increased risk of"
  },
  {
    "conteudo":"mortality according to waist circumference tertile.33"
  },
  {
    "conteudo":"Page 41"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"PD patients: Bazanelli et al. found a strong correlation between waist circumference and"
  },
  {
    "conteudo":"trunk fat (r=0.81, p<0.001) for both men and women, and a significant association with BMI"
  },
  {
    "conteudo":"(r=0.86, p<0.001).32 There was a moderate agreement between waist circumference and trunk"
  },
  {
    "conteudo":"fat (kappa=0.59) and area under the curve was 0.90. In a prospective evaluation of the same"
  },
  {
    "conteudo":"study, changes in waist circumference was also correlated with changes in trunk fat (r=0.49,"
  },
  {
    "conteudo":"p<0.001) and kappa of 0.48 indicated a moderate agreement between the tools. The authors"
  },
  {
    "conteudo":"concluded that waist circumference is a reliable marker of abdominal adiposity in PD"
  },
  {
    "conteudo":"patients."
  },
  {
    "conteudo":"BMI"
  },
  {
    "conteudo":"Twenty-four studies reported on the use of BMI to assess nutritional status, including 17"
  },
  {
    "conteudo":"prediction studies20, 27, 34-48 and nine correlation studies.15, 17, 21, 41, 49-53 There were no"
  },
  {
    "conteudo":"studies examining validity or reliability of using BMI in this population to classify"
  },
  {
    "conteudo":"nutritional status."
  },
  {
    "conteudo":"MHD patients: Eight studies examined MHD patients only. Seven studies examined"
  },
  {
    "conteudo":"mortality risk according to BMI category. In three studies,35, 47, 48 the authors examined"
  },
  {
    "conteudo":"mortality risk according to traditional weight categories (underweight, normal weight,"
  },
  {
    "conteudo":"overweight and obese), although in a study with Taiwanese participants,48 these categories"
  },
  {
    "conteudo":"were defined differently. In five additional studies, the authors examined risk according to 5"
  },
  {
    "conteudo":"to 11 BMI categories.34, 38, 40, 54, 55"
  },
  {
    "conteudo":"In one study that only compared two groups (< or >25 kg\/m2), the authors found no"
  },
  {
    "conteudo":"association between BMI and mortality at 10 years.20 However, in the remaining studies in"
  },
  {
    "conteudo":"which BMI was examined according to traditional weight status groups or by 5 to 11"
  },
  {
    "conteudo":"categories, there was consistently a higher risk of mortality for participants who were"
  },
  {
    "conteudo":"underweight, and lower risk for participants who were overweight or obese.34, 35, 38, 40, 47, 48"
  },
  {
    "conteudo":"Length of follow-up for these studies ranged from 1.34 to 10 years. There was an inverse"
  },
  {
    "conteudo":"relationship with mortality when BMI was measured as a continuous variable in three"
  },
  {
    "conteudo":"studies,40, 46, 47 but Harell’s C statistic was not significant in de Roij van Zuijdewijn et al.27"
  },
  {
    "conteudo":"Findings from correlation studies indicated that BMI was positively associated with"
  },
  {
    "conteudo":"albumin levels, fat and lean body mass (LBM) measured by a variety of methods in HD"
  },
  {
    "conteudo":"Page 42"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"patients. Beberashvili et al. showed that serum albumin was significantly and positively"
  },
  {
    "conteudo":"correlated with BMI and FM in MHD patients.49 The higher BMI group had greater LBM"
  },
  {
    "conteudo":"(p=0.001) and FM (p=0.0001), and higher phase angle and Extracellular Mass\/Body Cell"
  },
  {
    "conteudo":"Mass (p<0.05). MHD patients with elevated BMI demonstrate better nutritional status"
  },
  {
    "conteudo":"compared to normal BMI or overweight patients. Severity of inflammation was not related"
  },
  {
    "conteudo":"to BMI in MHD patients."
  },
  {
    "conteudo":"Bross et al. indicated that BMI had a strong linear correlation with total body fat percentage"
  },
  {
    "conteudo":"measured by near infrared radiation and BIA (Segal) (r ≥ 0.85) in MHD patient.17 Fat tissue"
  },
  {
    "conteudo":"index, as estimated by BIA, was significantly correlated with BMI in the study by Aatif et"
  },
  {
    "conteudo":"al.21 In another study, Kadiri et al. showed that BMI was positively correlated with FM"
  },
  {
    "conteudo":"(r=0.493, p=0.002), serum albumin (r=0.340, p=0.04), and anemia in MHD patients.50 BMI"
  },
  {
    "conteudo":"was negatively correlated with CRP (r=-0.065, p=0.702) but had no correlation with LBM"
  },
  {
    "conteudo":"(r=0.278, p=0.085). Kahraman et al. studied the relationship between CRP and BMI status"
  },
  {
    "conteudo":"and found that CRP levels were significantly higher in obese and underweight MHD"
  },
  {
    "conteudo":"patients compared with normal and overweight patients (p<0.05).51"
  },
  {
    "conteudo":"Steiber et al. found that mean BMI was significantly different across the 5 categories of"
  },
  {
    "conteudo":"SGA (p<0.05) in MHD patients.52 Visser et al. demonstrated that there was a strong"
  },
  {
    "conteudo":"correlation between the 7-point SGA scale and BMI in MHD patients (r=0.79, p<0.001), %"
  },
  {
    "conteudo":"fat (r=0.77, p<0.001).53"
  },
  {
    "conteudo":"MHD and PD patients: Three studies reported on the relationship between BMI and"
  },
  {
    "conteudo":"mortality in a combination of MHD and PD patients (Badve et al. reported results for MHD"
  },
  {
    "conteudo":"and PD patients separately). In Mathew et al., participants who survived had higher baseline"
  },
  {
    "conteudo":"BMIs compared to the group that did not survive, but BMI category was not a significant"
  },
  {
    "conteudo":"predictor.44 Hoogeveen et al. demonstrated that underweight and obesity were risk factors in"
  },
  {
    "conteudo":"a combination of MHD\/PD patients less than 65 years of age, but for those who were at"
  },
  {
    "conteudo":"least 65, there was no relationship between BMI and mortality.37 Lievense et al."
  },
  {
    "conteudo":"demonstrated that PD patients had lower mortality risk compared to MHD patients.42Leinig"
  },
  {
    "conteudo":"et al. showed that there was a positive correlation between BMI and FM in predialysis"
  },
  {
    "conteudo":"(r=0.67, p=0.0002), in MHD (r= 0.67, p=0.0002), and peritoneal dialysis (r=0.79, p<0.0001)"
  },
  {
    "conteudo":"patients.41 Nakao et al. indicated that BMI was significantly correlated with BPI in MHD"
  },
  {
    "conteudo":"Page 43"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"and PD patients (r values ranging from 0.778 to 0.886, p<0.0001).15 Hoogeveen et al."
  },
  {
    "conteudo":"followed dialysis patients < or ≥65 years of age for seven years. In the multivariable"
  },
  {
    "conteudo":"adjusted model, compared to those with “normal” weight status, those who were"
  },
  {
    "conteudo":"categorized as underweight (2.00 (1.30-3.07) and obese (1.57 (1.08-2.28) had a significantly"
  },
  {
    "conteudo":"higher hazard of mortality for those who were <65 years, but there was no significant"
  },
  {
    "conteudo":"relationship between weight status and mortality for those ≥65 years of age. 37"
  },
  {
    "conteudo":"PD patients: Four studies reported on the relationship between BMI and mortality in PD"
  },
  {
    "conteudo":"patients. Badve et al. found that underweight increased mortality risk at 2.3 years, but results"
  },
  {
    "conteudo":"regarding higher BMI categories were not consistent.34 Leinig et al. found no difference in"
  },
  {
    "conteudo":"mortality risk according to whether PD patients had a BMI < or >23 kg\/m2 at 2 years.41"
  },
  {
    "conteudo":"McDonald et al. found that, in adjusted analysis, PD patients who were obese had higher"
  },
  {
    "conteudo":"risk of mortality (up to 10 years) compared to patients with normal weight status.45 In the"
  },
  {
    "conteudo":"study by Kim et al., the group with the lowest quartile of BMI had the highest mortality risk"
  },
  {
    "conteudo":"at 2 years, but there were no other significant associations 39 In a systematic review"
  },
  {
    "conteudo":"performed by Ahmadi et al., authors confirmed an increased risk of 1 year mortality for"
  },
  {
    "conteudo":"people with CKD who were underweight, but this relationship did not persist for 2, 3 and 5"
  },
  {
    "conteudo":"year mortality. Conversely, Ahmadi et al. found that overweight\/obesity status decreased"
  },
  {
    "conteudo":"mortality risk at 1, but not 2, 3 or 5 years.56"
  },
  {
    "conteudo":"Non-dialyzed patients: Finally, two studies examined the relationship between BMI and"
  },
  {
    "conteudo":"mortality in non-dialyzed CKD patients. Madero, et al. examined risk according to BMI"
  },
  {
    "conteudo":"quartile and found no relationship.43, 57 Hanks et al. took a different approach and examined"
  },
  {
    "conteudo":"risk not only according to traditional BMI categories, but also according to whether"
  },
  {
    "conteudo":"participants were metabolically healthy.36 Of those who were metabolically healthy, there"
  },
  {
    "conteudo":"was decreased risk for overweight\/obese participants compared to those with a normal BMI."
  },
  {
    "conteudo":"However, there was no difference in mortality risk according to weight status in those who"
  },
  {
    "conteudo":"were metabolically unhealthy. These findings were consistent with a systematic review by"
  },
  {
    "conteudo":"Ahmadi et al. 57"
  },
  {
    "conteudo":"Post-transplant patients: A systematic review by Ahmadi et al. examined the relationship"
  },
  {
    "conteudo":"between BMI and mortality in 150,000+ adults with CKD with kidney transplant. Authors"
  },
  {
    "conteudo":"conclude that, compared to participants with “normal” weight status at baseline, those who"
  },
  {
    "conteudo":"were underweight [HR (95% CI): 1.09 (1.02, 1.20)] or overweight\/obese [1.20 (1.14, 1.23)]"
  },
  {
    "conteudo":"Page 44"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"were at increased hazard of mortality.58"
  },
  {
    "conteudo":"Near Infrared:"
  },
  {
    "conteudo":"Evidence examining the validity of near infrared radiation (NIR) as a measure of body"
  },
  {
    "conteudo":"composition was too limited to make recommendations."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"The guidelines for MF-BIA, DEXA and skinfold measurements require specialized"
  },
  {
    "conteudo":"equipment. Good quality calipers are needed to obtain an accurate measurement of SKF."
  },
  {
    "conteudo":"However, the measurer must be trained in order to obtain accurate results. To obtain waist"
  },
  {
    "conteudo":"circumference, only a measuring tape is required. Once again, the measurer must be trained"
  },
  {
    "conteudo":"on how to obtain this measure. MF-BIA is becoming more widely available as the"
  },
  {
    "conteudo":"technology advances. However, training is needed to understand and to appropriately"
  },
  {
    "conteudo":"interpret the output from the device."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"MF-BIA"
  },
  {
    "conteudo":"● The guideline for MF-BIA applies to all adult patients receiving MHD. The"
  },
  {
    "conteudo":"measure must be obtained post-dialysis on a non-conducting surface for an accurate"
  },
  {
    "conteudo":"assessment."
  },
  {
    "conteudo":"● When bioimpedance is performed in patients on PD, measurements should be"
  },
  {
    "conteudo":"done with an empty abdominal cavity (following PD fluid drainage) and bladder."
  },
  {
    "conteudo":"For individuals on MHD with residual kidney function, bladder should be empty."
  },
  {
    "conteudo":"● There are no potential risks or harms associated with the application of the guideline"
  },
  {
    "conteudo":"for MF-BIA in adult patients receiving MHD."
  },
  {
    "conteudo":"BMI"
  },
  {
    "conteudo":"● BMI is not an ideal marker of obesity, since it cannot differentiate between"
  },
  {
    "conteudo":"higher weights due to increased adiposity vs. muscularity and it cannot identify"
  },
  {
    "conteudo":"visceral adiposity, which has negative metabolic effects."
  },
  {
    "conteudo":"• To ensure accuracy of BMI, height should be measured periodically."
  },
  {
    "conteudo":"● There are no potential risks or harms associated with the application of the guideline"
  },
  {
    "conteudo":"Page 45"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"for BMI."
  },
  {
    "conteudo":"● The standard weight status categories that have been defined by the WHO according"
  },
  {
    "conteudo":"to BMI ranges for adults should be used in the CKD population; these include <18.5"
  },
  {
    "conteudo":"kg\/m2 for underweight; 18.5 to 24.9 kg\/m2 for normal weight; 25.0 to 29.9 kg\/m2 for"
  },
  {
    "conteudo":"overweight; and ≥30 kg\/m2 for obese. Population-specific BMI cut-offs to define"
  },
  {
    "conteudo":"weight status may be lower for Asian populations."
  },
  {
    "conteudo":"• Limited evidence suggested that obesity (BMI ≥30 kg\/m2) may be a risk factor for"
  },
  {
    "conteudo":"higher mortality in individuals who are on dialysis and under the age of 65."
  },
  {
    "conteudo":"Therefore, practitioners should consider patient age when determining mortality risk"
  },
  {
    "conteudo":"according to BMI."
  },
  {
    "conteudo":"• In patients on dialysis, weight to calculate BMI should be measured following"
  },
  {
    "conteudo":"dialysis treatment to improve accuracy."
  },
  {
    "conteudo":"Skinfold measurements"
  },
  {
    "conteudo":"● The guideline for skinfold measurements apply to all adult CKD patients,"
  },
  {
    "conteudo":"including post-transplant. However, for the measurements to be useful to the"
  },
  {
    "conteudo":"practitioner, longitudinal assessments must be done to provide meaningful"
  },
  {
    "conteudo":"information about changes in percent body fat for that patient."
  },
  {
    "conteudo":"● There are no potential risks or harms associated with the application of the guideline"
  },
  {
    "conteudo":"for skinfold measurements in all adult CKD patients."
  },
  {
    "conteudo":"● Skinfold measurements may not be accurate for obese patients, since calipers may"
  },
  {
    "conteudo":"have upper limits that do not accommodate high levels of adiposity."
  },
  {
    "conteudo":"Creatinine kinetics"
  },
  {
    "conteudo":"● The guideline for using creatinine kinetics to measure muscle mass applies to all adult"
  },
  {
    "conteudo":"CKD patients. However, the procedure requires the patient to collect his\/her urine for"
  },
  {
    "conteudo":"a 24-hour period and, preferably, to keep the collection on ice, which may make the"
  },
  {
    "conteudo":"procedure inconvenient for some patients. Furthermore, intake of meat or protein"
  },
  {
    "conteudo":"supplements containing creatine may contribute to urine creatinine excretion and this"
  },
  {
    "conteudo":"must be considered when calculating creatinine kinetics. In MHD patients, creatinine"
  },
  {
    "conteudo":"kinetics is more useful for patients who are anuric."
  },
  {
    "conteudo":"● There are no potential risks or harms associated with the application of the guideline"
  },
  {
    "conteudo":"Page 46"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"for creatinine kinetics in adult CKD patients."
  },
  {
    "conteudo":"Dual energy x-ray absorptiometry"
  },
  {
    "conteudo":"● DEXA is a valid technique for measuring body composition in adult CKD"
  },
  {
    "conteudo":"patients, including post-transplant patients. In MHD and PD patients, this is"
  },
  {
    "conteudo":"despite the measurement being influenced by over-hydration."
  },
  {
    "conteudo":"● DEXA is associated with very small amounts of radiation and this should be"
  },
  {
    "conteudo":"considered when weighing benefits and risks of this method for a particular"
  },
  {
    "conteudo":"individual. Ten screenings with DEXA results in a similar amount of radiation"
  },
  {
    "conteudo":"exposure as one chest x-ray."
  },
  {
    "conteudo":"Measuring body weight"
  },
  {
    "conteudo":"When using published weight norms in the anthropometric assessment of adult CKD"
  },
  {
    "conteudo":"patients, caution must be use as each norm has significant drawbacks."
  },
  {
    "conteudo":"● Ideal body weight (IBW) is the body weight associated with the lowest mortality for"
  },
  {
    "conteudo":"a given height, age, sex and frame size and is based on the Metropolitan Life"
  },
  {
    "conteudo":"Insurance Height and Weight Tables. [Caution: Not generalizable to the CKD"
  },
  {
    "conteudo":"population and data-gathering methods were not standardized.]"
  },
  {
    "conteudo":"● Hamwi method can be used to estimate LBM. [Caution: A quick and easy method"
  },
  {
    "conteudo":"for determining optimal body weight but has no scientific data to support its use.]"
  },
  {
    "conteudo":"● Standard Body Weight, NHANES II (SBW as per KDOQI Nutrition Practice"
  },
  {
    "conteudo":"Guidelines) describes the median body weight of average Americans from 1976 to"
  },
  {
    "conteudo":"1980 for height, age, sex and frame size. [Caution: Although data is validated and"
  },
  {
    "conteudo":"standardized and uses a large database of ethnically diverse groups, data is"
  },
  {
    "conteudo":"provided only on what individuals weigh, not what they should weigh in order to"
  },
  {
    "conteudo":"reduce morbidity and mortality.]"
  },
  {
    "conteudo":"● BMI often defines generalized obesity and CKD research, specific to dialysis patients,"
  },
  {
    "conteudo":"has identified that patients at higher BMIs have a lower mortality risk. [Caution: The"
  },
  {
    "conteudo":"researchers may not have statistically adjusted for all confounders related to"
  },
  {
    "conteudo":"comorbid conditions occurring in CKD on dialysis (diabetes, malignancy, etc.) and it"
  },
  {
    "conteudo":"is unclear how it may relate to CKD patients not on dialysis.]"
  },
  {
    "conteudo":"● Adjusted Body Weight is based on the theory that 25% of the excess body weight"
  },
  {
    "conteudo":"Page 47"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"(adipose tissue) in obese patients is metabolically active tissue. [Caution: This has"
  },
  {
    "conteudo":"not been validated for use in CKD and may either overestimate or underestimate"
  },
  {
    "conteudo":"energy and protein requirements.]"
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"● Anthropometric measurements for assessment of body composition should be done"
  },
  {
    "conteudo":"routinely in CKD patients; these include skinfold measurements, waist"
  },
  {
    "conteudo":"circumference and creatinine kinetics."
  },
  {
    "conteudo":"● BMI should be used routinely to assess weight status in CKD patients since it is"
  },
  {
    "conteudo":"useful in predicting mortality. However, in isolation, BMI is not sufficient to"
  },
  {
    "conteudo":"establish a diagnosis of PEW unless it is very low (<18 kg\/m2)"
  },
  {
    "conteudo":"● However, because of the cost associated with some of these measures (e.g., MF-"
  },
  {
    "conteudo":"BIA, DEXA), there is insufficient evidence for the workgroup to suggest the use of"
  },
  {
    "conteudo":"these measurements on a routine basis in clinical practice."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"MF-BIA"
  },
  {
    "conteudo":"● Determine the frequency with which MF-BIA measurements should be performed in"
  },
  {
    "conteudo":"CKD patients, particularly in individuals who are non-dialyzed, on PD or post-"
  },
  {
    "conteudo":"transplant."
  },
  {
    "conteudo":"● Determine the validity and reliability of these measurements compared to DEXA"
  },
  {
    "conteudo":"and anthropometric markers of nutritional status in PD, post-transplant and pre-"
  },
  {
    "conteudo":"dialysis patients."
  },
  {
    "conteudo":"BMI"
  },
  {
    "conteudo":"● Examine the predictive value of BMI with mortality and other markers of nutritional"
  },
  {
    "conteudo":"status in maintenance dialysis patients of different racial and ethnic backgrounds."
  },
  {
    "conteudo":"● Determine whether the BMI categories for dialysis patients are similar to the general"
  },
  {
    "conteudo":"population."
  },
  {
    "conteudo":"Creatinine kinetics"
  },
  {
    "conteudo":"● Determine the frequency with which creatinine kinetics should be measured and"
  },
  {
    "conteudo":"monitored."
  },
  {
    "conteudo":"Page 48"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Skinfold measurements"
  },
  {
    "conteudo":"● Determine the frequency with which skinfold measurements should be measured and"
  },
  {
    "conteudo":"monitored in the CKD population."
  },
  {
    "conteudo":"● Obtain a reference data set for maintenance dialysis patients of the same age, race and"
  },
  {
    "conteudo":"gender."
  },
  {
    "conteudo":"Waist circumference"
  },
  {
    "conteudo":"● Determine the frequency with which waist circumference should be measured and"
  },
  {
    "conteudo":"monitored in the CKD population."
  },
  {
    "conteudo":"● Obtain a reference data set for maintenance dialysis patients of the same age, race and"
  },
  {
    "conteudo":"gender."
  },
  {
    "conteudo":"Page 49"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.2 Statements on Assessment with Laboratory Measurements"
  },
  {
    "conteudo":"Single Biomarker Measurements"
  },
  {
    "conteudo":"1.2.1 In adults with CKD stages 1-5D and post-transplant, biomarkers such as"
  },
  {
    "conteudo":"normalized protein catabolic rate (nPCR), normalized protein catabolic rate (nPCR),"
  },
  {
    "conteudo":"serum albumin and\/or serum prealbumin may be considered complementary tools to"
  },
  {
    "conteudo":"assess nutritional status. However, they should not be interpreted in isolation to assess"
  },
  {
    "conteudo":"nutritional status as they are influenced by non-nutritional factors (OPINION)."
  },
  {
    "conteudo":"Serum Albumin Levels"
  },
  {
    "conteudo":"1.2.2 In adults with CKD on maintenance dialysis, serum albumin"
  },
  {
    "conteudo":"may be used as a predictor of hospitalization and mortality, with lower levels associated"
  },
  {
    "conteudo":"with higher risk (1A)."
  },
  {
    "conteudo":"Background\/ Rationale"
  },
  {
    "conteudo":"Assessments of nutritional status in patients with CKD have traditionally relied upon"
  },
  {
    "conteudo":"biochemical or other related calculated indices such as serum albumin, prealbumin, and"
  },
  {
    "conteudo":"normalized protein catabolic rate (nPCR) as diagnostic tools. Albumin is a major circulating"
  },
  {
    "conteudo":"protein that plays a number of biologic roles, such as maintaining osmotic pressure and"
  },
  {
    "conteudo":"transporting a variety of molecules. Serum prealbumin, also known as transthyretin, is another"
  },
  {
    "conteudo":"circulating protein produced by the liver with a shorter half-life than albumin, it is therefore"
  },
  {
    "conteudo":"more sensitive to rapid changes in nutritional status. nPCR is a common tool used to estimate"
  },
  {
    "conteudo":"protein intake and is calculated using the intradialytic rise in the blood urea nitrogen in MHD"
  },
  {
    "conteudo":"patients and from urinary urea from 24-hour urine collection in on-dialyzed CKD patients."
  },
  {
    "conteudo":"The advantages of such markers include the fact that they are easily quantifiable and available"
  },
  {
    "conteudo":"for each patient. However, these markers are known to be heavily influenced by inflammation,"
  },
  {
    "conteudo":"illness, liver failure, volume expansion and urinary or dialysate protein losses (or in the case"
  },
  {
    "conteudo":"of nPCR, protein balance and other factors). In fact, serum albumin is one of the best"
  },
  {
    "conteudo":"predictors of illness or death in patients with ESRD. In light of this, their utility in assessing"
  },
  {
    "conteudo":"nutritional status has been re-evaluated in recent years. Existing data suggest that such"
  },
  {
    "conteudo":"markers are not sufficiently reliable or valid to use in isolation for assessing nutritional status."
  },
  {
    "conteudo":"Instead, it should be used as part of a more comprehensive and inclusive evaluation as used"
  },
  {
    "conteudo":"for screening purposes."
  },
  {
    "conteudo":"Page 50"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Serum Albumin"
  },
  {
    "conteudo":"Sixteen observational studies that compared serum albumin concentration to other methods"
  },
  {
    "conteudo":"used to assess nutritional status, including twelve studies with MHD patients, two studies with"
  },
  {
    "conteudo":"PD patients, and two studies with both MHD and PD patients were included in this review"
  },
  {
    "conteudo":"MHD patients: Among the MHD studies, one was a prospective cohort study,27 two were"
  },
  {
    "conteudo":"retrospective cohort studies,20, 59 seven were cross-sectional studies.21, 49, 50, 60-63 Two"
  },
  {
    "conteudo":"studies were diagnostic validity or reliability studies.12, 64"
  },
  {
    "conteudo":"Gurreebun et al. determined that serum albumin concentration was a sensitive method for"
  },
  {
    "conteudo":"identifying patients at risk of PEW defined by the 7-point SGA score.64 In a study by Mancini,"
  },
  {
    "conteudo":"et al., albumin independently predicted bioimpedance vector analysis in patients with normal"
  },
  {
    "conteudo":"values of other nutritional indexes, but the association was not significant in with patients with"
  },
  {
    "conteudo":"worse nutritional values.12 Araujo et al. demonstrated that serum albumin concentration <3.5"
  },
  {
    "conteudo":"g\/dL were associated with higher odds of mortality over 10 years [OR (95%CI) = 2.34 (1.33-"
  },
  {
    "conteudo":"4.10); p=0.002].20 Campbell et al. found that low albumin concentration (<38 g\/L) were"
  },
  {
    "conteudo":"significantly associated with higher mortality and morbidity (length of hospital stay), but there"
  },
  {
    "conteudo":"was no adjustment for comorbidities.20, 59 De Roij van Zuijdewijn et al. determined that albumin"
  },
  {
    "conteudo":"concentration predicted all-cause mortality and was the most predictive of 8 other nutrition"
  },
  {
    "conteudo":"measures.27"
  },
  {
    "conteudo":"In Yelken et al., serum albumin concentration were significantly correlated with high"
  },
  {
    "conteudo":"sensitivity C-reactive protein (hsCRP), tricep skinfold, mid-arm circumference, and mid-arm"
  },
  {
    "conteudo":"muscle circumference (MAMC). 63 Serum albumin concentration were associated with nPCR"
  },
  {
    "conteudo":"and inflammatory markers;60, 62 BMI;50 7-point SGA score;61 and lean tissue index, but not fat"
  },
  {
    "conteudo":"tissue index from bioimpedance spectroscopy21 BMI and FM.49"
  },
  {
    "conteudo":"PD patients: Of the two studies in PD, one was a prospective cohort study 31 and the other was"
  },
  {
    "conteudo":"a retrospective cohort study.65 Leinig et al. demonstrated that hypoalbuminemia was a"
  },
  {
    "conteudo":"significant independent predictor of mortality [HR (95% CI): 2.3 (1.1-5.0) ] after 24 months of"
  },
  {
    "conteudo":"Page 51"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"follow-up.65 Churchill et al. described that for every g\/L increase in serum albumin, there was a"
  },
  {
    "conteudo":"2-year relative mortality risk (95% CI) of 0.94 (0.90, 0.97).31"
  },
  {
    "conteudo":"MHD and PD patients: Both MHD and PD patients were evaluated in two prospective cohort"
  },
  {
    "conteudo":"studies.44, 66 Mathew et al. found that serum albumin concentration did not predict mortality"
  },
  {
    "conteudo":"and was not correlated with lean tissue index.44 De Mutsert et al demonstrated a 1g\/dL"
  },
  {
    "conteudo":"decrease in serum albumin was associated with an increased mortality risk of 47% in MHD"
  },
  {
    "conteudo":"patients and 38% in PD patients.66 After adjusting for systemic inflammation, or for SGA and"
  },
  {
    "conteudo":"nPCR, these mortality risk ratios were not statistically significant indicating potential"
  },
  {
    "conteudo":"confounding effects of systemic inflammation."
  },
  {
    "conteudo":"In summary, one study showed that serum albumin concentration was a sensitive measure of"
  },
  {
    "conteudo":"nutritional status defined by 7-point SGA scores in MHD patients. Seven studies indicated"
  },
  {
    "conteudo":"that serum albumin was associated with other common markers of nutritional status in MHD"
  },
  {
    "conteudo":"patients. The preponderance of evidence suggested that lower serum albumin concentration"
  },
  {
    "conteudo":"predicts mortality in both MHD and PD patients."
  },
  {
    "conteudo":"Inflammatory Markers"
  },
  {
    "conteudo":"There were no studies examining the validity and\/or reliability of utilizing inflammatory"
  },
  {
    "conteudo":"markers to measure nutritional status. Thirteen studies examined correlations between"
  },
  {
    "conteudo":"inflammatory markers and other nutrition indices, including seven studies in MHD patients,"
  },
  {
    "conteudo":"one study in PD patients, two studies in both MHD and PD patients, one study in patients with"
  },
  {
    "conteudo":"kidney transplant, and two studies in pre-dialysis patients."
  },
  {
    "conteudo":"MHD patients: Among the MHD studies, all seven were cross-sectional studies.49-51, 60, 62, 63, 67"
  },
  {
    "conteudo":"hsCRP levels were positively associated with FM;67 and negatively associated with LBM,67"
  },
  {
    "conteudo":"serum albumin 60, 62, 63, 68and serum prealbumin62 concentrations. hsCRP was not associated"
  },
  {
    "conteudo":"with SGA score, nPCR, anthropometric indices, or BIA measurements.67 While CRP was not"
  },
  {
    "conteudo":"associated with BMI in Vannini et al.,67 there was a negative correlation in Kadiri et al.50"
  },
  {
    "conteudo":"Kahraman et al. found that CRP levels were highest in obese and underweight participants"
  },
  {
    "conteudo":"compared to their counterparts.51 Beberashvili et al. found no relationship between"
  },
  {
    "conteudo":"proinflammatory cytokine level and BMI.49"
  },
  {
    "conteudo":"Page 52"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"PD patients: de Araujo Antunes et al. conducted a cross-sectional study in PD patients."
  },
  {
    "conteudo":"Compared to patients with CRP level <1 mg\/dL, those with CRP level ≥1 mg\/dL had higher"
  },
  {
    "conteudo":"BMI (29.4 ± 6.1 vs. 24.4 ± 4.5 kg\/m ; p=0.009), % standard body weight (124.5 ± 25.4 vs."
  },
  {
    "conteudo":"106.8 ± 17.9 %; p=0.012), and % BF measured by SF-BIA (38.9 ± 6.3 vs. 26.2 ± 12.6 %;"
  },
  {
    "conteudo":"p<0.001)69."
  },
  {
    "conteudo":"MHD and PD patients: Isoyama et al. demonstrated that low handgrip strength, rather than"
  },
  {
    "conteudo":"low muscle mass measured with DEXA, was associated inflammatory markers including"
  },
  {
    "conteudo":"hsCRP, IL-6 and TNF-α.70 In addition, CRP levels were negatively associated with BIA phase"
  },
  {
    "conteudo":"angle.8"
  },
  {
    "conteudo":"Post-Transplant patients: Only one cross-sectional study was identified for kidney transplant"
  },
  {
    "conteudo":"recipients. In this study, malnutrition inflammation score (MIS) was positively correlated with"
  },
  {
    "conteudo":"IL-6 (p=0.231; p<0.001), TNF-a (p=0.102; p<0.001), and CRP levels (p=0.094; p=0.003).71"
  },
  {
    "conteudo":"Non-dialyzed patients: Both studies in pre-dialysis patients were cross-sectional in nature.72, 73 In"
  },
  {
    "conteudo":"a study by Wing et al., hsCRP levels were higher in the highest BMI quartile, but results with"
  },
  {
    "conteudo":"other cytokines were mixed. In Stages 2-4 CKD men, CRP levels were negatively associated"
  },
  {
    "conteudo":"with testosterone distribution.73"
  },
  {
    "conteudo":"In summary, many studies found correlations between higher inflammatory markers and"
  },
  {
    "conteudo":"suboptimal nutritional status, findings varied according to comparison measure. The"
  },
  {
    "conteudo":"relationship between BMI and inflammatory marker levels was unclear, and a U-shaped"
  },
  {
    "conteudo":"relationship may exist. MIS was associated with inflammation inflammatory in kidney"
  },
  {
    "conteudo":"transplant patients."
  },
  {
    "conteudo":"nPCR"
  },
  {
    "conteudo":"This evidence review included seven studies that examined the relationships between"
  },
  {
    "conteudo":"nPCR and comparative measures in CKD patients."
  },
  {
    "conteudo":"MHD patients: Of the three studies with MHD patients, one was a prospective cohort study27"
  },
  {
    "conteudo":"and the other two were cross-sectional studies.60, 62 In the study by de Roij van Zuijdewijn et"
  },
  {
    "conteudo":"al., nPNA (nPCR) was a significant predictor of all-cause mortality (Harrell's C statistic=0.56,"
  },
  {
    "conteudo":"Page 53"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"p<0.01), but the authors reported that MIS and serum albumin had the best predictive value.27"
  },
  {
    "conteudo":"Jones et al. and Molfino et al. found that nPCR was a significant predictor of serum albumin"
  },
  {
    "conteudo":"and prealbumin. 60, 62"
  },
  {
    "conteudo":"PD patients: Both prospective and cross-sectional studies were conducted in PD patients. The"
  },
  {
    "conteudo":"former showed that nPCR was negatively correlated with anthropometric measures of body"
  },
  {
    "conteudo":"composition, and positively correlated with composite nutritional index scores (r=0.32,"
  },
  {
    "conteudo":"p<0.001), but there was no relationship between nPCR and serum albumin.74 The latter study"
  },
  {
    "conteudo":"demonstrated that PCR was not correlated with LBM measured by creatinine kinetic method or"
  },
  {
    "conteudo":"MF-BIA.11"
  },
  {
    "conteudo":"MHD and PD patients: A cross-sectional study demonstrated that SGA was associated with"
  },
  {
    "conteudo":"nPCR (r=-0.29 p=0.027) in a group of MHD and PD patients.75"
  },
  {
    "conteudo":"Pre-dialysis patients: A cross-sectional study by Cigarran et al. indicated that nPNA (nPCR)"
  },
  {
    "conteudo":"levels were progressively reduced across decreasing tertiles of testosterone distribution"
  },
  {
    "conteudo":"(p<0.05) in male patients with stages 2-4 CKD.72"
  },
  {
    "conteudo":"In summary, nPCR was a predictor of albumin concentration and mortality in MHD patients."
  },
  {
    "conteudo":"In PD patients, the relationship between nPCR and body composition measurements was"
  },
  {
    "conteudo":"unclear, and the relationships with other measures of nutritional status varied."
  },
  {
    "conteudo":"Serum Prealbumin"
  },
  {
    "conteudo":"This evidence review included four studies that examined relationships between prealbumin"
  },
  {
    "conteudo":"concentration and comparative measures in CKD patients."
  },
  {
    "conteudo":"MHD patients: Of the three studies in MHD, one was a prospective cohort study9 and the other"
  },
  {
    "conteudo":"two were cross-sectional studies.21, 62 In the study by Molfino et al., pre-albumin concentrations"
  },
  {
    "conteudo":"were associated with nPCR and IL-6 levels.62 Prealbumin increased by 20.8 mg\/dL for each"
  },
  {
    "conteudo":"g\/kg increase in nPCR (p<0.001), and there was a decrease in pre-albumin concentration of"
  },
  {
    "conteudo":"0.94 mg\/dL for each increase in IL-6 concentration of 1 pg\/mL. In the multiple regression"
  },
  {
    "conteudo":"model, pre-albumin concentration increased by 1.8 mg\/dL for each kg increase in VAT"
  },
  {
    "conteudo":"(p=0.015). Fiedler et al. determined that pre-albumin concentration was predictive of 3-year"
  },
  {
    "conteudo":"Page 54"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"mortality and hospitalizations.9 CRP was correlated with prealbumin (r=- 0.45, p<0.001)"
  },
  {
    "conteudo":"concentration. Additionally, Aatif et al. demonstrated that lean and fat tissue index derived by"
  },
  {
    "conteudo":"bioimpedance spectroscopy were significantly correlated with pre-albumin concentration.21"
  },
  {
    "conteudo":"PD patients: In a cross-sectional study, Cigarran et al. found that pre-albumin concentration"
  },
  {
    "conteudo":"was progressively reduced across decreasing tertiles of testosterone in men with stages 2-4"
  },
  {
    "conteudo":"CKD (p<0.05).72"
  },
  {
    "conteudo":"In summary, serum prealbumin concentration were associated with nPCR, inflammatory"
  },
  {
    "conteudo":"markers, lean and fat tissue index, mortality, and hospitalizations in MHD patients. However,"
  },
  {
    "conteudo":"there were no studies examining validity and\/or reliability of this measure compared to a gold"
  },
  {
    "conteudo":"standard."
  },
  {
    "conteudo":"Special Discussions"
  },
  {
    "conteudo":"The biochemical markers must be obtained pre-dialysis for maintenance dialysis patients."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● The guideline for serum albumin applies to all adult patients with CKD on maintenance"
  },
  {
    "conteudo":"dialysis."
  },
  {
    "conteudo":"● There are no potential risks or harms associated with the application of the guideline for"
  },
  {
    "conteudo":"serum albumin in adult patients with CKD on maintenance dialysis."
  },
  {
    "conteudo":"• Gold standard method for measuring albumin is nephelometry, which is not commonly"
  },
  {
    "conteudo":"used in practice due to cost and time. In patients with ESRD patients, bromoscresol"
  },
  {
    "conteudo":"green (BCG) method should be used to estimate albumin, while in patients without"
  },
  {
    "conteudo":"ESRD bromocresol purple method is more accurate."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"General"
  },
  {
    "conteudo":"• Determine the incremental value of using one or more nutritional markers for better"
  },
  {
    "conteudo":"nutritional assessment and risk prediction."
  },
  {
    "conteudo":"• Develop risk prediction models using multiple nutritional markers."
  },
  {
    "conteudo":"• Determine the effects of established or promising nutritional interventions on"
  },
  {
    "conteudo":"Page 55"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"nutritional markers."
  },
  {
    "conteudo":"Inflammatory markers"
  },
  {
    "conteudo":"• Determine whether systemic inflammatory markers may be used to assess nutritional"
  },
  {
    "conteudo":"status in adult patients with CKD stages 3-5, including those on maintenance dialysis"
  },
  {
    "conteudo":"and with kidney transplantation."
  },
  {
    "conteudo":"nPCR"
  },
  {
    "conteudo":"• Determine frequency with which nPCR should be measured\/calculated."
  },
  {
    "conteudo":"Serum prealbumin concentration"
  },
  {
    "conteudo":"• Determine the frequency with which serum prealbumin concentration should be"
  },
  {
    "conteudo":"measured."
  },
  {
    "conteudo":"Page 56"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.3 Statement on Handgrip Strength"
  },
  {
    "conteudo":"1.3.1 In adults with CKD 1-5D, we suggest using handgrip strength as a surrogate"
  },
  {
    "conteudo":"measure of protein-energy status and functional status when baseline data (prior"
  },
  {
    "conteudo":"measures) are available for comparison (2B)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Handgrip strength (HGS) is a simple and reliable method to evaluate muscle function in"
  },
  {
    "conteudo":"patients with CKD. In addition, it can be used as an indirect measure of nutritional status in"
  },
  {
    "conteudo":"maintenance dialysis and non-dialyzed patients."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Five studies examined relationships between HGS and comparative measures in patients with"
  },
  {
    "conteudo":"CKD, including one study with non-dialyzed patients,76 one study with incident dialysis"
  },
  {
    "conteudo":"patients,70 two studies with MHD patients,77, 78and one study with PD patients.6 Overall,"
  },
  {
    "conteudo":"HGS was a valid measure of nutritional status compared to malnutrition inflammation score"
  },
  {
    "conteudo":"(MIS) in MHD patients (sensitivity=70-87%, specificity=43-66%)78 and was negatively"
  },
  {
    "conteudo":"associated with MIS in non-dialyzed patients (r=0.42; p<0.001),76 but results may vary"
  },
  {
    "conteudo":"according to confounding variables. HGS was correlated with LBM assessed by other"
  },
  {
    "conteudo":"methods, but there was no correlation with other markers of body composition or nutritional"
  },
  {
    "conteudo":"status in PD patients.6 In incident dialysis patients, HGS had higher correlations with"
  },
  {
    "conteudo":"nutritional status and inflammatory markers, and was more predictive of mortality than"
  },
  {
    "conteudo":"muscle mass measured by dual energy X-ray absorptiometry (DEXA).70"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"There is a cost associated with purchasing the equipment to measure HGS."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"• The guideline for HGS applies to all adult MHD, PD and non-dialyzed patients."
  },
  {
    "conteudo":"• The potential risk or harm associated with the application of the guideline for HGS in"
  },
  {
    "conteudo":"MHD patients involves the side of the body assessed. The measurement should be"
  },
  {
    "conteudo":"obtained on the opposite side of the vascular access. In all other patients (i.e. PD and"
  },
  {
    "conteudo":"pre-dialysis), there are no potential risks or harms. Staff need to be properly trained on"
  },
  {
    "conteudo":"performing the measurement and interpreting the results."
  },
  {
    "conteudo":"• Many individuals with CKD also have type 2 diabetes, a consequence of which may"
  },
  {
    "conteudo":"Page 57"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"include peripheral neuropathy. Practitioners should account for potential loss in HGS"
  },
  {
    "conteudo":"due to peripheral neuropathy in patients with type 2 diabetes when comparing"
  },
  {
    "conteudo":"measurements over time.79"
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Measuring HGS is simple; however, it is not routinely used in clinical practice."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"The workgroup recommends further research on HGS to determine:"
  },
  {
    "conteudo":"● the timing of the measurement (e.g. pre or post hemodialysis session, non-dialysis day)"
  },
  {
    "conteudo":"● the cutoff values that are correlated with other measures of muscle function used as"
  },
  {
    "conteudo":"surrogate measures of nutritional status"
  },
  {
    "conteudo":"● the best method to standardize the technique (e.g. position of the arm, the evaluation"
  },
  {
    "conteudo":"period, choice of arm side)"
  },
  {
    "conteudo":"● the reliability and validity of the measurement in comparison to a gold standard used as"
  },
  {
    "conteudo":"the preferred instrument to obtain the muscle function measurement"
  },
  {
    "conteudo":"● the association between HGS and other markers of physical function."
  },
  {
    "conteudo":"Page 58"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.4 Statement on Methods to Assess Energy Requirements"
  },
  {
    "conteudo":"Assessment of Resting Energy Expenditure"
  },
  {
    "conteudo":"1.4.1 In adults with CKD 1-5D and post-transplant, it is reasonable to use indirect"
  },
  {
    "conteudo":"calorimetry to measure resting energy expenditure when feasible and indicated, as it"
  },
  {
    "conteudo":"remains the gold standard for determining resting energy expenditure (OPINION)."
  },
  {
    "conteudo":"Resting Energy Expenditure Equations"
  },
  {
    "conteudo":"1.4.2 In adults with CKD 5D who are metabolically stable, we suggest that in the"
  },
  {
    "conteudo":"absence of indirect calorimetry, disease-specific predictive energy equations may be"
  },
  {
    "conteudo":"used to estimate resting energy expenditure as they include factors that may influence"
  },
  {
    "conteudo":"the metabolic rate in this population (2C)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Achieving energy balance is critical in persons diagnosed with CKD so that protein-energy"
  },
  {
    "conteudo":"malnutrition and wasting can be prevented or treated in susceptible persons. Thus, obtaining"
  },
  {
    "conteudo":"reliable data regarding dietary energy intake as well as having a valid measure for energy"
  },
  {
    "conteudo":"expenditure is paramount."
  },
  {
    "conteudo":"Indirect calorimetry remains as the best practice measure for determining resting energy"
  },
  {
    "conteudo":"expenditure (REE) in adults diagnosed with CKD stages 1-5, including those receiving renal"
  },
  {
    "conteudo":"replacement therapies such as MHD, PD or post-transplant. More research is needed to"
  },
  {
    "conteudo":"demonstrate whether handheld indirect calorimetric devices may be a suitable alternative in"
  },
  {
    "conteudo":"this population."
  },
  {
    "conteudo":"In the absence of indirect calorimetry, there are over 200 predictive energy equations available"
  },
  {
    "conteudo":"that may be able to estimate REE in patients diagnosed with CKD. Several have been shown"
  },
  {
    "conteudo":"to either over- or under-estimate REE in earlier stages of CKD as well as those patients treated"
  },
  {
    "conteudo":"with maintenance dialysis. There have been several cross-sectional studies that suggest that"
  },
  {
    "conteudo":"the energy requirements of patients with earlier stages of CKD may not be substantially"
  },
  {
    "conteudo":"different than healthy adults, but the evidence is limited. Recent research has shown that"
  },
  {
    "conteudo":"predictive energy equations specifically designed for patients with CKD on maintenance"
  },
  {
    "conteudo":"dialysis have lower bias and greater precision."
  },
  {
    "conteudo":"Even the best predictive models designed for CKD do not account for the contribution of"
  },
  {
    "conteudo":"Page 59"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"physical activity or structured exercise. Reliance on current estimates for physical activity may"
  },
  {
    "conteudo":"not determine total energy requirements accurately in this population."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"There were six studies which tested REE equations in CKD patients and compared them to a"
  },
  {
    "conteudo":"reference standard of indirect calorimetry.80-85 Two of the six studies used indirect calorimetry"
  },
  {
    "conteudo":"data to derive a disease-specific equation.80, 85 The Harris-Benedict equation over-estimated"
  },
  {
    "conteudo":"REE in four studies across the spectrum of CKD; e.g., Dias Rodrigues et al. (MHD),81"
  },
  {
    "conteudo":"Kamimura et al. (non-dialyzed, MHD and PD),82 Lee et al (CAPD )83 and Neyra et al (CRF,"
  },
  {
    "conteudo":"MHD and PD),84 but the Harris-Benedict equation underestimated REE in MHD participants"
  },
  {
    "conteudo":"in Vilar et al.85 (MHD). Similarly, the Schofield equation over-estimated REE in Dias"
  },
  {
    "conteudo":"Rodrigues et al. (MHD)81 and Kamimura et al. (non-dialyzed, MHD and PD),82 but under-"
  },
  {
    "conteudo":"estimated REE in Vilar et al. (MHD).85 Byham-Gray et al. demonstrated that the Maintenance"
  },
  {
    "conteudo":"Hemodialysis Equation more accurately predicted REE than the Mifflin-St. Joer equation.80"
  },
  {
    "conteudo":"Vilar et al. also found that their created equation for REE was best predictor of REE when"
  },
  {
    "conteudo":"comparedto traditional predictive energy equations.85 Generally, agreement between"
  },
  {
    "conteudo":"equations and methods was low-to-moderate."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Among patients with stage 5 CKD on MHD or PD, there are several factors that may influence"
  },
  {
    "conteudo":"energy expenditure beyond the traditional determinants (age, sex, and fat-free mass), such as"
  },
  {
    "conteudo":"hyperparathyroidism, hyperglycemia, and chronic inflammation that should be considered into"
  },
  {
    "conteudo":"the overall energy prescription. Energy needs will be variable depending on the health status of"
  },
  {
    "conteudo":"the patient (e.g., acutely ill versus chronically managed) as well as overall health goals (e.g.,"
  },
  {
    "conteudo":"weight maintenance, repletion or loss). Energy needs may be different depending on the stage"
  },
  {
    "conteudo":"of CKD and its respective treatment (dialysis versus transplantation). In the context of these"
  },
  {
    "conteudo":"recommendations, “metabolically stable” indicates absence of any active inflammatory or"
  },
  {
    "conteudo":"infectious diseases; no hospitalization within two weeks; absence of poorly controlled diabetes"
  },
  {
    "conteudo":"and consumptive diseases such as cancer; absence of antibiotics or immunosuppressive"
  },
  {
    "conteudo":"medications; and absence of significant short-term loss of body weight."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"• The RDN should consider a number of factors when determining the energy"
  },
  {
    "conteudo":"Page 60"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"requirements for adults diagnosed with CKD, and these include the patient’s overall"
  },
  {
    "conteudo":"health status, CKD diagnosis and associated therapies, level of physical activity, age,"
  },
  {
    "conteudo":"gender, weight status, disease-specific determinants, metabolic stressors, and treatment"
  },
  {
    "conteudo":"goals."
  },
  {
    "conteudo":"• Disease specific equations, such as the Maintenance Hemodialysis Equation, should be"
  },
  {
    "conteudo":"used when estimating energy requirements for the CKD population."
  },
  {
    "conteudo":"• Thermal effects of food may be decreased in individuals who are non-dialyzed"
  },
  {
    "conteudo":"compared to dialyzed due to lower protein intake."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Patients should be monitored routinely to assess whether energy requirements are being met"
  },
  {
    "conteudo":"satisfactorily. Changes in nutritional status should be treated and the energy prescription"
  },
  {
    "conteudo":"modified accordingly."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Determine the energy requirements across the spectrum of kidney disease and evaluate for"
  },
  {
    "conteudo":"the contribution of exercise and physical activity; i.e., indexing total energy expenditure in"
  },
  {
    "conteudo":"CKD."
  },
  {
    "conteudo":"● Uncover the key determinants of energy expenditure in CKD, enabling practitioners to"
  },
  {
    "conteudo":"account for them in the energy prescription."
  },
  {
    "conteudo":"● Develop and test predictive energy equations in CKD that can more accurately or precisely"
  },
  {
    "conteudo":"determine the individual’s unique energy requirements."
  },
  {
    "conteudo":"Page 61"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.5 Statement on Composite Nutritional Indices"
  },
  {
    "conteudo":"7-point Subjective Global Assessment (SGA)"
  },
  {
    "conteudo":"1.5.1 In adults with CKD 5D, we recommend the use of the 7-point Subjective Global"
  },
  {
    "conteudo":"Assessment as a valid and reliable tool for assessing nutritional status (1B)."
  },
  {
    "conteudo":"Malnutrition Inflammation Score (MIS)"
  },
  {
    "conteudo":"1.5.2 In adults with CKD on MHD and post-transplant, Malnutrition Inflammation"
  },
  {
    "conteudo":"Score may be used to assess nutritional status (2C)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Assessment of nutritional status in adults diagnosed with CKD stages 1-5 must occur on a"
  },
  {
    "conteudo":"routine basis in order to prevent and\/or treat malnutrition and wasting. The Nutrition Care"
  },
  {
    "conteudo":"Process begins with a nutrition screening, whereby key nutritional indicators may trigger"
  },
  {
    "conteudo":"further assessment and intervention. There are several nutrition screening mechanisms in"
  },
  {
    "conteudo":"clinical practice, but few are specific to CKD, and there are limited data on their validity and"
  },
  {
    "conteudo":"reliability. Most of the existing tools focus on identification of malnutrition risk; only one"
  },
  {
    "conteudo":"currently screens for PEW. Regardless of the mechanism used, the nutritional assessment"
  },
  {
    "conteudo":"conducted subsequent to the screening should be comprehensive and include the routine"
  },
  {
    "conteudo":"monitoring of nutrition care outcomes. The main components of the comprehensive nutrition"
  },
  {
    "conteudo":"assessment comprise anthropometric measurements, biomarkers, clinical symptoms exhibited"
  },
  {
    "conteudo":"on physical exam, dietary intake assessment, and medical\/psychosocial history. The"
  },
  {
    "conteudo":"availability of composite nutritional indices [e.g., the Subjective Global Assessment (SGA) or"
  },
  {
    "conteudo":"Malnutrition Inflammation Score (MIS)], collect such data and therefore assist the clinician in"
  },
  {
    "conteudo":"deciding about the individual’s nutritional status and eventual plan of care, and are specific to"
  },
  {
    "conteudo":"the unique nutritional requirements of this patient population."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"COMPOSITE NUTRITIONAL INDICES: SCREENING TOOLS"
  },
  {
    "conteudo":"Geriatric Nutrition Risk Index (GNRI)"
  },
  {
    "conteudo":"Three studies reported on the use of GNRI to assess nutritional status, including two"
  },
  {
    "conteudo":"validity\/reliability studies86, 87 and one prediction study in MHD patients.27 In one study, GNRI"
  },
  {
    "conteudo":"Page 62"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"had the greatest area under curve (using MIS as a reference) of the nutrition screening tools.87"
  },
  {
    "conteudo":"GNRI showed a significantly negative correlation with the MIS (r=-0.67, P 0.0001), and the"
  },
  {
    "conteudo":"most accurate GNRI cutoff to identify a malnourished patient according to the MIS was 91.2."
  },
  {
    "conteudo":"The GNRI’s sensitivity, specificity, and accuracy of a score of 91.2 in predicting malnutrition"
  },
  {
    "conteudo":"according to the MIS were 73%, 82%, and 79% respectively. Another study reported that GNRI"
  },
  {
    "conteudo":"had high inter-observer agreement score (k=0.98) and high intra-observer reproducibility"
  },
  {
    "conteudo":"(k=0.82).86In another study, GNRI was a significant predictor for mortality at 2.97 years"
  },
  {
    "conteudo":"(p<0.001) buthad lower predictive value for all-cause mortality compared to MIS and albumin"
  },
  {
    "conteudo":"levels.27"
  },
  {
    "conteudo":"Malnutrition Universal Screening Tool\/Malnutrition Screening Tool (MUST\/MST)"
  },
  {
    "conteudo":"Two validity\/reliability study reported on the use of MUST and MST tools to assess nutritional"
  },
  {
    "conteudo":"status in MHD patients.87, 88 A study by Lawson et al,, reported on the validity and reliability of"
  },
  {
    "conteudo":"both MUST and MST tool in MHD patients.88 The sensitivity of both the MUST and MST tool"
  },
  {
    "conteudo":"was low (53.8% for MUST; 48.7% for MST), indicating that they are not particularly sensitive"
  },
  {
    "conteudo":"at identifying individuals with malnutrition in this group, compared to SGA. Both tools have a"
  },
  {
    "conteudo":"high specificity (MUST=78.3%; MST=85.5%), so they are good at excluding individuals who"
  },
  {
    "conteudo":"are not malnourished. Reliability assessed by kappa was 0.58 for MUST (95% CI, 0.20 to 0.80)"
  },
  {
    "conteudo":"and 0.33 for MST (95% CI, 20.03 to 0.54). Both tools had an NPV or 60% and PPV for MUST"
  },
  {
    "conteudo":"was 73.7% and for MST was 78.7%. Though these tools are not sensitive enough to identify"
  },
  {
    "conteudo":"all malnourished renal in-patients, they are still fairly reliable and related to other nutrition"
  },
  {
    "conteudo":"status markers. In Yamada et al., the authors compared results from various malnutrition"
  },
  {
    "conteudo":"assessment tools to the reference standard of MIS.87 MUST and MST scores were both"
  },
  {
    "conteudo":"significantly associated with MIS (p<0.0001 for each). The ROC curves of the MUST and"
  },
  {
    "conteudo":"MST compared to MIS were the smallest of the tools measured, and sensitivity, specificity and"
  },
  {
    "conteudo":"accuracy to detect hypoalbuminemia were among the lowest of all tools considered, indicating"
  },
  {
    "conteudo":"these may not be the best tools to discriminate nutritional risk in patients on MHD."
  },
  {
    "conteudo":"Mini-Nutrition Assessment (MNA)"
  },
  {
    "conteudo":"Four studies reported on the use of MNA to assess nutritional status in MHD patients, three"
  },
  {
    "conteudo":"were validity\/reliability studies87, 89, 90 and one was a correlational study.91 Afsar et al."
  },
  {
    "conteudo":"Page 63"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"reported on the reliability of MNA tool compared to SGA 3-point scale.89 The reliability"
  },
  {
    "conteudo":"coefficients (alpha) for MNA was 0.93 (good degree of reproducibility). MNA might"
  },
  {
    "conteudo":"underestimate the nutritional status of patients on MHD who are not in an inflammatory state."
  },
  {
    "conteudo":"Hence, MNA may not be as reliable as SGA in detecting PEM in the MHD population."
  },
  {
    "conteudo":"Erdogan et al. compared MNA to Bio-electrical Impedance Analysis (BIA), reported a significant"
  },
  {
    "conteudo":"correlation between MNA score and single frequency-BIA (r=0.2, p=0.045), muscle mass"
  },
  {
    "conteudo":"(r=0.382; p<0.001) and visceral fat ratio (r=0.270; p=0.007).91 Authors concluded BIA is not as"
  },
  {
    "conteudo":"sensitive as MNA to detect early effects of secondary causes for malnutrition. Santin et al."
  },
  {
    "conteudo":"2015, compared SGA (7-point), MIS, MNA-Short Form (MNA-SF) to handgrip strength"
  },
  {
    "conteudo":"(HGS), albumin, c-reactive protein (CRP), and skinfolds. SGA and MNA-SF had fair"
  },
  {
    "conteudo":"agreement (kappa=0.24; p<0.001).90 The worst agreement was found between MIS and MNA-"
  },
  {
    "conteudo":"SF (kappa=0.14, none to slight; p<0.004). Again, both SGA and MIS had good concurrent and"
  },
  {
    "conteudo":"predictive validity for CKD population, whereas MNA-SF validity results were more"
  },
  {
    "conteudo":"comparable to non-CKD elderly individuals. Yamada et al., compared MNA to other"
  },
  {
    "conteudo":"nutritional tools and reported that MNA had lower area under curve (0.73) than GNRI and"
  },
  {
    "conteudo":"Nutritional Risk Score but higher than MUST and MST.87"
  },
  {
    "conteudo":"Nutrition Impact Symptoms (NIS)"
  },
  {
    "conteudo":"One validity study reported on the use of NIS score for identifying those at risk of malnutrition"
  },
  {
    "conteudo":"in patients on HD and concluded that NIS score is a useful nutrition screening tool for"
  },
  {
    "conteudo":"identifying who are at risk of malnutrition.92 NIS score >2 had the strongest predictive value"
  },
  {
    "conteudo":"for mortality and for predicting poor nutritional outcomes, behind the rating of malnourished"
  },
  {
    "conteudo":"by SGA. Concurrent validity indicated similar agreement between each of the malnutrition risk"
  },
  {
    "conteudo":"tools (patient-generated subjective global assessment (PG-SGA), an abbreviated PG-SGA and"
  },
  {
    "conteudo":"NIS). Serum albumin was negatively correlated with NIS (Spearman Rho= -0.161; p=0.018)."
  },
  {
    "conteudo":"Nutrition Screening Tool (NST)"
  },
  {
    "conteudo":"One validity study reported on the use of NST to assess nutritional status in PD patients. In this"
  },
  {
    "conteudo":"study, NST had a sensitivity of 0.84 (range: 0.74 to 0.94; p<0.05) and specificity of 0.9 (range:"
  },
  {
    "conteudo":"0.82 to 0.99; p<0.05) which is clinically acceptable.93"
  },
  {
    "conteudo":"Page 64"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Renal Nutrition Screening Tool (R-NST)"
  },
  {
    "conteudo":"In another study by Xia et al. in PD patients, the R-NST was compared to SGA-7 point scale.94"
  },
  {
    "conteudo":"Authors determined that the R-NST tool when compared to SGA- 7 point scale is valid to detect"
  },
  {
    "conteudo":"risk of malnutrition (sensitivity=97.3% (95% CI 90.7-99.7), specificity=74.4% (95% CI57.9-"
  },
  {
    "conteudo":"87.0), PPV=88.0% (95% CI 79.0-94.1), NPV=93.6% (95% CI 78.6-99.2). These results indicate"
  },
  {
    "conteudo":"that R-NST is a good tool for identifying renal in-patients at risk of undernutrition."
  },
  {
    "conteudo":"Protein Energy Wasting (PEW) score"
  },
  {
    "conteudo":"Two predictive studies reported on the use of PEW score to assess nutritional status. Leinig"
  },
  {
    "conteudo":"and colleagues identified that SGA and albumin were significant predictors of mortality, but"
  },
  {
    "conteudo":"BMI, mid-arm muscle circumference (MAMC) and PEW score did not predict mortality at 24"
  },
  {
    "conteudo":"months in PD patients.65 However, Moreau-Gaudry et al., a study conducted in patients on"
  },
  {
    "conteudo":"MHD recorded that PEW predicts survival. Each unit decrease in score was related with a 5-"
  },
  {
    "conteudo":"7% reduction in survival (p<0.01).95 This score can be helpful in identifying subgroups of"
  },
  {
    "conteudo":"patients with a high mortality rate and recommend nutrition support."
  },
  {
    "conteudo":"COMPOSITE NUTRITIONAL INDICES: ASSESSMENT TOOLS"
  },
  {
    "conteudo":"Subjective Global Assessment (SGA)"
  },
  {
    "conteudo":"Eleven studies examined the relationship between the 7-point SGA score and comparative"
  },
  {
    "conteudo":"measures, including three validity\/reliability studies52, 53, 90 and six additional prediction"
  },
  {
    "conteudo":"and\/or correlation studies.27, 61, 67, 96-98"
  },
  {
    "conteudo":"Three studies examined the validity and\/or reliability of the 7-point SGA score in MHD"
  },
  {
    "conteudo":"patients. In Visser et al., 7-point SGA score demonstrated fair inter-observer reliability [intra-"
  },
  {
    "conteudo":"class correlation (ICC) = 0.72] and good intra-observer reliability (ICC=0.88) in MHD"
  },
  {
    "conteudo":"patients.53 In Santin et al., 7-point SGA score had good agreement with MIS"
  },
  {
    "conteudo":"(κ=0.43; p<0.001) and MNA-SF (κ=0.24; p<0.001).90 In a study by Steiber, et al., SGA had fair"
  },
  {
    "conteudo":"interrater reliability (κ=0.5, Spearman’s Rho=0.7), substantial intra-rater reliability (κ=0.7,"
  },
  {
    "conteudo":"spearman’s Rho=0.8) (p<0001).52"
  },
  {
    "conteudo":"Page 65"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Three cohort studies examined whether the 7-point SGA score was predictive of hard outcomes"
  },
  {
    "conteudo":"in patients on MHD. In Perez et al., SGA was a significant predictor of mortality at 2 years after"
  },
  {
    "conteudo":"adjustments for significant confounders.97 In a study by de Roij van Zuijedewijn et al., SGA"
  },
  {
    "conteudo":"was a significant predictor (p<0.001) for mortality at 2.97 years, but had lower predictive value"
  },
  {
    "conteudo":"for all-cause mortality compared to MIS and albumin levels.27 de Mutsert and others reported"
  },
  {
    "conteudo":"that hazard of mortality increased with SGA in a dose-dependent manner among patients on"
  },
  {
    "conteudo":"dialysis.66 Compared to normal nutritional status, persons who had a SGA of 4-5 had an"
  },
  {
    "conteudo":"increased HR (95% CI) at 7-year mortality of 1.6 (1.3, 1.9) and SGA of 1–3 had an HR of 2.1"
  },
  {
    "conteudo":"(1.5, 2.8) at 7-year mortality. The strength of association increased in time-dependent models."
  },
  {
    "conteudo":"Finally, in a study with PD patients, every one unit increase in the 7-point SGA adapted for"
  },
  {
    "conteudo":"end-stage renal disease (ESRD)\/continuous ambulatory PD patients, there was a 25% decreased"
  },
  {
    "conteudo":"2 year mortality risk (p<0.05).31"
  },
  {
    "conteudo":"Six studies examined correlations between the 7-point SGA score and other measures of"
  },
  {
    "conteudo":"nutritional status. In Visser, et al., there was a strong correlation between the 7-point SGA"
  },
  {
    "conteudo":"score and BMI (r=0.79), % fat (r=0.77), and mid arm circumference (r=0.71) (all p<0.001)in"
  },
  {
    "conteudo":"MHD patients.53 In a study by Steiber et al., there were statistically significant differences in"
  },
  {
    "conteudo":"mean BMI and serum albumin according to SGA score in MHD patients (p<0.05).52"
  },
  {
    "conteudo":"Tapiawala et al. assessed the 7-point SGA score in patients with CKD, ESRD and those on"
  },
  {
    "conteudo":"all types of dialysis.98 SGA scores were not correlated with dietary protein and energy intake"
  },
  {
    "conteudo":"or serum albumin levels, but anthropometric measures correlated with the SGA scores"
  },
  {
    "conteudo":"(skinfolds r=0.2, mid-arm circumference r=0.5 and MAMC r=0.5). Authors concluded 7-"
  },
  {
    "conteudo":"point SGA is a reliable method of assessing nutritional status. Malgorzewicz et al. compared"
  },
  {
    "conteudo":"near-infrared measurements and albumin levels to the SGA 7-point score in MHD patients.61"
  },
  {
    "conteudo":"LBM measured by near-infrared was significantly decreased in malnourished patients"
  },
  {
    "conteudo":"(p<0.05) and there was a correlation between SGA score and LBM(r=0.5; p<0.05) as well as"
  },
  {
    "conteudo":"SGA score and albumin concentration (r=0.7; p<.05). In Vannini et al., SGA were associated"
  },
  {
    "conteudo":"with traditional nutritional markers, reinforcing validity for use among patients on MHD."
  },
  {
    "conteudo":"SGA score was not associated with CRP level.67 Jones et al. examined the relationship"
  },
  {
    "conteudo":"between 3-point SGA score and a composite nutritional score that included SGA (3 point"
  },
  {
    "conteudo":"and 7 point), BMI, % reference weight, skinfold and MAMC measurements and albumin"
  },
  {
    "conteudo":"levels in patients treated by MHD.96 Compared to the"
  },
  {
    "conteudo":"Page 66"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"composite score, the SGA score misclassified a “large number of subjects” and score was not"
  },
  {
    "conteudo":"associated with many nutrition parameters such as dietary intake, BMI or albumin levels."
  },
  {
    "conteudo":"In one study99, the authors utilized a version of the SGA that was adapted for patients on"
  },
  {
    "conteudo":"MHD, and in two studies,65, 100 the version of the SGA tool used was unclear. Garagarza et al."
  },
  {
    "conteudo":"compared bioimpedance spectroscopy measurements to SGA scores from a version modified"
  },
  {
    "conteudo":"for MHD99 that included a 5-point score comprising weight changes, eating habits,"
  },
  {
    "conteudo":"gastrointestinal symptoms, functional activity and comorbidities. PEW measured by BIS"
  },
  {
    "conteudo":"extracellular weight (ECW)\/body weight (BW) was positively associated with CRP (p=0.009)"
  },
  {
    "conteudo":"and SGA score (p=0.03). Leinig et al. examined the relationship between SGA score and"
  },
  {
    "conteudo":"mortality risk at 24 months in PD patients, but version of the SGA employed was unclear. SGA"
  },
  {
    "conteudo":"score was a significant predictor of mortality in PD patients.65 Passadakis et al. compared BIA"
  },
  {
    "conteudo":"measurements to SGA score in CAPD patients, but the version of SGA utilized was"
  },
  {
    "conteudo":"uncertain.100 SGA score was significantly correlated with impedance index (r=0.48; p=0.0038)"
  },
  {
    "conteudo":"and phase angle (r=0.43; p=0.0048)."
  },
  {
    "conteudo":"Malnutrition Inflammation Score (MIS)"
  },
  {
    "conteudo":"Eight studies reported on the use of MIS to assess nutritional status, including two"
  },
  {
    "conteudo":"validity\/reliability studies86, 90, four prediction studies9, 27, 97 and three correlation"
  },
  {
    "conteudo":"studies).71, 76, 101"
  },
  {
    "conteudo":"One study by Bebershavili et al. reported that MIS had moderate inter-observer agreement"
  },
  {
    "conteudo":"(k=0.62) and inter-observer reproducibility (k=0.77) and is a valid tool for longitudinal"
  },
  {
    "conteudo":"assessment of nutritional status of patients on MHD.86 Another study by Santin et al., indicated"
  },
  {
    "conteudo":"that MIS had good agreement with SGA (k=0.43, p<0.001) and worse agreement with MNA-"
  },
  {
    "conteudo":"SF (k= 0.14, p<0.004).90 MIS also had good concurrent and predictive validity for the MHD"
  },
  {
    "conteudo":"population."
  },
  {
    "conteudo":"Four studies reported on the use of MIS as a predictor of mortality.9, 27, 90, 97 Three of the"
  },
  {
    "conteudo":"studies reported that in patients on MHD, MIS is a significant predictor of mortality. 9, 27, 97 In"
  },
  {
    "conteudo":"one study, MIS was a significant predictor for mortality at 2.97 years (p<0.001), and best"
  },
  {
    "conteudo":"predictive"
  },
  {
    "conteudo":"Page 67"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"tool for all-cause mortality and secondary end-points like cardiovascular events in patients on"
  },
  {
    "conteudo":"MHD.27 Another study by Fiedler et al. also reported that MIS was predictive of both mortality"
  },
  {
    "conteudo":"and hospitalizations in patients treated by MHD with survival analysis indicated that MIS was"
  },
  {
    "conteudo":"one of the best predictors of mortality [HR 6.25 (2.82 – 13.87), p<0.001].9 Perez et al. also"
  },
  {
    "conteudo":"indicated that MIS was a significant predictor for 2 year mortality in MHD patients.97Finally, in"
  },
  {
    "conteudo":"Santin et al., while mild MIS did not predict mortality, severe MIS was a significant predictor of"
  },
  {
    "conteudo":"mortality in adjusted analysis [HR (95% CI): 5.13 (1.19, 13.7).90"
  },
  {
    "conteudo":"Three studies reported on the use of MIS and correlation with other tools. Amparo et al,"
  },
  {
    "conteudo":"indicated that there was a significant negative correlation between hand grip strength and MIS"
  },
  {
    "conteudo":"(r= -0.42, p<0.001) in predialysis subjects.76 Hou et al. indicated that MIS was strongly"
  },
  {
    "conteudo":"correlated with modified quantitative subjective global assessment (r=0.924) and inversely"
  },
  {
    "conteudo":"correlated with BIA (r= -0.213) in MHD patients.101 Molnar et al. reported that MIS showed"
  },
  {
    "conteudo":"significant negative correlations with abdominal circumference (p= -0.144; p<0.001) and pre-"
  },
  {
    "conteudo":"albumin level (p= -0.165; P<0.001), whereas significant positive correlation was seen with IL-"
  },
  {
    "conteudo":"6 (p=0.231; p<0.001), TNF-a (p=0.102; p<0.001), and CRP levels (p=0.094; p=0.003) in"
  },
  {
    "conteudo":"kidney transplant recipients.71 All studies show that MIS is a useful tool to assess nutritional"
  },
  {
    "conteudo":"status in CKD patients."
  },
  {
    "conteudo":"Other Composite Nutritional Indices"
  },
  {
    "conteudo":"Nutrition Risk Score"
  },
  {
    "conteudo":"A prediction study reported that Nutrition Risk Score was a good predictor of mortality (HR"
  },
  {
    "conteudo":"4.24 (1.92-9.38), p<0.001) in patients on MHD and was superior when compared to lab"
  },
  {
    "conteudo":"markers and BIA in predicting mortality.9"
  },
  {
    "conteudo":"Protein Nutrition Index (PNI)"
  },
  {
    "conteudo":"A reliability study investigated PNI as a predictor of survival in PD patients. Compared to the"
  },
  {
    "conteudo":"reference standard (nPNA (nPCR) ≤0.91 as malnutrition), the sensitivity, specificity, positive"
  },
  {
    "conteudo":"and negative predictive value of PNI were 0.4, 0.978, 0.901 and 0.783, respectively.102 This"
  },
  {
    "conteudo":"study indicated that PNI is a good predictor of mortality (even after adjusting for age and"
  },
  {
    "conteudo":"comorbidities). An increase in PNI score by 1 led to a 16% decrease in mortality risk."
  },
  {
    "conteudo":"Page 68"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Composite Score of Protein Energy Nutrition Status (cPENS)"
  },
  {
    "conteudo":"de Roij van Zuijdewijn et al. studied eight nutrition assessment tools used to predict all-cause"
  },
  {
    "conteudo":"mortality.27 Composite Score of Protein Energy Nutrition Status had a Harrell’s C statistics of"
  },
  {
    "conteudo":"0.63 (0.61 – 0.66) for predicting mortality. However, the study indicated that it had inadequate"
  },
  {
    "conteudo":"discrimination and calibration or a lower predictive value for mortality."
  },
  {
    "conteudo":"Other Measures"
  },
  {
    "conteudo":"Blumberg et al. compared the integrative score with the SGA-7-point scale in MHD patients."
  },
  {
    "conteudo":"Integrative clinical nutrition dialysis score is based on biochemical measures of albumin,"
  },
  {
    "conteudo":"creatinine, urea, cholesterol, CRP, dialysis adequacy, and weight change.103 With every unit"
  },
  {
    "conteudo":"increase in integrative score, the odds of death were significantly decreased (HR=0.929, 95%"
  },
  {
    "conteudo":"CI 0.885-0.974, p<0.002). SGA and integrative score were significantly correlated (n=69,"
  },
  {
    "conteudo":"r=0.853, p<0.01) and according to the author this is a useful prognostic tool to detect early"
  },
  {
    "conteudo":"nutrition deterioration."
  },
  {
    "conteudo":"A prediction study investigated which nutritional composed scoring system best predicts all-"
  },
  {
    "conteudo":"cause mortality in MHD patients.97 This study indicated that SGA and MIS are better"
  },
  {
    "conteudo":"predictors of all-cause mortality at 15.5 months in this study and International Society of Renal"
  },
  {
    "conteudo":"Nutrition and Metabolism criteria was not able to predict mortality in this sample."
  },
  {
    "conteudo":"One correlation study investigated the relationship between body adiposity index (BAI), BIA,"
  },
  {
    "conteudo":"anthropometrics, and DEXA.104 The correlation coefficient was higher between DEXA vs."
  },
  {
    "conteudo":"anthropometric measurements (r=0.76) and BAI (r=0.61) when compared to BIA (r=0.57) in"
  },
  {
    "conteudo":"the adjusted analysis (p<0.0001). Results suggest BIA estimates body fat with high accuracy in"
  },
  {
    "conteudo":"non-dialyzed CKD patients."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"The large body of literature on nutritional assessment and composite nutritional indices have"
  },
  {
    "conteudo":"been completed in CKD 5D. While some of these tools may be relevant and can be translated"
  },
  {
    "conteudo":"to earlier stages (1-4) CKD, there is a need for the practitioner to conduct a comprehensive"
  },
  {
    "conteudo":"Page 69"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"nutritional assessment comprising the main domains of the Nutrition Care Process."
  },
  {
    "conteudo":"PEW, a term supported by the International Society of Renal Nutrition and Metabolism,"
  },
  {
    "conteudo":"describes the complexity of nutritional and metabolic alterations that exist in CKD. While"
  },
  {
    "conteudo":"PEW definition is useful in identify patients with overt nutritional abnormalities, its sensitivity"
  },
  {
    "conteudo":"is low given its strict criteria. While comprehensive nutritional indices have been validated for"
  },
  {
    "conteudo":"the recognition of a poor nutritional status (e.g., malnutrition), it is unclear how well some of"
  },
  {
    "conteudo":"these same tools may be applied in the early identification of PEW."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Routine nutrition screening of adults diagnosed with CKD stages 1-5D should occur to"
  },
  {
    "conteudo":"allow for the identification and further assessment and treatment of nutritional concerns."
  },
  {
    "conteudo":"● A comprehensive nutrition assessment, using a composite nutritional index, should be"
  },
  {
    "conteudo":"conducted at the initial visit and completed whenever there is a change in health status or as"
  },
  {
    "conteudo":"per institutional or regulatory policies."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"The comprehensive nutrition assessment will guide the nutrition intervention prescribed. The"
  },
  {
    "conteudo":"clinician should monitor key nutrition care outcomes based on the treatment plan prescribed"
  },
  {
    "conteudo":"and re-assess and change the plan accordingly to achieve the goals established."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● More research is needed in trying to standardize the methods for nutrition screening"
  },
  {
    "conteudo":"mechanisms so that early identification and referral can result."
  },
  {
    "conteudo":"● Additional investigations should focus on what composite nutritional indices, if any, can be"
  },
  {
    "conteudo":"used reliably in earlier stages of CKD."
  },
  {
    "conteudo":"● More research is needed to examine which composite nutritional indices are appropriate"
  },
  {
    "conteudo":"for nutrition screening or assessment in people with CKD who are non-dialyzed."
  },
  {
    "conteudo":"● More research is needed examining validity and reliability of the GNRI and SGA tools in"
  },
  {
    "conteudo":"elderly people with CKD."
  },
  {
    "conteudo":"● Further development and testing of screening and assessment tools for PEW are necessary,"
  },
  {
    "conteudo":"especially in terms of response to nutritional interventions."
  },
  {
    "conteudo":"Page 70"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"1.6 Statement on Tools\/Methods Used to Assess Protein and Energy Intake"
  },
  {
    "conteudo":"Considerations when Assessing Dietary Intake"
  },
  {
    "conteudo":"1.6.1 In adults with CKD 3-5D and post-transplant, it is reasonable to assess factors"
  },
  {
    "conteudo":"beyond dietary intake (e.g. medication use, knowledge, beliefs, attitudes, behavior and"
  },
  {
    "conteudo":"access to food, depression, cognitive function etc.) to effectively plan nutrition"
  },
  {
    "conteudo":"interventions. (OPINION)."
  },
  {
    "conteudo":"3 Day Food Records to Assess Dietary Intake"
  },
  {
    "conteudo":"1.6.2 In adults with CKD 3-5D, we suggest the use of a 3-day food record, conducted"
  },
  {
    "conteudo":"during both dialysis and non-dialysis treatment days (when applicable), as a preferred"
  },
  {
    "conteudo":"method to assess dietary intake (2C)."
  },
  {
    "conteudo":"Alternative Methods of Assessing Dietary Intake"
  },
  {
    "conteudo":"1.6.3 In adults with CKD 3-5 (OPINION) and 5D (2D), 24-hour food recalls, food"
  },
  {
    "conteudo":"frequency questionnaires and normalized protein catabolic rate (nPCR)\/normalized"
  },
  {
    "conteudo":"protein catabolic rate (nPCR) may be considered as alternative methods of assessing"
  },
  {
    "conteudo":"dietary energy and protein intake (2D)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Poor nutritional intake and obesity are prevalent among patients diagnosed with CKD and"
  },
  {
    "conteudo":"therefore, it is important to monitor dietary intake that provides information on total energy,"
  },
  {
    "conteudo":"macro- and micro-nutrients as well as overall food\/liquid servings and eating patterns. In this"
  },
  {
    "conteudo":"context, it is important to identify reliable methods for estimating dietary intake in diverse care"
  },
  {
    "conteudo":"settings. Under- and over-reporting of intake are a concern in this population."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"A total of six studies reported on use of methods to assess protein and energy intake in CKD"
  },
  {
    "conteudo":"subjects.105-111"
  },
  {
    "conteudo":"Food Records\/Diary"
  },
  {
    "conteudo":"Based on the findings of four studies, food records\/diary for assessing dietary intake of protein"
  },
  {
    "conteudo":"and calories were reliable and correlated with reference standards. Food records can provide"
  },
  {
    "conteudo":"accurate information if patients are instructed and trained, and food intake is recorded for at"
  },
  {
    "conteudo":"least 7 days. 107-109. Two studies used food diary\/3-day food records to determine"
  },
  {
    "conteudo":"underreporting of energy intake in non-dialyzed and PD patients.105, 106 Underreporting was"
  },
  {
    "conteudo":"Page 71"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"noticed in 72.5% of non-dialyzed CKD patients and 52.5% PD patients. Both the studies"
  },
  {
    "conteudo":"indicated that underreporting was more pronounced in overweight patients. Shapiro et al."
  },
  {
    "conteudo":"compared energy intake measured by 3-day food record (dietitian interview-assisted) and REE"
  },
  {
    "conteudo":"measured by indirect calorimetry. Energy intake reported by interview-assisted food records were lower"
  },
  {
    "conteudo":"than measured REE.111"
  },
  {
    "conteudo":"Food Frequency Questionnaires"
  },
  {
    "conteudo":"Delgado et al. conducted a validation study comparing Block Brief 2000 food frequency"
  },
  {
    "conteudo":"questionnaire (BFFQ) against 3-day food diary records112 and found the Block Brief 2000"
  },
  {
    "conteudo":"food frequency questionnaire under-estimated energy and macronutrient intake in patients"
  },
  {
    "conteudo":"on hemodialysis. However, the use of simple calibration equations can be used to obtain"
  },
  {
    "conteudo":"intake similar to 3-day food diary records."
  },
  {
    "conteudo":"Protein Catabolic Rate"
  },
  {
    "conteudo":"Three studies examined the use of protein catabolic rate (PCR) to assess protein intake in CKD"
  },
  {
    "conteudo":"patients,110, 113, 114 and found significant correlations with reference standards for measuring"
  },
  {
    "conteudo":"dietary intake (ex: food records). However, PCR overestimated protein intake when daily"
  },
  {
    "conteudo":"protein intake was <1 g\/kg and when daily protein intake was >1 g\/kg it was underestimated by"
  },
  {
    "conteudo":"PCR. In PD patients, PNA (PCR) normalized to desirable body weight was correlated better"
  },
  {
    "conteudo":"with BUN (r=0.702) and Kt\/V (r=0.348). 114"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Despite the food record\/diary being the most reliable and valid measure of dietary intake"
  },
  {
    "conteudo":"among patients diagnosed with CKD, it does rely on accurate reporting inclusive of portion"
  },
  {
    "conteudo":"sizes. The food record may be seen as cumbersome to complete for several days and is limited"
  },
  {
    "conteudo":"to individuals that are able to read and record intake reliably. With the generation of"
  },
  {
    "conteudo":"smartphone applications, there has been a burgeoning interest in recording dietary intake using"
  },
  {
    "conteudo":"technology, with limited success in its adoption among certain subgroups (e.g., elderly). In"
  },
  {
    "conteudo":"non-dialyzed CKD patients. 24-hour urine collection to measure urine urea nitrogen (UUN),"
  },
  {
    "conteudo":"sodium and potassium is more reliable to yield estimates of DPI, sodium and potassium."
  },
  {
    "conteudo":"Dietary intake methods may need to be simplified, modified, or be combined with a few"
  },
  {
    "conteudo":"strategies in order to obtain reliable dietary intake data, with emphasis on them being"
  },
  {
    "conteudo":"Page 72"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"culturally appropriate."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Routine dietary assessment among adults diagnosed with CKD stages 1-5D should"
  },
  {
    "conteudo":"occur to allow for the identification and treatment of nutritional concerns related to"
  },
  {
    "conteudo":"nutrient intake."
  },
  {
    "conteudo":"• Assessing dietary intake using multiple, complementary methods, such as FFQ and"
  },
  {
    "conteudo":"24-hr urine collection to measure urine urea nitrogen, sodium and potassium, may"
  },
  {
    "conteudo":"be useful to confirm accuracy of dietary intake estimates."
  },
  {
    "conteudo":"● Dietary assessment should be conducted at the initial visit and completed whenever"
  },
  {
    "conteudo":"there is a change in health status or as per institutional or regulatory policies."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"A thorough assessment of dietary intake will guide the nutrition intervention prescribed. The"
  },
  {
    "conteudo":"clinician should monitor key nutrition care outcomes based on the treatment plan and re-assess"
  },
  {
    "conteudo":"and change the plan accordingly to achieve the goals established."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Identify the best methods for dietary assessment among adults diagnosed with CKD"
  },
  {
    "conteudo":"stages 1-5D and those receiving a kidney transplant."
  },
  {
    "conteudo":"● Focus on how to better determine instances of under- and over-reporting of dietary"
  },
  {
    "conteudo":"intake in this population."
  },
  {
    "conteudo":"● Further development and testing of dietary assessment tools to integrate technology and"
  },
  {
    "conteudo":"assist individuals with limited literacy, vision, and are culturally appropriate."
  },
  {
    "conteudo":"Page 73"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"GUIDELINE 2: MEDICAL NUTRITION THERAPY"
  },
  {
    "conteudo":"2.1 Statements on Medical Nutrition Therapy (MNT)"
  },
  {
    "conteudo":"MNT to Improve Outcomes"
  },
  {
    "conteudo":"2.1.1 In adults with CKD 1-5D, we recommend that a registered dietitian nutritionist"
  },
  {
    "conteudo":"(RDN, USA or international nutrition credential) in close collaboration with a"
  },
  {
    "conteudo":"physician, or other provider (nurse practitioner or physician assistant), provide medical"
  },
  {
    "conteudo":"nutrition therapy (MNT). Goals are to optimize nutritional status, and to minimize risks"
  },
  {
    "conteudo":"imposed by co-morbidities and alterations in metabolism on the progression of kidney"
  },
  {
    "conteudo":"disease (1C) and on adverse clinical outcomes (OPINION)."
  },
  {
    "conteudo":"MNT Content"
  },
  {
    "conteudo":"2.1.2 In adults with CKD 1-5D and post-transplant, it is reasonable to prescribe MNT"
  },
  {
    "conteudo":"that is tailored to the individuals’ needs, nutritional status and co-morbid conditions"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"MNT Monitoring and Evaluation"
  },
  {
    "conteudo":"2.1.3 In adults with CKD 3-5D and post-transplant, it is reasonable for the registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or an international equivalent to monitor and evaluate"
  },
  {
    "conteudo":"appetite, dietary intake, biochemical data, anthropometric measurements, and nutrition-"
  },
  {
    "conteudo":"focused physical findings to assess the effectiveness of medical nutrition therapy"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Individualized management of nutritional intake is a crucial aspect of care for individuals"
  },
  {
    "conteudo":"diagnosed with any stage of CKD, including those on maintenance dialysis and those who have"
  },
  {
    "conteudo":"received a kidney transplant. These patients are vulnerable for nutritional abnormalities, which"
  },
  {
    "conteudo":"are associated with higher risk for morbidity, mortality, and length of hospital stay. Nutritional"
  },
  {
    "conteudo":"needs change throughout the disease course, from the earlier stages of CKD to the post-"
  },
  {
    "conteudo":"transplant period. The metabolic abnormalities and co-morbid diseases that often accompany"
  },
  {
    "conteudo":"CKD further emphasize the need for specialized nutrition health care. Therefore, it is essential"
  },
  {
    "conteudo":"that such individuals receive tailored nutrition assessment and counseling in the form of MNT."
  },
  {
    "conteudo":"MNT is a collaborative approach that typically requires the medical expertise and prescription"
  },
  {
    "conteudo":"of MNT by a physician or other provider (nurse practitioner, physician assistant) and"
  },
  {
    "conteudo":"implementation by an RDN, or international equivalent). These roles are not mutually"
  },
  {
    "conteudo":"exclusive and involve ongoing team-patient analysis and discussion. Participating providers"
  },
  {
    "conteudo":"Page 74"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"and RDN are recommended to have received specialized education and training in nutrition"
  },
  {
    "conteudo":"and CKD in accordance with the requirements set forth by local regulations."
  },
  {
    "conteudo":"Medical Nutrition Therapy (MNT)"
  },
  {
    "conteudo":"In 2002, the then American Dietetic Association published a nutrition care model that provided"
  },
  {
    "conteudo":"evidence-based, high-quality standardized care for patients with CKD, non-dialyzed and post-"
  },
  {
    "conteudo":"transplant.115 The document was later revised in 2010, which reported that nutrition care"
  },
  {
    "conteudo":"provided by an RD up to twice monthly over a one-year period can have a valuable role in the"
  },
  {
    "conteudo":"medical care of the CKD patients by:"
  },
  {
    "conteudo":"● Providing nutrition assessment and interventions to delay kidney disease progression in"
  },
  {
    "conteudo":"addition to co-morbid conditions such as diabetes mellitus, cardiovascular disease,"
  },
  {
    "conteudo":"dyslipidemia, gout, nephrolithiasis;"
  },
  {
    "conteudo":"● Utilizing behavioral methods to individualize the approach and minimize barriers to"
  },
  {
    "conteudo":"individualized goals;"
  },
  {
    "conteudo":"● Providing individualized meal plans and follow up on adherence and successful"
  },
  {
    "conteudo":"implementation. Interventions include but are not limited to weight management and"
  },
  {
    "conteudo":"maintenance\/repletion of patient nutritional status;"
  },
  {
    "conteudo":"● Addressing inflammation, supporting obtaining a euvolemic state, contributing to"
  },
  {
    "conteudo":"correction of electrolyte abnormalities, assisting in anemia management and managing"
  },
  {
    "conteudo":"bone disease through nutrition assessment and dietary interventions including"
  },
  {
    "conteudo":"individualized meal plans;"
  },
  {
    "conteudo":"● Assisting identifying medication errors and need for adjustment- in collaboration with"
  },
  {
    "conteudo":"nephrology Provider (Medical Doctor, Nurse Practitioner, Physician Assistant);"
  },
  {
    "conteudo":"● Providing and updating nutrition therapy as new knowledge emerges."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"MNT requires nutrition screening and assessment of nutritional status to provide individualized"
  },
  {
    "conteudo":"treatment for specific disease states. CKD patients are on a dynamic nutrition trajectory"
  },
  {
    "conteudo":"according to their disease stage and MNT is needed at each stage of CKD. Metabolic"
  },
  {
    "conteudo":"abnormalities, acid base, fluid and electrolyte balances often change as CKD progresses. For"
  },
  {
    "conteudo":"Page 75"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"example, a patient can be hypokalemic during Stage 2 CKD requiring potassium"
  },
  {
    "conteudo":"supplementation and a high potassium diet. Months or years later, this same patient during"
  },
  {
    "conteudo":"Stage 4 CKD might become hyperkalemic, requiring medication adjustment and dietary"
  },
  {
    "conteudo":"potassium restriction rather than supplementation. Should this same patient receive a kidney"
  },
  {
    "conteudo":"transplant, they might stabilize potassium balance and have no need for potassium"
  },
  {
    "conteudo":"supplementation or dietary potassium restriction. This type of complicated CKD patients"
  },
  {
    "conteudo":"requires specialized nutrition health care and ongoing monitoring by a nephrology RDN."
  },
  {
    "conteudo":"Sixteen RCTs examining the effect of MNT on nutrition-related outcomes were identified in"
  },
  {
    "conteudo":"the systematic review. However, these studies were heterogeneous in terms of the populations"
  },
  {
    "conteudo":"(five studies included patients who were non-dialyzed, nine included patients on MHD, one"
  },
  {
    "conteudo":"included patients on CAPD, and one included patients post-transplant); interventions (ex:"
  },
  {
    "conteudo":"RDNs utilized various methods of nutritional counseling among the studies); and outcomes"
  },
  {
    "conteudo":"(ex: protein intake, serum phosphate, serum albumin, BMI, and dyslipidemia. Intervention"
  },
  {
    "conteudo":"durations ranged from four weeks to two years."
  },
  {
    "conteudo":"CKD Progression"
  },
  {
    "conteudo":"In four of the studies ranging from 4 weeks to 4 months, authors found no effect of MNT on"
  },
  {
    "conteudo":"CKD progression in non-dialyzed patients compared to participants receiving standard"
  },
  {
    "conteudo":"nutrition education for CKD, which may or may not have also been provided by an RDN."
  },
  {
    "conteudo":"Interventions ranged from one in-person contact plus phone contacts with the RDN for 12"
  },
  {
    "conteudo":"weeks (Stage 4 CKD)116 to a multi-disciplinary intervention including 4 weeks of weekly"
  },
  {
    "conteudo":"counselling with an RDN (Stages 3-4 CKD)117 to 2, two-hour cooking classes and a"
  },
  {
    "conteudo":"shopping tour (Stages 2-4 CKD)118 to nutrition counselling plus nutrition education for four"
  },
  {
    "conteudo":"months (Stages 3-5 CKD).119"
  },
  {
    "conteudo":"SGA Scores"
  },
  {
    "conteudo":"Three RCTs, including two study populations, reported on the effect of MNT on SGA scores."
  },
  {
    "conteudo":"Campbell et al. demonstrated that malnourished Stage 4 CKD patients’ SGA scores"
  },
  {
    "conteudo":"significantly improved in the intervention group compared to the control group, for whom"
  },
  {
    "conteudo":"malnutrition by SGA score increased.116 The intervention consisted of nutritional counselling"
  },
  {
    "conteudo":"Page 76"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"from an RDN for 12 weeks, with an emphasis on self-management techniques, face-to-face"
  },
  {
    "conteudo":"consultation at baseline, and telephone consultation every two weeks for the first month, and"
  },
  {
    "conteudo":"then monthly for the next 2 months. In Leon et al., MHD participants received monthly"
  },
  {
    "conteudo":"consultation by RDN for 12 months.120 Intervention RDNs were trained to determine"
  },
  {
    "conteudo":"potential barriers to achieving normal albumin levels for each patient, to attempt to overcome"
  },
  {
    "conteudo":"the barriers, and to monitor for improvements in barriers. There was no difference in the"
  },
  {
    "conteudo":"percentage of participants that had improved or decreased SGA scores between groups."
  },
  {
    "conteudo":"BMI"
  },
  {
    "conteudo":"Four RCTs examined the effect of MNT interventions on BMI, including two studies with non-"
  },
  {
    "conteudo":"dialyzed patients (Stages 3-5 CKD),117, 119 one study with MHD participants120 and one with"
  },
  {
    "conteudo":"post- transplant patients.121 Howden et al. examined the effect of a 12-month multi-disciplinary"
  },
  {
    "conteudo":"lifestyle intervention on BMI in patients with stages 3-4 CKD.117 The intervention group"
  },
  {
    "conteudo":"received 4 weeks of group behavioral and lifestyle modification sessions provided by an RDN"
  },
  {
    "conteudo":"and a psychologist. Mean BMI significantly decreased in the intervention group compared to"
  },
  {
    "conteudo":"the standard care group (p<0.01). Paes-Barreto et al., examined the effect of MNT on BMI 119"
  },
  {
    "conteudo":"in participants with stages 3-5 CKD who received individualized dietary counselling monthly"
  },
  {
    "conteudo":"for four months. In addition to the routine counselling, an intervention group received intensive"
  },
  {
    "conteudo":"counselling, which included nutrition education materials emphasizing a low-protein and low-"
  },
  {
    "conteudo":"sodium diet. There was a significantly greater decrease in BMI in the intervention group"
  },
  {
    "conteudo":"compared to the standard care group (p<0.01). In Leon et al., MHD participants received"
  },
  {
    "conteudo":"monthly consultation by an RDN to determine and address barriers to reaching normal serum"
  },
  {
    "conteudo":"albumin levels for 12 months.120 There was no effect on BMI, though this was not the objective"
  },
  {
    "conteudo":"of the intervention. Finally, in Orazio et al., intervention participants received RDN counselling"
  },
  {
    "conteudo":"using a Mediterranean-style diet, which consisted of a low glycemic index and moderate energy"
  },
  {
    "conteudo":"deficit. MNT counselling was based the Stages of Change Model.121 There was no difference in"
  },
  {
    "conteudo":"change in BMI between groups after 2 years."
  },
  {
    "conteudo":"In a meta-analysis of two studies, participants who received MNT had a greater mean (95% CI)"
  },
  {
    "conteudo":"decrease in BMI compare to the control groups [-0.89 (=1.52, -0.25) kg\/m2].119, 121 Results"
  },
  {
    "conteudo":"Page 77"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"regarding effect of MNT on arm and waist circumference as well as body composition were"
  },
  {
    "conteudo":"limited and unclear."
  },
  {
    "conteudo":"Phosphate Levels"
  },
  {
    "conteudo":"Eight studies examined the effect of MNT on phosphorus\/phosphate levels in MHD patients for"
  },
  {
    "conteudo":"durations ranging from 8 weeks to 6 months. In Ashurst et al. and Lou et al., phosphorus-"
  },
  {
    "conteudo":"focused education, provided once and monthly for 6 months, respectively, significantly"
  },
  {
    "conteudo":"improved (decreased) mean serum phosphate levels.122, 123 In Karavetian et al., weekly"
  },
  {
    "conteudo":"education nutrition counselling for 2 months also decreased phosphate levels (p<0.01).124"
  },
  {
    "conteudo":"However, Morey et al. also used phosphorus-focused RDN counselling and education, monthly"
  },
  {
    "conteudo":"for 6 months, and found no difference in change in phosphate levels between groups at 6"
  },
  {
    "conteudo":"months.125"
  },
  {
    "conteudo":"Participants receiving a multi-disciplinary nutrition education program did not have any"
  },
  {
    "conteudo":"changes in phosphate levels compared to participants receiving an oral nutrition supplement"
  },
  {
    "conteudo":"(ONS).126 In Reese et al., participants who were coached by a trained RDN about dietary and"
  },
  {
    "conteudo":"medication adherence (≥3 times a week) for 10 weeks were compared to patients receiving a"
  },
  {
    "conteudo":"financial incentive or usual care.127 There were no between-group differences in change in"
  },
  {
    "conteudo":"phosphate levels. There was no effect of MNT in the form of dietary counselling in CAPD"
  },
  {
    "conteudo":"patients128 or in the form of RDN counselling plus low-protein and low-sodium diet education"
  },
  {
    "conteudo":"in non-dialyzed patients119 on phosphate levels, but the objectives of these studies were to"
  },
  {
    "conteudo":"improve energy, protein and sodium intake."
  },
  {
    "conteudo":"Meta-analysis of four studies with comparable data revealed that, mean (95% CI)"
  },
  {
    "conteudo":"phosphorus\/phosphate levels were decreased -0.715 (-1.395, -0.034) mg\/dL, however"
  },
  {
    "conteudo":"heterogeneity is high (I2=67.71%, p=0.015). Thus, there was evidence that MNT decreased"
  },
  {
    "conteudo":"phosphorus\/phosphate levels in MHD patients,125, 126, 129 but effect on phosphorus\/phosphate"
  },
  {
    "conteudo":"levels as well as the effect on calcium or potassium levels in non-dialyzed patients,119 was"
  },
  {
    "conteudo":"unclear."
  },
  {
    "conteudo":"Lipid Profile"
  },
  {
    "conteudo":"Three RCTs examined the effect of MNT from an RDN on lipid profile.117, 118, 126 In"
  },
  {
    "conteudo":"Hernandez-Morante et al., MHD participants in the intervention group received a 12-session"
  },
  {
    "conteudo":"multi- disciplinary Nutrition Education Program over four months, including group and"
  },
  {
    "conteudo":"Page 78"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"individual therapy, while control participants received an oral nutrition supplement three"
  },
  {
    "conteudo":"days\/week.126Within group analysis showed no significant changes in mean triglycerides"
  },
  {
    "conteudo":"and total cholesterol levels over 4 months. There was a significant increase in mean low-"
  },
  {
    "conteudo":"density lipoprotein cholesterol (LDL-C) and a significant decrease in mean high-density"
  },
  {
    "conteudo":"lipoprotein cholesterol (HDL-C) in both groups over the 4-month study period (p<0.001 for"
  },
  {
    "conteudo":"each measure). Between-group analysis was not reported."
  },
  {
    "conteudo":"Both Howden et al. and Flesher et al. examined the effect of MNT in Stages 3-4 CKD"
  },
  {
    "conteudo":"participants. In Howden et al., intervention participants received a multi-disciplinary lifestyle"
  },
  {
    "conteudo":"intervention for 12 months.117 It included 4 weeks of group behavioral and lifestyle"
  },
  {
    "conteudo":"modification by an RDN and a psychologist. No significant changes were observed in"
  },
  {
    "conteudo":"triglyceride or total, HDL or LDL cholesterol levels between the 2 groups. In Flesher et al., in"
  },
  {
    "conteudo":"addition to the standard nutrition care for CKD, the intervention group received cooking"
  },
  {
    "conteudo":"classes over 4 weeks for 2 hours per session and a shopping tour led by an RDN.118 No"
  },
  {
    "conteudo":"significant difference was observed in mean total cholesterol level between the 2 groups."
  },
  {
    "conteudo":"Pooled analysis confirmed no effect of MNT on total cholesterol and triglyceride levels."
  },
  {
    "conteudo":"However, in pooled analysis, LDL levels were decreased by MNT (Mean (95% CI): -6.022 (-"
  },
  {
    "conteudo":"7.754, -4.290) mg\/dL. There was no clear effect of MNT on blood pressure (BP)."
  },
  {
    "conteudo":"Protein intake"
  },
  {
    "conteudo":"Six RCTs examined the effect of MNT on protein intake in CKD patients. Two of those studies"
  },
  {
    "conteudo":"targeted protein intake as their primary outcome of the MNT provided to the participants."
  },
  {
    "conteudo":"Paes-Barreto et al. educated non-dialysis patients on eating a low protein diet (LPD),119 while"
  },
  {
    "conteudo":"Leon et al. counseled MHD participants on following a high protein diet.120 Both studies showed"
  },
  {
    "conteudo":"high compliance of recommended protein intake among the participants in the intervention"
  },
  {
    "conteudo":"group as compared to the control group. The other four studies did not show any significant"
  },
  {
    "conteudo":"differences in protein intake between the intervention and control groups, but protein intake was"
  },
  {
    "conteudo":"not the primary outcome."
  },
  {
    "conteudo":"The utilization of MNT protocols has the potential to preserve nutritional status, modify risk"
  },
  {
    "conteudo":"factors for progression of kidney disease, as well as assist with living with CKD from a diet"
  },
  {
    "conteudo":"Page 79"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"and lifestyle prospective through teaching patient’s healthy food choices in an"
  },
  {
    "conteudo":"individualized manner."
  },
  {
    "conteudo":"Special Discussions"
  },
  {
    "conteudo":"The full utility and value of MNT provided by the RDN on both nutrition outcomes and risk of"
  },
  {
    "conteudo":"morbidity, mortality and hospitalizations has not yet been fully identified. The impact of the"
  },
  {
    "conteudo":"RDN in many disease states and the value of repeated contacts with an RDN on specific"
  },
  {
    "conteudo":"nutrition parameters has been documented in the literature 130. This is particularly true for CKD"
  },
  {
    "conteudo":"patients as well as in other disease states and metabolic phenotypes such as obesity that affect"
  },
  {
    "conteudo":"CKD risk and exacerbation of CKD progression. While MNT outcomes research is still in its"
  },
  {
    "conteudo":"infancy, the studies that do exist exhibit important relationships on nutrition parameters and"
  },
  {
    "conteudo":"other outcomes. An MNT database that monitors MNT intervention effectiveness on nutrition"
  },
  {
    "conteudo":"and overall outcome parameters would enable the formalization of this analysis. Studies that"
  },
  {
    "conteudo":"prove causality or significant association between MNT application and patient outcomes is"
  },
  {
    "conteudo":"currently in progress. In addition, the strength of the evidence in studies reviewed prohibits"
  },
  {
    "conteudo":"strong recommendations due to the variability in study populations, protocols and analyses."
  },
  {
    "conteudo":"Therefore, this section included recommendations that are mostly opinion based."
  },
  {
    "conteudo":"MNT facilitates the delivery of Nutrition Practice Guidelines through a systemic approach of"
  },
  {
    "conteudo":"delivery that is based on scientific evidence and expert opinion. The education, content and"
  },
  {
    "conteudo":"practice expertise for the provision of MNT individualized care is found within the scope of"
  },
  {
    "conteudo":"practice of the RDN with expertise in nephrology."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Evidence based protocols are inherent to MNT but do not replace individualized"
  },
  {
    "conteudo":"modification."
  },
  {
    "conteudo":"● Implementation of MNT for CKD patients requires the formation of a fiscal structure"
  },
  {
    "conteudo":"that will support the integration of MNT into routine medical management of CKD"
  },
  {
    "conteudo":"patients. The interest level to integrate MNT into clinical practice exists by many"
  },
  {
    "conteudo":"nephrology and general medicine clinics, however, the lack of adequate reimbursement"
  },
  {
    "conteudo":"for RDN services may preclude the opportunity to pursue implementation."
  },
  {
    "conteudo":"Page 80"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"● Demand for MNT is growing as the global prevalence of CKD increases."
  },
  {
    "conteudo":"Reimbursement policies for disease prevention need to include MNT. Legislation"
  },
  {
    "conteudo":"awareness is needed to disseminate the value of MNT."
  },
  {
    "conteudo":"● MNT may be delivered through telehealth options, in order to improve patient"
  },
  {
    "conteudo":"education and successful maintenance of nutrition interventions and adherence."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Monitoring and evaluation of MNT on patient’s nutritional parameters is an essential"
  },
  {
    "conteudo":"component of treatment and includes assessment of patient’s labs, nutritional status, etiology of"
  },
  {
    "conteudo":"kidney disease, lifestyle (stress, exercise, evaluation of smoking and alcohol use, etc.), and"
  },
  {
    "conteudo":"patient identified nutrition goals."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Development of an MNT database is imperative to the formalization of MNT outcomes"
  },
  {
    "conteudo":"research."
  },
  {
    "conteudo":"● Evaluation of the Impact of MNT care on progression of kidney disease by analysis of"
  },
  {
    "conteudo":"association with risk factors of co-morbid conditions is necessary."
  },
  {
    "conteudo":"● Patient outcomes pertaining to the individualized nutrition plan formulated for patients"
  },
  {
    "conteudo":"and \/or group classes to evaluate the effectiveness of the therapy should be explored in"
  },
  {
    "conteudo":"future studies."
  },
  {
    "conteudo":"• Research examining access to MNT as well as methods (ex: fiscal, referral, etc.) that"
  },
  {
    "conteudo":"support MNT access for individuals with CKD."
  },
  {
    "conteudo":"Page 81"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"GUIDELINE 3: PROTEIN AND ENERGY INTAKE"
  },
  {
    "conteudo":"3.0 Statement on Energy Intake"
  },
  {
    "conteudo":"3.0.1 In adults with CKD 1-5D (1C) and post-transplant (OPINION) who are"
  },
  {
    "conteudo":"metabolically stable, we recommend prescribing an energy intake of 25-35 kcal\/kg"
  },
  {
    "conteudo":"LBM per day based on age, gender, level of physical activity, body composition,"
  },
  {
    "conteudo":"weight status goals, CKD stage, and concurrent illness or presence of inflammation"
  },
  {
    "conteudo":"to maintain normal nutritional status."
  },
  {
    "conteudo":"3.1 Statements on Protein Amount"
  },
  {
    "conteudo":"Protein Restriction, Non-Dialysis"
  },
  {
    "conteudo":"3.1.1 In adults with CKD 3-5 who are metabolically stable, we recommend protein"
  },
  {
    "conteudo":"restriction with or without keto acid analogs, to reduce risk for ESRD\/death (1A) and"
  },
  {
    "conteudo":"improve QoL (1C). Protein restriction should be supervised by a registered dietitian"
  },
  {
    "conteudo":"nutritionist (RDN) or equivalent in collaboration with a physician."
  },
  {
    "conteudo":"● a low protein diet providing 0.55 to 0.60 g dietary protein\/kg ideal body"
  },
  {
    "conteudo":"weight\/day, OR"
  },
  {
    "conteudo":"● a very-low protein diet providing 0.28 to 0.43 g dietary protein\/kg ideal"
  },
  {
    "conteudo":"body weight\/day with additional keto acid analogs to meet protein"
  },
  {
    "conteudo":"requirements (0.55 to 0.60 g \/kg body weight\/day)"
  },
  {
    "conteudo":"Dietary Protein Intake, Maintenance Hemodialysis and Peritoneal Dialysis"
  },
  {
    "conteudo":"3.1.2 In adults with CKD on MHD (1C) and PD (OPINION) who are metabolically"
  },
  {
    "conteudo":"stable, we recommend prescribing a dietary protein intake of 1.0 -1.2 g \/kg ideal body"
  },
  {
    "conteudo":"weight per day to maintain a stable nutritional status."
  },
  {
    "conteudo":"Dietary Protein Intake, Diabetes Mellitus"
  },
  {
    "conteudo":"3.1.3 In the adult with CKD 3-5 and who have diabetes, it is reasonable to prescribe a"
  },
  {
    "conteudo":"dietary protein intake of 0.8 – 0.9 g \/kg ideal body weight per day to maintain a stable"
  },
  {
    "conteudo":"nutritional status and optimize glycemic control (OPINION)."
  },
  {
    "conteudo":"3.1.4 In adults with CKD on MHD and PD and who have diabetes, it is reasonable to"
  },
  {
    "conteudo":"prescribe a dietary protein intake of 1.0 -1.2 g \/kg ideal body weight per day to"
  },
  {
    "conteudo":"maintain a stable nutritional status. For patients at risk of hyper and\/or hypoglycemia,"
  },
  {
    "conteudo":"higher levels of dietary protein intake may need to be considered to maintain glycemic"
  },
  {
    "conteudo":"control (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Page 82"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Protein metabolism in the body is responsible for adequate growth in children and maintenance"
  },
  {
    "conteudo":"of body protein mass such as muscle mass in adults. Every day, approximately 250 g of protein"
  },
  {
    "conteudo":"are catabolized, leading to protein catabolic products, such as urea and many other known or"
  },
  {
    "conteudo":"unidentified compounds. Most of these degradation products are normally cleared by the"
  },
  {
    "conteudo":"kidneys and excreted in urine. When kidney function declines, there will be an accumulation"
  },
  {
    "conteudo":"of these by-products into the blood, which will progressively impair organ function131 This has"
  },
  {
    "conteudo":"been clearly identified for compounds such as P-cresylsulphate, indoxyl-sulphate, trimethyl"
  },
  {
    "conteudo":"aminoxide, fibroblast-growth factor 23, which are now considered as uremic toxins. Secondly,"
  },
  {
    "conteudo":"protein intake is responsible for a major fraction of kidney workload, and many experimental"
  },
  {
    "conteudo":"and clinical research have confirmed the renal effects of a protein load and a deleterious role of"
  },
  {
    "conteudo":"the renal hyperfiltration response associated with protein intake. Therefore, in a situation of"
  },
  {
    "conteudo":"nephron reduction, such as CKD, reducing protein intake will reduce hyperfiltration, with an"
  },
  {
    "conteudo":"additive effect to those of angiotensin-reducing drugs.131 As a consequence of both actions,"
  },
  {
    "conteudo":"reducing uremia and uremic toxins on one hand and improving renal hemodynamics on the"
  },
  {
    "conteudo":"other hand, a reduction in protein intake may reduce clinical symptoms and postpone the need to"
  },
  {
    "conteudo":"start maintenance dialysis treatment."
  },
  {
    "conteudo":"In the context of these recommendations, “metabolically stable” indicates absence of any active"
  },
  {
    "conteudo":"inflammatory or infectious diseases; no hospitalization within two weeks; absence of poorly"
  },
  {
    "conteudo":"controlled diabetes and consumptive diseases such as cancer; absence of antibiotics or"
  },
  {
    "conteudo":"immunosuppressive medications; and absence of significant short-term loss of body weight."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Energy Intake"
  },
  {
    "conteudo":"Energy metabolism maybe impaired in patients with chronic kidney disease. Hence, maintaining"
  },
  {
    "conteudo":"adequate energy intake is necessary to prevent protein-energy wasting."
  },
  {
    "conteudo":"Evidence from ten controlled trials in pre-dialysis population and from 3 studies in MHD patients"
  },
  {
    "conteudo":"indicates that energy intake ranging from 30-35 kcal\/kg\/d helps maintain neutral nitrogen balance"
  },
  {
    "conteudo":"and nutritional status.132-144However, it is important to remember that many other factors may"
  },
  {
    "conteudo":"influence energy expenditure beyond traditional determinants like age, sex, and fat-free"
  },
  {
    "conteudo":"mass. Some of these factors include hyperparathyroidism, hyperglycemia, and chronic"
  },
  {
    "conteudo":"Page 83"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"inflammation that should be considered into the overall energy prescription, health status (e.g.,"
  },
  {
    "conteudo":"acutely ill versus chronically managed), overall health goals, and weight maintenance--repletion"
  },
  {
    "conteudo":"or loss."
  },
  {
    "conteudo":"There is still paucity of controlled metabolic studies, as well as long-term well-designed"
  },
  {
    "conteudo":"outpatient clinical trials studying energy intake in this population. Results from an old metabolic"
  },
  {
    "conteudo":"study examining energy requirements in MHD (sample size = 6) indicated that mean energy"
  },
  {
    "conteudo":"intake of 35 kcal\/kg\/d helped maintain neutral nitrogen balance and body composition.145"
  },
  {
    "conteudo":"Another similar study in 6 individuals indicated that average intake of 38 kcal was desirable to"
  },
  {
    "conteudo":"maintain neutral nitrogen balance.146 Recent review articles not included in this evidence review,"
  },
  {
    "conteudo":"also suggest that energy intake in the range of 30-35 kcal\/kg\/d is appropriate to maintain"
  },
  {
    "conteudo":"maintains neutral nitrogen balance and nutritional status.131, 147"
  },
  {
    "conteudo":"Protein intake"
  },
  {
    "conteudo":"Reducing protein intake may impair nutritional status in individuals at risk for PEW. However,"
  },
  {
    "conteudo":"it is a well-known fact that adults in western countries eat too much protein (1.35 g"
  },
  {
    "conteudo":"protein\/kg\/d) as compared with their optimal daily needs, estimated to be 0.8 g protein\/kg\/day."
  },
  {
    "conteudo":"Further, metabolic balances in healthy adults and CKD patients have confirmed that, provided"
  },
  {
    "conteudo":"a sufficient energy intake (e.g., above 30 kcal\/kg\/d), the protein intake level can be safely"
  },
  {
    "conteudo":"decreased to 0.55-0.6 g protein\/kg\/d. A further reduction in protein intake to 0.3-0.4 g"
  },
  {
    "conteudo":"protein\/kg\/d can be achieved with the addition of pills of keto acid analogs to ensure a"
  },
  {
    "conteudo":"sufficient balance of the essential amino acids (EAAs) normally brought by animal proteins,"
  },
  {
    "conteudo":"which are essentially absent in these low protein vegan-like diets."
  },
  {
    "conteudo":"PROTEIN RESTRICTION ALONE"
  },
  {
    "conteudo":"In adults with CKD\/kidney transplant, thirteen RCTs reported the effect of protein restriction"
  },
  {
    "conteudo":"only (no supplementation) on outcomes of interest.136, 138, 143, 144, 148-156 Duration of the"
  },
  {
    "conteudo":"follow-up in the included studies ranged from 3 months to 48 months. (Appendix – study"
  },
  {
    "conteudo":"characteristics table)"
  },
  {
    "conteudo":"Survival\/Renal Death"
  },
  {
    "conteudo":"Research reports a beneficial effect of protein restriction (0.55-0.6 g\/kg\/d) on ESRD\/death in"
  },
  {
    "conteudo":"Page 84"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"adults with CKD. In adults with CKD, 5 RCTs reported findings on effect of protein restriction"
  },
  {
    "conteudo":"on survival\/deaths. Three studies clearly indicated a beneficial effect of moderate restriction in"
  },
  {
    "conteudo":"dietary protein on the development of ESRD\/death.140, 151, 155 Rosman et al. indicated people"
  },
  {
    "conteudo":"consuming 0.6 g\/kg\/d of protein had better survival (55%) compared to patients consuming free"
  },
  {
    "conteudo":"protein intake (40%).155 Hansen et al. indicated that death or ESRD was significantly lower in"
  },
  {
    "conteudo":"low protein intake group (0.6g\/kg\/d) (10%) compared to usual protein intake (27%).151"
  },
  {
    "conteudo":"Locatelli et al. also showed that LPD (0.6 g\/kg\/d) had fewer events (27\/192) compared to usual"
  },
  {
    "conteudo":"protein intake (1g\/kg\/d) (42\/188), borderline significant (p<0.06).140 Whereas, Cianciaruso et"
  },
  {
    "conteudo":"al. indicated that cumulative incidences of death and dialysis therapy start were unaffected by"
  },
  {
    "conteudo":"the diet regimen, and low protein intake group (0.55 g\/kg\/d) does not seem to confer a survival"
  },
  {
    "conteudo":"advantage compared with a moderate protein intake group (0.80 g\/kg\/d) but may be explained"
  },
  {
    "conteudo":"by a relatively small sample size.148 Pooled together, results from the secondary analysis on the"
  },
  {
    "conteudo":"number of events of death\/ESRD combined from the three studies indicated a beneficial effect"
  },
  {
    "conteudo":"of protein restriction on death \/ESRD (OR 0.621 CI: 0.391, 0.985). 140, 148, 151"
  },
  {
    "conteudo":"Quality of Life"
  },
  {
    "conteudo":"Research reports an improved quality of life of a protein restricted diet in one study. In adults"
  },
  {
    "conteudo":"with CKD, one RCT examined the effect of protein restriction on quality of life.143 QoL scores"
  },
  {
    "conteudo":"at the end of the study indicated that the protein restricted group had significantly higher scores"
  },
  {
    "conteudo":"for general health (MD 4.0, 95% CI: 3.1, 4.86) and physical status (MD 10.0, 95% CI: 9.1,"
  },
  {
    "conteudo":"10.9) compared to the control group (0.6 g\/kg\/d vs 46.3g protein\/day; p<0.05)."
  },
  {
    "conteudo":"Glomerular Filtration Rate"
  },
  {
    "conteudo":"In adults with CKD, 5 RCT’s reported on effect of protein-restricted diet on GFR. Results from"
  },
  {
    "conteudo":"the all the studies indicated that LPD (0.55-0.6 g\/kg body weight) had no significant effect on"
  },
  {
    "conteudo":"GFR compared to the control group (0.8 g\/kg protein). Hansen et al. indicated that at a 6-month"
  },
  {
    "conteudo":"follow-up time, there was a comparable and significant decline in GFR in both groups.151"
  },
  {
    "conteudo":"However, the difference between groups was insignificant (p=0.87). Sanchez et al. indicated"
  },
  {
    "conteudo":"that GFR rates decreased by 17.2% in the control group compared to only 6.9% in low protein"
  },
  {
    "conteudo":"group (NS between groups).143 Cianciaruso et al. indicated no effect of diet assignments was"
  },
  {
    "conteudo":"noted on eGFR and proteinuria (0.55g\/kg\/d vs 0.80 g\/kg\/d).148 Juesudason et al. reported that"
  },
  {
    "conteudo":"dietary treatment had no effect on changes in eGFR.152 Meloni et al. (stage 3) also indicated no"
  },
  {
    "conteudo":"Page 85"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"effect of protein restriction on eGFR decline (0.6g\/kg\/d). 157 Decline in GFR was reported by"
  },
  {
    "conteudo":"three studies, a pooled analysis of these studies indicated no clear effect of protein restriction"
  },
  {
    "conteudo":"without supplementation on eGFR (SMD -0.002, CI: -0.192, 0.188)."
  },
  {
    "conteudo":"Phosphate Levels"
  },
  {
    "conteudo":"In adults with CKD, two RCT’s reported mixed results regarding the effect of protein"
  },
  {
    "conteudo":"restriction on serum phosphate levels.149, 154 Rosman et al. indicated that patients in the protein"
  },
  {
    "conteudo":"restriction group had significantly lower serum phosphate levels (used less phosphate binders)"
  },
  {
    "conteudo":"(0.4-0.6 vs 0.8 g) (p<0.05).154 Whereas, Cianciaruso et al., indicated that phosphate levels were"
  },
  {
    "conteudo":"similar in the two groups throughout the entire period of follow-up (0.55 g protein\/kg\/d group"
  },
  {
    "conteudo":"vs 0.8 g protein\/kg\/d).149"
  },
  {
    "conteudo":"Dietary Intake"
  },
  {
    "conteudo":"Seven randomized controlled studies136, 143, 144, 150-152, 157 and 1 NRCT138 reported on dietary"
  },
  {
    "conteudo":"intake. Dietary intake was used as a compliance measure in most of the studies. These studies"
  },
  {
    "conteudo":"indicated that protein intake was lower in groups assigned to low-protein diet (0.6 g\/kg\/d)"
  },
  {
    "conteudo":"compared to control or standard groups (0.8-1.3 g\/kg\/d). In one study, the average protein"
  },
  {
    "conteudo":"intake during the entire duration of follow-up was higher than expected in both the groups"
  },
  {
    "conteudo":"(CPD=1.03 ± 0.18, LPD=0.78 ± 0.17 g protein\/kg\/d).150 Follow-up of at least 1.5 years"
  },
  {
    "conteudo":"indicated that compliance to diet did not change in time in either group. Hansen et al. reported"
  },
  {
    "conteudo":"an estimated dietary protein intake at 4 years significantly lower in LPD compared to"
  },
  {
    "conteudo":"Page 86"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"usual PD group (p=0.005).151 Jesudason et al. showed that the moderate protein intake group"
  },
  {
    "conteudo":"increased their protein intake (NS) and standard protein group decreased their protein intake.152"
  },
  {
    "conteudo":"In the study by Kloppenburg et al. the protein intake during the high protein diet was higher"
  },
  {
    "conteudo":"than during the regular protein diet.136 Kuhlmann et al. reported that protein intake was not"
  },
  {
    "conteudo":"significantly different among the groups.138 However, total energy intake significantly differed"
  },
  {
    "conteudo":"among each other. In the Meloni et al. study, patients in the low protein group were maintaining"
  },
  {
    "conteudo":"their intake at 0.68 g protein\/kg\/d level which was significantly lower than the free protein diet"
  },
  {
    "conteudo":"group.157 Phosphate intake was also significantly lower in the LPD group. Sanchez et al."
  },
  {
    "conteudo":"showed that protein intake in the LPD group decreased significantly from baseline to end of the"
  },
  {
    "conteudo":"study (p<0.05).143 Energy intake tended to decrease during the study duration in both thegroups"
  },
  {
    "conteudo":"but it was non-significant. In Williams et al. study, compared to control, only dietary protein"
  },
  {
    "conteudo":"and phosphate restriction group had significantly lower protein intake level.144 Finally,"
  },
  {
    "conteudo":"Cianciaruso et al. reported that the 2 groups (LPD vs MPD) maintained significantly different"
  },
  {
    "conteudo":"protein intakes (p<0.05), with a difference between the 2 groups of 0.17 ±0.05 g\/d, which lasted"
  },
  {
    "conteudo":"from month 6 until the study end.148 Dietary intake can be used as a compliance index to the"
  },
  {
    "conteudo":"diet."
  },
  {
    "conteudo":"Nutritional status"
  },
  {
    "conteudo":"Research findings indicated that protein restriction did not affect serum albumin levels or"
  },
  {
    "conteudo":"anthropometrics in adult CKD patients. In adults with CKD, 2 RCTs reported no effect of"
  },
  {
    "conteudo":"protein restriction (0.55-0.9 g protein\/kg\/d) on serum albumin levels compared to control group"
  },
  {
    "conteudo":"(0.8-1.3 g protein\/kg\/d).136, 148 In adults with CKD, one RCT reported no effect of protein"
  },
  {
    "conteudo":"restriction (55-70 g\/d) on anthropometrics compared to control group (90-120 g\/d).152"
  },
  {
    "conteudo":"Blood pressure"
  },
  {
    "conteudo":"Two RCT’s reported no effect of protein-restriction (0.6 g\/kg body weight vs usual) on BP"
  },
  {
    "conteudo":"values.151, 152 Hansen et al. reported that BP changes were comparable in the two groups during"
  },
  {
    "conteudo":"follow-up period.151 BP was equally and significantly reduced during the study compared to"
  },
  {
    "conteudo":"baseline in both groups. Jesudason et al. reported no overall changes in BP for both the groups."
  },
  {
    "conteudo":"However, there was a time-by-treatment interaction (p<0.05) for diastolic BP.152 Diastolic BP"
  },
  {
    "conteudo":"was lower throughout the follow-up period in the moderate protein intake group."
  },
  {
    "conteudo":"Page 87"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"Lipid profile"
  },
  {
    "conteudo":"Research reported an improvement in serum lipid profile during a LPD. Coggins et al."
  },
  {
    "conteudo":"determined that an intervention diet providing 0.28 kg\/kg\/d showed significant decreases in"
  },
  {
    "conteudo":"total cholesterol, HDL, and LDL between baseline and 6-month follow-up (p<0.05).158 The"
  },
  {
    "conteudo":"diet providing 0.575 g\/kg\/d reported trends for decreases in total and LDL-C between baseline"
  },
  {
    "conteudo":"and 6-month follow-up (p<0.10). Cianciaruso et al. showed a significant decrease in LDL"
  },
  {
    "conteudo":"values in the LPD group, but not in the moderate protein intake group."
  },
  {
    "conteudo":"PROTEIN RESTRICTION + KETOACID ANALOGS SUPPLEMENT"
  },
  {
    "conteudo":"In international settings where ketoacid analogs (KAA) are available, a very-low protein-"
  },
  {
    "conteudo":"controlled diet may be considered. For adults with CKD without diabetes, not on dialysis,"
  },
  {
    "conteudo":"with an eGFR below 20ml per minute per 1.73m2, a very-low protein diet (VLPD) providing"
  },
  {
    "conteudo":"0.28g to 0.43g protein\/kg\/d with addition of keto acid (KA) analogs to meet protein"
  },
  {
    "conteudo":"requirements may be recommended."
  },
  {
    "conteudo":"In adults with CKD including kidney transplant, fourteen studies reported the effect of protein"
  },
  {
    "conteudo":"restriction + KA supplementation on outcomes of interest. One non-randomized controlled"
  },
  {
    "conteudo":"trial (NRCT),132 and 13 RCTs were included.133, 135, 137, 139, 141, 142, 158-164"
  },
  {
    "conteudo":"Survival\/renal death"
  },
  {
    "conteudo":"In adults with CKD (stages 3 to 5), 4 RCTs reported mixed effect of protein- restricted diet+"
  },
  {
    "conteudo":"KA on renal survival\/RRT.134, 141, 162, 163 Garneata and Mircescu et al. indicated a significantly"
  },
  {
    "conteudo":"lower percentage of patients in the VLPD+ KA group required RRT initiation throughout the"
  },
  {
    "conteudo":"therapeutic intervention.134, 141 Whereas, Levey and Malvy et al. indicated no effect, but"
  },
  {
    "conteudo":"Malvy study was unpowered.162, 163 Pooled analysis of two studies that reported RRT"
  },
  {
    "conteudo":"incidence indicated that protein restricted diet + KA has a lower risk ratio for incidence of"
  },
  {
    "conteudo":"RRT (RR 0.412, CI: 0.219, 0.773).134, 141 Levey et al. indicated that after controlling for"
  },
  {
    "conteudo":"protein intake from food and supplement from the studies evaluated, assignment to the VLPD"
  },
  {
    "conteudo":"did not have a significant effect on renal failure\/death risk.162 Malvy et al. also indicated no"
  },
  {
    "conteudo":"effect of protein restriction +KA on renal survival.163 Whereas, Mircescu et al. indicated a"
  },
  {
    "conteudo":"statistically"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 87"
  },
  {
    "conteudo":"significantly lower percentage of patients in the VLPD+KA group required RRT initiation"
  },
  {
    "conteudo":"throughout the therapeutic intervention (4% vs. 27%);141 and Garneata et al. also indicated a"
  },
  {
    "conteudo":"delay in dialysis initiation.134 Both Garneata and Mircescu are newer studies134, 141 and shorter"
  },
  {
    "conteudo":"in duration (12 to 15 months) compared to Levey and Malvy (Levey-2.2 years).162, 163 When"
  },
  {
    "conteudo":"pooled together, there is probably an overall benefit of dietary protein restriction + KA"
  },
  {
    "conteudo":"supplementation on RRT\/renal survival in CKD stage 3 to 5 patients (RR 0.65, CI 0.49 to 0.85,"
  },
  {
    "conteudo":"p<0.001)."
  },
  {
    "conteudo":"eGFR"
  },
  {
    "conteudo":"A VLPD supplemented with keto-analogues (0.28-0.4 g protein\/kg\/d) could help preserve renal"
  },
  {
    "conteudo":"function in stage 3 to 5 CKD patients. One study was conducted in PD patients, and GFR was"
  },
  {
    "conteudo":"preserved. In adults with CKD, 1 NRCT132 and 4 randomized controlled trial134, 141, 142, 161, 162"
  },
  {
    "conteudo":"reported on effect of protein-restricted diet+ KA analog (0.28 - 0.4g\/kg body weight) on eGFR."
  },
  {
    "conteudo":"Results from the all the 6 studies indicated that VLPD +KA (0.3-0.4 g\/kg body weight)"
  },
  {
    "conteudo":"supplementation helped preserve eGFR, whereas, subjects assigned to LPD only (0.58-0.68"
  },
  {
    "conteudo":"g\/kg protein) did indicate decline in eGFR. All studies were conducted in subjects in stages 3 to"
  },
  {
    "conteudo":"5. Pooled analysis for all five studies was not possible to conduct."
  },
  {
    "conteudo":"Bellizi reported that GFR significantly decreased in the control group.132 Garneata et al."
  },
  {
    "conteudo":"indicated that the decrease in eGFR was less in KA group compared with LPD.134 Klahr et al."
  },
  {
    "conteudo":"indicated that compared with usual protein group, the low-protein group had a more rapid GFR"
  },
  {
    "conteudo":"decline in the first four months (p=0.004) but slower decline from the first four months to the"
  },
  {
    "conteudo":"end (p=0.009).161 Among patients with GFR of 13-24 ml\/min\/1.73m2 (MDRD study 2), there"
  },
  {
    "conteudo":"was a trend for slower GFR decline in the VLPD group when compared with the low-protein"
  },
  {
    "conteudo":"group (p=0.07). Levey et al. (post-hoc analysis of MDRD) indicated that at a fixed level of"
  },
  {
    "conteudo":"protein intake from food only, assignment to a VLPD was associated with a decrease (trend) in"
  },
  {
    "conteudo":"the steepness of the mean GFR slope of 1.19 mL\/min\/yr (p=0.063).162 Similarly, after"
  },
  {
    "conteudo":"controlling for protein intake from food and supplement, assignment to the VLPD did not"
  },
  {
    "conteudo":"improve the rate of decline in GFR (p=0.71). Mircescu et al. indicated that eGFR did not"
  },
  {
    "conteudo":"change significantly in patients receiving VLPD+KA but significantly decreased in the LPD"
  },
  {
    "conteudo":"group (p<0.05), suggesting renal protection for VLPD+KA.141 Prakesh et al. also indicated that"
  },
  {
    "conteudo":"eGFR"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 88"
  },
  {
    "conteudo":"stayed unchanged in the KA supplemented group, however, it significantly decreased in the"
  },
  {
    "conteudo":"placebo group (p=0.015). Keto-supplemented diet over the 9-month period helped preserve the"
  },
  {
    "conteudo":"eGFR.142"
  },
  {
    "conteudo":"Electrolyte levels"
  },
  {
    "conteudo":"VLPD supplemented with keto-analogues (0.28-0.4 g protein\/kg\/d) could potentially decrease"
  },
  {
    "conteudo":"serum phosphate and improve some markers of bone metabolism (calcium, parathyroid"
  },
  {
    "conteudo":"hormone). Four randomized controlled studies (stages 4-5)133, 141, 154, 163 indicated a decrease in"
  },
  {
    "conteudo":"serum phosphate levels at the end of intervention among LPD+ KAA groups. One study with"
  },
  {
    "conteudo":"MHD patients also demonstrated a decrease in serum phosphate in the LPD +KAA group.139"
  },
  {
    "conteudo":"Feiten et al. indicated that serum phosphate did not change in the LPD group but tended to"
  },
  {
    "conteudo":"decrease in the VLPD + KA group (within VLPD, p=0.07). Serum PTH concentration did not"
  },
  {
    "conteudo":"significantly change in the VLPD + KA group; however, it increased significantly in the LPD"
  },
  {
    "conteudo":"group (p=0.01).133 Li et al. in MHD patients indicated that in the LPD +KA group, no"
  },
  {
    "conteudo":"significant changes in serum calcium were observed, however, mean serum phosphate levels"
  },
  {
    "conteudo":"significantly fell at the end of the study (p<0.001) compared to the NPD group.139 Mircescu et"
  },
  {
    "conteudo":"al. in stages 4 and 5 patients indicated that in the VLPD+KAA group a significant increase was"
  },
  {
    "conteudo":"seen in serum calcium levels post intervention (p<0.05); serum phosphate levels decreased"
  },
  {
    "conteudo":"(p<0.05); whereas no statistical changes were observed in the LPD group.141 In the study by"
  },
  {
    "conteudo":"Rosman et al., patients in the LPD group showed significantly lower serum phosphate levels"
  },
  {
    "conteudo":"and used less phosphate binders (p<0.05).154 In a recent meta-analysis, it was reported that"
  },
  {
    "conteudo":"serum phosphate levels were lower in patients supplemented very low protein intake in two"
  },
  {
    "conteudo":"randomized studies from China.165"
  },
  {
    "conteudo":"Dietary intake"
  },
  {
    "conteudo":"Research findings indicate that a VLPD supplemented with KA (0.28-0.40 g protein\/kg\/d) can"
  },
  {
    "conteudo":"effectively be achieved. Dietary intake can be used as a compliance index to the diet. Five"
  },
  {
    "conteudo":"randomized controlled studies and 1 NRCT (4 studies with CKD stage 3-5 patients and 1 with"
  },
  {
    "conteudo":"PD patients) reported on dietary intake. These studies indicated that protein intake was lower in"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 89"
  },
  {
    "conteudo":"groups assigned to low-protein diet or very-low-protein diet groups compared to control or"
  },
  {
    "conteudo":"standard groups. Dietary intake was used as a compliance measure in most of the studies."
  },
  {
    "conteudo":"In Bellizi (stage 4 and 5), at 6 months, protein intake and salt intake were significantly lower in"
  },
  {
    "conteudo":"VLPD than LPD (p<0.0001).132 Feiten et al. (stage 4) reported a reduction in protein intake in"
  },
  {
    "conteudo":"the VLPD supplemented group; energy intake did not change in both groups during the whole"
  },
  {
    "conteudo":"study, and was low (approximately 23 kcal\/lg\/d).133 Phosphorus intake decreased significantly"
  },
  {
    "conteudo":"only in the VLPD + KA group. Calcium intake was low and did not change during the"
  },
  {
    "conteudo":"intervention period for both groups. In Herselma et al. study, protein intake during intervention"
  },
  {
    "conteudo":"was significantly reduced from baseline in both groups.135 In the study of Jian et al. in PD"
  },
  {
    "conteudo":"patients, dietary protein intake between groups LP and HP was different in the 6th and 10th"
  },
  {
    "conteudo":"month (p<0.05).159 Kopple et al. looked at both protein and energy intake (CKD stage 3 and 4),"
  },
  {
    "conteudo":"compared to usual protein diet, low-protein diet had significantly lower dietary protein intake"
  },
  {
    "conteudo":"in study A (p≤0.001).137 Compared to LPD, VLPD had significantly lower dietary protein intake"
  },
  {
    "conteudo":"in study B (p≤0.001). Dietary energy intake in low-protein diet was significantly lower in study"
  },
  {
    "conteudo":"A (p≤0.001) compared to usual protein diet, however, there was no significant difference"
  },
  {
    "conteudo":"between LPD and VLPD in study B (p>0.05). Mircescu et al. (CKD Stages 4 and 5) results"
  },
  {
    "conteudo":"indicated that compliance with prescribed diet was good throughout the study in both arms.141"
  },
  {
    "conteudo":"Nutritional status"
  },
  {
    "conteudo":"Research reports that a VLPD supplemented with keto-analogues (0.28-0.4 g protein\/kg\/d) had"
  },
  {
    "conteudo":"no significant effect on serum albumin levels and nutritional status as measured by SGA, and"
  },
  {
    "conteudo":"effects on anthropometry were inconclusive. In adults with CKD, 6 RCTs133, 134, 137, 141, 142, 159"
  },
  {
    "conteudo":"and 1 NRCT132 reported no effect of very LPD and KA intervention on serum albumin levels."
  },
  {
    "conteudo":"Jian et al. and Garneata et al. were the only studies that studied effect of protein restriction +"
  },
  {
    "conteudo":"ketoanalogues supplementation on SGA and no statistically significant effect was noticed.134,"
  },
  {
    "conteudo":"159 Both the studies indicated that nutritional status was maintained."
  },
  {
    "conteudo":"In the study by Kopple et al., (MDRD study B, CKD stages 3 and 4), no significant differences"
  },
  {
    "conteudo":"in anthropometrics measurements were observed between groups (p>0.05).137 Malvy et al."
  },
  {
    "conteudo":"reported that for the patients in the VLPD group, a significant weight loss was observed at the"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 90"
  },
  {
    "conteudo":"end of the study (p<0.01) and lean and FM were reduced in this group at the end of study."
  },
  {
    "conteudo":"Moderate protein group indicated no difference for weight variables. Garneata et al. in a larger"
  },
  {
    "conteudo":"and more recent study, reported no differences throughout the study period in both groups for"
  },
  {
    "conteudo":"BMI, MAMC, and TSF.134"
  },
  {
    "conteudo":"Blood pressure"
  },
  {
    "conteudo":"The effects of a VLPD supplemented with keto-analogues (0.28-0.40 g protein\/kg\/d) on blood"
  },
  {
    "conteudo":"pressure are inconclusive. In adults with CKD, 1 NRCT132 and 2 RCTs135, 141 reported mixed"
  },
  {
    "conteudo":"effect of a protein-restricted diet (0.3-0.4 g\/kg\/d) + KA supplements on BP. Only one study"
  },
  {
    "conteudo":"showed a significant reduction in systolic BP and diastolic BP.132 In this study, the VLPD had"
  },
  {
    "conteudo":"antihypertensive effect in response to the reduction of sodium intake, type of protein intake and"
  },
  {
    "conteudo":"ketoanalogue supplements, independent of actual protein intake. The other two studies reported"
  },
  {
    "conteudo":"no effect of protein-restricted diet + ketoanalogues on BP.135, 141"
  },
  {
    "conteudo":"Lipid Profile"
  },
  {
    "conteudo":"Research indicates that a VLPD supplemented with ketoanalogues (0.28-0.40 g protein\/kg\/d)"
  },
  {
    "conteudo":"could improve serum lipid profile of CKD patients. In adults with CKD, 1 NRCT132 and 4 RCTs"
  },
  {
    "conteudo":"reported on the effects of a protein-restricted diet (0.3-0.4 g\/kg\/d) + ketoanalogues on serum"
  },
  {
    "conteudo":"lipid profile.133, 134, 158, 163 Feiten et al. and Malvy et al. reported no effect of VLPD +"
  },
  {
    "conteudo":"ketoanalogues on serum lipid profile,133, 163 whereas, Bellizi et al. indicated a decrease in TC and"
  },
  {
    "conteudo":"TG only in the VLPD group. Coggins et al. indicated a significant decrease in TC, HDL, LDL in"
  },
  {
    "conteudo":"the VLPD group.158 Garneata et al. showed that cholesterol levels remained stable during the"
  },
  {
    "conteudo":"entire duration of the study however patients were taking statins\/fibrates as standard therapy.134"
  },
  {
    "conteudo":"Dietary Protein Intake, Diabetes Mellitus"
  },
  {
    "conteudo":"Nutrition play a significant role in the management of individuals with diabetic kidney disease"
  },
  {
    "conteudo":"(DKD) in conjunction with pharmacological interventions. The goal is to maintain optimal"
  },
  {
    "conteudo":"glycemic control and at the same time maintain adequate protein and energy intake to achieve"
  },
  {
    "conteudo":"optimal nutritional status. There are some previous guidelines that suggest that 0.8 g\/kg body"
  },
  {
    "conteudo":"weight\/day among those with CKD stages 1-4 and also for CKD stage 5.166 However, KDIGO"
  },
  {
    "conteudo":"guidelines suggested that more liberalization with protein restriction and recommended that 0.8"
  },
  {
    "conteudo":"g\/kg body weight\/day be maintained and avoiding levels above 1.3 g\/kg\/body weight.167"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 91"
  },
  {
    "conteudo":"Evidence from controlled trials in this non-dialyzed DKD population has been conflicting. 151, 157,"
  },
  {
    "conteudo":"168-173 Recent meta-analysis does show small beneficial impact of LPD on eGFR decline;"
  },
  {
    "conteudo":"however, the heterogeneity was really high (the type of diabetes, stages of CKD, types on"
  },
  {
    "conteudo":"interventions, duration, adherence to recommendations).174, 175"
  },
  {
    "conteudo":"For the DKD patients receiving dialysis, evidence from observational studies indicated low"
  },
  {
    "conteudo":"dietary protein intake is associated with higher hospitalization rates and higher risk of mortality."
  },
  {
    "conteudo":"176, 177 The KDOQI guideline for dialysis patients suggests dietary protein intake of >1.2 g\/kg"
  },
  {
    "conteudo":"body weight\/day to manage the protein catabolism and losses of protein in dialysate."
  },
  {
    "conteudo":"Ko et al. conducted an extensive review of existing guidelines and original research in patients"
  },
  {
    "conteudo":"with DKD and indicated that dietary protein intake of 0.8 g\/kg body weight\/day was advised for"
  },
  {
    "conteudo":"DKD not on dialysis and dietary protein intake >1.2 g\/kg body weight\/day was advised for DKD"
  },
  {
    "conteudo":"patients on dialysis.178"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"These diets should be progressively installed to allow a careful dietary counselling and"
  },
  {
    "conteudo":"adequate compliance. Although such diets are not associated with wasting in carefully"
  },
  {
    "conteudo":"monitored research studies, on a routine basis, attention should be focused on energy intake"
  },
  {
    "conteudo":"which may decrease over time and induce wasting. A potential beneficial effect of reducing"
  },
  {
    "conteudo":"protein intake relies on the fact that it also reduced glomerular hyperfiltration and potentially"
  },
  {
    "conteudo":"protects them from hyperfiltration, accelerated hyalinosis and proteinuria. On a nutritional"
  },
  {
    "conteudo":"point of view, reducing protein from animal source and moving towards more vegetal protein"
  },
  {
    "conteudo":"sources also reduced acid production and metabolic acidosis. These effects are mostly"
  },
  {
    "conteudo":"observed for more reduced protein intakes (0.3-0.5 g\/kg protein\/kg\/d) supplemented with"
  },
  {
    "conteudo":"KAs."
  },
  {
    "conteudo":"Are LPD\/VLPD+ ketoanalogues indicated for CKD patients with PEW? This question cannot"
  },
  {
    "conteudo":"easily be answered since it may depend on the cause of patient wasting. For example, an acute"
  },
  {
    "conteudo":"catabolic state may induce PEW despite nutrient intake that is normally considered adequate."
  },
  {
    "conteudo":"Therefore, priority should be given to the correction of etiology of wasting and protein intake"
  },
  {
    "conteudo":"should be increased until the wasting state improves. An LPD\/VLPD + KA diet should not be"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 92"
  },
  {
    "conteudo":"started during a catabolic state in CKD patients."
  },
  {
    "conteudo":"Do LPD and VLPD+ ketoanalogues have impact on the nutritional status? In a post-hoc"
  },
  {
    "conteudo":"analysis of the MDRD study,137 the authors compared the randomized groups (LPD versus"
  },
  {
    "conteudo":"VLPD+ ketoanalogues) for various outcomes related to nutritional status. Overall, the results"
  },
  {
    "conteudo":"demonstrate the safety of dietary protein restriction over two to three years in patients with"
  },
  {
    "conteudo":"moderate to advanced CKD. However, there were small but significant changes from baseline"
  },
  {
    "conteudo":"in some nutritional indices, and minimal differences between the randomized groups in some of"
  },
  {
    "conteudo":"these changes. In both LPD and VLPD+ ketoanalogues, both protein and energy intake"
  },
  {
    "conteudo":"declined. Serum albumin rose, while serum transferrin, body weight, percentage of body fat,"
  },
  {
    "conteudo":"arm muscle area and urine creatinine excretion declined. In a longitudinal study looking at"
  },
  {
    "conteudo":"body composition, a VLPD+ ketoanalogues diet induced a small decline in LBM on the"
  },
  {
    "conteudo":"average of 1.2 kg, with concomitant increase in FM, mainly in the first 3 months; these"
  },
  {
    "conteudo":"parameters subsequently stabilized and even improve slightly thereafter.179 Other short-term"
  },
  {
    "conteudo":"studies did not show noticeable effects of LPD and VLPD+ ketoanalogues on nutritional"
  },
  {
    "conteudo":"parameters. Nevertheless, small anthropometric measurement’s decline observed in some"
  },
  {
    "conteudo":"studies are of concern since, in routine practice, LPD and VLPD+ ketoanalogues are used on"
  },
  {
    "conteudo":"the long term and because of the adverse effect of protein-energy wasting in patients with end-"
  },
  {
    "conteudo":"stage renal disease. This is why physicians who prescribe low-protein diets must regularly"
  },
  {
    "conteudo":"monitor patients' protein and energy intake and nutritional status."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"Energy intake"
  },
  {
    "conteudo":"• The registered dietitian nutritionist (RDN) should consider a number of factors when"
  },
  {
    "conteudo":"determining the energy requirements for adults diagnosed with CKD, and these include"
  },
  {
    "conteudo":"the patient’s overall health status, CKD diagnosis and associated therapies, level of"
  },
  {
    "conteudo":"physical activity, age, gender, weight status, metabolic stressors, and treatment goals"
  },
  {
    "conteudo":"• Patients should be monitored routinely to assess whether energy requirements are being"
  },
  {
    "conteudo":"met satisfactorily. Changes in nutritional status should be treated and the energy"
  },
  {
    "conteudo":"prescription modified accordingly"
  },
  {
    "conteudo":"• Among patients with stage 5 CKD on maintenance dialysis (hemodialysis or peritoneal"
  },
  {
    "conteudo":"dialysis), there are several factors that may influence energy expenditure, beyond the"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 93"
  },
  {
    "conteudo":"traditional determinants (age, sex, and fat-free mass), such as hyperparathyroidism,"
  },
  {
    "conteudo":"hyperglycemia, and chronic inflammation that should be considered into the overall"
  },
  {
    "conteudo":"energy prescription"
  },
  {
    "conteudo":"• Energy needs will be variable depending on the health status of the patient, e.g., acutely"
  },
  {
    "conteudo":"ill versus chronically managed and overall health goals, weight maintenance, repletion or"
  },
  {
    "conteudo":"loss."
  },
  {
    "conteudo":"• Energy needs may be different depending on the stage of CKD and its respective"
  },
  {
    "conteudo":"treatment (dialysis vs transplantation)."
  },
  {
    "conteudo":"• IBW is the body weight associated with the lowest mortality for a given height, age, sex"
  },
  {
    "conteudo":"and frame size and is based on the Metropolitan Life Insurance Height and Weight Tables"
  },
  {
    "conteudo":"and many other methods. [Caution: Not generalizable to the CKD population and data-"
  },
  {
    "conteudo":"gathering methods were not standardized.]. The IBW can also be estimated as follows: in"
  },
  {
    "conteudo":"males as 50.0 kg + 2.3 kg for each inch over 5 ft (each 2.5 cm over 152.4 cm) and in"
  },
  {
    "conteudo":"females as 45.5 kg + 2.3 kg for each inch over 5 ft."
  },
  {
    "conteudo":"Protein restriction"
  },
  {
    "conteudo":"● Increase the training and number of specialized renal dietitians worldwide who could"
  },
  {
    "conteudo":"effectively and safely implement low and very low protein diets."
  },
  {
    "conteudo":"● Promote low protein products to simplify dietary counseling and help achieving"
  },
  {
    "conteudo":"LPD."
  },
  {
    "conteudo":"● BE more aggressive with the dietary interventions to improve symptoms when chronic"
  },
  {
    "conteudo":"dialysis is not a treatment option or need to be postponed (vascular access maturation,"
  },
  {
    "conteudo":"organizing preemptive renal transplant)."
  },
  {
    "conteudo":"● The need for food information is important to obtain a good compliance to the"
  },
  {
    "conteudo":"restricted protein intake. However, therapeutic education can help patients to improve"
  },
  {
    "conteudo":"personal motivation, and can even become a personal goal to achieve. Getting more"
  },
  {
    "conteudo":"interested in food harvesting, preparation, and cooking may improve quality of life. In"
  },
  {
    "conteudo":"addition, postponing initiation of dialysis undoubtedly maintains a better quality of"
  },
  {
    "conteudo":"life rather than undergoing chronic dialysis.180"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 94"
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Compliance to diets should be monitored frequently during the first year of dietary intervention"
  },
  {
    "conteudo":"by dietary interviews (3 is optimal) and 24- hour urine collection for urine urea nitrogen"
  },
  {
    "conteudo":"content. Then yearly follow-up may be recommended until start of maintenance dialysis."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Determine whether a LPD has an additive or a synergistic effect to that of renin"
  },
  {
    "conteudo":"angiotensin aldosterone antagonists or newer nephroprotective agents (i.e. SGLT2"
  },
  {
    "conteudo":"inhibitors) on proteinuria and nephroprotection through RCTs."
  },
  {
    "conteudo":"● Examine the impact of a low and very-low protein dies with or without KA on digestive"
  },
  {
    "conteudo":"microbiota in CKD patients."
  },
  {
    "conteudo":"● Investigate at what is the best CKD stage to start dietary protein intake modification."
  },
  {
    "conteudo":"● Examine ways to improve adherence and compliance with LPD, VLPD+KA diets"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 95"
  },
  {
    "conteudo":"3.2 Statement on Protein Type"
  },
  {
    "conteudo":"3.2.1 In adults with CKD 1-5D (1B) and post-transplant (OPINION), there is"
  },
  {
    "conteudo":"inadequate evidence to recommend a particular protein type (plant vs animal) in terms of"
  },
  {
    "conteudo":"the effects on nutritional status, calcium or phosphorus levels, or the blood lipid profile."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Vegetable protein diets (VPD) may have beneficial effects on health. A recent population-"
  },
  {
    "conteudo":"based study suggested soy or soy isoflavones intake significantly reduced the risk of"
  },
  {
    "conteudo":"postmenopausal breast cancer.181 Oxidative stress significantly decreased in postmenopausal"
  },
  {
    "conteudo":"women when treated with VPD (soy isoflavones) and in vitro experiments have shown that"
  },
  {
    "conteudo":"VPD protects against inflammation in vascular endothelial cells.182 These findings lead to the"
  },
  {
    "conteudo":"development of preventive strategies for human health and disease. For example, the US Food"
  },
  {
    "conteudo":"and Drug Administration suggested that the intake of 25 g soy protein daily may prevent the"
  },
  {
    "conteudo":"risk of coronary heart disease due to reduced serum lipids and lipoproteins."
  },
  {
    "conteudo":"In CKD patients, VPD may have positive biological actions and possibly clinical benefits"
  },
  {
    "conteudo":"through a variety of mechanisms. In vitro studies showed that VPD reduce the expression of"
  },
  {
    "conteudo":"renin-angiotensin.183 Studies in rodents demonstrated that VPD retard the development and"
  },
  {
    "conteudo":"progression of CKD, vs animal protein diets (APD),184 presumably through favorable effects"
  },
  {
    "conteudo":"on GFR. In addition, a vegetarian diet, was associated with a significant reduction in serum"
  },
  {
    "conteudo":"phosphate and FGF-23 levels in predialysis CKD patients.185 As a result, it was thought that"
  },
  {
    "conteudo":"VPD may be used in helping to reduce phosphorus load and potentially CKD progression in"
  },
  {
    "conteudo":"this group of patients."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Three randomized controlled trials (CKD 5D) and two randomized crossover (Stage 3-4 CKD)"
  },
  {
    "conteudo":"trials compared the impact of vegetable-based protein (VPD) vs animal-based (APD) protein"
  },
  {
    "conteudo":"intake on biomarkers and health outcomes in patients with CKD."
  },
  {
    "conteudo":"Serum Albumin"
  },
  {
    "conteudo":"Protein type did not affect nutritional status as measured by serum albumin. In Soroka et al.,"
  },
  {
    "conteudo":"serum albumin significantly increased after both VPD and APD, compared to the pre-study"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 96"
  },
  {
    "conteudo":"diet, but there was no significant difference on serum albumin between VPD and APD.186Fanti"
  },
  {
    "conteudo":"et al. found no significant difference between VPD and APD on serum albumin levels.187Tabibi"
  },
  {
    "conteudo":"et al. found a significant (p<0.05) increase in serum albumin levels within both groups, but no"
  },
  {
    "conteudo":"significant difference found between groups.188 Finally, Chen et al. found no significant"
  },
  {
    "conteudo":"differences in serum albumin between groups.189 However, the power to discriminate might"
  },
  {
    "conteudo":"have been insufficient due to the small number of patients enrolled. In pooled analysis of four"
  },
  {
    "conteudo":"studies, there was no effect of protein type on serum albumin levels."
  },
  {
    "conteudo":"Protein catabolic rate (PCR)"
  },
  {
    "conteudo":"VPD may be associated with a decrease in PCR after 6 months, but evidence was limited. In"
  },
  {
    "conteudo":"Saroka et al., PCR was significantly (p<0.05) lower after 6 month of VPD compared to the pre-"
  },
  {
    "conteudo":"study diet, but there were no changes in the APD diet.186 In a secondary analysis, there was a"
  },
  {
    "conteudo":"mean difference (95% CI) of -0.10 (-0.17, -0.03) g\/kg\/d in PCR values in the VPD vs the APD."
  },
  {
    "conteudo":"This might have been the consequence of a slightly reduced absorption of protein from vegetal"
  },
  {
    "conteudo":"source (estimated to be 90% of animal protein)."
  },
  {
    "conteudo":"Pre-albumin levels"
  },
  {
    "conteudo":"VPD did not affect serum pre-albumin levels compared to a control group, but evidence was"
  },
  {
    "conteudo":"limited. Fanti et al. found no significant difference between VPD and APD on serum albumin"
  },
  {
    "conteudo":"or pre-albumin levels after receiving soy protein for 8 weeks, compared to the control group.187"
  },
  {
    "conteudo":"Inflammatory Markers (CRP, IL-6, TNF-α)"
  },
  {
    "conteudo":"Protein type did not affect inflammatory markers. Fanti et al. compared the impact of a soy"
  },
  {
    "conteudo":"protein vs a milk protein supplement on inflammation.187 No significant differences were"
  },
  {
    "conteudo":"found within or between groups for CRP, IL-6 or TNF-α levels."
  },
  {
    "conteudo":"Calcium and Phosphorus levels"
  },
  {
    "conteudo":"There was no effect of protein type on plasma\/serum or urinary calcium levels. VPD for 7 days"
  },
  {
    "conteudo":"to 6 months did not affect plasma\/serum phosphate levels, but did decrease 24-hour urinary"
  },
  {
    "conteudo":"phosphate levels by a mean difference of -126.6 (-200.4, -52.7) mg. Soroka et al. found no"
  },
  {
    "conteudo":"significant difference between VPD, APD, or pre-study diet on urinary sodium, potassium or"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 95"
  },
  {
    "conteudo":"calcium; or serum calcium or phosphate.186 Urinary phosphate was significantly lower after the"
  },
  {
    "conteudo":"VPD vs the APD and pre-study diet. In a small randomized crossover trial in predialysis"
  },
  {
    "conteudo":"patients, Moe et al. demonstrated that plasma phosphate levels were significantly higher in the"
  },
  {
    "conteudo":"APD vs the VPD group at day 7 (p=0.02), but there was no difference in urinary phosphorus"
  },
  {
    "conteudo":"excretion.185 There were no differences in plasma calcium or urinary calcium excretion levels"
  },
  {
    "conteudo":"between groups. In pooled analysis of these 2 studies, there was no effect of VPD, compared"
  },
  {
    "conteudo":"to APD, on serum\/plasma phosphate. However, VPD did decrease 24-hour urinary phosphate"
  },
  {
    "conteudo":"levels by a mean difference (95% CI) of -126.6 (-200.4, -52.7) mg."
  },
  {
    "conteudo":"Total, LDL and HDL Cholesterol, Triglyceride levels"
  },
  {
    "conteudo":"Protein type did not affect lipid profile in Stage 4 and 5D CKD patients. Three studies"
  },
  {
    "conteudo":"examined the effect of VPD vs APD on blood lipid panel. Chen et al. compared the impact of a"
  },
  {
    "conteudo":"soy protein vs a milk protein supplement on plasma lipids during 12 weeks in MHD patients"
  },
  {
    "conteudo":"with and without hyperlipidemia.189 In patients without hyperlipidemia, no significant"
  },
  {
    "conteudo":"differences were found in total cholesterol, LDL-C, HDL-C and triglycerides levels within or"
  },
  {
    "conteudo":"between groups. In hyperlipidemic patients however, soy protein lead to a significant decrease"
  },
  {
    "conteudo":"in total cholesterol, LDL cholesterol and triglyceride levels, compared to milk protein, whereas"
  },
  {
    "conteudo":"HDL significantly increased. Tabibi et al. compared the impact of a soy protein supplement vs"
  },
  {
    "conteudo":"control in PD patients and found no significant impact on total cholesterol, LDL-C, HDL-C and"
  },
  {
    "conteudo":"triglycerides levels in the intervention group.188 Soroka et al. found no significant differences"
  },
  {
    "conteudo":"after VPD, APD or pre-study diet on total cholesterol, LDL-C and triglycerides TG, in stage 4"
  },
  {
    "conteudo":"CKD patients.186 HDL-C level was significantly lower after VPD compared to the pre-study"
  },
  {
    "conteudo":"diet. In pooled analysis of 3 studies, there was no mean difference in total, LDL or HDL-C"
  },
  {
    "conteudo":"levels or triglyceride levels between groups."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"VPDs have been studied to test metabolic hypotheses in CKD patients. Particularly, the fact"
  },
  {
    "conteudo":"that phosphorus may be less absorbed during a VPD diet may benefit calcium and phosphate"
  },
  {
    "conteudo":"metabolism. This becomes more important since currently processed food contains much"
  },
  {
    "conteudo":"added inorganic phosphorus as compared with VPD. The fat content of VPD possesses a"
  },
  {
    "conteudo":"healthier profile and may benefit patients in long-term studies. Finally, toxic middle molecules"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 96"
  },
  {
    "conteudo":"such as P-cresyl sulfate, indoxyl-sulfate and trimethylamine oxide (TMAO), almost"
  },
  {
    "conteudo":"exclusively produced from animal source protein, could be reduced by VPD and this"
  },
  {
    "conteudo":"hypothesis should be tested in long-term clinical trials in CKD patients. As demonstrated in"
  },
  {
    "conteudo":"other subtopics of this guideline, VPD has shown reduction in acid load, increase in dietary"
  },
  {
    "conteudo":"fiber intake, reduction of phosphorus, and body weight. There is increasing interest in the role"
  },
  {
    "conteudo":"of VPD in CKD due to the benefits of this dietary pattern on cardiovascular disease risk factors"
  },
  {
    "conteudo":"in the general population. However, current evidence from RCTs specifically comparing"
  },
  {
    "conteudo":"benefits of VPD vs APD in CKD patients is limited."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Work with patients to help them meet their individualized dietary protein intake needs."
  },
  {
    "conteudo":"● Based on CKD patient’s preference for animal or plant-based protein ensure that they"
  },
  {
    "conteudo":"meet their dietary protein needs and that their diets provide adequate essential amino"
  },
  {
    "conteudo":"acids."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Compliance to diets should be monitored frequently during the first year of dietary intervention"
  },
  {
    "conteudo":"by dietary interviews (3 is optimal). Then yearly follow-up may be recommended until start of"
  },
  {
    "conteudo":"maintenance dialysis."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Conduct adequately powered randomized clinical trials to study the effect of VPD on"
  },
  {
    "conteudo":"mortality, CKD progression, proteinuria, markers of mineral and bone metabolism, and"
  },
  {
    "conteudo":"urinary phosphorus excretion in CKD patients."
  },
  {
    "conteudo":"● Examine the effects of VPD on the lipid profile in hyperlipidemic CKD patients."
  },
  {
    "conteudo":"● Examine the impact of VPD on generation of toxic middle molecules."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 97"
  },
  {
    "conteudo":"3.3 Statements on Dietary Patterns"
  },
  {
    "conteudo":"Mediterranean Diet"
  },
  {
    "conteudo":"3.3.1 In adults with CKD 1-5 (non-dialysis) and post-transplant, with or without"
  },
  {
    "conteudo":"dyslipidemia, we suggest that prescribing a Mediterranean Diet may improve lipid"
  },
  {
    "conteudo":"profiles (2C)."
  },
  {
    "conteudo":"Fruits and Vegetables"
  },
  {
    "conteudo":"3.3.2 In adults with CKD 1-4, we suggest that prescribing increased fruit and vegetable"
  },
  {
    "conteudo":"intake may decrease body weight, blood pressure and net acid production (NEAP) (2C)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Dietary patterns reflect the variety of foods which represent habitual dietary intake.190Particular"
  },
  {
    "conteudo":"dietary patterns, including the Mediterranean diet, the Dietary Approach to Stop Hypertension"
  },
  {
    "conteudo":"(DASH), plant-based and diets high in fruits and vegetables (including Vegetarian diets) are"
  },
  {
    "conteudo":"examples of healthy dietary patterns which have been the subject of interest in nutritional"
  },
  {
    "conteudo":"epidemiology.191 A whole -diet approach considers the synergistic effects of nutrients resulting"
  },
  {
    "conteudo":"in cumulative effects on health and disease.191"
  },
  {
    "conteudo":"CKD presents many challenges for nutrition management, including increased risk of death"
  },
  {
    "conteudo":"and appreciable cardiovascular disease burden among affected persons. Traditionally, nutrition"
  },
  {
    "conteudo":"education has focused on individual nutrients, such as protein, phosphorus, potassium and"
  },
  {
    "conteudo":"sodium. Recent evidence has linked healthy dietary patterns with reduced chronic CVD and"
  },
  {
    "conteudo":"mortality risk in the healthy population.192-194 However, these relationships have not been"
  },
  {
    "conteudo":"explored conclusively with the CKD population."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"While various dietary patterns were investigated (Fruits and Vegetables, Mediterranean Diet,"
  },
  {
    "conteudo":"Low Fructose Diet, Hypolipidemic, Carbohydrate restricted- low iron, polyphenol-enriched"
  },
  {
    "conteudo":"diet (CR-LIPE), High-protein\/Low-carbohydrate), there was little evidence examining the"
  },
  {
    "conteudo":"efficacy of most of these patterns in controlled trials. Hence, only the Mediterranean and High"
  },
  {
    "conteudo":"Fruit and Vegetable dietary patterns had sufficient evidence to create recommendations."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 98"
  },
  {
    "conteudo":"Mediterranean dietary pattern"
  },
  {
    "conteudo":"eGFR"
  },
  {
    "conteudo":"One RCT reported on the effect of Mediterranean dietary pattern on eGFR.195 Mekki et al."
  },
  {
    "conteudo":"indicated no clear effect of Mediterranean dietary pattern on eGFR at 90 days post intervention"
  },
  {
    "conteudo":"in adults with CKD stage 2. Additional research on the effect of Mediterranean dietary pattern"
  },
  {
    "conteudo":"is needed."
  },
  {
    "conteudo":"Lipid profile"
  },
  {
    "conteudo":"Limited evidence from three studies, two of which examined non-dialyzed patients (CKD"
  },
  {
    "conteudo":"stages 2 and 3) and one of which examined post-transplant patients, demonstrated that the"
  },
  {
    "conteudo":"Mediterranean diet improved lipid panel by decreasing total cholesterol (TC), low-density"
  },
  {
    "conteudo":"lipoprotein (LDL-C) and triglyceride (TG) level compared to control groups."
  },
  {
    "conteudo":"Two controlled trials reported on the effect of Mediterranean dietary pattern on lipid profile in"
  },
  {
    "conteudo":"non-dialyzed patients.195, 196 In the RCT, Mekki et al. (stage 2) reported a 35% reduction in TC"
  },
  {
    "conteudo":"(p<0.05) in the Mediterranean diet group, whereas, no change in TC was observed in the"
  },
  {
    "conteudo":"control group. LDL-C levels and TG levels were also reduced compared to standard care.195 In"
  },
  {
    "conteudo":"an NRCT, Daniele et al. reported a significant reduction in TC in both Mediterranean diet"
  },
  {
    "conteudo":"group and organic Mediterranean diet group.196 However, most reduction was noted in the"
  },
  {
    "conteudo":"organic Mediterranean diet group. In post-transplant patients, one RCT reported that"
  },
  {
    "conteudo":"Mediterranean diet led to significant reduction in TC, TG and LDL-C levels compared with a"
  },
  {
    "conteudo":"low-fat diet.195, 197"
  },
  {
    "conteudo":"Other Outcomes"
  },
  {
    "conteudo":"Compared to a control group, the Mediterranean Diet had no clear effect on BP in post-"
  },
  {
    "conteudo":"transplant patients 197 or on CRP levels in stage 2 patients. 195"
  },
  {
    "conteudo":"However, one NRCT reported on the effect of Mediterranean dietary pattern on"
  },
  {
    "conteudo":"albuminuria in stage 2 and 3 CKD adults, and both Mediterranean diet groups"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 99"
  },
  {
    "conteudo":"(normal and organic) had significant reductions in albuminuria values compared to low protein"
  },
  {
    "conteudo":"group.196"
  },
  {
    "conteudo":"High Fruit and Vegetable Dietary Pattern"
  },
  {
    "conteudo":"CKD Progression"
  },
  {
    "conteudo":"In adults with stages 3-4 CKD, fruits and vegetables dietary pattern has mixed effects on eGFR"
  },
  {
    "conteudo":"compared with oral bicarbonate supplementation.198, 199"
  },
  {
    "conteudo":"Body Weight"
  },
  {
    "conteudo":"Two RCTs reported on the effect of a fruit and vegetable dietary pattern on body weight in"
  },
  {
    "conteudo":"adults with CKD. Goraya et al. reported that the group following the fruit and vegetable"
  },
  {
    "conteudo":"dietary pattern had greater net body weight loss than both oral bicarbonate and standard care"
  },
  {
    "conteudo":"groups (p<0.05).199 Goraya et al. reported lower body weight in adults with CKD stages 3-4"
  },
  {
    "conteudo":"following a fruit and vegetable dietary pattern compared to oral bicarbonate supplementation"
  },
  {
    "conteudo":"group at 1-year follow up (p<0.01). (Mean Difference= -5.09 kg, 95% CI - 7.73,2.44;"
  },
  {
    "conteudo":"I2=56%).198"
  },
  {
    "conteudo":"Blood Pressure"
  },
  {
    "conteudo":"Three studies (2 RCT, 1 NRCT) reported on the effect of increased fruit and vegetable intake"
  },
  {
    "conteudo":"on BP in adults with CKD. All three studies indicated that increased intake of fruit and"
  },
  {
    "conteudo":"vegetable had a significant effect on lowering systolic BP compared to oral bicarbonate"
  },
  {
    "conteudo":"supplement intake group or standard care group.198-200 Goraya et al. indicated reductions in"
  },
  {
    "conteudo":"systolic BPs in all groups, however, the 3-year value for the fruits and vegetables group was"
  },
  {
    "conteudo":"lower than those in HCO and control.199 Goraya et al. showed that compared to HCO group,"
  },
  {
    "conteudo":"3 3"
  },
  {
    "conteudo":"the fruit and vegetables group had lower systolic BP at 1-year follow up (p<0.01).198Goraya et"
  },
  {
    "conteudo":"al. (NRCT) showed that fruit and vegetable intake, but not control or HCO , significantly"
  },
  {
    "conteudo":"3"
  },
  {
    "conteudo":"decreased systolic BP in individuals with CKD Stages 1 and 2 (p<0.001).200Pooled analysis of"
  },
  {
    "conteudo":"data from Goraya et al. 2013 and Goraya et al. 2014 indicated a MeanDifference (95% CI) of"
  },
  {
    "conteudo":"-5.6, CI: -8.3, -2.8 mmHg. Increased intake of fruits and vegetable"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 100"
  },
  {
    "conteudo":"dietary pattern lowered systolic BP compared to oral bicarbonate supplement intake or"
  },
  {
    "conteudo":"standard care group in adults with CKD stages 1 - 4."
  },
  {
    "conteudo":"Comparison with recent research"
  },
  {
    "conteudo":"A recent systematic review (SR) examined the effect of dietary patterns on CKD outcomes"
  },
  {
    "conteudo":"using cohort studies.201 In agreement with the current analysis of controlled trials, Kelly et al."
  },
  {
    "conteudo":"found no effect of dietary pattern on CKD progression in studies with follow-ups ranging from"
  },
  {
    "conteudo":"4 to 6.4 years. However, unlike the current SR, Kelly et al. were able to demonstrate a"
  },
  {
    "conteudo":"relationship between a dietary pattern rich in vegetables, fruit, fish, cereals, whole grains, fiber,"
  },
  {
    "conteudo":"legumes, and nuts and seeds, and lower in red meat, sodium, and refined sugars in studies"
  },
  {
    "conteudo":"reporting outcomes from 4 to 13 years of follow up [RR (95% CI): 0.73 (95% CI, 0.63 to"
  },
  {
    "conteudo":"0.83)].201"
  },
  {
    "conteudo":"A recent Cochrane review of 6 RCTs evaluated dietary patterns in CKD (one study (n=191) of"
  },
  {
    "conteudo":"a carbohydrate-restricted low-iron, polyphenol enriched diet, two studies (n=355) of a"
  },
  {
    "conteudo":"Mediterranean diet, two studies (n=181) of increased fruit and vegetable intake and one study"
  },
  {
    "conteudo":"(n=12) of a high protein\/low carbohydrate diet). From this review, dietary interventions had"
  },
  {
    "conteudo":"uncertain effects on all-cause mortality and cardiovascular events. However, with low quality"
  },
  {
    "conteudo":"evidence, there was reduced systolic and diastolic BP, and higher GFR and albumin levels"
  },
  {
    "conteudo":"following dietary interventions.202"
  },
  {
    "conteudo":"Although the intervention studies examining dietary patterns in CKD are limited, there is"
  },
  {
    "conteudo":"consistent evidence from observational analyses on dietary patterns containing fruits,"
  },
  {
    "conteudo":"vegetables, whole grains, lean meats, low fat dairy and low added salt, and improved clinical"
  },
  {
    "conteudo":"outcome (notably mortality) in CKD.201 A recent study confirmed that intake of nuts, low-fat"
  },
  {
    "conteudo":"dairy products, and legumes are protective against the development of CKD\".203 There is"
  },
  {
    "conteudo":"therefore a need to undertake future trials to further investigate more holistic dietary"
  },
  {
    "conteudo":"interventions over single nutrient approaches in these patients. Dietary pattern may improve"
  },
  {
    "conteudo":"additional outcomes not reported in the systematic review, including constipation."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 101"
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Safety of various dietary patterns, including the DASH and Mediterranean diet, with"
  },
  {
    "conteudo":"high intakes of fruit and vegetables must be determined on in individual basis in"
  },
  {
    "conteudo":"advanced stages of kidney disease, especially in regard to serum potassium control"
  },
  {
    "conteudo":"and adequacy of protein intake."
  },
  {
    "conteudo":"● Individualized support and follow-up may be required to support patients in"
  },
  {
    "conteudo":"implementing complex dietary changes."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Adherence to dietary patterns in clinical trials can be challenging. Engaging a process of self-"
  },
  {
    "conteudo":"monitoring against food group targets may assist with supporting adherence."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Establish the optimal method to support dietary change to implement dietary patterns"
  },
  {
    "conteudo":"into clinical trials with CKD."
  },
  {
    "conteudo":"● Conduct large-scale, pragmatic clinical trials implementing Mediterranean, DASH"
  },
  {
    "conteudo":"and\/or dietary guideline-based dietary pattern in CKD patients to determine the effect"
  },
  {
    "conteudo":"on clinical outcomes including kidney disease progression and cardiovascular disease."
  },
  {
    "conteudo":"● Evaluate the association of multiple dietary patterns with CKD progression in a large"
  },
  {
    "conteudo":"cohort with established CKD over a longer duration than currently available (i.e. >10"
  },
  {
    "conteudo":"years)."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 102"
  },
  {
    "conteudo":"GUIDELINE 4: NUTRITIONAL SUPPLEMENTATION"
  },
  {
    "conteudo":"4.1 Statement on Oral, Enteral and Parenteral Nutrition (IDPN) Supplementation"
  },
  {
    "conteudo":"Oral Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.1.1 In adults with CKD 3-5D (2D) and post-transplant (OPINION) at risk of or"
  },
  {
    "conteudo":"with protein-energy wasting, we suggest a minimum of a 3-month trial of oral"
  },
  {
    "conteudo":"nutritional supplements to improve nutritional status if dietary counselling alone does"
  },
  {
    "conteudo":"not achieve sufficient energy and protein intake to meet nutritional requirements."
  },
  {
    "conteudo":"Enteral Nutrition Supplementation"
  },
  {
    "conteudo":"4.1.2 In adults with CKD 1-5D, with chronically inadequate intake and whose protein"
  },
  {
    "conteudo":"and energy requirements cannot be attained by dietary counselling and oral nutritional"
  },
  {
    "conteudo":"supplements, it is reasonable to consider a trial of enteral tube feeding (OPINION)."
  },
  {
    "conteudo":"Total and Intradialytic Parenteral Nutrition (IDPN) Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.1.3 In adults with CKD on MHD with protein-energy wasting, we suggest a trial of"
  },
  {
    "conteudo":"IDPN for MHD patients, TPN for CKD patients and AA dialysate for PD patients to"
  },
  {
    "conteudo":"improve and maintain nutritional status if nutrition requirements cannot be met with"
  },
  {
    "conteudo":"existing oral and enteral intake (2C)"
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Protein-energy wasting (PEW) is common among patients with CKD, especially those"
  },
  {
    "conteudo":"undergoing maintenance dialysis therapy,204 and is associated with increased morbidity and"
  },
  {
    "conteudo":"mortality.205 The etiology of PEW in patients with CKD is complex and multifactorial, and"
  },
  {
    "conteudo":"includes reduced energy and protein intake resulting from anorexia and dietary restrictions,"
  },
  {
    "conteudo":"inflammation, hypercatabolism, protein losses during dialysis, metabolic acidosis, uremic"
  },
  {
    "conteudo":"toxicity, and the presence of comorbid conditions.204, 205 As a result, patients with CKD may"
  },
  {
    "conteudo":"develop an imbalance between dietary intake and nutritional requirements. Indeed, many"
  },
  {
    "conteudo":"patients with CKD consume less protein and energy than their recommended intakes even"
  },
  {
    "conteudo":"when individualized dietary counselling is provided by a renal dietician.206"
  },
  {
    "conteudo":"When dietary counselling alone proves insufficient to bridge the gap between protein-energy"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 105"
  },
  {
    "conteudo":"intake and the target requirements in patients with CKD, provision of oral nutritional"
  },
  {
    "conteudo":"supplements (ONS) is often the next appropriate step to prevent and treat PEW. Therefore, it is"
  },
  {
    "conteudo":"important to establish the effectiveness of ONS on nutritional status, clinical outcomes and"
  },
  {
    "conteudo":"quality of life in patients with CKD."
  },
  {
    "conteudo":"Although feeding through the gastrointestinal route should be the preferred choice of"
  },
  {
    "conteudo":"nutritional supplementation, feeding through the parenteral route (i.e. total parenteral"
  },
  {
    "conteudo":"nutrition), may be a safe and convenient approach for patients who cannot tolerate oral or"
  },
  {
    "conteudo":"enteral administration of nutrients.204 In MHD patients, utilization of the hemodialysis access"
  },
  {
    "conteudo":"for TPN provides a significant advantage by eliminating the need for an additional permanent"
  },
  {
    "conteudo":"venous catheter placement. Since HD access is routinely utilized for the HD procedure. TPN"
  },
  {
    "conteudo":"can be conveniently administered during HD via the dialysis tubing. This type of TPN"
  },
  {
    "conteudo":"administration is called “intradialytic parenteral nutrition (IDPN)”."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"This evidence review included fifteen clinical trials, twelve of which were RCTs207-217 and"
  },
  {
    "conteudo":"three NRCTs.218-220 Most of the studies examined the effect of ONS in patients on MHD."
  },
  {
    "conteudo":"However, Moretti et al.213 included patients on MHD and PD with the results merged;"
  },
  {
    "conteudo":"Gonzalez-Espinoza et al.211 and Teixido-Planas et al.214 studied patients on PD only; and Wu"
  },
  {
    "conteudo":"et al.217 studied patients with CKD, stages 3-4. No studies were performed in patients with"
  },
  {
    "conteudo":"CKD with kidney allografts. Most of the studies examined the effect of oral protein-energy or"
  },
  {
    "conteudo":"protein-based ONS using commercial products. However, Allman et al.207 used a glucose-"
  },
  {
    "conteudo":"polymer ONS and Wu et al.217 used a non-protein calorie ONS. Four studies used renal-"
  },
  {
    "conteudo":"specific protein-energy ONS.210, 212, 219, 220 A major drawback of the literature was the limited"
  },
  {
    "conteudo":"use of a placebo group, though most studies did include a comparator group which was"
  },
  {
    "conteudo":"defined as participants not receiving ONS or receiving only nutritional counselling. Study"
  },
  {
    "conteudo":"durations ranged from 12 weeks to 13½ months. Seven of the RCTs included participants with"
  },
  {
    "conteudo":"some level of malnutrition at baseline.207-211, 216, 221 In contrast, five studies did not actively"
  },
  {
    "conteudo":"enroll malnourished patients.212-215, 217 Of the NRCTs Sezer et al.220 enrolled malnourished"
  },
  {
    "conteudo":"patients as defined by serum albumin or weight loss, Cheu et al.218 enrolled patients with"
  },
  {
    "conteudo":"hypoalbuminemia, and Scott et al.219 did not actively recruit patients with malnutrition."
  },
  {
    "conteudo":"Mortality, Hospitalizations, and Quality of Life"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 106"
  },
  {
    "conteudo":"One NRCT examined the effect of ONS on mortality in 276 patients on MHD who received for"
  },
  {
    "conteudo":"ONS for a low serum albumin versus 194 similar patients who refused ONS or in whom"
  },
  {
    "conteudo":"treatment was deemed inappropriate.218 No difference in mortality [HR (95% CI); 0.70 (0.36,"
  },
  {
    "conteudo":"1.35)] was noted over a median duration of 13.5 months."
  },
  {
    "conteudo":"Two RCTs213, 216 and one NRCT218 evaluated the effect of ONS on hospitalization over a period"
  },
  {
    "conteudo":"of 6 to 13.5 months in patients on MHD or PD. A pooled analysis of the two RCTs213, 218 found"
  },
  {
    "conteudo":"no significant difference in odds of hospitalization by group assignment, but a NRCT218"
  },
  {
    "conteudo":"reported a 34% reduction in hospitalization risk [0.66 (0.50, 0.85)] by 12 months in patients"
  },
  {
    "conteudo":"receiving ONS compared to controls."
  },
  {
    "conteudo":"Three studies (two RCTs209, 210 and one NRCT219) each of three months’ duration examined the"
  },
  {
    "conteudo":"effect of ONS on quality of life (QOL) measures in patients on MHD. One RCT209 and one"
  },
  {
    "conteudo":"NRCT219 reported that patients receiving general209 or renal-specific219 protein-energy ONS"
  },
  {
    "conteudo":"had higher QOL scores in the domains of physical functioning209, 219 and bodily pain209"
  },
  {
    "conteudo":"compared to receiving dietary advice only209 or no supplementation,219 but another RCT210"
  },
  {
    "conteudo":"reported that renal-specific protein-energy ONS did not influence QOL scores in any domain."
  },
  {
    "conteudo":"A pooled analysis of the two RCTs209, 219 found that ONS did not significantly influence"
  },
  {
    "conteudo":"bodily pain, physical functioning, or general health QOL domain scores."
  },
  {
    "conteudo":"CKD Progression"
  },
  {
    "conteudo":"A RCT217 conducted for 24 weeks examined the effect of an energy-based ONS on progression"
  },
  {
    "conteudo":"of CKD in 109 patients with CKD 3-4 who were following a low-protein diet. While no"
  },
  {
    "conteudo":"difference in serum creatinine or eGFR was observed between ONS and controls, there was a"
  },
  {
    "conteudo":"comparative reduction in proteinuria in the ONS arm (p<0.05)."
  },
  {
    "conteudo":"Composite Nutritional Scores & Biochemical Markers of Nutritional Status"
  },
  {
    "conteudo":"A 3-month RCT in 18 patients on MHD examined the effect of a food-based ONS on"
  },
  {
    "conteudo":"Subjective Global Assessment (SGA) scores.209 Authors describe a significantly greater SGA"
  },
  {
    "conteudo":"improvement in patients receiving ONS compared to patients receiving nutritional guidance"
  },
  {
    "conteudo":"only. One NRCT found that ONS over a six-month period did not influence the Malnutrition"
  },
  {
    "conteudo":"Inflammation Score (MIS) as compared to dietary advice.220"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 107"
  },
  {
    "conteudo":"Fifteen studies (twelve RCTs207-211, 213-217, 222 and three NRCTs218-220) examined the effect of"
  },
  {
    "conteudo":"ONS on serum albumin in patients with 3-5D. These included eleven in patients on MHD 3 to"
  },
  {
    "conteudo":"13.5 months’ duration, one RCT213 in patients on MHD and PD of 6 months’ duration, two"
  },
  {
    "conteudo":"RCTs211, 214 in patients on PD of 6 months’ duration, and one217 in patients with CKD 3-4 of"
  },
  {
    "conteudo":"24 weeks’ duration. Overall, the literature suggested that protein-energy ONS modestly"
  },
  {
    "conteudo":"improved serum albumin levels though the results should be interpreted with caution. A pooled"
  },
  {
    "conteudo":"analysis of 11 studies207-214, 217, 219, 220 that included patients with CKD 3-5D found that ONS"
  },
  {
    "conteudo":"modestly improved serum albumin as compared to controls [mean difference (95% CI); 0.121"
  },
  {
    "conteudo":"(0.006, 0.236) g\/dL]. However, a subgroup analysis found the effect to be significant only"
  },
  {
    "conteudo":"when using protein-energy ONS209, 210, 212, 214, 219, 220 [mean difference (95% CI); 0.16 (0.08,"
  },
  {
    "conteudo":"0.24) g\/dl] and not energy207, 217 or protein-based208, 211, 213 supplements. Heterogeneity of results"
  },
  {
    "conteudo":"in the pooled analysis was high (I2=68.3%, p<0.001) so results should be interpreted"
  },
  {
    "conteudo":"cautiously."
  },
  {
    "conteudo":"One RCT210 in 86 patients on MHD reported that ONS did not influence serum pre-albumin"
  },
  {
    "conteudo":"levels as compared to dietary advice. Two RCTs of 3-6 months’ duration in patients on MHD"
  },
  {
    "conteudo":"reported conflicting effects of ONS on total protein, perhaps related to type of ONS.207, 208"
  },
  {
    "conteudo":"The first study of 30 patients reported a positive effect on total protein using an amino acid-"
  },
  {
    "conteudo":"based ONS208 while a second of 21 patients found no effect of a 6-month energy-based ONS"
  },
  {
    "conteudo":"intervention.207 Two studies (a RCT207 and a NRCT219) in patients on MHD of 3-6 months’"
  },
  {
    "conteudo":"duration found no effect of ONS on serum transferrin, either individually or in a pooled"
  },
  {
    "conteudo":"analysis."
  },
  {
    "conteudo":"Anthropometric Measurements"
  },
  {
    "conteudo":"The effect of ONS on anthropometric indices varied in large part according to the type of ONS"
  },
  {
    "conteudo":"used, with the greatest effects being seen in one study207 that used an energy based ONS."
  },
  {
    "conteudo":"Body Mass Index (BMI): Seven studies (six RCTs207-212 and one NRCT220) evaluated the effect"
  },
  {
    "conteudo":"of ONS on BMI over a 3-6-month period. Six of the studies were conducted in patients on"
  },
  {
    "conteudo":"MHD207-210, 212, 220 and one in patients on PD.211 A pooled analysis demonstrated no overall"
  },
  {
    "conteudo":"effect of ONS on BMI though the study using an energy-based ONS noted a rise in"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 106"
  },
  {
    "conteudo":"BMI.207 Overall, the heterogeneity was moderate (I2=49.8%, p=0.06)."
  },
  {
    "conteudo":"Body Weight: Six studies (5 RCTs and 1 NRCT) investigated the effect of ONS on body"
  },
  {
    "conteudo":"weight over 3 to 6 months in patients on MHD,207, 208, 215, 219 PD, 214 and with CKD 3-"
  },
  {
    "conteudo":"4.217Overall, ONS was linked to increased body weight but mainly in patients on MHD"
  },
  {
    "conteudo":"consuming an energy-based supplement. However, one RCT in patients on PD that used"
  },
  {
    "conteudo":"a protein-based ONS reported increased body weight.214 A pooled analysis of all six"
  },
  {
    "conteudo":"studies207, 208, 214, 215, 217, 219 found higher body weight in the ONS group compared to the"
  },
  {
    "conteudo":"control arm [mean (95% CI);2.77 (1.19, 4.36) kg] in patients with CKD 3-5D. However,"
  },
  {
    "conteudo":"the difference was mainly driven by energy based ONS in patients on MHD."
  },
  {
    "conteudo":"Dialysis Target Weight: Four studies (3 RCTs209, 210, 221 and 1 NRCT220) in patients on"
  },
  {
    "conteudo":"MHD209, 210, 220, 221 examined the effect of ONS on dialysis target weight over a 3 to 6-month"
  },
  {
    "conteudo":"period. Overall, no effect of ONS on target weight was observed, though one NRCT220"
  },
  {
    "conteudo":"reported an increase in target weight using a renal-specific protein-energy ONS220 as did one"
  },
  {
    "conteudo":"RCT222 using a protein-based ONS. A pooled analysis of three studies209, 210, 220 found no"
  },
  {
    "conteudo":"overall effect. Hiroshige et al. reported results in a figure and could not be included in pooled"
  },
  {
    "conteudo":"analysis."
  },
  {
    "conteudo":"Lean Body Mass\/Fat Free Mass\/Muscle Mass: Seven trials (six RCTs207-209, 214, 215, 222 and"
  },
  {
    "conteudo":"NRCT220) in patients on MHD207-209, 215, 220, 222 or PD214 studied the effect of ONS on markers of"
  },
  {
    "conteudo":"lean mass over 3 to 6 months. Overall, ONS increased LBM or fat free mass only in patients on"
  },
  {
    "conteudo":"MHD who received an energy based ONS. In patients on MHD, the effect of protein based"
  },
  {
    "conteudo":"ONS on LBM was mixed. In a pooled analysis of 6 studies207-209, 214, 215, 220 ONS was associated"
  },
  {
    "conteudo":"with a significant increase in LBM or fat free mass [mean difference (95% CI); 1.18 (0.16,"
  },
  {
    "conteudo":"2.20) kg] compared to the control arm, but a subgroup analysis found the effect to be significant"
  },
  {
    "conteudo":"only in patients on MHD using energy-based ONS."
  },
  {
    "conteudo":"Body Fat: Seven studies (six RCTs207-209, 212, 215, 222 and one NRCT220) in patients on MHD"
  },
  {
    "conteudo":"evaluated the effect of ONS on body fat over a period of 3 to 6 months. A pooled analysis of"
  },
  {
    "conteudo":"six studies207-209, 212, 215, 220 reported no overall effect of ONS on body FM though subgroup"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 107"
  },
  {
    "conteudo":"analyses demonstrated that energy207 and protein-energy209, 212, 220 based ONS significantly"
  },
  {
    "conteudo":"increased body FM compared to controls, but protein-based ONS had no effect."
  },
  {
    "conteudo":"Skinfold Measurements: Five studies (four RCTs207, 209, 211, 214 and one NRCT220) in patients with"
  },
  {
    "conteudo":"CKD on MHD207, 209, 220 or PD211, 214examined the effect of ONS on skinfold measurements over"
  },
  {
    "conteudo":"a 3 to 6-month period. A pooled analysis of 4 studies207, 211, 214, 220reported that ONS significantly"
  },
  {
    "conteudo":"increased skinfold measurements [mean difference (95% CI); 3.91 (0.93, 6.90) mm] compared to"
  },
  {
    "conteudo":"dietary counselling or no supplementation, but this effect was significant only in patients on MHD"
  },
  {
    "conteudo":"using energy based ONS."
  },
  {
    "conteudo":"Arm or Muscle Circumference: Four RCTs in patients on MHD207, 209 or PD211, 214 evaluated the"
  },
  {
    "conteudo":"effect of ONS on arm or muscle circumference over a 3 to 6-month period. None of the studies"
  },
  {
    "conteudo":"showed any effect."
  },
  {
    "conteudo":"Dietary Intake"
  },
  {
    "conteudo":"Protein: Ten studies (nine RCTs207-211, 213, 214, 217, 222 and one NRCT220) examined the effect of"
  },
  {
    "conteudo":"ONS on protein intake as estimated by nPCR\/nPNA (nPCR), 24-hour dietary recall or"
  },
  {
    "conteudo":"multiple-day food records with study durations of three to six months. Overall, protein-based"
  },
  {
    "conteudo":"supplements (AA208 or BCAA222) increased reported protein intake and nPCR in patients on"
  },
  {
    "conteudo":"MHD and PD but energy207, 217 or protein-energy supplements did not influence either marker"
  },
  {
    "conteudo":"in patients with CKD 3-5D. A pooled analysis of seven studies208-211, 213, 214, 220 found that"
  },
  {
    "conteudo":"ONS significantly increased nPCR in patients on dialysis [standardized mean difference (95%"
  },
  {
    "conteudo":"CI); 0.29 (0.04, 0.53)], suggesting a potentially clinically relevant effect. However a subgroup"
  },
  {
    "conteudo":"analysis found the effect to be significant only in persons receiving protein-based208, 211, 213 but"
  },
  {
    "conteudo":"not protein-energy based ONS.209, 210, 214, 220 Similar results were noted in a pooled analysis of"
  },
  {
    "conteudo":"three studies210, 211, 214 examining the effects of ONS on reported protein intake where ONS"
  },
  {
    "conteudo":"increased reported protein intake only in one study that supplemented egg albumin protein.211"
  },
  {
    "conteudo":"Energy"
  },
  {
    "conteudo":"Six RCTs207, 210-212, 217, 222 with study duration of 3 to 6 months examined the effect of ONS on"
  },
  {
    "conteudo":"energy intake in patients on MHD,207, 210, 212, 222 on PD,211 and with CKD, stages 3-4.217 Overall"
  },
  {
    "conteudo":"ONS raised energy intake though the effect was limited to patients on MHD receiving"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 108"
  },
  {
    "conteudo":"renal-specific protein-energy ONS. Four out of five studies in patients on dialysis reported that"
  },
  {
    "conteudo":"ONS increased energy intake.207, 210-212, 222 However, a subgroup analysis found the effect to be"
  },
  {
    "conteudo":"significant only for patients on MHD receiving protein-energy ONS,210, 212 but not receiving"
  },
  {
    "conteudo":"protein-211 or energy-based217 ONS alone. The only study in patients with CKD 3-4 found no"
  },
  {
    "conteudo":"improvement in energy intake using a non-protein calorie ONS.217"
  },
  {
    "conteudo":"Phosphorus and Calcium"
  },
  {
    "conteudo":"An RCT of 3 months’ duration in patients on MHD found no effect"
  },
  {
    "conteudo":"on phosphorus or calcium intake.210"
  },
  {
    "conteudo":"Other Biochemical Markers (CPR, anemia indices, electrolyte levels)"
  },
  {
    "conteudo":"Seven studies (six RCTs208-210, 212, 215, 217 and one NRCT220) of 3-6 months’ duration in patients"
  },
  {
    "conteudo":"on MHD208-210, 212, 215, 220 and CKD 3-4217 found no effect of ONS on CRP. Seven studies (five"
  },
  {
    "conteudo":"examined"
  },
  {
    "conteudo":"RCTs207-209, 211, 215 and two NRCT 208, 220) in patients on MHD207-209, 215, 220 or PD211"
  },
  {
    "conteudo":"the effect of ONS on markers of anemia over a 3 to 6-month period. Overall, ONS had no"
  },
  {
    "conteudo":"effect on these markers. Five studies (four RCTs209, 211, 215, 217and one NRCT219) examined the"
  },
  {
    "conteudo":"effect of ONS on serum calcium, phosphate, and potassium levels over 3 to 6 months. Three"
  },
  {
    "conteudo":"of the trials were in patients on MHD209, 215, 219, one was in patients on PD211, and one was in"
  },
  {
    "conteudo":"patients with CKD 3-4.217 None of the studies found any effect on ONS on these electrolytes."
  },
  {
    "conteudo":"Five studies (four RCTs207, 211, 212, 217and one NRCT220) examined the effect of ONS on plasma"
  },
  {
    "conteudo":"lipids over 3 to 6 months."
  },
  {
    "conteudo":"IDPN"
  },
  {
    "conteudo":"This evidence review encompassed three studies that examined the effects of IDPN on"
  },
  {
    "conteudo":"nutritional status and clinical outcomes in MHD patients, including one NRCT221 and two"
  },
  {
    "conteudo":"RCTs.223, 224 In all these studies, participants were malnourished. In Hiroshige et al.,221"
  },
  {
    "conteudo":"participants in the intervention group received dietary counselling from an RDN and an IDPN"
  },
  {
    "conteudo":"infusion of 200 ml 50% dextrose, 200 ml 7.1% EAAs, and 200 ml 20% lipid emulsion,"
  },
  {
    "conteudo":"providing 2400 kcal and 42.3 g amino acid for one year. Results were compared to a group"
  },
  {
    "conteudo":"receiving dietary counselling only (control group). In Cano et al.223 all participants were given"
  },
  {
    "conteudo":"an oral nutritional supplements (ONS) providing 25 g\/protein\/day and 500 kcal\/day for one"
  },
  {
    "conteudo":"year, and the intervention group additionally received IDPN to meet target ranges of 30 to 35"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 109"
  },
  {
    "conteudo":"kcal\/day and 1.2 g\/protein\/kg\/day; and included a standard lipid emulsion of 50% glucose, 50%"
  },
  {
    "conteudo":"non-protein energy supply, and a standard amino acid solution.223 In Toigo et al., participants in"
  },
  {
    "conteudo":"the intervention group were given (EAAs) IV formula for 6 months.224 Results were compared"
  },
  {
    "conteudo":"to participants in the intervention group where they received an isonitrogenous standard formula"
  },
  {
    "conteudo":"containing both non-essential amino acids (NEAAs) and EAAs for 6 months. Both groups"
  },
  {
    "conteudo":"simultaneously received 500ml of 10% glucose. Participants were followed up for an additional"
  },
  {
    "conteudo":"6 months."
  },
  {
    "conteudo":"Mortality and hospitalization"
  },
  {
    "conteudo":"Only one study examined and found no effect of IDPN on mortality and hospitalization. In"
  },
  {
    "conteudo":"Cano et al., statistical comparisons were not provided but the authors described no significant"
  },
  {
    "conteudo":"differences in mortality or hospitalization events between ONS only and IDPN with ONS"
  },
  {
    "conteudo":"groups. 223"
  },
  {
    "conteudo":"Anthropometric measurements"
  },
  {
    "conteudo":"The three studies examined the effect of IDPN therapy on anthropometric measurements in"
  },
  {
    "conteudo":"malnourished MHD patients.221, 223, 224 The findings from these studies indicated that IDPN, in"
  },
  {
    "conteudo":"combination with dietary counselling221 or ONS,223 increased BMI221, 223 dry body weight,221"
  },
  {
    "conteudo":"skinfold measurements, 221 and MAMC221 compared to dietary counselling only. However,"
  },
  {
    "conteudo":"similar improvement in BMI was observed when adequate and comparable protein and energy"
  },
  {
    "conteudo":"were given to patients receiving ONS only.223 Compared to a standard IDPN formulation of"
  },
  {
    "conteudo":"both EAAs and NEAAs, an IDPN formulation with EAAs did not affect % desirable body"
  },
  {
    "conteudo":"weight, skinfold measurements, and AMA.219"
  },
  {
    "conteudo":"Laboratory markers of nutritional status (albumin, pre-albumin, transferrin, and nPCR)"
  },
  {
    "conteudo":"Three studies221, 223, 224 examined the effect of IDPN on laboratory markers of nutritional"
  },
  {
    "conteudo":"status in malnourished MHD patients. The results from these studies concluded that IDPN in"
  },
  {
    "conteudo":"conjunction with dietary counselling221 or ONS223 increased albumin,221, 223 pre-albumin,223 or"
  },
  {
    "conteudo":"transferrin levels,221 but similar improvements in albumin and pre-albumin levels were"
  },
  {
    "conteudo":"observed when adequate and comparable protein and energy were provided to patients"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 110"
  },
  {
    "conteudo":"receiving ONS only.223 Compared to a standard IDPN formulation of both EAAs and NEAAs,"
  },
  {
    "conteudo":"an IDPN formulation with EAAs only did not affect albumin and transferrin levels.224"
  },
  {
    "conteudo":"Other laboratory markers (inflammation (CRP); hemoglobin, lipid profile)"
  },
  {
    "conteudo":"One study evaluated and found no effect of IDPN on inflammation in malnourished"
  },
  {
    "conteudo":"hemodialysis patients. Cano et al. reported no change in CRP levels in either ONS only or"
  },
  {
    "conteudo":"IDPN+ONS groups, although data was not provided.223"
  },
  {
    "conteudo":"One study examined and found no effect of IDPN therapy with EAAs only vs standard IDPN"
  },
  {
    "conteudo":"formulation with both EAAs and NEAAs on hemoglobin levels in malnourished MHD patients"
  },
  {
    "conteudo":"after 6 months.224"
  },
  {
    "conteudo":"Two studies examined the effect of IDPN on lipid profile. The results from these studies"
  },
  {
    "conteudo":"showed that combining IDPN with dietary counselling221 or ONS223 did not affect total"
  },
  {
    "conteudo":"cholesterol221 or triglyceride levels.221, 223"
  },
  {
    "conteudo":"Dietary intake (energy and protein intake)"
  },
  {
    "conteudo":"Two studies221, 223 examined the effect of IDPN on dietary intake in malnourished MHD"
  },
  {
    "conteudo":"patients. The findings from these studies showed inconclusive effects of IDPN on dietary"
  },
  {
    "conteudo":"energy and protein intakes."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"A complete nutritional assessment should be performed prior to considering ONS and should"
  },
  {
    "conteudo":"be repeated at regular intervals during the supplementation period."
  },
  {
    "conteudo":"IDPN therapy does not alter patient’s eating behavior, nor does it encourage healthy eating"
  },
  {
    "conteudo":"habits. Patients on IDPN may suffer from time-limitation due to MHD frequency and duration."
  },
  {
    "conteudo":"Because IDPN is usually given for 4 hours during dialysis thrice weekly, it may not provide"
  },
  {
    "conteudo":"sufficient calories and protein to meet long-term nutritional requirements. TPN is usually"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 111"
  },
  {
    "conteudo":"administered on a daily basis. The potential of IDPN to meet target protein and energy"
  },
  {
    "conteudo":"requirements in MHD patients mainly depends on the actual difference between these targets"
  },
  {
    "conteudo":"and spontaneous dietary intakes via ONS or dietary counselling. If the difference can be met"
  },
  {
    "conteudo":"by the IDPN regimen, the workgroup felt that IDPN should be considered in conjunction with"
  },
  {
    "conteudo":"ONS or dietary counselling."
  },
  {
    "conteudo":"This evidence reviews suggested that IDPN offers no further benefit over ONS. It was"
  },
  {
    "conteudo":"postulated that markers of nutritional status improved irrespective of the route of nutrient"
  },
  {
    "conteudo":"administration as long as dietary protein and energy targets are met.223 However, a direct"
  },
  {
    "conteudo":"comparison between IDPN and ONS was lacking, this would only imply that ONS is equally"
  },
  {
    "conteudo":"effective as IDPN when oral intake is possible. Since ONS was included in the intervention"
  },
  {
    "conteudo":"arm as well, the inferiority of IDPN over ONS cannot be confirmed."
  },
  {
    "conteudo":"A recently published a RCT investigating the effect of IDPN therapy on pre-albumin and other"
  },
  {
    "conteudo":"biochemical and clinical nutritional markers in malnourished MHD patients,225 demonstrated"
  },
  {
    "conteudo":"that IDPN therapy increased pre-albumin levels and was superior to nutritional counselling"
  },
  {
    "conteudo":"after 16 weeks. This study was not included in this evidence review because the date of"
  },
  {
    "conteudo":"publication was beyond the cut-off time for study inclusion. In this study, patients randomized"
  },
  {
    "conteudo":"to the intervention group received standardized nutritional counselling plus IDPN three times"
  },
  {
    "conteudo":"weekly for 16 weeks. There were no within-group changes and between-group differences at"
  },
  {
    "conteudo":"week 16 in other clinical and biochemical nutritional markers (BMI, albumin, transferrin, PCR,"
  },
  {
    "conteudo":"phase angle alpha, and SGA)."
  },
  {
    "conteudo":"Implementation Considerations"
  },
  {
    "conteudo":"•"
  },
  {
    "conteudo":"ONS should be prescribed two to three times daily and patients should be advised to take"
  },
  {
    "conteudo":"ONS preferably 1 hour after meals rather than as a meal replacement in order to maximize"
  },
  {
    "conteudo":"benefit.204"
  },
  {
    "conteudo":"• Monitored in-center provision of high-protein meals or ONS during MHD may be a useful"
  },
  {
    "conteudo":"strategy to increase total protein and energy intake.226 Many of the perceived negative"
  },
  {
    "conteudo":"effects of intradialytic feeding such as postprandial hypotension, aspiration risk, infection"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 112"
  },
  {
    "conteudo":"control and hygiene, as well as diabetes and phosphorus control can be avoided with"
  },
  {
    "conteudo":"careful monitoring."
  },
  {
    "conteudo":"• ONS prescription should take into account patient preference. The acceptability of ONS in"
  },
  {
    "conteudo":"terms of appearance, smell, taste, texture, and type of preparation (milkshake type, juice"
  },
  {
    "conteudo":"type, pudding type, protein\/energy bar, or fortification powder) should be carefully"
  },
  {
    "conteudo":"considered."
  },
  {
    "conteudo":"• Energy-dense and low-electrolyte, renal-specific ONS may be necessary to increase protein"
  },
  {
    "conteudo":"and energy intake and avoid fluid and electrolyte derangements."
  },
  {
    "conteudo":"• Increased risk of infectious complications and the high cost of IDPN are the greatest"
  },
  {
    "conteudo":"barriers for regular use of IDPN."
  },
  {
    "conteudo":"• MHD patients meeting all of the following three criteria may benefit from IDPN therapy:"
  },
  {
    "conteudo":"1) evidence of protein-energy malnutrition and inadequate dietary protein and\/or energy"
  },
  {
    "conteudo":"intake; 2) inability to administer or tolerate adequate oral nutrition, including food"
  },
  {
    "conteudo":"supplements or enteral feeding; and 3) protein and energy requirements can be met when"
  },
  {
    "conteudo":"IDPN is used in conjunction with oral intake or enteral feeding."
  },
  {
    "conteudo":"• IDPN therapy should not be considered as a long-term approach of nutritional support. It"
  },
  {
    "conteudo":"should be discontinued and ONS should be attempted as soon as improvements in"
  },
  {
    "conteudo":"nutritional status are observed and patients are capable of using oral or enteral route."
  },
  {
    "conteudo":"• If IDPN therapy in conjunction with oral intake does not achieve the nutritional"
  },
  {
    "conteudo":"requirements of the patient, or the gastrointestinal tract is malfunctioned, then total"
  },
  {
    "conteudo":"parenteral nutrition (TPN) given on a daily basis should be considered."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Gastrointestinal side effects can influence adherence to ONS227 and extended periods of"
  },
  {
    "conteudo":"monotonous supplementation can lead to flavor and taste fatigue as well as non-adherence to"
  },
  {
    "conteudo":"the prescribed ONS. Therefore, regular monitoring and evaluation during the supplementation"
  },
  {
    "conteudo":"period is crucial and adjustments to the ONS prescription may be necessary to improve"
  },
  {
    "conteudo":"adherence and optimize effectiveness. Nutritional status should be monitored regularly"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 113"
  },
  {
    "conteudo":"throughout the supplementation period in order to evaluate effectiveness of ONS."
  },
  {
    "conteudo":"Ongoing monitoring and evaluation of nutritional status during IDPN therapy is necessary."
  },
  {
    "conteudo":"Serum glucose should be closely monitored during and post MHD. In the case of insulin"
  },
  {
    "conteudo":"requirement, the use of subcutaneous short-acting insulin analogs should be chosen to avoid"
  },
  {
    "conteudo":"post-dialytic hypoglycemia. The ultrafiltration rate should be adjusted to remove the extra"
  },
  {
    "conteudo":"fluid provided by IDPN."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"• Adequately powered RCTs are necessary to evaluate the impact of ONS on long-term"
  },
  {
    "conteudo":"survival, hospitalization, and quality of life in patients throughout the range of CKD."
  },
  {
    "conteudo":"An ongoing study will help address this unmet need [NCT02933151]."
  },
  {
    "conteudo":"• In addition, further research is needed to define the optimal composition and scheduling"
  },
  {
    "conteudo":"of ONS as well as define the patient subgroups most likely to benefit."
  },
  {
    "conteudo":"• Adequately powered and long-term clinical trials comparing the independent effects of"
  },
  {
    "conteudo":"IDPN compared to ONS on nutritional status, morbidity, mortality and quality of life"
  },
  {
    "conteudo":"are required."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 114"
  },
  {
    "conteudo":"4.2 Statement on Nutrition – Dialysate"
  },
  {
    "conteudo":"Dialysate Protein-Energy Supplementation"
  },
  {
    "conteudo":"4.2.1 In adults with CKD on peritoneal dialysis with protein-energy wasting, we"
  },
  {
    "conteudo":"suggest not substituting conventional dextrose dialysate with amino acid dialysate as a"
  },
  {
    "conteudo":"general strategy to improve nutritional status (2C), although in selected cases of"
  },
  {
    "conteudo":"protein-wasting when energy intake is adequate, 1.1% amino acid dialysate with alkali"
  },
  {
    "conteudo":"supplements may ameliorate protein deficits (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Protein-energy wasting is common among patients on maintenance PD, and is associated with"
  },
  {
    "conteudo":"increased morbidity and mortality.228 Inflammation, acidosis, insulin resistance, insufficient"
  },
  {
    "conteudo":"dietary intakes of protein and energy as a result of anorexia, and peritoneal losses of proteins"
  },
  {
    "conteudo":"and amino acids contribute to protein-energy wasting.229 Intraperitoneal amino acids (IPAA)"
  },
  {
    "conteudo":"supplementation was introduced to compensate for low protein intake and protein losses."
  },
  {
    "conteudo":"Substituting amino acids for glucose in PD solutions should increase the amino acid intake and"
  },
  {
    "conteudo":"decrease the net amino acid losses of the patient, thereby increasing the net intake of protein"
  },
  {
    "conteudo":"precursors.230 IPAA supplementation may also reduce the infused carbohydrate load, thereby"
  },
  {
    "conteudo":"reducing the risk of hyperglycemia and the tendency to hypertriglyceridemia.230"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"This evidence review included three studies that examined the effect of IPAA supplementation"
  },
  {
    "conteudo":"on nutritional status in malnourished PD patients, including two RCTs231, 232 and one non-"
  },
  {
    "conteudo":"randomized crossover trial.233 In the two RCTs,231, 232 results were compared between those"
  },
  {
    "conteudo":"receiving traditional 1.5% dextrose dialysate vs those who replaced one to two daily exchanges"
  },
  {
    "conteudo":"of 1.5% dextrose dialysate with 1.1% amino acid dialysate. Study durations ranged from 3"
  },
  {
    "conteudo":"months231 to 3 years.232 In the non-randomized crossover trial, Misra et al. utilized the same"
  },
  {
    "conteudo":"study design in which the participants were assigned to each exposure (amino acid dialysate for"
  },
  {
    "conteudo":"one exchange\/day or dextrose dialysate only) for 6 months.233 In all of these studies, PD"
  },
  {
    "conteudo":"patients demonstrated some level of malnutrition or protein energy wasting. In Misra et al.,233"
  },
  {
    "conteudo":"the majority of patients were presented with hypoalbuminemia; in Li et al.,232 all patients were"
  },
  {
    "conteudo":"malnourished; and in Jones et al.,231 participants were mildly to moderately malnourished."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 115"
  },
  {
    "conteudo":"Anthropometric Measurements and Laboratory Measures of Nutritional Status"
  },
  {
    "conteudo":"Two RCTs examined the effect of IPAA therapy on anthropometric measurements in"
  },
  {
    "conteudo":"malnourished PD patients.231, 232 MAMC, triceps skinfold measurements and FM were"
  },
  {
    "conteudo":"maintained at 3 months231, 232 and 3 years232 in both IPAA and dextrose dialysate groups. The"
  },
  {
    "conteudo":"results from these studies indicated that substituting amino acid dialysate for dextrose dialysate"
  },
  {
    "conteudo":"had no effect on anthropometric measurements."
  },
  {
    "conteudo":"Two RCTs231, 232 and one non-randomized crossover trial233 examined the effect IPAA"
  },
  {
    "conteudo":"supplementation on serum albumin, pre-albumin, and transferrin levels in malnourished PD"
  },
  {
    "conteudo":"patients. One randomized-controlled trial evaluated the effect of IPAA supplementation on"
  },
  {
    "conteudo":"total protein level.231 The findings from these studies concluded that substituting amino acid"
  },
  {
    "conteudo":"dialysate for dextrose dialysate in malnourished PD patients did not affect serum albumin, pre-"
  },
  {
    "conteudo":"albumin, transferrin, and total protein levels compared to those receiving dextrose dialysate"
  },
  {
    "conteudo":"only."
  },
  {
    "conteudo":"Electrolyte levels (phosphorus\/phosphate, bicarbonate, and potassium levels)"
  },
  {
    "conteudo":"One RCT231 and one non-randomized crossover trial233 examined the effect of IPAA"
  },
  {
    "conteudo":"supplementation on electrolyte levels in malnourished PD patients. The findings from these"
  },
  {
    "conteudo":"studies suggested that substituting amino acid dialysate for dextrose dialysate in malnourished"
  },
  {
    "conteudo":"PD patients decreased their phosphate and bicarbonate levels, but the effect on potassium"
  },
  {
    "conteudo":"levels was unclear."
  },
  {
    "conteudo":"Jones et al. showed that serum potassium and phosphate levels decreased significantly in"
  },
  {
    "conteudo":"IPAA group and levels were different between groups at 3 months (p<0.05 for each"
  },
  {
    "conteudo":"measure).231 In contrast, Misra et al. showed no within-group changes in potassium, phosphate"
  },
  {
    "conteudo":"or bicarbonate levels in either IPAA or dextrose dialysate groups.233 However, when averaged"
  },
  {
    "conteudo":"across time, patients receiving IPAA therapy had lower mean phosphate (p=0.018) and"
  },
  {
    "conteudo":"bicarbonate levels (p=0.002). In secondary analysis, the IPAA groups in Jones et al.231 and"
  },
  {
    "conteudo":"Misra et al.233 demonstrated a mean difference (95% CI) of -0.50 (-0.87, -0.13) mEq\/L in"
  },
  {
    "conteudo":"potassium and -1.10 (-1.43, -0.77) mmol\/L in bicarbonate levels respectively when"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 116"
  },
  {
    "conteudo":"compared to the dextrose dialysate group. In pooled analysis, there was a mean difference"
  },
  {
    "conteudo":"(95% CI) of -0.55 (-0.70, -0.41) mg\/dL in phosphate levels in the IPAA group compared to the"
  },
  {
    "conteudo":"dextrose dialysate group."
  },
  {
    "conteudo":"Dietary intake (protein and energy intake)"
  },
  {
    "conteudo":"One randomized-controlled trial examined the effect of IPAA supplementation on total and"
  },
  {
    "conteudo":"oral protein and energy intakes in malnourished PD patients.232 Compared to baseline intake"
  },
  {
    "conteudo":"levels, total protein intake increased in the IPAA group beginning at 6 months and continuing"
  },
  {
    "conteudo":"until 3 years (p=0.002 for each measure), but there was no significant difference between"
  },
  {
    "conteudo":"IPAA and dextrose dialysate groups. Compared to baseline intake, total energy intake"
  },
  {
    "conteudo":"increased in the IPAA group at 6 months (p<0.001) and 3 years (p=0.002), but it decreased in"
  },
  {
    "conteudo":"the dextrose dialysate group (p<0.001), though there were no significant differences between"
  },
  {
    "conteudo":"groups. Similar results were observed for oral and peritoneal energy intake only. nPNA"
  },
  {
    "conteudo":"(nPCR) increased in the IPAA group at 3 years, but decreased in the dextrose dialysate group,"
  },
  {
    "conteudo":"and values were significantly different between groups at 3 years (p<0.001)."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"The recommendation statement is based on two randomized-controlled and one non-"
  },
  {
    "conteudo":"randomized crossover trials. The included studies only assessed intermediate nutrition-related"
  },
  {
    "conteudo":"outcome measures, including dietary intake (total energy and protein intakes, and oral energy"
  },
  {
    "conteudo":"intake); laboratory markers of nutritional status (serum albumin, pre-albumin, transferrin, and"
  },
  {
    "conteudo":"total protein levels); and anthropometry (MAMC, triceps skinfold and FM). The effects of"
  },
  {
    "conteudo":"substituting amino acid dialysate for conventional dextrose dialysate on patient survival,"
  },
  {
    "conteudo":"hospitalization, other clinical outcomes and quality of life have not been adequately evaluated."
  },
  {
    "conteudo":"The long-term effect of IPAA therapy remains unclear."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"• IPAA supplementation decreased bicarbonate levels,233 and mild acidosis may occur in"
  },
  {
    "conteudo":"some patients,229, 230 although it is readily treatable."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 117"
  },
  {
    "conteudo":"• In diabetic patients on PD with uncontrolled hyperglycemia, substituting amino acid for"
  },
  {
    "conteudo":"glucose in PD solutions may serve as an immediate strategy for glycemic control."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"Adequately powered long-term RCTs are required to evaluate the effects of IPAA therapy on"
  },
  {
    "conteudo":"nutritional status, patient survival, hospitalization, other clinical outcomes and quality of life in"
  },
  {
    "conteudo":"PD patients at risk or with PEW."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 118"
  },
  {
    "conteudo":"4.3 Statement on Long Chain Omega-3 Polyunsaturated Fatty Acids"
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Mortality and Cardiovascular disease"
  },
  {
    "conteudo":"4.3.1 In adults with CKD on MHD or post-transplant, we suggest not routinely"
  },
  {
    "conteudo":"prescribing long-chain n-3 PUFA, including those derived from fish or flaxseed and"
  },
  {
    "conteudo":"other oils, to lower risk of mortality (2C) or cardiovascular events (2B)."
  },
  {
    "conteudo":"4.3.2 In adults with CKD on PD, it is reasonable not to routinely prescribe long-chain"
  },
  {
    "conteudo":"n-3 PUFA, including those derived from fish or flaxseed and other oils, to lower risk of"
  },
  {
    "conteudo":"mortality or cardiovascular events (OPINION)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Lipid Profile"
  },
  {
    "conteudo":"4.3.3 In adults with CKD on MHD, we suggest that 1.3-4 g\/d long-chain n-3 PUFA"
  },
  {
    "conteudo":"may be prescribed to reduce triglycerides and LDL cholesterol (2C) and raise HDL"
  },
  {
    "conteudo":"levels (2D)."
  },
  {
    "conteudo":"4.3.4 In adults with CKD on PD, it is reasonable to consider prescribing 1.3-4 g\/d long-"
  },
  {
    "conteudo":"chain n-3 PUFA to improve the lipid profile (OPINION)."
  },
  {
    "conteudo":"4.3.5 In adults with CKD 3-5, we suggest prescribing ~ 2g\/d long-chain n-3 PUFA to"
  },
  {
    "conteudo":"lower serum triglyceride levels (2C)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for AV Graft and Fistula Patency"
  },
  {
    "conteudo":"4.3.6 In adults with CKD on MHD, we suggest not routinely prescribing fish oil to"
  },
  {
    "conteudo":"improve primary patency rates in patients with AV grafts (2B) or fistulas (2A)."
  },
  {
    "conteudo":"LC n-3 PUFA Nutritional Supplements for Kidney Allograft Survival"
  },
  {
    "conteudo":"4.3.7 In adults with CKD with kidney allograft, we suggest not routinely prescribing"
  },
  {
    "conteudo":"long-chain n-3 PUFA to reduce the number of rejection episodes or improve graft"
  },
  {
    "conteudo":"survival (2D)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) include eicosapentaenoic"
  },
  {
    "conteudo":"(EPA) and docosapentaenoic and docohexaenoic acids (DHA), both of which are obtained"
  },
  {
    "conteudo":"primarily from dietary sources like cold-water fish (i.e. fish oil), or linoleic acid, which is"
  },
  {
    "conteudo":"derived from flaxseed or certain other vegetable oils. In recent decades LC n-3 PUFA have"
  },
  {
    "conteudo":"demonstrated protean biologic effects that mediate eicosanoid production, cell membrane"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 119"
  },
  {
    "conteudo":"physiology, signal transduction, metabolism, apoptosis, oxidation, and inflammation."
  },
  {
    "conteudo":"Accordingly, they have been tested in a variety of medical conditions. Of particular interest has"
  },
  {
    "conteudo":"been their putative effects on cardiac membrane stabilization leading to possible reduction of"
  },
  {
    "conteudo":"malignant arrhythmias and sudden cardiac death. Patients with CKD have been documented to"
  },
  {
    "conteudo":"have some of the lowestblood levels of LC n-3 PUFA on record,234 thus making them"
  },
  {
    "conteudo":"potentially very suitable candidates for supplementation interventions. In fact, LC n-3 PUFA"
  },
  {
    "conteudo":"supplementation has been studied as possible therapy for a number of conditions commonly"
  },
  {
    "conteudo":"observed in patients with CKD including dyslipidemia, hemodialysis access failure,"
  },
  {
    "conteudo":"cardiovascular disease and death, as well as for their immunomodulatory effects in patients"
  },
  {
    "conteudo":"with kidney allografts."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Thirty-five RCTs studied the impact of LC n-3 PUFA supplementation on a variety of health"
  },
  {
    "conteudo":"biomarkers and outcomes in adults with CKD 2-5D and kidney transplant. Twenty-four of"
  },
  {
    "conteudo":"these studies included patients on MHD as the target population, though one study also"
  },
  {
    "conteudo":"included patients on PD.235 Nearly all the interventions used fish oil as the main source of LC"
  },
  {
    "conteudo":"n-3 PUFA but flaxseed oil235 and ground flaxseed 236 were also studied. Study length (4"
  },
  {
    "conteudo":"weeks to 2 years) and size (12-567 participants) varied widely. The heterogeneity of this"
  },
  {
    "conteudo":"literature in terms of the absolute and relative amounts of n-3 PUFA supplemented, the type"
  },
  {
    "conteudo":"of placebo used, and study duration makes it more difficult to provide conclusive evidence"
  },
  {
    "conteudo":"for or against the use of LC n-3 PUFA as a treatment option."
  },
  {
    "conteudo":"All-Cause Mortality and Cardiovascular Events"
  },
  {
    "conteudo":"Despite the putative overall benefits of LC n-3 PUFA and the elevated risk of death in patients"
  },
  {
    "conteudo":"with CKD, three RCTs demonstrated no improvement in mortality with supplementation."
  },
  {
    "conteudo":"However, the studies were heterogeneous in terms of study population (one in patients with"
  },
  {
    "conteudo":"MHD237, two in patients with CKD with kidney allografts 238, 239, the dose of LC n-3 PUFA"
  },
  {
    "conteudo":"(Maachi et al. 1.44g\/d EPA + 0.96g\/d DHA; Berthoux et al. 1.62g\/d EPA+1.08g\/d DHA;"
  },
  {
    "conteudo":"Svensson et al. 2006 0.77g\/d EPA+ 0.64g\/d DHA) and the study duration (1-2 years), with the"
  },
  {
    "conteudo":"combined study population being fairly modest in size (n=264)."
  },
  {
    "conteudo":"Two well-designed but modestly sized (combined n=351) RCTs in patients on MHD reported"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 120"
  },
  {
    "conteudo":"mixed results on the effect of LC n-3 PUFA supplementation on cardiovascular events.237, 240"
  },
  {
    "conteudo":"Lok et al. 240 reported that 4 g\/day fish oil (1.6 g\/d EPA, 0.8 g\/d DHA) for 12 months as"
  },
  {
    "conteudo":"compared to corn oil-based placebo significantly lowered the cardiovascular event rate 0.41"
  },
  {
    "conteudo":"(0.20 to 0.85) (p=0.02) and improved cardiovascular event-free survival 0.43 (0.19 to 0.96)"
  },
  {
    "conteudo":"(p=0.04) but did not influence the number of patients with one or more events 0.78 (0.55 to"
  },
  {
    "conteudo":"1.09) (p=0.15). All were secondary outcomes in a trial designed to study MHD vascular"
  },
  {
    "conteudo":"access. In a secondary prevention trial, Svensson et al. reported that 1.7 g\/d fish oil (0.77 g\/d"
  },
  {
    "conteudo":"EPA and 0.64 g\/d DHA) for two years had no effect on the primary combined endpoint of"
  },
  {
    "conteudo":"cardiovascular events or death as compared to olive oil-based placebo237 but did improve the"
  },
  {
    "conteudo":"secondary endpoints of myocardial infarctions (0.30 (0.10, 0.92) (p=0.036) and major"
  },
  {
    "conteudo":"coronary events (0.40 (0.17, 0.97) (p=0.043)."
  },
  {
    "conteudo":"Hemodialysis Access"
  },
  {
    "conteudo":"Previous studies have suggested that LC n-3 PUFA, in particular those derived from fish oil,"
  },
  {
    "conteudo":"have anti-proliferative, antioxidant, and vasodilatory effects. This was the impetus for the four"
  },
  {
    "conteudo":"RCTs that examined whether LC n-3 PUFA supplementation could improve patency of"
  },
  {
    "conteudo":"arteriovenous grafts (AVG) or fistulas (AVF) in patients on MHD. Of the three RCTs240-242"
  },
  {
    "conteudo":"studying AV graft survival, the two smallest (using 0.96-1.76 g\/d EPA and 0.6-0.96 g\/d DHA)"
  },
  {
    "conteudo":"had mixed results with one showing no benefit at six months (n=29)241 and the other (n=24)"
  },
  {
    "conteudo":"reporting higher primary patency rates compared to placebo group at 1 year (p<0.03).242 The"
  },
  {
    "conteudo":"third and much larger trial (n=201) noted a borderline statistically significant improvement in"
  },
  {
    "conteudo":"the loss of native patency at one year 0.78 [0.60-1.03](p=0.064) after providing 1.6 g\/d EPA"
  },
  {
    "conteudo":"and 0.8 g\/d DHA.240 While the overall results are not clearly positive they do suggest at a"
  },
  {
    "conteudo":"possible beneficial effect. However, by far the largest study in this field (n=567), which"
  },
  {
    "conteudo":"examined patency rates in new AVF at 12 months243, reported that fish oil 4 g\/d (1.84 g\/d EPA"
  },
  {
    "conteudo":"and 1.52 g\/d DHA) had no benefit."
  },
  {
    "conteudo":"Rejection Episodes and Graft Survival in Kidney Allografts"
  },
  {
    "conteudo":"While LC n-3 PUFA have been reported to mediate the immunologic response, they have not"
  },
  {
    "conteudo":"yet demonstrated any benefits on kidney transplant. Two RCTs239, 244 with differing study"
  },
  {
    "conteudo":"interventions (2.4g\/d EPA + DHA for one year, 9 vs 18 g\/d EPA for 26 weeks) found no"
  },
  {
    "conteudo":"benefit on rejection episodes or a relationship between supplementation dose and rejection"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 121"
  },
  {
    "conteudo":"episodes.244 Supplementation using approximately 2.5 g\/d EPA+DHA also did not influence"
  },
  {
    "conteudo":"graft survival.238, 239"
  },
  {
    "conteudo":"Glomerular Filtration Rate and CKD Progression"
  },
  {
    "conteudo":"Based on six RCTs with widely differing study design and populations (CKD stage 3, MHD,"
  },
  {
    "conteudo":"kidney allografts),238, 239, 244-247 fish oil supplementation was not found to influence estimated"
  },
  {
    "conteudo":"or measured GFR. In the study by Guebre Egziabher et al, participants received 1.8g of n-3"
  },
  {
    "conteudo":"fatty acids, but authors do not describe EPA or DHA amount.246 In the study by Bennett et al,"
  },
  {
    "conteudo":"participants received “9 or 18g\/d EPA capsules”.244 In the remaining studies, EPA dose ranged"
  },
  {
    "conteudo":"from 0.46-1.62g\/d and DHA ranged from 0.25-1.08g\/d."
  },
  {
    "conteudo":"Similarly, fish oil supplementation for 8-12 weeks did not influence serum creatinine levels in"
  },
  {
    "conteudo":"three studies of non-dialyzed patients who used placebo or non-placebo-based control groups."
  },
  {
    "conteudo":"In the study by Guebre Egziabher et al, participants received 1.8g\/d of n-3 fatty acids, but"
  },
  {
    "conteudo":"authors do not describe EPA or DHA amount.246 In the remaining studies, EPA amount ranged"
  },
  {
    "conteudo":"from 0.69-1.44g\/d and DHA amount ranged from 0.25-0.96g\/d. 245, 246, 248"
  },
  {
    "conteudo":"Blood Pressure (BP)"
  },
  {
    "conteudo":"Five RCTs examined the effect of LC n-3 PUFA supplementation on BP, two in non-dialyzed"
  },
  {
    "conteudo":"patients (no stage reported)247, 248, two in patients on MHD240, 249, and one in patients with"
  },
  {
    "conteudo":"CKD with kidney allografts244. The results were mixed. In non-dialyzed patients, Svensson et"
  },
  {
    "conteudo":"al. reported that fish oil (0.96g\/d from DHA and 1.44g\/d EPA) for 8 weeks did not affect BP248"
  },
  {
    "conteudo":"while Mori et al. found that fish oil (0.38g\/d DHA and 0.46g\/d EPA) for 8 weeks lowered both"
  },
  {
    "conteudo":"systolic (mean±SEM, (-3.3 (±0.7)) and diastolic (-2.9 (± 0.5)), (p<0.0001 for each change)"
  },
  {
    "conteudo":"blood pressures.247 A pooled analysis of these two trials did not find an overall beneficial"
  },
  {
    "conteudo":"effect. In patients on MHD, Lok et al. reported an improvement in systolic BP in patients on"
  },
  {
    "conteudo":"MHD with fish oil (0.8g\/d DHA and 1.6g\/d EPA) for one year [Mean Difference (95% CI): -"
  },
  {
    "conteudo":"8.10 (-15.4, -0.85), p=0.014)240 and a reduction in the number of BP medications but no effect"
  },
  {
    "conteudo":"on diastolic BP. In contrast, Khajehdehi et al. found no effect at all on BP of 1.5 g\/day fish oil"
  },
  {
    "conteudo":"(DHA and EPA content not reported) as compared to placebo for two months.249 Data from"
  },
  {
    "conteudo":"these two trials could not be pooled. Bennett et al. randomized patients with CKD with kidney"
  },
  {
    "conteudo":"allografts and reported no benefit of “9 or 18 g EPA capsules” per day versus placebo for 26"
  },
  {
    "conteudo":"weeks244 on systolic BP but did note a reduction in diastolic BP in both EPA arms (p<0.05 for"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 122"
  },
  {
    "conteudo":"each) only."
  },
  {
    "conteudo":"Lipid Profiles"
  },
  {
    "conteudo":"Nineteen separate RCTs (though one without a true control group250) addressed the impact of"
  },
  {
    "conteudo":"LC n-3 PUFA supplementation on lipid levels. Thirteen studied patients on MHD235, 236, 241,"
  },
  {
    "conteudo":"179"
  },
  {
    "conteudo":"251-259 (with one study also including patients on PD ), four studied patients with CKD 2-"
  },
  {
    "conteudo":"185,186,199,200"
  },
  {
    "conteudo":"5 , and two studied patients with CKD with kidney allografts244, 260. The"
  },
  {
    "conteudo":"studies ranged greatly in terms of the type of supplement (seventeen with fish oil, two with"
  },
  {
    "conteudo":"flaxseed oil or ground flaxseed (2 g\/d oil in Lemos and 40g\/d seed in Khalatbari)) and"
  },
  {
    "conteudo":"duration (3-6 months). Additionally, amount and reporting of dosing was inconsistent."
  },
  {
    "conteudo":"Studies reporting amount of specific LC n-3 PUFAs described doses ranging from 0.42-"
  },
  {
    "conteudo":"1.8g\/d EPA and 0.25-0.82g\/d DHA. The specific amounts of EPA and DHA were not clear"
  },
  {
    "conteudo":"in several studies.244, 246, 249, 252, 257, 258"
  },
  {
    "conteudo":"Triglycerides: Eighteen RCTs studied the impact of LC n-3 PUFA on serum triglycerides."
  },
  {
    "conteudo":"Seven of the thirteen trials studying patients with MHD found no effect235, 241, 251, 252, 255,"
  },
  {
    "conteudo":"256, 258 and six reported a reduction in levels.235, 236, 249, 254, 257, 259 In a pooled analysis of"
  },
  {
    "conteudo":"twelve of these studies, LC n-3 PUFA supplementation lowered triglyceride levels by an"
  },
  {
    "conteudo":"average (95% CI) of -33.78 (-63.21, -4.36) mg\/dL as compared to placebo\/controls,"
  },
  {
    "conteudo":"though heterogeneity was high (I2=92.36%, p<0.001). While outcomes did not appear to"
  },
  {
    "conteudo":"be related to study quality or duration, triglyceride lowering tended to be associated with"
  },
  {
    "conteudo":"using lower doses of LC n-3 PUFA (0.42-0.96g\/d EPA and 0.24-0.6g\/d DHA daily),"
  },
  {
    "conteudo":"flaxseed oil (2g\/day) or ground flaxseed (40g\/day), a counterintuitive finding."
  },
  {
    "conteudo":"Interestingly, positive results were more consistent in non-dialyzed patients245, 247, 248, 250"
  },
  {
    "conteudo":"where fish oil supplementation (1.8g\/d total or 0.46-1.44g\/d EPA with 0.25-0.96g\/d"
  },
  {
    "conteudo":"DHA) for 8-12 weeks consistently lowered triglycerides."
  },
  {
    "conteudo":"Total Cholesterol: The literature did not suggest a beneficial effect of LC n-3 PUFA"
  },
  {
    "conteudo":"supplementation on total cholesterol. Eleven of thirteen studies in patients on MHD reported"
  },
  {
    "conteudo":"no effect (0.42-1.8g EPA and 0.24-1.14g DHA per day for 4 weeks-6 months) .235, 241, 249, 251,"
  },
  {
    "conteudo":"252, 254-259, while the two studies supplementing with flaxseed oil (2g\/d for 120 days)235 or"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 123"
  },
  {
    "conteudo":"ground flaxseed (40 g\/d for 8 weeks)236 noted a significant reduction in total cholesterol"
  },
  {
    "conteudo":"levels (though one study did not compare differences between groups 236). A pooled analysis"
  },
  {
    "conteudo":"of all 13 studies did not find any effect on mean total cholesterol but did note a high level of"
  },
  {
    "conteudo":"heterogeneity in the data (I2=95.77%, p<0.001). Three of four supplementation studies in"
  },
  {
    "conteudo":"non-dialyzed patients reported no effect on total cholesterol levels237, 247, 250 while the fourth"
  },
  {
    "conteudo":"demonstrated a reduction at three months (p<0.05) with no difference between arms.245"
  },
  {
    "conteudo":"Results could not be pooled for these four studies. While Ramezani et al. 260 reported lower"
  },
  {
    "conteudo":"cholesterol levels in CKD patients with kidney allografts compared to placebo after 6"
  },
  {
    "conteudo":"months of supplementation with 1.76g\/d EPA with 0.96g\/d DHA in fish oil, Schmitz et al.242"
  },
  {
    "conteudo":"found no such benefit in a similar population."
  },
  {
    "conteudo":"LDL Cholesterol"
  },
  {
    "conteudo":"Eight of twelve studies in patients on MHD found no benefit of supplementation,235, 251, 252, 254,"
  },
  {
    "conteudo":"256-259 while four reported a reduction in LDL.235, 236, 241, 249 Two of the four positive studies"
  },
  {
    "conteudo":"supplemented with fish oil (1.5g total in Khajehdehi et al.249 and 0.96g\/d EPA with 0.6g\/d DHA"
  },
  {
    "conteudo":"in 241 while the other two used flaxseed oil or ground flaxseed.235, 236 (with both latter studies"
  },
  {
    "conteudo":"observing a drop in LDL).235, 236 Study quality or duration or the type of comparison group used"
  },
  {
    "conteudo":"did not influence the outcome. A pooled analysis of all twelve studies noted an improvement in"
  },
  {
    "conteudo":"LDL only when excluding the flaxseed-based supplement studies [mean difference (95% CI): -"
  },
  {
    "conteudo":"5.26 (-9.51, -1.00) mg\/dL] and even then, the result was clinically marginal. In non-dialyzed"
  },
  {
    "conteudo":"patients, four studies of 8-12 weeks length using fish oil found no effect on LDL (1.8g\/d total in"
  },
  {
    "conteudo":"Guebre-Egziabher et al. and 0.46-1.44g\/d EPA with 0.25-0.96g\/d DHA).237, 245, 247, 250 In patients"
  },
  {
    "conteudo":"with CKD with kidney allografts, one study reported that EPA “9g capsules” per day increased"
  },
  {
    "conteudo":"LDL levels (but a higher dose did not) while another study reported negative results.242, 244"
  },
  {
    "conteudo":"HDL Cholesterol"
  },
  {
    "conteudo":"Seventeen RCTs included HDL as an outcome. Though HDL may be influenced by physical"
  },
  {
    "conteudo":"activity, smoking status, and gender, the preponderance of these studies did not control for"
  },
  {
    "conteudo":"these factors. Of the twelve studies in patients on MHD six reported negative"
  },
  {
    "conteudo":"results235, 251, 252, 254, 256, 258 and six found that HDL levels were increased.235, 236, 241, 249, 257, 259"
  },
  {
    "conteudo":"Effects were not clearly influenced by study quality or duration. However, the positive studies"
  },
  {
    "conteudo":"tended to use lower doses of LC n-3 PUFA (0.72-0.96g\/d EPA with 0.42-0.6g\/d DHA),"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 124"
  },
  {
    "conteudo":"flaxseed oil (2g\/day), or ground flaxseed (40g\/day). In a pooled analysis of all twelve studies,"
  },
  {
    "conteudo":"LC n-3 PUFA supplementation was found to raise HDL by a mean (95% CI) of 7.1 (0.52,"
  },
  {
    "conteudo":"13.63) mg\/dL. However, the heterogeneity was high overall. Results were mixed in the four"
  },
  {
    "conteudo":"trials of pre- dialysis patients, with two showing a benefit248, 250 and two reporting no effect.245,"
  },
  {
    "conteudo":"247 Again, the outcome was not clearly influenced by quality of study, study duration or dosage,"
  },
  {
    "conteudo":"and results could not be pooled. Finally, the only study in CKD patients with kidney allografts"
  },
  {
    "conteudo":"showed no benefit.244"
  },
  {
    "conteudo":"Inflammatory Markers"
  },
  {
    "conteudo":"The putative anti-inflammatory effects of LC n-3 PUFA were tested on two established"
  },
  {
    "conteudo":"biomarkers of inflammation."
  },
  {
    "conteudo":"C-Reactive Protein"
  },
  {
    "conteudo":"Fifteen RCTs studied the effect of fish oil supplementation on circulating CRP. In pre-dialysis"
  },
  {
    "conteudo":"patients throughout the stages of CKD, fish oil either compared to placebo247, 261 or at varying"
  },
  {
    "conteudo":"doses250 had no effect. The pattern in patients on MHD was similar. A pooled analysis of ten"
  },
  {
    "conteudo":"studies235, 236, 241, 251, 254-256, 262-264 found no effect of LC n-3 PUFA supplementation (nine"
  },
  {
    "conteudo":"using fish oil containing 0.42-1.8g\/d EPA with 0.24-1.14g\/d DHA, one using 2g\/d flaxseed"
  },
  {
    "conteudo":"oil) on circulating CRP as compared to placebo (MD -1.73 mg\/L, 95% CI: -3.54, 0.09). Ewers"
  },
  {
    "conteudo":"et al. found that fat supplementation (which also included fats other than LC-n-3 PUFA and"
  },
  {
    "conteudo":"specific n-3 PUFAs were not described) was associated with a reduction in CRP (p=0.01)"
  },
  {
    "conteudo":"after 12 weeks as compared to non-supplemented patients.252"
  },
  {
    "conteudo":"Interleukin-6"
  },
  {
    "conteudo":"Six RCTs studied the effect of LC n-3 PUFA on circulating IL-6. Neither of the two studies in"
  },
  {
    "conteudo":"predialysis patients comparing fish oil supplementation to placebo or at varying doses found a"
  },
  {
    "conteudo":"significant effect on IL-6 (one study reported 1.8g\/d n-3 PUFAs total and one reported"
  },
  {
    "conteudo":"1.4g\/d EPA with 1.0g DHA)250, 265, nor did a pooled analysis of four studies in patients on"
  },
  {
    "conteudo":"MHD (MD 5.32 pg\/ml, 95% CI: -5.637, 16.275) in which participants received 0-1.93g\/d EPA"
  },
  {
    "conteudo":"with 0.72-0.97g\/d DHA.254, 262, 264, 266"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 125"
  },
  {
    "conteudo":"The clinical impact of LC n-3 PUFA supplementation in patients with CKD was challenging to"
  },
  {
    "conteudo":"assess due to short study durations, modest sample sizes, and broad heterogeneity in the"
  },
  {
    "conteudo":"composition of the supplements and the dosing strategies. Furthermore, baseline LC n-3 PUFA"
  },
  {
    "conteudo":"levels (either in blood or tissues) were not typically used to target populations that would most"
  },
  {
    "conteudo":"benefit. This is an important but often overlooked point because the putative benefits of LC n-3"
  },
  {
    "conteudo":"PUFA supplementation may be inversely related to baseline blood or tissue"
  },
  {
    "conteudo":"concentrations.234, 267"
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● LC n-3 PUFA supplementation considerations will differ depending on whether the"
  },
  {
    "conteudo":"intervention is diet-based or capsule-based."
  },
  {
    "conteudo":"● For dietary interventions the goal of supplementation must be clearly defined. If it is to"
  },
  {
    "conteudo":"raise blood levels of α-linolenic acid then supplementation should focus on soybean, flaxseed,"
  },
  {
    "conteudo":"and other oils as well as meat and dairy products. If it is to raise EPA or DHA blood\/tissue"
  },
  {
    "conteudo":"levels then the primary dietary sources must be sardine, mackerel, salmon and other high-"
  },
  {
    "conteudo":"content marine-based foods.268 Potential limitations to dietary supplementation include their"
  },
  {
    "conteudo":"relatively high cost and difficulty in achieving high daily intake. In addition, the source and"
  },
  {
    "conteudo":"processing method will influence LC n-3 PUFA foodstuff content. For example, farmed fish"
  },
  {
    "conteudo":"typically (but not always) has lower LC n-3 PUFA compared to wild fish, while frying fish"
  },
  {
    "conteudo":"could alter the n-3\/n-6 ratio which may be of clinical significance.269"
  },
  {
    "conteudo":"● Capsule-based supplementation involves a set of different considerations. While dozens of"
  },
  {
    "conteudo":"commercial LC n-3 PUFA supplements are available, quality control is often lacking.270 This"
  },
  {
    "conteudo":"makes precise dosing recommendations difficult. An alternative route is to have the patient"
  },
  {
    "conteudo":"obtain supplements via physician prescription (e.g. icosapent ethyl, omega-3 ethyl esters). For"
  },
  {
    "conteudo":"either option cost could be an issue. Achieving high dose supplementation will be easier with"
  },
  {
    "conteudo":"capsules then through dietary consumption. Adverse effects of capsule-based supplementation"
  },
  {
    "conteudo":"may lead to gastrointestinal side effects like stomach upset and eructation (though the latter can"
  },
  {
    "conteudo":"be masked by different formulations). Theoretical risks like bleeding have not been borne out"
  },
  {
    "conteudo":"in clinical trials. LC n-3 PUFA content is listed on the website of the National Institutes of"
  },
  {
    "conteudo":"Health271"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 126"
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"There is no need to routinely monitor dietary LC n-3 PUFA intake other than in the context of"
  },
  {
    "conteudo":"general dietary counselling. An exception would be if the patient is specifically instructed to"
  },
  {
    "conteudo":"consume greater dietary quantities of LC n-3 PUFA."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● There are no adequately powered studies into whether LC n-3 PUFA reduces"
  },
  {
    "conteudo":"cardiovascular risk, and in particular sudden cardiac death, in the high-risk CKD population."
  },
  {
    "conteudo":"This is a high priority topic and there is currently an ongoing RCT looking into these"
  },
  {
    "conteudo":"outcomes.272"
  },
  {
    "conteudo":"● The dosage and ratio of LC n-3 PUFA to be supplemented as well as the quality control"
  },
  {
    "conteudo":"and purity of the supplement used should all be carefully considered in any study design. For"
  },
  {
    "conteudo":"example, a recent RCT found that a highly purified form of EPA ethyl esters (with no ALA or"
  },
  {
    "conteudo":"DHA included) at a high dose (4 g\/daily) available only in prescription form was effective in"
  },
  {
    "conteudo":"reducing cardiovascular risk.273 This is in contrast to several negative trials in recent years that"
  },
  {
    "conteudo":"used different formulations and doses of LC n-3 PUFA."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 127"
  },
  {
    "conteudo":"GUIDELINE 5: MICRONUTRIENTS"
  },
  {
    "conteudo":"5.0 Statements for General Guidance"
  },
  {
    "conteudo":"Dietary Micronutrient Intake"
  },
  {
    "conteudo":"5.0.1 In adults with CKD 3-5D and post-transplant, it is reasonable for the"
  },
  {
    "conteudo":"registered dietitian nutritionist (RDN) or international equivalent to encourage"
  },
  {
    "conteudo":"eating a diet that meets the recommended dietary allowance (RDA) for adequate"
  },
  {
    "conteudo":"intake for all vitamins and minerals (OPINION)."
  },
  {
    "conteudo":"Micronutrient Assessment and Supplementation"
  },
  {
    "conteudo":"5.0.2 In adults with CKD 3-5D and post-transplant, it is reasonable for the registered"
  },
  {
    "conteudo":"dietitian nutritionist (RDN) or international equivalent, in close collaboration with a"
  },
  {
    "conteudo":"physician or physician assistant, to assess dietary vitamin intake periodically and to"
  },
  {
    "conteudo":"consider multivitamin supplementation for individuals with inadequate vitamin intake"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Micronutrient Supplementation, Dialysis"
  },
  {
    "conteudo":"5.0.3 In adults with CKD 5D who exhibit inadequate dietary intake for sustained"
  },
  {
    "conteudo":"periods of time, it is reasonable to consider supplementation with multivitamins,"
  },
  {
    "conteudo":"including all the water-soluble vitamins, and essential trace elements to prevent or treat"
  },
  {
    "conteudo":"micronutrient deficiencies (OPINION)."
  },
  {
    "conteudo":"RATIONALE\/BACKGROUND"
  },
  {
    "conteudo":"Micronutrients are essential for metabolic function and hence maintaining an adequate intake"
  },
  {
    "conteudo":"of these micronutrients is important. For healthy individuals, many countries have established"
  },
  {
    "conteudo":"dietary reference intakes (DRIs) for individual micronutrients. However, there is a paucity of"
  },
  {
    "conteudo":"guidance regarding appropriate intake for people with chronic diseases. There is some"
  },
  {
    "conteudo":"evidence to indicate that patients with CKD are likely to be deficient in certain micronutrients."
  },
  {
    "conteudo":"Some of the common reasons for this include insufficient dietary intake, dietary prescription"
  },
  {
    "conteudo":"may limit vitamin-rich foods (particularly water-soluble vitamins), dialysis procedure may"
  },
  {
    "conteudo":"contribute to micronutrient loss, improper absorption of vitamins, and certain medications and"
  },
  {
    "conteudo":"illness. Due to these concerns, there is a trend for routinely prescribing multivitamin"
  },
  {
    "conteudo":"supplements. Findings from the DOPPS study indicate that more than 70% of MHD patients"
  },
  {
    "conteudo":"in United States take supplements. However, there is insufficient evidence to indicate whether"
  },
  {
    "conteudo":"micronutrients or multivitamin supplementation is beneficial or detrimental in this population."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 128"
  },
  {
    "conteudo":"DETAILED JUSTIFICATION"
  },
  {
    "conteudo":"At present there is a paucity of good-quality evidence to either support or oppose routine"
  },
  {
    "conteudo":"supplementation on micronutrients, including multivitamins. There is some evidence to state"
  },
  {
    "conteudo":"that that patients with CKD might be deficient in thiamine,274-276 riboflavin,277 vitamin B-"
  },
  {
    "conteudo":"6278-280vitamin C,281, 282 Vitamin K,283-285 and\/or vitamin D286. However, most of the"
  },
  {
    "conteudo":"supporting evidence on deficiencies is for the MHD population and not much has been"
  },
  {
    "conteudo":"explored in other stages of CKD or for those on peritoneal dialysis or post-transplant."
  },
  {
    "conteudo":"This SR included a comprehensive search of controlled trials evaluating the effects of"
  },
  {
    "conteudo":"micronutrient supplementation (both water- and fat-soluble) in patients with CKD. A total of"
  },
  {
    "conteudo":"80 controlled trials were included in the systematic review (Folic acid alone- 14 trials, folic"
  },
  {
    "conteudo":"acid + B vitamins- 13 trials, vitamin E- 8 trials, Vitamin K- 1 trial, vitamin D- 14 trials,"
  },
  {
    "conteudo":"vitamin B12- 4 trials, vitamin c- 8 trials, thiamine- 1, Zinc- 10 trials, Selenium- 7 trials). Some"
  },
  {
    "conteudo":"of the good quality evidence from these articles led to development of recommendation"
  },
  {
    "conteudo":"statements for specific micronutrients (see specific sections)."
  },
  {
    "conteudo":"However, the current evidence in this field has significant limitations. A majority of the"
  },
  {
    "conteudo":"included studies in this SR did not report either baseline status of micronutrients examined or"
  },
  {
    "conteudo":"dietary intake during the trials. Moreover, the outcomes reported by these studies varied"
  },
  {
    "conteudo":"significantly across the studies, making it difficult to synthesize evidence. Also, the dosage of"
  },
  {
    "conteudo":"supplementation and duration of intervention varied across studies. Included studies primarily"
  },
  {
    "conteudo":"reported the effect of micronutrient supplementation on the serum level of the micronutrient"
  },
  {
    "conteudo":"being supplemented. The quality of evidence from these trials ranged from very low quality to"
  },
  {
    "conteudo":"moderate quality for a majority of the micronutrients. Due to these significant limitations, it is"
  },
  {
    "conteudo":"very difficult to provide recommendations regarding the exact levels of supplementation or"
  },
  {
    "conteudo":"routine supplementation for all patients with CKD. On the other hand, there is some evidence"
  },
  {
    "conteudo":"to support that there might be some individuals who are at higher risk of certain micronutrient"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 129"
  },
  {
    "conteudo":"deficiencies. Taking all these issues into consideration, the expert panel felt that it was"
  },
  {
    "conteudo":"important to draft expert opinion-based recommendations statements to guide practitioners"
  },
  {
    "conteudo":"and to emphasize the need for individualization of micronutrient use."
  },
  {
    "conteudo":"In recent years, there have been a few systematic or narrative reviews on the topic of"
  },
  {
    "conteudo":"micronutrient supplementation in patients with CKD. The findings from these SRs are in"
  },
  {
    "conteudo":"line with findings from the current SR. Tucker et al., in a detailed review of micronutrients"
  },
  {
    "conteudo":"in patients on MHD, states that there is insufficient evidence to support routine"
  },
  {
    "conteudo":"supplementation and instead supplementation should be individualized and based on clinical"
  },
  {
    "conteudo":"judgement.287 Similarly, Jankowska et al. and Kosmadakis G et al., also state that there is"
  },
  {
    "conteudo":"insufficient evidence to support or oppose supplementation and more good quality trials are"
  },
  {
    "conteudo":"needed to help clarify evidence in this area.288, 289"
  },
  {
    "conteudo":"SPECIAL DISCUSSIONS"
  },
  {
    "conteudo":"Certain CKD population might be at higher risk of micronutrient deficiencies, and this must"
  },
  {
    "conteudo":"be taken into consideration. For example, pregnant women, gastric bypass surgery patients,"
  },
  {
    "conteudo":"patients with anorexia with poor intake, patients with malabsorption conditions, patients"
  },
  {
    "conteudo":"following vegetarian diets, and patients taking certain medications may have different"
  },
  {
    "conteudo":"micronutrient needs."
  },
  {
    "conteudo":"Nutrition Focused Physical Examination should be conducted with patients to identify if"
  },
  {
    "conteudo":"signs and symptoms of certain vitamin and mineral deficiency are present. These can be used"
  },
  {
    "conteudo":"in combination with lab measures to get a complete picture of problem."
  },
  {
    "conteudo":"If patients with CKD are meeting their recommended intake as assessed by 24-hr recall"
  },
  {
    "conteudo":"and have poor nutritional status, then it is likely that they might be at-risk for"
  },
  {
    "conteudo":"micronutrient deficiencies and appropriate intervention is required."
  },
  {
    "conteudo":"IMPLEMENTATION CONSIDERATIONS"
  },
  {
    "conteudo":"● Gather patient information on whether they are taking any micronutrient"
  },
  {
    "conteudo":"or multivitamin supplements."
  },
  {
    "conteudo":"• Suggested vitamin intake should be based on recommendations for the general"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 130"
  },
  {
    "conteudo":"population (ex: Recommended Dietary Allowance) unless there are specific"
  },
  {
    "conteudo":"considerations requiring modification."
  },
  {
    "conteudo":"● Assess Dietary intake, including consideration of fortified foods."
  },
  {
    "conteudo":"● Supplementation dose should be individualized based on each patient’s needs and risk"
  },
  {
    "conteudo":"profile."
  },
  {
    "conteudo":"FUTURE RESEARCH"
  },
  {
    "conteudo":"● Well-designed trials are needed to investigate if supplementation improves outcomes."
  },
  {
    "conteudo":"These trials should limit inclusion to a certain baseline status (ex:"
  },
  {
    "conteudo":"deficiency\/insufficiency) or adjust for baseline status in results. Researchers should"
  },
  {
    "conteudo":"consider the effect of dietary intake of micronutrients on findings."
  },
  {
    "conteudo":"● There is a need to determine how dietary interventions targeting micronutrient intake"
  },
  {
    "conteudo":"may affect relevant outcomes."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 131"
  },
  {
    "conteudo":"5.1 Statements on Folic Acid & Vitamin B12"
  },
  {
    "conteudo":"Folic Acid Supplementation for Hyperhomocysteinemia"
  },
  {
    "conteudo":"5.1.1 In adults with CKD 3-5D and post-transplant who have hyperhomocysteinemia"
  },
  {
    "conteudo":"associated with kidney disease, we recommend not routinely supplementing folate with"
  },
  {
    "conteudo":"or without B-complex since there is no evidence demonstrating reduction in"
  },
  {
    "conteudo":"cardiovascular outcomes (1A)."
  },
  {
    "conteudo":"Folic Acid Supplementation for Folic Acid Deficiency and Insufficiency"
  },
  {
    "conteudo":"5.1.2 In adults with CKD 1-5 D (2B) and post-transplant (OPINION), we suggest"
  },
  {
    "conteudo":"prescribing folate, Vit B12 and\/or B-complex supplement to correct for folate or"
  },
  {
    "conteudo":"Vitamin B12 deficiency\/insufficiency based on clinical signs and symptoms (2B)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Folic acid is involved in the synthesis of several amino acids, including serine, glycine,"
  },
  {
    "conteudo":"methionine, and histidine. Folic acid can be provided by dietary sources as well as over-the-"
  },
  {
    "conteudo":"counter nutritional supplements. Over-the-counter supplements come in various forms, such as"
  },
  {
    "conteudo":"folic acid, methyl folate (also known as L-methyl folate, L-5-methyl folate or MTHF), and"
  },
  {
    "conteudo":"folinic acid, among others. Folic acid’s primary mechanism of action is its role as a one-carbon"
  },
  {
    "conteudo":"donor. Folic acid is reduced to methyl folate which helps transfer single methyl groups in"
  },
  {
    "conteudo":"various metabolic reactions in the body. Folic acid also plays a role in the functioning of the"
  },
  {
    "conteudo":"nervous system, in DNA synthesis and in cell division. Food sources rich in folic acid include"
  },
  {
    "conteudo":"green leafy vegetables, fruits, yeast, and liver. Even though intake of food naturally rich in"
  },
  {
    "conteudo":"folic acid is limited in patients with CKD due to their high potassium content, folic acid"
  },
  {
    "conteudo":"deficiency among this patient population seems to be rare. This is especially true since 1996,"
  },
  {
    "conteudo":"when folic acid fortification of enriched cereal grain products was mandated in the United"
  },
  {
    "conteudo":"States and Canada.287 Because folate, vitamin B12 and vitamin B6 assist in the conversion of"
  },
  {
    "conteudo":"homocysteine to methionine (and therefore reduce serum homocysteine levels), they have"
  },
  {
    "conteudo":"received considerable attention as a putative treatment for cardiovascular disease in patients"
  },
  {
    "conteudo":"with CKD."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 132"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Mortality, Cardiovascular Outcomes and Vascular Function"
  },
  {
    "conteudo":"Four RCTs did not show any effect of folic acid when taken with vitamins B6 and B12 on hard"
  },
  {
    "conteudo":"outcomes, including all-cause mortality and\/or cardiovascular events in patients with stage 5"
  },
  {
    "conteudo":"CKD, on MHD or PD, and post-transplant.290-293 Folic acid and other B-vitamin"
  },
  {
    "conteudo":"supplementation ranged from 2.5-40 mg\/d folic acid, 1.4-100 mg\/d B6, 150 µg\/week- 2 mg\/d"
  },
  {
    "conteudo":"B12 for a duration of 2-5 years."
  },
  {
    "conteudo":"Folic acid (alone) intake of 1 to 5 mg\/day for 4 to 40 weeks showed no effect on flow mediated"
  },
  {
    "conteudo":"dilation.294, 295 Additionally, folic acid supplementation did not alter the risk of cardiovascular"
  },
  {
    "conteudo":"outcomes in four RCTs.296-299 The 4 RCTs included patients with CKD, stage 5 non- dialyzed"
  },
  {
    "conteudo":"and on PD and MHD. The folic acid supplementation dose ranged from 1-15 mg\/day and"
  },
  {
    "conteudo":"supplementation duration ranged from 1-3.6 years in these studies."
  },
  {
    "conteudo":"Supplementation with folic acid in combination with other B-vitamins did not improve total"
  },
  {
    "conteudo":"cholesterol levels, intima media thickness (IMT) or BP in MHD patients. Doses ranged from 5"
  },
  {
    "conteudo":"mg to 15 mg folic acid and a B-complex vitamin for 3 to 6 months.300, 301"
  },
  {
    "conteudo":"CKD Progression"
  },
  {
    "conteudo":"One RCT examined the effect of folic acid supplementation on CKD progression.302 In a sub-"
  },
  {
    "conteudo":"study of a larger primary stroke prevention trial including 15,104 participants with CKD Stage"
  },
  {
    "conteudo":"3 diagnosed with hypertension and taking the angiotensin converting enzyme inhibitor"
  },
  {
    "conteudo":"enalapril being randomized to receive 0.8 mg\/day of folic acid or placebo for a median of 4.4"
  },
  {
    "conteudo":"years. Compared to the group receiving enalapril and placebo, the enalapril + folic acid group"
  },
  {
    "conteudo":"significantly reduced the adjusted risk of CKD progression (Hazard Ratio (95% CI): 0.45"
  },
  {
    "conteudo":"(0.27, 0.76); p=0.003), which was the sub-study’s primary outcome.302 The limitation of this"
  },
  {
    "conteudo":"study was that a placebo alone group (without enalapril) was not included."
  },
  {
    "conteudo":"Two other RCTs showed no effect of supplementation with folic acid with vitamins B6 and"
  },
  {
    "conteudo":"B12 on the risk of dialysis initiation\/ESRD in participants with stages 3-5 chronic kidney"
  },
  {
    "conteudo":"disease and those post-transplant.290, 292"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 133"
  },
  {
    "conteudo":"Serum Homocysteine Levels"
  },
  {
    "conteudo":"Fourteen studies examined the effect of folic acid supplementation alone on plasma"
  },
  {
    "conteudo":"homocysteine levels.294-299, 302-309 Participants included were those with CKD, non-dialyzed (4"
  },
  {
    "conteudo":"studies), on MHD (10 studies) and PD (4 studies), and post-transplant (1 study). In the ten"
  },
  {
    "conteudo":"RCTs, folic acid supplements ranged from 0.8-60 mg\/day and duration varied from 4 weeks to"
  },
  {
    "conteudo":"4.4 years in patients of various stages of CKD. All but one study concluded that folic acid"
  },
  {
    "conteudo":"supplementation significantly decreased homocysteine levels.295"
  },
  {
    "conteudo":"Thirteen RCTs examined the effect of supplementation with folate and other B-vitamins on"
  },
  {
    "conteudo":"homocysteine levels.290-293, 300, 301, 310-316 Serum homocysteine level was a primary outcome of"
  },
  {
    "conteudo":"interest in eight studies.300, 301, 310-312, 314-316 Twelve out of 13 studies found that folic acid with"
  },
  {
    "conteudo":"other B vitamin supplementation decreased homocysteine levels in participants with CKD"
  },
  {
    "conteudo":"Stages 3-5, on MHD, PD and post-transplant. Supplementation doses in these studies ranged"
  },
  {
    "conteudo":"from 2.5-40 mg\/d folic acid (one study utilized 3 mg IV folinic acid\/week), 1 µg\/d oral to 1000"
  },
  {
    "conteudo":"mg\/week IV B12, and 1.4-100 mg B6 and supplementation duration ranged from 8 weeks to 5"
  },
  {
    "conteudo":"years."
  },
  {
    "conteudo":"CRP and IL-6 Levels"
  },
  {
    "conteudo":"Daily oral folic acid (5 mg) with a B-complex vitamin for 3 months was associated with a"
  },
  {
    "conteudo":"decrease in CRP, but not IL-6, levels in a RCT that included 121 patients on MHD.300"
  },
  {
    "conteudo":"Folic acid and B12 Levels"
  },
  {
    "conteudo":"Six RCTs reported that supplementation of folic acid alone increased serum folic acid levels in"
  },
  {
    "conteudo":"participants with stages 3-5 CKD and those on MHD and PD.294, 299, 302, 305, 306, 309 When folic"
  },
  {
    "conteudo":"acid with vitamins B6 and B12 was provided, it is worth noting that serum folic acid level"
  },
  {
    "conteudo":"increased with a daily intake of 5 mg for 3 months, or a daily intake of 2.5 mg for a longer time"
  },
  {
    "conteudo":"frame. In the Mann et al. study that included patients on MHD, serum folic acid significantly"
  },
  {
    "conteudo":"increased with an intake of 2.5 mg after 2 years of supplementation as compared to the control"
  },
  {
    "conteudo":"group.293 In Chiu et al., a supplementation of 3 mg folinic acid weekly via IV for 3 months did"
  },
  {
    "conteudo":"not result in a significant increase in serum folic acid levels in participants with stage 3 – 5"
  },
  {
    "conteudo":"CKD or were on MHD and PD.312"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 134"
  },
  {
    "conteudo":"Of the ten studies that examined the effect of supplementation of folic acid with B-complex,"
  },
  {
    "conteudo":"nine found a significant increase in serum folic acid levels.291-293, 300, 301, 310, 311, 313, 316 Doses"
  },
  {
    "conteudo":"ranged from 2.5-60 mg folic acid and study duration ranged from 4 weeks to 5 years."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Folate status is most often assessed through measurement of folate levels in the plasma,"
  },
  {
    "conteudo":"serum, or red blood cells. Serum or plasma folate levels reflect recent dietary intake, so"
  },
  {
    "conteudo":"deficiency must be diagnosed by repeated measures of serum or plasma folate. In contrast,"
  },
  {
    "conteudo":"RBC folate levels are more reflective of folate tissue status than serum folate and represent"
  },
  {
    "conteudo":"vitamin status at the time the RBC was synthesized (i.e. longer-term folate status). Usually,"
  },
  {
    "conteudo":"RBC folate concentrations diminish after about 4 months of low folate intake reflecting the"
  },
  {
    "conteudo":"120-day life span of RBC in healthy individuals. In patients with CKD such concentrations"
  },
  {
    "conteudo":"often decrease more rapidly reflecting the shorter RBC life span in CKD. Excessive folate"
  },
  {
    "conteudo":"intake inhibits zinc absorption in the gut by forming a complex with zinc in the intestinal"
  },
  {
    "conteudo":"lumen."
  },
  {
    "conteudo":"High intake of folic acid may mask signs of pernicious anemia leading to undetected"
  },
  {
    "conteudo":"progression of neurological disease. Based on the 2015 USRDS annual report, more than"
  },
  {
    "conteudo":"2\/3 (38.9%) of the patients who are on dialysis are 65 years or older. Older people have a"
  },
  {
    "conteudo":"higher risk of impaired gastrointestinal function. Since absorption of vitamin B12 is"
  },
  {
    "conteudo":"dependent on Intrinsic Factor and normal gut function and since the latter is often at least"
  },
  {
    "conteudo":"partially impaired in older individuals, assessment of serum vitamin B12 may be necessary if"
  },
  {
    "conteudo":"folate supplementation is considered."
  },
  {
    "conteudo":"Serum homocysteine levels, vitamin B12 and folate levels monitoring may be considered for"
  },
  {
    "conteudo":"patients who take certain medications such as methotrexate, nitrous oxide, 6-azaridine,"
  },
  {
    "conteudo":"phenytoin, carbamazepine, oral contraceptives, and excessive alcohol intake that can"
  },
  {
    "conteudo":"interfere with folate absorption."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Vitamin B deficiencies may be identified by clinical signs and symptoms."
  },
  {
    "conteudo":"Assessment of serum vitamin B12 should be considered if folate supplementation is"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 135"
  },
  {
    "conteudo":"administered."
  },
  {
    "conteudo":"• High folic acid intake may mask signs of pernicious anemia and undetected"
  },
  {
    "conteudo":"progression of neurological disease, and thus levels of folate and vitamin B12 should"
  },
  {
    "conteudo":"be monitored if folate is being supplemented."
  },
  {
    "conteudo":"• Suggested vitamin intake should be based on recommendations for the general"
  },
  {
    "conteudo":"population (ex: Recommended Dietary Allowance) unless there are specific"
  },
  {
    "conteudo":"considerations requiring modification."
  },
  {
    "conteudo":"• Individualization of therapy, including supplementation dosage, is essential to the"
  },
  {
    "conteudo":"management of any comorbid condition."
  },
  {
    "conteudo":"• Individualization should include patient age since adults over 50 years may have"
  },
  {
    "conteudo":"increased needs due to the prevalence of athrophic gastritis in this population."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Serum\/plasma\/RBC folate level, serum vitamin B12 should be assessed as appropriate"
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Conduct dose response studies for folic acid intake especially in people undergoing"
  },
  {
    "conteudo":"chronic dialysis and persons who are taking medications that interfere with the"
  },
  {
    "conteudo":"intestinal absorption, serum levels, or actions of folate and\/or vitamin B12."
  },
  {
    "conteudo":"● Assess the recommended daily allowance of folic acid and other B vitamins in various"
  },
  {
    "conteudo":"stages of CKD and various types of kidney diseases."
  },
  {
    "conteudo":"● Examine the prevalence of serum folate deficiency in patients with various stages of"
  },
  {
    "conteudo":"CKD."
  },
  {
    "conteudo":"● Given one preliminary positive report, conduct more RCTs to confirm whether folic"
  },
  {
    "conteudo":"acid intake may slow down CKD progression."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 136"
  },
  {
    "conteudo":"5.2 Statement on Vitamin C"
  },
  {
    "conteudo":"Vitamin C Supplementation"
  },
  {
    "conteudo":"5.2.1 In adults with CKD 1-5D and post-transplant who are at risk of Vitamin C"
  },
  {
    "conteudo":"deficiency it is reasonable to consider supplementation to meet the recommended intake"
  },
  {
    "conteudo":"of at least 90 mg\/d for men and 75 mg\/d for women (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"There are currently limited studies identifying daily vitamin C requirements for individuals"
  },
  {
    "conteudo":"with CKD at all stages of the disease. Amount of daily intake and optimal serum levels of"
  },
  {
    "conteudo":"vitamin C required to maintain nutritional health, reverse deficiency, and to avoid toxicity are"
  },
  {
    "conteudo":"unclear. Studies included for this current review evaluated the effect of vitamin C"
  },
  {
    "conteudo":"supplementation on nutritional status, inflammation, anthropometrics, micronutrient levels,"
  },
  {
    "conteudo":"electrolytes levels, fluid status, serum uric acid levels, lipid levels, morbidity events, quality of"
  },
  {
    "conteudo":"life, mortality and hospitalizations. Limited data from a very small number of studies prohibit"
  },
  {
    "conteudo":"definitive evidence-based conclusions for all the above surrogate and hard outcomes."
  },
  {
    "conteudo":"Therefore, we suggest that individualized decision-making is the best clinical approach to"
  },
  {
    "conteudo":"determine if vitamin C supplementation, or termination of supplementation, is required for"
  },
  {
    "conteudo":"adults with CKD stages 1-5D and post-transplant."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Nine studies examined the effect of vitamin C on nutrition-related outcomes in the CKD"
  },
  {
    "conteudo":"population, including five RCTs, 317-321 one randomized crossover trial282 and three"
  },
  {
    "conteudo":"comparative studies.322, 323 All studies examined MHD patients. Two studies (Canavese et al."
  },
  {
    "conteudo":"and Singer et al.) also included PD patients and those with eGFR <20mL\/min.321"
  },
  {
    "conteudo":"Quality of Life (QoL), Mortality, and Hospitalizations"
  },
  {
    "conteudo":"In adults with CKD, one RCT (250 mg oral ascorbic acid 3x\/week for 3 months)321 and one"
  },
  {
    "conteudo":"comparative study323 (500 mg oral vitamin C\/day for 2 years) measured the effect of vitamin C"
  },
  {
    "conteudo":"supplementation, compared to either a placebo or control, on hard outcomes, including all-"
  },
  {
    "conteudo":"cause mortality, QoL or hospitalizations events."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 137"
  },
  {
    "conteudo":"Singer et al. reported no changes in symptom, cognitive, or nausea sub-scales of the KDQOL-"
  },
  {
    "conteudo":"SF in either the vitamin C supplemented or placebo groups in MHD\/PD participants.321 QOL"
  },
  {
    "conteudo":"was the primary outcome of interest. Approximately 40% of participants were vitamin C"
  },
  {
    "conteudo":"deficient at baseline. In a comparative study by Ono et al., there were no differences in"
  },
  {
    "conteudo":"mortality rates or hospitalization events between vitamin C supplemented and non-"
  },
  {
    "conteudo":"supplemented periods in MHD participants.323 Mortality was a primary outcome measure."
  },
  {
    "conteudo":"Baseline vitamin C status was not reported."
  },
  {
    "conteudo":"In summary, Vitamin C supplementation did not affect QOL, mortality or hospitalizations in"
  },
  {
    "conteudo":"MHD patients, but evidence was extremely limited. Evidence based recommendations for the"
  },
  {
    "conteudo":"use of vitamin C in this patient population for these endpoints could not be provided."
  },
  {
    "conteudo":"Nutritional Status Parameters: serum Albumin, Pre-albumin, Transferrin, and Protein"
  },
  {
    "conteudo":"Nitrogen Appearance"
  },
  {
    "conteudo":"Three studies examined the effect of vitamin C supplementation on nutritional status in MHD"
  },
  {
    "conteudo":"participants: one RCT,319 one randomized crossover trial,282 and one comparative study.322."
  },
  {
    "conteudo":"However, nutritional status was not the primary outcome of interest. In Zhang et al., all"
  },
  {
    "conteudo":"patients were vitamin C-deficient at baseline,282 while in DeVriese, et al. 44% of participants"
  },
  {
    "conteudo":"were deficient at baseline.322 In Fumeron et al., vitamin C deficiency status at baseline was"
  },
  {
    "conteudo":"unclear.319 All outcomes were reported as quantitative values but were not compared to a"
  },
  {
    "conteudo":"reference standard. Supplementation dosage and duration ranged from 750 mg\/week for 2"
  },
  {
    "conteudo":"months319 to 1500 mg\/week for 3 months.322"
  },
  {
    "conteudo":"All three studies reported no effect of supplementation on albumin levels, as did pooled"
  },
  {
    "conteudo":"analysis of two of the RCTs. Zhang et al. measured the effect of vitamin C supplementation on"
  },
  {
    "conteudo":"pre-albumin levels in a randomized crossover trial with MHD participants.282 While one"
  },
  {
    "conteudo":"supplemented group experienced an increase in pre-albumin levels after three months of"
  },
  {
    "conteudo":"supplementation with 200 mg vitamin C, pre-albumin levels did not change in the other group"
  },
  {
    "conteudo":"after the same intervention. Therefore, the effect of vitamin C supplementation on pre-albumin"
  },
  {
    "conteudo":"levels is unclear. Fumeron et al. supplemented MHD participants with 750 mg\/week of vitamin"
  },
  {
    "conteudo":"C for 2 months.319 There were no significant changes in transferrin levels in either"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 138"
  },
  {
    "conteudo":"group. DeVriese et al. measured nPNA (nPCR) in a NRCT and found no effect of vitamin C"
  },
  {
    "conteudo":"supplementation on nPNA (nPCR) following supplementation with 360mg\/week or 1500mg\/"
  },
  {
    "conteudo":"week for 9 months in MHD patients.322"
  },
  {
    "conteudo":"CRP levels"
  },
  {
    "conteudo":"Three studies examined the effect of oral vitamin C supplementation on CRP levels in MHD"
  },
  {
    "conteudo":"participants 282, 319, 322 and found no significant effects compared to placebo or control groups,"
  },
  {
    "conteudo":"but evidence was limited."
  },
  {
    "conteudo":"Vitamin C Levels\/deficiency"
  },
  {
    "conteudo":"Four RCTs282, 317, 319, 321 and two comparative studies.322, 323 examined the effect of Vitamin"
  },
  {
    "conteudo":"C supplementation in doses ranging from 360-3500 mg\/week and duration ranging from 3"
  },
  {
    "conteudo":"months to 2 years. In summary, oral vitamin C supplementation increased serum vitamin C"
  },
  {
    "conteudo":"levels in MHD patients and decreased the proportion of participants who were vitamin C"
  },
  {
    "conteudo":"deficient\/insufficient (cut-offs were 11.44 and 23.0 µmol\/L). However, in pooled analysis of"
  },
  {
    "conteudo":"three RCTS, the increase in vitamin C levels may not be clinically significant. The quality of"
  },
  {
    "conteudo":"evidence in this regard remains low. Other CKD populations such as non-dialysis CKD 1-5,"
  },
  {
    "conteudo":"PD and post-transplant participants remain poorly studied."
  },
  {
    "conteudo":"These studies did not analyze the effects of vitamin C supplementation on optimal dosing or"
  },
  {
    "conteudo":"thresholds for toxicity. The potential for toxicity was acknowledged with dosage ranges"
  },
  {
    "conteudo":"maintained at 200-250 mg daily or three times weekly in most studies. The study by Ono that"
  },
  {
    "conteudo":"dosed MHD patients with daily 500 mg oral Vitamin C daily for 2 years reported an"
  },
  {
    "conteudo":"aggravation of hyperoxalemia.323 De-Vriese et al. had subjects dosed as 360 mg per week for 0-"
  },
  {
    "conteudo":"3 months followed by 1500mg\/week dosing x 3-6 months and then no supplementations for 6-9"
  },
  {
    "conteudo":"months in MHD patients. This study reported an increase in plasma malondialdehyde.322"
  },
  {
    "conteudo":"Supplementation with vitamin C increased the low levels but there is a potential risk of toxicity"
  },
  {
    "conteudo":"that requires monitoring."
  },
  {
    "conteudo":"Lipid Levels: Total Cholesterol, Triglycerides, LDL, HDL-C, LDL:HDL Ratio"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 139"
  },
  {
    "conteudo":"The results of three trials, 317, 320, 322 demonstrated that vitamin C supplementation of 125-200"
  },
  {
    "conteudo":"mg\/d for 3 months may decrease total cholesterol and LDL cholesterol levels, but there was no"
  },
  {
    "conteudo":"effect on triglyceride or HDL cholesterol levels. Vitamin C supplementation of 125-200"
  },
  {
    "conteudo":"mg\/day decreased LDL:HDL ratio or prevented the increase seen in the placebo group."
  },
  {
    "conteudo":"There were several limitations to this evidence including a small number of studies, small"
  },
  {
    "conteudo":"sample sizes and low evidence quality. It is important to note that the study by Khajehdehi, et"
  },
  {
    "conteudo":"al. included supplementing patients with potentially toxic doses of ergocalciferol, 50,000 IU"
  },
  {
    "conteudo":"daily x 3 months.320 The impact of this amount of vitamin D on study outcome parameters, if"
  },
  {
    "conteudo":"any, cannot be ascertained."
  },
  {
    "conteudo":"Treatment of anemia with vitamin C supplementation was beyond the scope of this guideline."
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Current nutritional requirements or Recommended Dietary Intake of vitamin C for individuals"
  },
  {
    "conteudo":"with CKD stages 1-5D and post-transplant are not known and are based on those from the"
  },
  {
    "conteudo":"general population. The prevalence of vitamin C deficiency may vary according to the stage of"
  },
  {
    "conteudo":"CKD and dialysis modality. Toxicity is a possible concern for excessive vitamin C"
  },
  {
    "conteudo":"supplementation."
  },
  {
    "conteudo":"The above findings do not however preclude the importance of assessing for vitamin C"
  },
  {
    "conteudo":"supplementation or when to discontinuing supplementation. Ongoing monitoring of overall"
  },
  {
    "conteudo":"food intake and nutrition status is required to assess for vitamin C deficiency. An"
  },
  {
    "conteudo":"individualized approach to evaluation and monitoring of vitamin C status is ideally"
  },
  {
    "conteudo":"accomplished by the nephrology care team that includes Nephrologist, Nurse Practitioner,"
  },
  {
    "conteudo":"Physician Assistant, and RDN."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"• Initiation and cessation of vitamin C supplementation as well as supplementation dose"
  },
  {
    "conteudo":"should take into account of the subject’s nutritional status, dietary intake, co-morbid"
  },
  {
    "conteudo":"conditions and dialysis modality."
  },
  {
    "conteudo":"• Suggested vitamin intake should be based on recommendations for the general"
  },
  {
    "conteudo":"population (ex: Recommended Dietary Allowance) unless there are specific"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 140"
  },
  {
    "conteudo":"considerations requiring modification."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Higher doses of Vitamin C supplementation (500 mg daily) have been shown to increase serum"
  },
  {
    "conteudo":"oxalate levels. Vitamin C is a potent physiologic antioxidant. Lipid metabolism may be affected"
  },
  {
    "conteudo":"by vitamin C supplementation and patients receiving vitamin C supplementation should have"
  },
  {
    "conteudo":"lipid fractions monitored. Vitamin C also affects immune function, and carnitine metabolism."
  },
  {
    "conteudo":"Patients with any malabsorption or diseases of an inflammatory nature may be more prone to"
  },
  {
    "conteudo":"having lower plasma vitamin C levels than the general population. Therefore, supplementation"
  },
  {
    "conteudo":"dose should take into consideration of medical history, co-morbid conditions, and concomitant"
  },
  {
    "conteudo":"medications. Measurement of serum oxalate levels may be considered in patients prescribed"
  },
  {
    "conteudo":"high doses of vitamin C and\/or who are susceptible to calcium oxalate stone formation."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Identify methods to assess vitamin C status. Current methods utilize serum levels of"
  },
  {
    "conteudo":"vitamin C, but reliability is unclear."
  },
  {
    "conteudo":"● Ascertain the optimal vitamin C status of CKD population including CKD stages 1-5D and"
  },
  {
    "conteudo":"those with kidney transplant."
  },
  {
    "conteudo":"● Confirm the recommended dietary allowance for vitamin C in various CKD population and"
  },
  {
    "conteudo":"the supplemental vitamin C dose that will prevent vitamin C deficiency without increasing"
  },
  {
    "conteudo":"risk of toxicity."
  },
  {
    "conteudo":"● If feasible, evaluate the effect of vitamin C supplementation on hard outcomes including"
  },
  {
    "conteudo":"survival, hospitalization, cardiovascular events as well as quality of life measures with"
  },
  {
    "conteudo":"RCTs in CKD population."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 141"
  },
  {
    "conteudo":"5.3 Statements on Vitamin D"
  },
  {
    "conteudo":"Vitamin D Supplementation for Vitamin D Deficiency and Insufficiency"
  },
  {
    "conteudo":"5.3.1 In adults with CKD 1-5 D (2C) and post-transplant (OPINION), we suggest"
  },
  {
    "conteudo":"prescribing vitamin D supplementation in the form of cholecalciferol or ergocalciferol"
  },
  {
    "conteudo":"to correct 25(OH)D deficiency\/insufficiency."
  },
  {
    "conteudo":"Vitamin D Supplementation with Proteinuria"
  },
  {
    "conteudo":"5.3.2 In adults with CKD with nephrotic range proteinuria, it is reasonable to"
  },
  {
    "conteudo":"consider supplementation of cholecalciferol, ergocalciferol or other safe and effective"
  },
  {
    "conteudo":"25(OH)D precursors (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol) are recognized as a pro-"
  },
  {
    "conteudo":"hormones and comprise a group of fat-soluble secosteroids. A unique aspect of vitamin D as a"
  },
  {
    "conteudo":"nutrient is that it can be synthesized by the human body through the action of sunlight. These"
  },
  {
    "conteudo":"dual sources of vitamin D (diet and sunlight) make it challenging to develop dietary reference"
  },
  {
    "conteudo":"intake values.324 The classic actions of vitamin D are the regulation of calcium and phosphorus"
  },
  {
    "conteudo":"homeostasis contributing to bone health. More recently, there has been a growing interest in"
  },
  {
    "conteudo":"the potential pleiotropic actions of vitamin D on immune, cardiovascular and neurological"
  },
  {
    "conteudo":"systems and on antineoplastic activity since extra-renal organs possess the enzymatic capacity"
  },
  {
    "conteudo":"to convert 25 (OH)D to 1,25(OH)2D.325"
  },
  {
    "conteudo":"Insufficiency\/deficiency of vitamin D, assessed by serum concentration of calcidiol"
  },
  {
    "conteudo":"[25(OH)D], has been found to be common in the general population and even more prevalent"
  },
  {
    "conteudo":"in patients with CKD stages 3-5D.286, 326, 327 For most experts, vitamin D insufficiency is"
  },
  {
    "conteudo":"defined as a serum 25(OH)D level between 20–29 ng\/mL, deficiency is considered as"
  },
  {
    "conteudo":"25(OH)D levels of less than 20 ng\/mL and sufficiency serum 25(OH)D equal or greater than"
  },
  {
    "conteudo":"30 ng\/mL.328"
  },
  {
    "conteudo":"A number of factors or conditions are implicated in suboptimal vitamin D status in patients"
  },
  {
    "conteudo":"with CKD, including aging, diabetes mellitus, obesity, reduced sun exposure, loss of"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 142"
  },
  {
    "conteudo":"urinary\/dialysate vitamin D binding protein (DBP), impaired tubular 25(OH) reabsorption"
  },
  {
    "conteudo":"and dietary restrictions.329-332 Considering the high prevalence of vitamin D"
  },
  {
    "conteudo":"deficiency\/insufficiency in CKD\/ESRD and the potential benefits of restoring the vitamin D"
  },
  {
    "conteudo":"status the K\/DOQI ( 2003) and KDIGO (2017 ) Clinical Practice Guidelines for CKD-MBD"
  },
  {
    "conteudo":"have proposed ergocalciferol or cholecalciferol supplementation.333, 334"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Vitamin D Levels and Deficiency"
  },
  {
    "conteudo":"Despite differences in dosing regimens and vitamin D status at baseline, supplementation"
  },
  {
    "conteudo":"was effective in increasing 25(OH)D serum concentration in 14 RCTs, including in the"
  },
  {
    "conteudo":"form of ergocalciferol335, 336 and cholecalciferol.337-348 This effect was demonstrated in HD"
  },
  {
    "conteudo":"patients (8 studies), HD and PD patients combined (1 study), stages 1-4 CKD patients (4"
  },
  {
    "conteudo":"studies) and in 1 study with any CKD participants. Five studies reported that ergocalciferol"
  },
  {
    "conteudo":"using doses 50,000 IU\/week and dose dependent on status335, 336 and cholecalciferol in"
  },
  {
    "conteudo":"doses ranging from 25,000-50,000 IU\/week improved vitamin D status.337, 338, 341, 345 There"
  },
  {
    "conteudo":"were significant effects noted after three months of supplementation. However, there was"
  },
  {
    "conteudo":"no difference in vitamin D deficiency status between non-dialyzed groups receiving two"
  },
  {
    "conteudo":"different dosing regimens.343"
  },
  {
    "conteudo":"A meta-analysis was conducted to determine odds of vitamin D sufficiency according to"
  },
  {
    "conteudo":"vitamin D supplementation, which included Bhan et al. (each group compared to the placebo"
  },
  {
    "conteudo":"group), Delanaye et al., Massart et al., and Alvarez et al.335, 337, 341, 345 Participants that were"
  },
  {
    "conteudo":"supplemented with vitamin D had an OR (95% CI) of 9.31 (3.38, 24.7) (p<0.001) of being"
  },
  {
    "conteudo":"vitamin D sufficient (defined as either >30 or 32 ng\/mL), though there was moderate"
  },
  {
    "conteudo":"2"
  },
  {
    "conteudo":"heterogeneity in the data (I =51.84; p=0.08). Additionally, data from eight studies were"
  },
  {
    "conteudo":"pooled to determine mean difference (95% CI) in vitamin D levels according to vitamin D"
  },
  {
    "conteudo":"supplementation. There was a mean increase of 21.06 (17.46, 24.66) ng\/mL in the vitamin D"
  },
  {
    "conteudo":"supplemented groups compared to the placebo groups, but heterogeneity was moderate"
  },
  {
    "conteudo":"2"
  },
  {
    "conteudo":"(I =67.3%; p=0.003), so results should be interpreted with caution."
  },
  {
    "conteudo":"Calcium and Phosphorus Levels"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 143"
  },
  {
    "conteudo":"In adults with chronic kidney disease, twelve studies examined the effect of vitamin D"
  },
  {
    "conteudo":"intake on biomarkers and\/or health outcomes.253, 335-337, 339-341, 343-347 Moderate quality"
  },
  {
    "conteudo":"evidence demonstrated no effect of vitamin D"
  },
  {
    "conteudo":"supplementation on calcium or phosphorus levels."
  },
  {
    "conteudo":"In predominantly vitamin D deficient participants, there was no effect of ergocalciferol"
  },
  {
    "conteudo":"supplementation on effect of calcium levels in doses of 50,000 IU\/week or \/month or"
  },
  {
    "conteudo":"in individualized doses.335, 336 The effect of cholecalciferol on calcium levels was"
  },
  {
    "conteudo":"unclear with seven studies finding no effect on calcium levels and three studies"
  },
  {
    "conteudo":"determining supplementation increased calcium levels. In Massart et al., there was no"
  },
  {
    "conteudo":"effect of"
  },
  {
    "conteudo":"25,000 IU weekly cholecalciferol on proportion of HD participants reaching target levels at 3"
  },
  {
    "conteudo":"months. There was no clear pattern of effect according to participant population, deficiency"
  },
  {
    "conteudo":"status or vitamin D dosage. In pooled analysis of four studies in which data could be"
  },
  {
    "conteudo":"combined, there was no effect of vitamin D supplementation on calcium levels [MD (95%"
  },
  {
    "conteudo":"CI): 0.07 (-0.18, 0.31) mg\/dL].253, 336, 341, 347"
  },
  {
    "conteudo":"Vitamin D supplementation had no effect on phosphorus levels with ergocalciferol"
  },
  {
    "conteudo":"supplementation (2 studies with doses of 50,000 IU\/week or \/month or in individualized"
  },
  {
    "conteudo":"doses) or cholecalciferol doses ranging from 50,0000 IU\/day to 50,000 IU\/month (10 studies)."
  },
  {
    "conteudo":"In pooled analysis of five RCTs, there was no effect of vitamin D supplementation on"
  },
  {
    "conteudo":"phosphorus levels [MD (95% CI): -0.15 (-0.44, 0.15) (mg\/dL)].253, 336, 341, 346, 347"
  },
  {
    "conteudo":"Special Discussions"
  },
  {
    "conteudo":"Due to the complex nature of vitamin D, the present guideline is focused on the effect of"
  },
  {
    "conteudo":"vitamin D supplementation, in the forms of cholecalciferol and ergocalciferol, on vitamin D"
  },
  {
    "conteudo":"insufficiency\/deficiency in patients with CKD and not on outcomes related to CKD-MBD or"
  },
  {
    "conteudo":"other clinical disturbances. Supplementation of prehormone and activated forms of vitamin"
  },
  {
    "conteudo":"D, calcidiol and calcitriol, were not included in this guideline."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 144"
  },
  {
    "conteudo":"There are potential benefits of vitamin D supplementation (cholecalciferol or ergocalciferol)"
  },
  {
    "conteudo":"in"
  },
  {
    "conteudo":"CKD. A systematic review with meta-analysis of observational and randomized studies"
  },
  {
    "conteudo":"showed a significant decline in PTH levels with cholecalciferol or ergocalciferol"
  },
  {
    "conteudo":"supplementation in patients who are non-dialyzed, on hemodialysis or peritoneal dialysis,"
  },
  {
    "conteudo":"and renal transplant recipients.349 However, whether such improvements translate into"
  },
  {
    "conteudo":"clinically significant outcomes is yet to be determined."
  },
  {
    "conteudo":"Cross-sectional analysis of Third National Health and Nutrition Examination Survey"
  },
  {
    "conteudo":"(NHANES III) showed progressively higher prevalence of albuminuria with decreasing"
  },
  {
    "conteudo":"25(OH)D levels.350 In a prospective cohort study vitamin D deficiency was associated"
  },
  {
    "conteudo":"with a higher incidence of albuminuria.351 There are limited randomized clinical trials"
  },
  {
    "conteudo":"investigating the effect of cholecalciferol or calcifediol on proteinuria in CKD and the"
  },
  {
    "conteudo":"results are inconclusive.352, 353"
  },
  {
    "conteudo":"Implementation Considerations"
  },
  {
    "conteudo":"● The optimal serum 25(OH)D concentration for patients with CKD and the"
  },
  {
    "conteudo":"concentration at which patients with CKD are considered deficient\/insufficient is not"
  },
  {
    "conteudo":"well defined but is generally considered to be the same as in the general population,"
  },
  {
    "conteudo":"although there is no absolute consensus about the definition of vitamin D sufficiency."
  },
  {
    "conteudo":"For most experts, vitamin D insufficiency is defined as a serum 25(OH)D level"
  },
  {
    "conteudo":"between"
  },
  {
    "conteudo":"20–29 ng\/mL, deficiency is considered as 25(OH)D levels of less than 20 ng\/mL"
  },
  {
    "conteudo":"and sufficiency serum 25(OH)D equal or greater than 30 ng\/mL.328"
  },
  {
    "conteudo":"● Both the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney"
  },
  {
    "conteudo":"Disease"
  },
  {
    "conteudo":"Improving Global Outcomes (KDIGO) experts recommend checking and"
  },
  {
    "conteudo":"supplementing low serum 25(OH)D levels in CKD and dialysis patients.333, 354 In the"
  },
  {
    "conteudo":"most recent update of the KDIGO guidelines on bone mineral disorder, it is"
  },
  {
    "conteudo":"suggested based on low quality evidence that patients with CKD stage 1–5D have"
  },
  {
    "conteudo":"25(OH)D levels measured, and repeated testing should be individualized according"
  },
  {
    "conteudo":"to baseline values and interventions. However, there was no clear suggestion on how"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 145"
  },
  {
    "conteudo":"frequently 25(OH)D levels should be reviewed.333"
  },
  {
    "conteudo":"● With respect to vitamin D supplementation, current guidelines suggest that patients"
  },
  {
    "conteudo":"with CKD stages 1–5D and vitamin D insufficiency\/deficiency should receive"
  },
  {
    "conteudo":"supplementation using the same strategies recommended for the general population."
  },
  {
    "conteudo":"However, even for the general population, the optimal dosage of supplementation"
  },
  {
    "conteudo":"varies among the main guidelines. It has been recommended 1000–2000 IU\/d of"
  },
  {
    "conteudo":"cholecalciferol for vitamin D repletion for the general population. However, KDOQI"
  },
  {
    "conteudo":"acknowledges that patients with CKD may require a more aggressive therapeutic"
  },
  {
    "conteudo":"plan.354"
  },
  {
    "conteudo":"● There is also a debate regarding which form of vitamin D should be used,"
  },
  {
    "conteudo":"ergocalciferol or cholecalciferol. In the general population there appears to be some"
  },
  {
    "conteudo":"advantage of"
  },
  {
    "conteudo":"using cholecalciferol over ergocalciferol.355 Since in CKD there is no clear"
  },
  {
    "conteudo":"evidence about the superiority of cholecalciferol, clinicians should use the form"
  },
  {
    "conteudo":"commercially available in the context of their clinical practice."
  },
  {
    "conteudo":"● The tolerable upper intake levels (UL) proposed by the Institute of Medicine (IOM)"
  },
  {
    "conteudo":"for the general population is 4,000 IU\/day.356There is no recommendation of safe"
  },
  {
    "conteudo":"dose of cholecalciferol or ergocalciferol supplementation to prevent for toxicity or"
  },
  {
    "conteudo":"adverse effects such as hypercalcemia or hyperphosphatemia in CKD. However,"
  },
  {
    "conteudo":"periodically measurement of serum calcium and phosphorus should be considered"
  },
  {
    "conteudo":"especially for patients who are on calcium-containing phosphate binders and\/or on"
  },
  {
    "conteudo":"vitamin D active analogs."
  },
  {
    "conteudo":"Future Research"
  },
  {
    "conteudo":"There is a need of well-designed trials to determine:"
  },
  {
    "conteudo":"● Optimal definition of vitamin D adequacy"
  },
  {
    "conteudo":"● 25(OH)D thresholds for supplementation"
  },
  {
    "conteudo":"● Dosing, timing of administration and type of vitamin D analogues in the CKD"
  },
  {
    "conteudo":"population"
  },
  {
    "conteudo":"● Risks and benefits of vitamin D supplementation in the CKD population"
  },
  {
    "conteudo":"● Long- term goals of vitamin D supplementation in the CKD population"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 146"
  },
  {
    "conteudo":"5.4 Statement on Vitamins E and A"
  },
  {
    "conteudo":"Vitamins A and E Supplementation and Toxicity"
  },
  {
    "conteudo":"5.4.1 In adults with CKD on MHD or PD, it is reasonable to not routinely supplement"
  },
  {
    "conteudo":"vitamin A or E because of the potential for vitamin toxicity. However, if"
  },
  {
    "conteudo":"supplementation is warranted, it is reasonable to use caution and monitor patients for"
  },
  {
    "conteudo":"toxicity (OPINION)."
  },
  {
    "conteudo":"Rational\/Background"
  },
  {
    "conteudo":"Vitamin E is a fat-soluble nutrient recognized for antioxidant properties. There are eight known"
  },
  {
    "conteudo":"naturally occurring forms of vitamin E,324 but alpha-tocopherol is the only known form of"
  },
  {
    "conteudo":"vitamin E that meets human requirements and is the form found in plasma. Therefore, Dietary"
  },
  {
    "conteudo":"Reference Intake (DRI) for vitamin E is only available for alpha-tocopherol. The RDA for"
  },
  {
    "conteudo":"vitamin E was determined by identifying serum levels of vitamin E that provided protection to"
  },
  {
    "conteudo":"erythrocyte survival when exposed to hydrogen peroxide."
  },
  {
    "conteudo":"While vitamin E supplements are typically provided as alpha-tocopherol, products containing"
  },
  {
    "conteudo":"other tocopherols and tocotrienols have been reported.324 The potency of synthetic alpha-"
  },
  {
    "conteudo":"tocopherol (RRR-alpha-tocopherol, labeled as D or d) is not identical to the natural form. This"
  },
  {
    "conteudo":"is because synthetic alpha-tocopherol contains eight stereoisomers of which only 4 are found in"
  },
  {
    "conteudo":"tissues and serum. Synthetic alpha-tocopherol: all rac-alpha-tocopherol, labeled as dl or DL is"
  },
  {
    "conteudo":"therefore only half as active as the natural form, therefore requiring 50% more IU to receive a"
  },
  {
    "conteudo":"dose equivalent to the natural source.324 Most supplements provide vitamin E as alpha-"
  },
  {
    "conteudo":"tocopherol in a 100-400mg dose."
  },
  {
    "conteudo":"Vitamin E is a fat-soluble vitamin. The potential risk of vitamin E toxicity is primarily related"
  },
  {
    "conteudo":"to the use of supplements.324, 357 High doses of vitamin E supplements in the form of alpha-"
  },
  {
    "conteudo":"tocopherol have been reported to cause bleeding and\/or disrupt blood coagulation in vivo and"
  },
  {
    "conteudo":"there are some in vivo data that suggest alpha-tocopherol inhibits platelet aggregation.357 The"
  },
  {
    "conteudo":"RDA for vitamin E for normal adult men and woman is 15mg per day (22.4 IU). The Food and"
  },
  {
    "conteudo":"Nutrition Board has defined an upper level of intake for vitamin E in the form of alpha-"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 147"
  },
  {
    "conteudo":"tocopherol and the stereoisomer forms in synthetic vitamin E supplements as 1500 IU and"
  },
  {
    "conteudo":"1100 IU\/day respectively. While not definitive, these levels of intake appear to be the"
  },
  {
    "conteudo":"safety limit with regard to the potential of vitamin E to confer bleeding risk."
  },
  {
    "conteudo":"Several studies evaluated the effects of Vitamin E coated dialyzer membranes on"
  },
  {
    "conteudo":"biocompatibility, blood pressure during dialysis and oxidative stress.358, 359 However, results"
  },
  {
    "conteudo":"were inconclusive. Data regarding the effect of vitamin E coated dialyzers on hemoglobin,"
  },
  {
    "conteudo":"lipid profile and nutritional status were inconclusive and study design for these trials and the"
  },
  {
    "conteudo":"meta-analyses were of low quality.360"
  },
  {
    "conteudo":"Studies examining daily vitamin A requirements for individuals with various stages of CKD"
  },
  {
    "conteudo":"are lacking. Optimal serum levels of vitamin E are not defined for this population. Daily"
  },
  {
    "conteudo":"vitamin E required to maintain nutritional health, reverse deficiency, and to avoid toxicity in"
  },
  {
    "conteudo":"CKD population are unclear. Vitamin A was initially investigated in the systematic review, but"
  },
  {
    "conteudo":"there were no dietary trials available, only trials in which vitamin A was delivered"
  },
  {
    "conteudo":"intravenously, which was considered beyond the scope of this guideline."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"The eight studies included for this review examined the effect of oral vitamin E"
  },
  {
    "conteudo":"supplementation in adults with CKD on serum indices and health outcomes.320, 361-367 In three of"
  },
  {
    "conteudo":"these studies, vitamin E supplementation was combined with α-lipoic acid supplementation"
  },
  {
    "conteudo":"(ALA).361, 364, 367 All studies examined MHD patients as the target population, except for Ramos"
  },
  {
    "conteudo":"et al.,367 who examined Stages 3-5 CKD subjects. Subjects in Hodkova et al. were vitamin E"
  },
  {
    "conteudo":"repleted, but baseline vitamin E status was not reported for any of the other studies.365"
  },
  {
    "conteudo":"All- Cause Mortality and Cardiovascular Disease Outcomes"
  },
  {
    "conteudo":"Participants with CKD (serum creatinine ≥1.4 to 2.3 mg\/dL) and high risk for cardiovascular"
  },
  {
    "conteudo":"events were given 400 IU daily oral vitamin E for a median of 4.5 years.366 Compared to the"
  },
  {
    "conteudo":"placebo group, there was no difference in total mortality between groups. Additionally, there"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 149"
  },
  {
    "conteudo":"was no difference in the relative risk of myocardial infarction (MI), stroke, death from CV"
  },
  {
    "conteudo":"causes, unstable angina, heart failure hospitalizations, heart failure, TIA or composite or MI,"
  },
  {
    "conteudo":"stroke, or death from cardiovascular causes between groups."
  },
  {
    "conteudo":"Boaz et al. examined the effect of vitamin E supplementation on CVD endpoints (primary"
  },
  {
    "conteudo":"outcome) and all-cause mortality.362 MHD subjects with pre-existing CVD were supplemented"
  },
  {
    "conteudo":"with daily oral 800 IU oral vitamin E for a median of 519 days. Risk of all-cause mortality was"
  },
  {
    "conteudo":"not significantly different between groups. The vitamin E group had a significantly decreased"
  },
  {
    "conteudo":"risk of experiencing a CVD endpoint compared to the control group,"
  },
  {
    "conteudo":"but the RR for fatal and non-fatal MIs, ischemic stroke and PVD were not significantly"
  },
  {
    "conteudo":"different between groups."
  },
  {
    "conteudo":"Based on these limited data, vitamin E supplementation did not affect all-cause mortality."
  },
  {
    "conteudo":"Results regarding the effects of vitamin E supplementation on CVD outcomes were mixed,"
  },
  {
    "conteudo":"Differences may be due to the population studied or vitamin E dosage. In pooled analysis"
  },
  {
    "conteudo":"conducted in the current systematic review, there was no effect of vitamin E supplementation"
  },
  {
    "conteudo":"on CVD outcomes, though heterogeneity of results was high."
  },
  {
    "conteudo":"Anthropometric Measures"
  },
  {
    "conteudo":"Two RCTs examined the effect of vitamin E supplementation on nutritional status in MHD"
  },
  {
    "conteudo":"participants.361, 363 Participants received either tocotrienols (90 mg) and tocopherols (20 mg)"
  },
  {
    "conteudo":"for16 weeks or 400 IU oral vitamin E\/day, 600 mg alpha lipoic acid (ALA)\/day, or both for 2"
  },
  {
    "conteudo":"months. While there were no changes in albumin levels between groups in the former study"
  },
  {
    "conteudo":"(Daud et al.), in Ahmadi et al., SGA score was improved in the vitamin E, ALA, and combined"
  },
  {
    "conteudo":"supplementation groups compared to placebo. SGA was the primary outcome of interest in this"
  },
  {
    "conteudo":"study. Vitamin E deficiency status at baseline was not described in either study."
  },
  {
    "conteudo":"Three RCTs examined the effect of oral vitamin E supplementation on anthropometric"
  },
  {
    "conteudo":"measures.361, 363, 367 All studies reported no effect of vitamin E supplementation on BMI or"
  },
  {
    "conteudo":"body weight. Anthropometric measurements were not the primary outcomes of interest in any"
  },
  {
    "conteudo":"of these studies."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 150"
  },
  {
    "conteudo":"Inflammatory Markers: CRP and IL-6 (Interleukin-6)"
  },
  {
    "conteudo":"Five studies examined the effect of vitamin E supplementation on inflammatory biomarkers,"
  },
  {
    "conteudo":"particularly CRP and IL-6 levels.361, 363-365, 367 In three of the studies these inflammatory"
  },
  {
    "conteudo":"markers were the primary outcomes of interest.361, 365, 367 Himmelfarb et al. and Ramos et al."
  },
  {
    "conteudo":"gave vitamin E supplementation in combination with α-lipoic acid,364, 367 and Ahmadi et al."
  },
  {
    "conteudo":"examined vitamin E supplements alone and in combination with α-lipoic acid.361 All studies"
  },
  {
    "conteudo":"assessed the effect of oral vitamin E supplementation on the CRP inflammatory marker levels"
  },
  {
    "conteudo":"in patients with CKD Stages 3-5 and MHD participants. None of them found any effect of"
  },
  {
    "conteudo":"vitamin E supplementation ranging from 400-800 IU oral vitamin E per day (with or without"
  },
  {
    "conteudo":"600 mg α-lipoic acid) for durations ranging from 5 weeks to 6 months on CRP levels."
  },
  {
    "conteudo":"Three of the studies also measured IL-6 and found no relationship between vitamin E"
  },
  {
    "conteudo":"supplementation and IL-6 levels.363, 364, 367 Ramos et al. (Stages 3-5 CKD) and Himmelfarb et"
  },
  {
    "conteudo":"al. (MHD patients) both supplemented with daily oral 666 IU mixed tocopherols (Vitamin E) +"
  },
  {
    "conteudo":"ALA 600 mg for 8 weeks and 6 months, respectively.364, 367 Neither found an effect of"
  },
  {
    "conteudo":"supplementation on serum IL-6 levels. However, Ahmadi et al. found that oral vitamin E alone"
  },
  {
    "conteudo":"(400 IU per day) or in combination with 600 mg α-lipoic acid per day, reduced IL-6 cytokine"
  },
  {
    "conteudo":"levels in MHD participants.361 In pooled analysis of two RCTs that utilized vitamin E alone or"
  },
  {
    "conteudo":"with α- lipoic acid, there was no effects on IL-6 levels compared to the placebo groups."
  },
  {
    "conteudo":"Serum Vitamin E Levels"
  },
  {
    "conteudo":"Two RCTs examined the effect of daily oral vitamin E supplementation on vitamin E"
  },
  {
    "conteudo":"levels.362, 365 Both studies included MHD patients. Hodkova et al. found that serum vitamin E"
  },
  {
    "conteudo":"levels increased in the vitamin E supplemented group (α-tocopherol 400 mg\/888 IU) after 5"
  },
  {
    "conteudo":"weeks, but no change in the control. Between group differences were not reported.365 Boaz et"
  },
  {
    "conteudo":"al. found that the vitamin E supplemented group had significantly higher vitamin E levels"
  },
  {
    "conteudo":"compared to the placebo group when MHD participants with pre-existing CVD were"
  },
  {
    "conteudo":"supplemented with 800 IU oral vitamin E\/day for a median of 519 days, but between group"
  },
  {
    "conteudo":"differences were not reported.362 In pooled analysis of the two RCTs that examined vitamin E"
  },
  {
    "conteudo":"supplementation alone, there was no significant effect of supplementation compared to the"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 151"
  },
  {
    "conteudo":"placebo\/control group. Therefore, available evidence indicates that vitamin E supplementation"
  },
  {
    "conteudo":"alone does not affect vitamin E levels."
  },
  {
    "conteudo":"Lipid Levels"
  },
  {
    "conteudo":"Daily oral vitamin E supplementation of 110 mg for four months 363 and 200 mg for three"
  },
  {
    "conteudo":"months (Khajehdehi et al.) did not change serum triglyceride, total cholesterol or LDL (low"
  },
  {
    "conteudo":"density lipoprotein) levels but demonstrated efficacy of increasing HDL-C levels.253"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"As a result of the limited number of high-quality studies, (see study selection criteria) and the"
  },
  {
    "conteudo":"variability in the outcomes reported in these trials, there is insufficient evidence to make"
  },
  {
    "conteudo":"recommendations on vitamin E intake for CKD patients. The nutritional requirements or"
  },
  {
    "conteudo":"Recommended Dietary Intake of vitamin E for individuals with CKD stages 1-5, those"
  },
  {
    "conteudo":"undergoing chronic dialysis and post-transplant are unknown. Dose response studies"
  },
  {
    "conteudo":"identifying the relation between Vitamin E intake and serum levels of vitamin E are not"
  },
  {
    "conteudo":"available. The prevalence of vitamin E deficiency in CKD population is unclear. The potential"
  },
  {
    "conteudo":"of vitamin E toxicity with supplementation is a concern for this fat-soluble vitamin."
  },
  {
    "conteudo":"There is a potential for toxicity in those patients who are being supplemented. High doses of"
  },
  {
    "conteudo":"vitamin E supplementation has the potential to increase risk of hemorrhagic stroke and impair"
  },
  {
    "conteudo":"platelet aggregation. Vitamin E interacts with anticoagulant and antiplatelet medications and"
  },
  {
    "conteudo":"therefore caution is advised on vitamin E supplementation for CKD patients already receiving"
  },
  {
    "conteudo":"these medications."
  },
  {
    "conteudo":"Vitamin A was investigated in this SR, however there were no trials examining dietary intake"
  },
  {
    "conteudo":"of vitamin A, and supplementation trials included IV vitamin A, which the WG determined"
  },
  {
    "conteudo":"qualified it as a medication vs a nutritional supplement. However, the same concerns regarding"
  },
  {
    "conteudo":"toxicity of vitamin E supplementation apply to vitamin A supplementation."
  },
  {
    "conteudo":"Recommendations cannot be made with regard to vitamins A or E supplementation in CKD"
  },
  {
    "conteudo":"population. An individualized approach is required in considering the need to supplement"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 152"
  },
  {
    "conteudo":"vitamins A or E supplementation or terminate supplementation in adult CKD population"
  },
  {
    "conteudo":"and there is also a need to monitor for toxicity with supplementation."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Implementation of vitamin E supplementation should consider individual"
  },
  {
    "conteudo":"patient’s nutritional status, dietary intake, concomitant medications, co-morbid"
  },
  {
    "conteudo":"conditions particularly with regard to baseline cardiovascular disease, and lipid"
  },
  {
    "conteudo":"levels."
  },
  {
    "conteudo":"● Oral doses >= 400 IU of vitamin E are not recommended without at least"
  },
  {
    "conteudo":"intermittent monitoring of serum vitamin E levels."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Platelet count should be monitored as should any changes in medical status, medications,"
  },
  {
    "conteudo":"and nutritional status."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Identify methods to assess vitamin E status. Current methods utilize serum levels"
  },
  {
    "conteudo":"of vitamin E, but the sensitivity and reliability of this approach are unclear."
  },
  {
    "conteudo":"● Ascertain the optimal vitamin E status of CKD population including CKD stages 1-5,"
  },
  {
    "conteudo":"those on dialysis and those that have received a kidney transplant."
  },
  {
    "conteudo":"● The potential role of vitamin E treated dialyzer membranes on preventing intradialytic"
  },
  {
    "conteudo":"hypotension, improving nutritional status, decreasing\/preventing intradialytic"
  },
  {
    "conteudo":"inflammation, and anemia resistance is not yet defined. Ongoing studies in this area"
  },
  {
    "conteudo":"are indicated to further define the role of vitamin E treated dialyzer membranes."
  },
  {
    "conteudo":"● Investigate the recommended dietary vitamin E intake that will prevent vitamin E"
  },
  {
    "conteudo":"deficiency and the recommended supplemental dose of vitamin E that will correct vitamin"
  },
  {
    "conteudo":"E deficiency without increasing the risk of toxicity, including investigation of the effects"
  },
  {
    "conteudo":"of larger doses of oral vitamin E (i.e. 800 IU\/day)."
  },
  {
    "conteudo":"● Examine the effects of vitamin E supplementation on hard outcomes including"
  },
  {
    "conteudo":"cardiovascular disease, morbidity and mortality using RCTs."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 153"
  },
  {
    "conteudo":"5.5 Statements on Vitamin K"
  },
  {
    "conteudo":"Anticoagulant Medication and Vitamin K Supplementation"
  },
  {
    "conteudo":"5.5.1 In adults with CKD 1-5D and post-transplant, it is reasonable that patients"
  },
  {
    "conteudo":"receiving anticoagulant medicines known to inhibit vitamin K activity (e.g., warfarin"
  },
  {
    "conteudo":"compounds) do not receive vitamin K supplements (OPINION)."
  },
  {
    "conteudo":"Background"
  },
  {
    "conteudo":"Vitamin K is a fat-soluble vitamin that acts as a cofactor for gamma-glutamyl carboxylase"
  },
  {
    "conteudo":"which enables the carboxylation of vitamin K-dependent proteins producing coagulation"
  },
  {
    "conteudo":"factors. Coagulation factors II, VII, IX and X are the most well-known vitamin K-dependent"
  },
  {
    "conteudo":"proteins, and deficiency in these factors can lead to impairment in blood clotting. Vitamin K"
  },
  {
    "conteudo":"also enables normal calcification processes to proceed in bone and soft tissues. Matrix Gla"
  },
  {
    "conteudo":"protein (MGP) is a vitamin K-dependent protein produced by vascular smooth muscle cells"
  },
  {
    "conteudo":"(VSMCs) that is a powerful inhibitor of vascular calcification in culture media and of intimal"
  },
  {
    "conteudo":"atherosclerotic plaque calcification. After carboxylation, MGP binds to calcium crystals,"
  },
  {
    "conteudo":"inhibiting further crystal growth. MGP binds to bone morphogenetic protein-2 (BMP-2)"
  },
  {
    "conteudo":"thereby blocking the differentiation of VSMCs towards osteochondrogenic type cells."
  },
  {
    "conteudo":"Vitamin K participates in the enzymatic carboxylation of proteins controlling bone calcium"
  },
  {
    "conteudo":"deposition (e.g., osteocalcin) and plays an important role in normal bone formation and"
  },
  {
    "conteudo":"structure."
  },
  {
    "conteudo":"Hence Vitamin K, by facilitating carboxylation of certain proteins, has major effects on blood"
  },
  {
    "conteudo":"clothing, preventing soft tissue calcification, including vascular calcification and controlling"
  },
  {
    "conteudo":"bone calcium crystal formation."
  },
  {
    "conteudo":"Two classes of vitamin K compounds are primarily responsible for vitamin K activity,"
  },
  {
    "conteudo":"phylloquinone (vitamin K1) and menaquinones (vitamin K2).368 Phylloquinone is found"
  },
  {
    "conteudo":"primarily in foods, especially green and leafy vegetables (e.g., spinach, kale, cabbage,"
  },
  {
    "conteudo":"broccoli), plant based oils found in many food products, and cow’s milk. There are more than"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 154"
  },
  {
    "conteudo":"10 menaquinones which differ in the number of isoprenoid units in its side chain. Most"
  },
  {
    "conteudo":"menaquinones are produced by bacteria. Menaquinone 4 is different and appears to be"
  },
  {
    "conteudo":"produced in vivo from phylloquinone.368, 369 Menaquinones are found in dairy products (yogurt)"
  },
  {
    "conteudo":"meats, and fermented foods, and also synthesized in the intestine by colonic bacteria. The"
  },
  {
    "conteudo":"Intestinal absorption of vitamin K requires biliary and pancreatic secretions and occurs in the"
  },
  {
    "conteudo":"small intestine where vitamin K is incorporated into chylomicrons. The role of the"
  },
  {
    "conteudo":"menaquinones in vitamin K function and nutritional needs is still not completely understood."
  },
  {
    "conteudo":"Large doses of vitamin E may induce vitamin K deficiency.369"
  },
  {
    "conteudo":"Detailed Justification & Special Discussion"
  },
  {
    "conteudo":"The United States Institute of Medicine states that the Adequate Intake of vitamin K is 120 and"
  },
  {
    "conteudo":"90 micrograms per day for adult men and women, respectively.370, 371 These values are based"
  },
  {
    "conteudo":"on median vitamin K intakes reported in the NHANES III data. Globally, dietary"
  },
  {
    "conteudo":"recommendations for vitamin K usually vary from 50 to 120 micrograms\/day.372 These"
  },
  {
    "conteudo":"recommendations do not differentiate phylloquinone from menaquinone intake. At the time"
  },
  {
    "conteudo":"the US Institute of Medicine recommendations were set, the food composition databases on"
  },
  {
    "conteudo":"which these recommendations were made only contained the phylloquinone content of foods."
  },
  {
    "conteudo":"Hence, these current recommendations are based on phylloquinone, which is the major form"
  },
  {
    "conteudo":"of vitamin K in Western diets."
  },
  {
    "conteudo":"Increasing age, platelet count and serum urea and creatinine and lower serum albumin"
  },
  {
    "conteudo":"concentrations were associated with more severe elevation in prothrombin time in patients"
  },
  {
    "conteudo":"taking antibiotics.373, 374 Vitamin K supplements may return prothrombin time to normal in such"
  },
  {
    "conteudo":"patients.374 Patients receiving antibiotics who have poor intake and at higher risk of bleeding"
  },
  {
    "conteudo":"(e.g., surgical patients) may be considered for vitamin K supplements, particularly if they have"
  },
  {
    "conteudo":"acute kidney injury or chronic kidney disease.373 However, the foregoing conclusions were"
  },
  {
    "conteudo":"essentially based on observational studies of small number of patients."
  },
  {
    "conteudo":"A study of the NHANES data indicated that 72.1% of adults with mild-moderate CKD (eGFR-"
  },
  {
    "conteudo":"EPI 58 mL\/min\/1.73m2) had vitamin K intake below the recommended adequate Intake (AI)"
  },
  {
    "conteudo":"level (mean, 97.5 µg\/day; 95%CI, 89.7-105.3).375 Studies in Italy confirmed that daily intake of"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 155"
  },
  {
    "conteudo":"vitamin K1 in MHD patients is commonly below recommended levels.372 Several"
  },
  {
    "conteudo":"observational studies in advanced CKD (stages 3-5) or MHD patients indicated that serum"
  },
  {
    "conteudo":"vitamin K1 (phylloquinone) and vitamin K2 (menaquinone) concentrations were frequently"
  },
  {
    "conteudo":"low and that serum levels of other uncarboxylated compounds which, when elevated,"
  },
  {
    "conteudo":"indicated vitamin K deficiency were increased.376, 377"
  },
  {
    "conteudo":"The recommended dietary vitamin K intake for patients with CKD 1-5, including those with"
  },
  {
    "conteudo":"the nephrotic syndrome, those who are undergoing MHD or PD or those who are post-"
  },
  {
    "conteudo":"transplant recipients were not defined and were based on that derived for the general"
  },
  {
    "conteudo":"population. In MHD patients, vitamin K intake and serum vitamin K levels are often low or"
  },
  {
    "conteudo":"undetectable, and serum uncarboxylated osteocalcin and PIVKA-II are commonly"
  },
  {
    "conteudo":"elevated.303,304"
  },
  {
    "conteudo":"Vitamin K Levels"
  },
  {
    "conteudo":"Only one short term randomized controlled study has been published that examined the effects"
  },
  {
    "conteudo":"of vitamin K supplements on vitamin K status in MHD patients.377 No such studies have been"
  },
  {
    "conteudo":"carried out in other stages of CKD or in PD patients or those post-transplant. The study"
  },
  {
    "conteudo":"involved small number of patients who received, by random assignment, supplements of 45,"
  },
  {
    "conteudo":"135 or 360 micrograms per day of vitamin K2 (menaquinone-7) for only six weeks. In"
  },
  {
    "conteudo":"general, there was a dose dependent increase in serum vitamin K2 and decrease in serum"
  },
  {
    "conteudo":"MGP, osteocalcin and PIVKD-II. Mean serum vitamin K2 rose to previously reported"
  },
  {
    "conteudo":"dpuc uc"
  },
  {
    "conteudo":"normal values with the 45 µg\/day dose and to modestly above normal values with the 135 and"
  },
  {
    "conteudo":"360 µg\/day doses. Serum MGP, osteocalcin and PIVKD-II decreased most with the 360"
  },
  {
    "conteudo":"dpuc uc"
  },
  {
    "conteudo":"µg\/day dose, but concentrations still tended to be above normal with this dose."
  },
  {
    "conteudo":"There are currently several clinical trials of vitamin K supplements in MHD patients, and more"
  },
  {
    "conteudo":"information regarding vitamin K supplementation should be available within the near"
  },
  {
    "conteudo":"future.283, 378, 379 (Clinical Trials Identifier: NCT01528800; NCT01742273; NCT2610933;"
  },
  {
    "conteudo":"NCT02870829; UMIN000011490; UMIN000017119). There is a paucity of data on the long-"
  },
  {
    "conteudo":"term safety of different vitamin K intakes and especially of vitamin K supplements and of the"
  },
  {
    "conteudo":"value, if any, of taking different vitamin K compounds. Individuals receiving vitamin K"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 156"
  },
  {
    "conteudo":"supplements should not receive anticoagulant medicines that inhibit vitamin K activity (e.g.,"
  },
  {
    "conteudo":"warfarin compounds)."
  },
  {
    "conteudo":"Implementation Considerations"
  },
  {
    "conteudo":"• Patients receiving antibiotics who have poor intake and at higher risk of bleeding (e.g.,"
  },
  {
    "conteudo":"surgical patients) may be considered for vitamin K supplements, particularly if they"
  },
  {
    "conteudo":"have acute kidney injury or chronic kidney disease.373 However, the foregoing"
  },
  {
    "conteudo":"conclusions were essentially based on observational studies of small number of"
  },
  {
    "conteudo":"patients."
  },
  {
    "conteudo":"• The RDN may provide dietary assessment\/counseling related to excess dietary intake of"
  },
  {
    "conteudo":"Vitamin K or irregular excess intake of foods containing high vitamin K; and providing"
  },
  {
    "conteudo":"education regarding dietary sources of vitamin K."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"• Considering the high prevalence of bone disorders and severe atherosclerotic and"
  },
  {
    "conteudo":"coronary artery vascular disease in CKD patients and the relationship of these disorders"
  },
  {
    "conteudo":"to calcium deposition in these tissues, there is a great need to more precisely define the"
  },
  {
    "conteudo":"dietary vitamin K requirements and the value, if any, for routine vitamin K supplements"
  },
  {
    "conteudo":"in patients with different types and stages of CKD and with vascular calcification."
  },
  {
    "conteudo":"• Examine the confounding effects of different co-morbid conditions on the dietary"
  },
  {
    "conteudo":"requirements for vitamin K intake and the need for vitamin K supplements and the dose"
  },
  {
    "conteudo":"of such supplements in patients with kidney disease."
  },
  {
    "conteudo":"• Examine the physiology and metabolism of vitamin K in people with CKD, with"
  },
  {
    "conteudo":"particular regard to evaluate why vitamin K deficiency appears to be more common in"
  },
  {
    "conteudo":"people with advanced CKD, including those undergoing chronic dialysis."
  },
  {
    "conteudo":"• Evaluate the long-term clinical effects including the safety and potential risks, if any, of"
  },
  {
    "conteudo":"vitamin K supplements."
  },
  {
    "conteudo":"• Examine whether there are interactions between vitamin K supplements and"
  },
  {
    "conteudo":"anticoagulants that are not warfarin-type compounds."
  },
  {
    "conteudo":"• Examine whether dietary intake of vitamin K1 and vitamin K2 have any different"
  },
  {
    "conteudo":"clinically important effects."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 157"
  },
  {
    "conteudo":"5.6 Statement on Trace Minerals – Selenium and Zinc"
  },
  {
    "conteudo":"Selenium and Zinc Supplementation"
  },
  {
    "conteudo":"5.6.1 In adults with CKD 1-5D, we suggest not routinely supplementing selenium or"
  },
  {
    "conteudo":"zinc since there is little evidence that it improves nutritional, inflammatory or"
  },
  {
    "conteudo":"micronutrient status (2C)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Selenium is a trace element that has known antioxidant properties and plays a role in enzymatic"
  },
  {
    "conteudo":"activities inside the body. It acts as a cofactor for the reduction in important antioxidant enzymes"
  },
  {
    "conteudo":"like glutathione peroxidase and thus protects against oxidation. Several studies have suggested"
  },
  {
    "conteudo":"that MHD patients have low levels of selenium compared with healthy controls, and deficiency"
  },
  {
    "conteudo":"of this trace element may contribute to increased oxidative stress and inflammation.380-383 There"
  },
  {
    "conteudo":"is also some preliminary suggestion that low selenium levels may be associated with increased"
  },
  {
    "conteudo":"death risk in MHD patients, especially death due to infections.382"
  },
  {
    "conteudo":"Zinc is an essential micronutrient and forms a component of bio-membranes. It functions not"
  },
  {
    "conteudo":"only as an antioxidant but also has anti-inflammatory effects and prevents free radicals-induced"
  },
  {
    "conteudo":"injury during inflammation. There is some suggestion that marginal zinc intake may be"
  },
  {
    "conteudo":"associated with an increased risk of cardiovascular disease in general population384 and zinc has"
  },
  {
    "conteudo":"been shown to protect against atherosclerosis by inhibiting the oxidation of low-density"
  },
  {
    "conteudo":"lipoprotein cholesterol in animal studies.68 Zinc deficiency has been shown to increase oxidative"
  },
  {
    "conteudo":"stress and NF-κB DNA-binding activity and induce inflammation in experimental models.385-387"
  },
  {
    "conteudo":"Zinc is also essential for insulin synthesis and release and glucose homeostasis388 and zinc"
  },
  {
    "conteudo":"deficiency has been suggested to impair insulin secretion and decrease leptin levels.389 Studies"
  },
  {
    "conteudo":"have reported a high prevalence of zinc deficiency in hemodialysis patients.390-392"
  },
  {
    "conteudo":"The current Recommended Dietary Allowance (RDA) for zinc is 8 mg\/d for women and 11 mg\/d"
  },
  {
    "conteudo":"for men in the general population and for selenium is 55mcg\/d for women and men. Whether"
  },
  {
    "conteudo":"similar amount of intake is recommended in various CKD stages and maintenance dialysis"
  },
  {
    "conteudo":"population is currently not known."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 158"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Selenium"
  },
  {
    "conteudo":"In adults with chronic kidney disease (CKD), seven studies have examined the effect of selenium"
  },
  {
    "conteudo":"intake on biomarkers and other surrogate health outcomes. Most of the studies utilized oral"
  },
  {
    "conteudo":"selenium supplementation and all studies were performed in MHD patients. Koenig et al."
  },
  {
    "conteudo":"examined the effect of intravenous selenium supplementation393 and Stockler-Pinto examined"
  },
  {
    "conteudo":"the effect of selenium supplementation in the form of a Brazil nut.394 Selenium dosages generally"
  },
  {
    "conteudo":"ranged from 175-1400 µg per week. The selenium dosage in Stockler-Pinto et al. was not"
  },
  {
    "conteudo":"described (1 Brazil nut\/day) and in Koenig et al., the parenteral dose of selenium used was much"
  },
  {
    "conteudo":"higher (400 mg 3 times a week) compared to other studies. Study duration ranged from 14 days"
  },
  {
    "conteudo":"to 6 months. In Temple et al., participants’ selenium status at baseline was normal.395 In a study"
  },
  {
    "conteudo":"by Tonelli et al., 28% of treatment group versus 15% of placebo group had low selenium levels"
  },
  {
    "conteudo":"after supplementation.396 Around 20% of participants were selenium deficient in Stockler-Pinto"
  },
  {
    "conteudo":"et al., and the remaining studies did not report selenium status at baseline.394"
  },
  {
    "conteudo":"Nutritional Status"
  },
  {
    "conteudo":"Only one very short-term (12 weeks) randomized placebo-controlled study examined the effect"
  },
  {
    "conteudo":"of oral selenium supplementation of 200µg per day on nutritional status in 80 MHD patients. 397"
  },
  {
    "conteudo":"The study reported a significantly greater reduction in SGA and malnutrition-inflammation score"
  },
  {
    "conteudo":"in the selenium group compared to the placebo group. However, no significant difference was"
  },
  {
    "conteudo":"observed in serum albumin concentrations between the two groups.397 The same study by Salehi"
  },
  {
    "conteudo":"et al. did not observe any difference in the median changes of CRP levels between selenium"
  },
  {
    "conteudo":"and placebo groups. Although a smaller increase in interleukin-6 levels was observed in selenium"
  },
  {
    "conteudo":"group compared to placebo group,397 this is the only study that examined inflammation as an"
  },
  {
    "conteudo":"outcome. Thus, there is not enough evidence to make recommendation of selenium"
  },
  {
    "conteudo":"supplementation for malnutrition-inflammation syndrome in MHD patients."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 159"
  },
  {
    "conteudo":"Selenium Levels"
  },
  {
    "conteudo":"Although two short-term small randomized controlled studies provided some evidence that"
  },
  {
    "conteudo":"selenium supplementation may be useful in increasing plasma and erythrocyte selenium"
  },
  {
    "conteudo":"levels,395, 398 it is not known if selenium supplementation may impact on any patient health-"
  },
  {
    "conteudo":"related or hard clinical outcomes. Only one short-term randomized study by Salehi et al."
  },
  {
    "conteudo":"examined the effects of oral selenium supplementation on lipid levels. The results showed no"
  },
  {
    "conteudo":"difference between selenium group and control group in any of the lipid parameters including"
  },
  {
    "conteudo":"triglyceride, total cholesterol, low density lipoprotein- and high-density lipoprotein-"
  },
  {
    "conteudo":"cholesterol.397"
  },
  {
    "conteudo":"Zinc"
  },
  {
    "conteudo":"Nutritional Status"
  },
  {
    "conteudo":"Three small short-term RCTs examined the effects of zinc supplementation on nutrition status"
  },
  {
    "conteudo":"in MHD patients. The study duration ranged from 8 weeks to 90 days. The dose of zinc"
  },
  {
    "conteudo":"supplementation ranged from a daily dose of 11mg, 50mg to 100mg elemental zinc.399-401 In the"
  },
  {
    "conteudo":"study by Argani et al., serum albumin levels increased in the zinc supplemented group but there"
  },
  {
    "conteudo":"was no change in the placebo group.399 Guo et al. examined zinc supplementation of 11mg daily"
  },
  {
    "conteudo":"for 8 weeks in a cohort of 65 MHD patients with low baseline zinc level (<80mg\/dL). Descriptive"
  },
  {
    "conteudo":"quantitative data was not provided but the authors concluded that protein nitrogen appearance"
  },
  {
    "conteudo":"and albumin levels significantly increased in zinc supplemented group but not in control group.400"
  },
  {
    "conteudo":"Jern et al. showed that protein catabolic rate increased with 50mg zinc supplementation for 90"
  },
  {
    "conteudo":"days but no change in placebo group.401 Between group differences were not provided in these"
  },
  {
    "conteudo":"studies. The data from these three small low-quality trials were regarded as inconclusive and not"
  },
  {
    "conteudo":"enough to make recommendation."
  },
  {
    "conteudo":"Lipid Profile"
  },
  {
    "conteudo":"Four short-term RCTs examined the effect of oral zinc supplementation on lipid levels.399, 402-404"
  },
  {
    "conteudo":"The studies by Argani et al. and Rahimi-Ardabili et al. administered 100 mg oral zinc daily to"
  },
  {
    "conteudo":"MHD patients for two months.399, 403 Argani et al. showed no changes in cholesterol and"
  },
  {
    "conteudo":"triglyceride levels with zinc supplementation.399 Rahimi-Ardabili et al. showed that cholesterol"
  },
  {
    "conteudo":"levels increased significantly in the placebo group but no change in the treatment group and total"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 160"
  },
  {
    "conteudo":"cholesterol levels were not different between the two groups after 2 months’ study 403. In the"
  },
  {
    "conteudo":"other two studies, Roozbeh et al.404 and Chevalier et al. 402 both supplemented MHD patients with"
  },
  {
    "conteudo":"50 mg zinc daily for six weeks and 90 days, respectively. All patients in both these two studies"
  },
  {
    "conteudo":"were zinc deficient at baseline (<80ug\/dL). Both studies showed that total cholesterol, LDL-C,"
  },
  {
    "conteudo":"HDL-C and serum triglyceride levels increased in zinc supplemented group but no change in the"
  },
  {
    "conteudo":"control group. The conclusions by the authors in these studies suggested that this increase in"
  },
  {
    "conteudo":"lipid parameters was desirable.402, 404 Pakfetrat et al. examined the effect of 50 mg oral zinc per"
  },
  {
    "conteudo":"day for 6 weeks in MHD patients, and found that significantly decreased homocysteine levels"
  },
  {
    "conteudo":"decreased in the zinc supplemented group compared to the placebo group.405 Two studies"
  },
  {
    "conteudo":"examined the effects of zinc supplementation on inflammatory parameters, but results were"
  },
  {
    "conteudo":"inconclusive.406 Data on the effects of zinc supplementation on body weight and BMI were"
  },
  {
    "conteudo":"mixed and limited. 399, 407"
  },
  {
    "conteudo":"Zinc Levels"
  },
  {
    "conteudo":"Six RCTs examined zinc supplementation in relation to serum zinc levels in MHD patients.396,"
  },
  {
    "conteudo":"399, 400, 402, 404, 408 All except Tonelli’s study 396 described zinc deficiency at baseline. The dosage of"
  },
  {
    "conteudo":"zinc supplementation used ranged from 11mg to 110mg. Study duration ranged from 5 weeks up"
  },
  {
    "conteudo":"to 6 months. In the study by Tonelli and co-workers, zinc levels in the medium dose (50mg per"
  },
  {
    "conteudo":"day) but not the low dose (25mg per day) group were significantly higher than the non-"
  },
  {
    "conteudo":"supplemented group at 90 days and 180 days after supplementation.396 A pooled analysis of these"
  },
  {
    "conteudo":"6 studies showed a mean (95% confidence intervals) increase of 30.97 (17.45, 44.59) ug\/dL of"
  },
  {
    "conteudo":"serum zinc levels after supplementation compared to control group. However, heterogeneity was"
  },
  {
    "conteudo":"high. Furthermore, it is not known if zinc supplementation in deficient patients may impact on"
  },
  {
    "conteudo":"any health-related outcomes or clinical hard outcomes in CKD and dialysis patients. The long-"
  },
  {
    "conteudo":"term effects or any toxicity of zinc supplementation are also unclear at this stage."
  },
  {
    "conteudo":"There were no identified studies examining the effect of zinc supplementation on dysgeusia in"
  },
  {
    "conteudo":"patients with CKD, though this topic has been explored in other populations.409"
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"• Suggested intake should be based on recommendations for the general population (ex:"
  },
  {
    "conteudo":"Recommended Dietary Allowance) unless there are specific considerations requiring"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 161"
  },
  {
    "conteudo":"modification."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"There are no specific guidelines for monitoring selenium and zinc deficiency or supplementation."
  },
  {
    "conteudo":"However, although unlikely, practitioners should be aware of signs and symptoms of severe"
  },
  {
    "conteudo":"selenium and zinc deficiency in CKD Stage 3-5D patients."
  },
  {
    "conteudo":"Future research recommendations"
  },
  {
    "conteudo":"● Conduct population-based cohort studies to determine the prevalence and importance of"
  },
  {
    "conteudo":"selenium and zinc deficiency across different stages of CKD and kidney transplant patients"
  },
  {
    "conteudo":"as well as dialysis modality and examine whether selenium or zinc deficiency may be related"
  },
  {
    "conteudo":"to various surrogate and hard clinical outcomes."
  },
  {
    "conteudo":"● Conduct adequately powered clinical trials of long enough duration to evaluate whether"
  },
  {
    "conteudo":"selenium or zinc supplementation in deficient CKD and maintenance dialysis patients may"
  },
  {
    "conteudo":"improve various surrogate markers of inflammation and protein energy wasting, lipid"
  },
  {
    "conteudo":"parameters, wound healing, dysgeusia and other health outcomes in dose dependent manner."
  },
  {
    "conteudo":"Limited data suggest that further randomized trials should recruit specifically selenium"
  },
  {
    "conteudo":"deficient patients."
  },
  {
    "conteudo":"● The safety of prescribing zinc in non-deficient dialysis patients also needs to be determined."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 162"
  },
  {
    "conteudo":"GUIDELINE 6: ELECTROLYTES"
  },
  {
    "conteudo":"6.1 Statements: Acid Load"
  },
  {
    "conteudo":"Dietary Management of net acid production (NEAP)"
  },
  {
    "conteudo":"6.1.1 In adults with CKD 1-4, we suggest reducing net acid production (NEAP)"
  },
  {
    "conteudo":"through increased dietary intake of fruits and vegetables (2C) in order to reduce the rate"
  },
  {
    "conteudo":"of decline of residual kidney function."
  },
  {
    "conteudo":"Bicarbonate Maintenance"
  },
  {
    "conteudo":"6.1.2 In adults with CKD 3-5D, we recommend reducing net acid production"
  },
  {
    "conteudo":"(NEAP) through increased bicarbonate supplementation (1C) in order to reduce the"
  },
  {
    "conteudo":"rate of decline of residual kidney function."
  },
  {
    "conteudo":"6.1.3 In adults with CKD 3-5D, it is reasonable to maintain serum bicarbonate levels at"
  },
  {
    "conteudo":"24 - 26 mmol\/L (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Acid base homeostasis is maintained by urinary acidification using titratable anions, such as"
  },
  {
    "conteudo":"phosphate, to trap proteins, and trapping ammonia that is generated as ammonium in an acid"
  },
  {
    "conteudo":"urine. As kidney function declines, the net acidification requirement by residual nephrons"
  },
  {
    "conteudo":"increases. This leads to increased ammonia production per residual nephron and requires"
  },
  {
    "conteudo":"delivery of glutamine to the residual nephrons. The increased per nephron need for increased"
  },
  {
    "conteudo":"acidification and ammonia genesis is in part endothelin controlled and may increase injury to"
  },
  {
    "conteudo":"residual nephrons. Acid retention also would have the potential to promote muscle wasting as"
  },
  {
    "conteudo":"part of the homeostatic processes of normalizing acid base status. Metabolic acidosis increases"
  },
  {
    "conteudo":"skeletal muscle proteolysis by a ubiquitin proteasome pathway that degrades actin potentially"
  },
  {
    "conteudo":"having adverse nutritional impact on the patient accompanied by an increase in protein"
  },
  {
    "conteudo":"catabolic rate."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Eleven studies examined the association between dietary acid load\/oral bicarbonate"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 163"
  },
  {
    "conteudo":"supplements on health outcomes in the CKD population. Of the included studies, there were"
  },
  {
    "conteudo":"four RCTs,198, 199, 410, 411 one NRCT,200 three non-controlled studies,412-414 two prospective"
  },
  {
    "conteudo":"cohort studies,415, 416 and one retrospective cohort study.417"
  },
  {
    "conteudo":"CKD Progression; effect of reducing net acid production"
  },
  {
    "conteudo":"Studies aimed at evaluating the effect of reduction in net acid production (NEAP) have been"
  },
  {
    "conteudo":"two-fold; either directly reducing NEAP by administration of sodium bicarbonate, or by dietary"
  },
  {
    "conteudo":"alteration using fruits and vegetables, which both decrease NEAP and alter the composition"
  },
  {
    "conteudo":"and quantity of dietary protein partially confounding the effect of reduction of NEAP alone."
  },
  {
    "conteudo":"In adults with CKD, four RCTs,198, 199, 410, 411 one non-RCT,200 two non-controlled studies,413,"
  },
  {
    "conteudo":"414 two prospective cohort studies,415, 416 and one retrospective cohort study417 examined the"
  },
  {
    "conteudo":"effects of dietary fruit and vegetable or oral bicarbonate supplements on CKD progression. In"
  },
  {
    "conteudo":"patients with CKD stages 2-4 (20-65 mL\/min per 1.73 m2 in available studies) higher quartiles"
  },
  {
    "conteudo":"of net endogenous acid production (NEAP) were associated with greater I 125iothalamate"
  },
  {
    "conteudo":"glomerular filtration rate (iGFR) decline (p-trend=0.02).416 In CKD stages 3-5 not on dialysis"
  },
  {
    "conteudo":"(≤ 60 mL\/min per 1.73 m2) higher NEAP is associated with CKD progression (p<0.05 for all"
  },
  {
    "conteudo":"quartile groups).417 In CKD stages 3-4 (≥15 or <60 mL\/min per 1.73 m2) compared to lowest"
  },
  {
    "conteudo":"dietary acid load tertile, highest dietary acid load had greater relative hazard of ESRD"
  },
  {
    "conteudo":"(p=0.05).415"
  },
  {
    "conteudo":"Studies reducing NEAP by the use of administration of oral sodium bicarbonate are not"
  },
  {
    "conteudo":"confounded by alteration in dietary protein composition and easier to study in randomized"
  },
  {
    "conteudo":"controlled prospective manner. In studies involving patients with CKD Stages 4-5, the oral"
  },
  {
    "conteudo":"sodium bicarbonate group had significant greater creatinine clearance after 18 and 24 months"
  },
  {
    "conteudo":"(p<0.05). Rapid CKD progression (creatine clearance loss of >3ml\/min per 1.73m2\/yr) was"
  },
  {
    "conteudo":"lower in the oral sodium bicarbonate group (RR: 0.15; 95% CI: 0.06-0.40). Development of"
  },
  {
    "conteudo":"ESRD was lower in the oral sodium bicarbonate group (RR: 0.13; 95% CI: 0.04-0.40).410 In"
  },
  {
    "conteudo":"another study of CKD Stages 4-5; not on dialysis, there was no significant difference in"
  },
  {
    "conteudo":"creatinine clearance between before and after intervention (p>0.05).414 In patients with less"
  },
  {
    "conteudo":"impaired kidney function at baseline (CKD Stage 3), there was a reduction in eGFR in all"
  },
  {
    "conteudo":"groups, however, at 3 years, lesser reduction in eGFR was observed with HCO3 group or fruits"
  },
  {
    "conteudo":"and vegetables than usual care group.199"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 164"
  },
  {
    "conteudo":"In a study by Goraya et al., in patients with CKD Stage 4 using either fruits and vegetables or"
  },
  {
    "conteudo":"NaHCO3 as the intervention, plasma creatinine levels were comparable between the subjects"
  },
  {
    "conteudo":"treated either with HCO3 or fruits and vegetables at baseline and 1-year follow-up (p=0.99,"
  },
  {
    "conteudo":"0.49, respectively), eGFR were comparable between the two groups at baseline and 1-year"
  },
  {
    "conteudo":"follow-up (p=0.84, 0.32, respectively).198 This study does not isolate the effects of alteration in"
  },
  {
    "conteudo":"dietary composition and NEAP sufficiently to establish which intervention is associated with"
  },
  {
    "conteudo":"any biological change observed."
  },
  {
    "conteudo":"The outcome of studies in patients with CKD Stages 1-2 are less clear and the outcomes not as"
  },
  {
    "conteudo":"definitive. This may in part be due to the fact that the per nephron stress of maintaining"
  },
  {
    "conteudo":"acid\/base balance is reduced, either decreasing the renal risk of acidification below a critical"
  },
  {
    "conteudo":"threshold, or by reducing the power necessary to measure an effect. Additionally, studies that"
  },
  {
    "conteudo":"alter NEAP by changing dietary composition are confounded by other variables, such as amino"
  },
  {
    "conteudo":"acid load and quality. One of the outcome variables measured was urinary albumin excretion."
  },
  {
    "conteudo":"Net urine albumin excretion was not different among the three groups in CKD Stage 1 patients"
  },
  {
    "conteudo":"(p>0.05). However, in CKD Stage 2 patients, fruits and vegetables had greater decrease in net"
  },
  {
    "conteudo":"urine albumin excretion than both HCO3 and control (p<0.05) and HCO3 group had greater"
  },
  {
    "conteudo":"decrease in net urine albumin excretion than control (p<0.05).200 It should be noted that a"
  },
  {
    "conteudo":"change in diet towards higher intake of fruit and vegetables is a different and more complex"
  },
  {
    "conteudo":"intervention than change in NEAP since the amino acid load and composition is changed. This"
  },
  {
    "conteudo":"may affect urinary protein loss and have an effect on progression that is independent of NEAP"
  },
  {
    "conteudo":"if the patient population has significant proteinuria."
  },
  {
    "conteudo":"Hospitalization"
  },
  {
    "conteudo":"The effects of oral bicarbonate supplements on hospitalization in CKD patients were mixed,"
  },
  {
    "conteudo":"though evidence is limited. In adults with chronic kidney disease, two RCTs410, 411 examined"
  },
  {
    "conteudo":"the effects of oral bicarbonate supplements on hospitalization. Among CKD Stage 5D"
  },
  {
    "conteudo":"(peritoneal dialysis), compared with placebo group, intervention group had lower hospital"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 165"
  },
  {
    "conteudo":"admission (trend) and hospital length of stay (p=0.07 and 0.02, respectively).411 In CKD Stages"
  },
  {
    "conteudo":"4-5; pre-dialysis, there was no significance difference in hospitalization for heart failure between"
  },
  {
    "conteudo":"the two groups (p=N\/A).410"
  },
  {
    "conteudo":"Nutritional Status"
  },
  {
    "conteudo":"In CKD patients Stages 3-5 including ones on maintenance dialysis, oral bicarbonate"
  },
  {
    "conteudo":"supplements improved nutritional status (e.g., SGA scores, nPCR, albumin, and prealbumin) in"
  },
  {
    "conteudo":"most studies. Oral bicarbonate supplements increased overall SGA scores (2.7 g\/day)411 and"
  },
  {
    "conteudo":"lowered nPNA (nPCR) (de Brito-Ashurst -~1800 mg\/day).410 Except for Kooman et al.,412"
  },
  {
    "conteudo":"(dialysate bicarbonate and oral sodium bicarbonate (1500-3000 mg) if pre-dialytic bicarbonate"
  },
  {
    "conteudo":"did not reach desired level), the other three studies observed positive effects of oral bicarbonate"
  },
  {
    "conteudo":"supplements on serum albumin or prealbumin levels (de Brito-Ashurst -~1800 mg\/day;410"
  },
  {
    "conteudo":"Movilli et al., - mean dose 2.7±0.94 g\/day; 1–4 g\/day;413 Verove et al. – mean dose"
  },
  {
    "conteudo":"4.5±1.5g\/d.414 Oral bicarbonate supplements also had no effects on TSF measurements.412 de"
  },
  {
    "conteudo":"Brito-Ashurst et al., (~1800 mg\/day)410 noted significant increases in mid arm muscle"
  },
  {
    "conteudo":"circumference (MAMC) measurements with oral sodium bicarbonate, while Kooman et al. did"
  },
  {
    "conteudo":"not.412"
  },
  {
    "conteudo":"Two RCTs410, 411 and three non-controlled studies412-414 examined the effects of oral"
  },
  {
    "conteudo":"bicarbonate supplements on nutritional status in adults with CKD. In CKD Stage 5; peritoneal"
  },
  {
    "conteudo":"dialysis, the oral bicarbonate group had higher overall SGA scores starting at 24 weeks (p-"
  },
  {
    "conteudo":"value <0.0003).411 In CKD Stages 4-5; pre-dialysis, the oral sodium bicarbonate group had"
  },
  {
    "conteudo":"significant lower nPNA (nPCR) at 12 and 24 months (p<0.05) and the oral sodium"
  },
  {
    "conteudo":"bicarbonate group had significant higher serum albumin at 12 and 24 months (p<0.05).410"
  },
  {
    "conteudo":"In contrast, in a group of CKD Stage 5; hemodialysis patients, there was no significant"
  },
  {
    "conteudo":"difference in serum albumin among time points (p>0.05).412 In CKD Stage 5; hemodialysis,"
  },
  {
    "conteudo":"oral sodium bicarbonate increased serum albumin level (p=0.01).413"
  },
  {
    "conteudo":"Among CKD patient Stages 4-5; pre-dialysis, oral sodium bicarbonate increased both serum"
  },
  {
    "conteudo":"albumin and prealbumin levels between before and after intervention (p<0.05).414 Among"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 166"
  },
  {
    "conteudo":"CKD Stages 1-2 compared to control and HCO3, fruit and vegetable group had significantly"
  },
  {
    "conteudo":"greater decrease in body weight at the end of the intervention for both individuals with CKD"
  },
  {
    "conteudo":"stage 1 and stage 2 (p<0.05 for both). No difference between HCO3 and control.200 Thus there"
  },
  {
    "conteudo":"does not appear to be a significant effect of reduction in NEAP on nutritional status in patients"
  },
  {
    "conteudo":"with CKD 1-2. In CKD Stage 4 compared to HCO3 group, FV group had lower weight at 1-"
  },
  {
    "conteudo":"year follow up (p<0.01) – baseline weight did not differ between the two groups (p=0.24).198"
  },
  {
    "conteudo":"In CKD Stage 3, fruits and vegetables had greater net body weight loss than both HCO3 and"
  },
  {
    "conteudo":"control (p<0.05) and control group had greater net body weight loss than HCO3 group"
  },
  {
    "conteudo":"(p<0.05).199"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"In Stage 5 MHD patients, higher bicarbonate in the dialysate bath is associated with increased"
  },
  {
    "conteudo":"mortality in epidemiological studies.418 In an analysis of the DOPPS data, it was reported"
  },
  {
    "conteudo":"MHD patients with either very low bicarbonate (< 17) or very high predialysis bicarbonate"
  },
  {
    "conteudo":"(>27) concentrations are at the greatest mortality risk.419 Paradigms that may apply to patients"
  },
  {
    "conteudo":"with residual renal function or those undergoing continuous therapy, such as peritoneal"
  },
  {
    "conteudo":"dialysis, do not directly apply to hemodialysis patients who are experiencing large changes in"
  },
  {
    "conteudo":"acid base equilibrium rapidly and\/or discontinuously. Higher bicarbonate concentration in"
  },
  {
    "conteudo":"hemodialysis patients may also be reflective of lower protein intake."
  },
  {
    "conteudo":"Research on this topic is complicated by the fact that the effect of acidosis differs with the level"
  },
  {
    "conteudo":"of residual kidney function. With advanced CKD, net acid load has a higher potential to"
  },
  {
    "conteudo":"contribute to loss of kidney function."
  },
  {
    "conteudo":"Dietary intervention is more complex, since the effects of specific amino acids or other dietary"
  },
  {
    "conteudo":"constituents on both renal outcomes as well as vascular and bone pathophysiology"
  },
  {
    "conteudo":"(Calcium\/Phosphorous) may play a role that is independent from their effect on acid base"
  },
  {
    "conteudo":"physiology."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Acid load is a consequence of protein load and is inversely associated with potassium"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 167"
  },
  {
    "conteudo":"intake. The estimation of net acid intake is (NEAP (mEq\/d) = -10.2 + 54.5 (protein"
  },
  {
    "conteudo":"[g\/d]\/potassium [mEq\/d]). NEAP can be reduced by administration of sodium"
  },
  {
    "conteudo":"bicarbonate or sodium or potassium citrate or by reduction in dietary acid content by"
  },
  {
    "conteudo":"changing the dietary pattern to increase fruits and vegetables. of fruit and vegetables."
  },
  {
    "conteudo":"The latter can be accomplished by reduction in dietary protein intake and changing its"
  },
  {
    "conteudo":"composition. Low protein intake may have the added benefit of slowing the rate of"
  },
  {
    "conteudo":"progression of kidney disease through other mechanisms (See Section 3.1). In the"
  },
  {
    "conteudo":"MDRD study, patients randomized to low protein intake exhibited a significant"
  },
  {
    "conteudo":"increase in serum bicarbonate,420 so that there is an interaction between intake of"
  },
  {
    "conteudo":"protein and net acid. Separating the effect of reduction in acid load and the effect of"
  },
  {
    "conteudo":"change in dietary protein amount and composition on outcomes is challenging."
  },
  {
    "conteudo":"• When increasing fruits and vegetables intake to correct acid load please use"
  },
  {
    "conteudo":"caution and monitor potassium levels."
  },
  {
    "conteudo":"Monitoring and Evaluation"
  },
  {
    "conteudo":"Clinical trials have demonstrated compliance with expected changes in acid base status"
  },
  {
    "conteudo":"as evaluated by measurement of serum bicarbonate:"
  },
  {
    "conteudo":"Consuming fruit and vegetable in the amount that could reduce dietary acid by 50%"
  },
  {
    "conteudo":"generally had positive effects on acid-base biomarkers.198-200 Fruit and vegetable increased"
  },
  {
    "conteudo":"plasma total CO2 (though not significant in one study)200 and decreased potential renal acid"
  },
  {
    "conteudo":"load and 8h NAE. Except for Goraya et al., (0.5 mEq\/kg\/day),200 oral bicarbonate"
  },
  {
    "conteudo":"supplements also had positive effects on acid-base biomarkers by increasing plasma total"
  },
  {
    "conteudo":"CO2 or bicarbonate levels and decreasing potential renal acid load and 8h NAE in six studies"
  },
  {
    "conteudo":"with different supplement combinations and dosages."
  },
  {
    "conteudo":"No hyperkalemia events were noted in the studies of Goraya et al. who provided a diet rich"
  },
  {
    "conteudo":"in fruits and vegetables to patients with advanced CKD.198 However, we note that inclusion"
  },
  {
    "conteudo":"criteria in those studies considered patients at low hyperkalemia risk not consuming RAS"
  },
  {
    "conteudo":"inhibitors. While no studies have formally evaluated the contribution of dietary potassium to"
  },
  {
    "conteudo":"hyperkalemia risk in these patients, we recommend caution if a fruit and vegetable rich diets"
  },
  {
    "conteudo":"is to be recommended to control metabolic acidosis. A close monitoring of serum\/plasma"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 168"
  },
  {
    "conteudo":"potassium levels is encouraged, and fruit\/vegetable consumption should be temporarily"
  },
  {
    "conteudo":"limited if the patient is considered at risk of hyperkalemia. Monitoring of circulating"
  },
  {
    "conteudo":"potassium is specially recommended in patients with CKD stage 4 or more, including those"
  },
  {
    "conteudo":"on dialysis, as this is the kidney function range where inabilities to compensate dietary"
  },
  {
    "conteudo":"potassium occur."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Research is needed to identify the contribution of NEAP to that of protein intake to"
  },
  {
    "conteudo":"progression of kidney disease as well as to increase urinary protein excretion. It is"
  },
  {
    "conteudo":"unknown what if any of the injurious effect of protein is contributed by acid load."
  },
  {
    "conteudo":"● Increased dietary acid intake is believed to contribute to loss of kidney function"
  },
  {
    "conteudo":"and sarcopenia. Further understanding of the optimal threshold for translation of"
  },
  {
    "conteudo":"these benefits to morbidity and mortality is necessary."
  },
  {
    "conteudo":"● With regard to the effects of fruits and vegetables, it is important to separate the effect"
  },
  {
    "conteudo":"of other aspects of differences in dietary composition; amino acid composition,"
  },
  {
    "conteudo":"carbohydrate composition from the control diet from the effects of acid load."
  },
  {
    "conteudo":"● Increasing pH during intermittent hemodialysis does not improve clinical outcomes. It"
  },
  {
    "conteudo":"is important to establish optimal intradialytic bicarbonate concentration and dialytic"
  },
  {
    "conteudo":"bicarbonate delivery to patients receiving MHD, as well as to understand the"
  },
  {
    "conteudo":"contribution of reduced protein intake to higher serum bicarbonate in HD patients."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 169"
  },
  {
    "conteudo":"6.2 Statements on Calcium"
  },
  {
    "conteudo":"Total Calcium Intake"
  },
  {
    "conteudo":"6.2.1 In adults with CKD 3-4 not taking active vitamin D analogs, we suggest that a"
  },
  {
    "conteudo":"total elemental calcium intake of 800-1,000 mg\/d (including dietary calcium, calcium"
  },
  {
    "conteudo":"supplementation and calcium-based phosphate binders) be prescribed to maintain a"
  },
  {
    "conteudo":"neutral calcium balance (2B)."
  },
  {
    "conteudo":"6.2.2 In adults with CKD 5D, it is reasonable to adjust calcium intake (dietary"
  },
  {
    "conteudo":"calcium, calcium supplements or calcium-based binders) with consideration of"
  },
  {
    "conteudo":"concurrent use of vitamin D analogs and calcimimetics in order to avoid"
  },
  {
    "conteudo":"hypercalcemia (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Calcium is a multivalent cation important for many biologic and cellular functions."
  },
  {
    "conteudo":"Approximately 99% of total body calcium is found in the skeleton and the remainder is present"
  },
  {
    "conteudo":"in the extracellular and intracellular spaces. In addition to its role in maintenance of bone"
  },
  {
    "conteudo":"health, calcium serves a vital role in nerve impulse transmission, muscular contraction, blood"
  },
  {
    "conteudo":"coagulation, hormone secretion, and intercellular adhesion."
  },
  {
    "conteudo":"Calcium balance is tightly regulated by the concerted action of calcium absorption in the"
  },
  {
    "conteudo":"intestine, reabsorption in the kidney, and exchange from bone, which are all under the control"
  },
  {
    "conteudo":"of calciotropic hormones triggered by demand for calcium."
  },
  {
    "conteudo":"Serum calcium concentrations are maintained in the normal range until very late in CKD when"
  },
  {
    "conteudo":"it decreases slightly.421 However, calcium balance in CKD is poorly understood. Calcium"
  },
  {
    "conteudo":"deficiency due to decreased intestinal calcium absorption is a stimulus for the development of"
  },
  {
    "conteudo":"secondary hyperparathyroidism and resultant bone disorders. On the other hand, calcium"
  },
  {
    "conteudo":"excess may promote extra-osseous calcification contributing to increasing the risk of"
  },
  {
    "conteudo":"cardiovascular disease and mortality of these patients.422 In kidney transplant, calcium balance"
  },
  {
    "conteudo":"is even more complex and depends on several factors such as the post-transplant renal"
  },
  {
    "conteudo":"function, the persistence of hyperparathyroidism, the previous bone disease and the"
  },
  {
    "conteudo":"immunosuppressive therapy.423"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 170"
  },
  {
    "conteudo":"Serum calcium levels do not reflect the overall body calcium balance and may not be very"
  },
  {
    "conteudo":"informative except at extremes. The maintenance of serum calcium in the normal range in"
  },
  {
    "conteudo":"CKD depends on several factors such as bone turnover, mineral regulating hormones, degree of"
  },
  {
    "conteudo":"kidney function, use of vitamin D analogues, dialysate calcium concentration and calcium"
  },
  {
    "conteudo":"intake especially from supplements. A careful medical and nutritional history may provide"
  },
  {
    "conteudo":"some insight into the adequacy of calcium intake. However, due to the multifactorial causes of"
  },
  {
    "conteudo":"altered calcium metabolism in CKD, the establishment of adequate amount of dietary calcium"
  },
  {
    "conteudo":"is challenging and depends on the investigation of calcium balance."
  },
  {
    "conteudo":"The evidence review included three small short-term clinical trials in pre-dialysis CKD patients"
  },
  {
    "conteudo":"that investigated the effect of calcium intake in food or supplements on mineral bone"
  },
  {
    "conteudo":"biomarkers and on calcium balance. No other outcomes were investigated in these studies."
  },
  {
    "conteudo":"Calcium Balance and other Lab Measures"
  },
  {
    "conteudo":"In an NRCT, 51 patients in the early stage of CKD (creatinine clearance: 66 to 82 mL\/min)"
  },
  {
    "conteudo":"were placed in a low protein (40g\/d) and low phosphorus (600 mg\/d) diet supplemented with or"
  },
  {
    "conteudo":"without 0.5 g\/d of elemental calcium for 10 days.424 A decrease in intact parathyroid hormone"
  },
  {
    "conteudo":"(iPTH) was observed only in the group receiving calcium supplementation and no changes in"
  },
  {
    "conteudo":"serum calcium, phosphorus and calcitriol were found in the other groups."
  },
  {
    "conteudo":"In a crossover study, six patients with CKD stages 3 and 4 consumed controlled high (2,000"
  },
  {
    "conteudo":"mg\/d) and low calcium diets (800 mg\/d) for 9 days.425 Calcium balance was slightly negative"
  },
  {
    "conteudo":"to neutral in both patients and healthy controls on the low calcium diet (- 91±113 and -"
  },
  {
    "conteudo":"144±174 mg\/d respectively, p>0.05) and more positive in patients than in controls on the high"
  },
  {
    "conteudo":"calcium diet (759±120 and 464±225 mg\/d respectively, p<0.05). Serum calcium and"
  },
  {
    "conteudo":"phosphate concentrations were unchanged and iPTH and 1,25-dihydroxivitamin D decreased"
  },
  {
    "conteudo":"in the high calcium diet."
  },
  {
    "conteudo":"In a 3-week randomized cross-over balance study, eight patients with CKD stages 3 and 4 were"
  },
  {
    "conteudo":"randomized to a controlled calcium intake of 2457 mg\/day (1,500 mg of elemental calcium"
  },
  {
    "conteudo":"from calcium carbonate used as phosphate binder + 957 mg\/day of dietary calcium) versus"
  },
  {
    "conteudo":"placebo (957 mg\/day of dietary calcium).426 The calcium balance was neutral in the placebo"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 171"
  },
  {
    "conteudo":"and positive in the calcium carbonate groups (508 vs. 61 mg\/d, respectively, p=0.002). Serum"
  },
  {
    "conteudo":"calcium, phosphate and iPTH concentrations were unchanged in both groups."
  },
  {
    "conteudo":"Despite the small number of patients investigated, these well performed balance studies showed"
  },
  {
    "conteudo":"that a dietary calcium intake of approximately 800 to 1,000 mg\/d may be adequate to maintain"
  },
  {
    "conteudo":"calcium balance in patients CKD stages 3 and 4 who are not receiving active vitamin D"
  },
  {
    "conteudo":"analogs, at least at short term.427 These values are close to the current estimated average"
  },
  {
    "conteudo":"requirement (EAR-800-1000 mg\/d) and the recommended dietary allowance (RDA- 1000-1200"
  },
  {
    "conteudo":"mg\/d) for healthy individuals proposed by the Institute of Medicine."
  },
  {
    "conteudo":"Special Discussions"
  },
  {
    "conteudo":"In maintenance dialysis patients, calcium balance is more complex. In addition to dietary"
  },
  {
    "conteudo":"calcium load and use of vitamin D analogs, calcium concentration in the dialysate and mode of"
  },
  {
    "conteudo":"dialysis also determine the mass balance of calcium. Studies using a mathematical modeling"
  },
  {
    "conteudo":"have shown a positive calcium balance mass in patients on MHD.428, 429 According to estimates"
  },
  {
    "conteudo":"and assumptions made, extracellular fluid calcium increased with an elemental daily calcium"
  },
  {
    "conteudo":"intake >1.5 g and was numerically more positive when patients are given active vitamin D"
  },
  {
    "conteudo":"analogs.428 The excess of extracellular calcium is deposited in either osseous or extraosseous"
  },
  {
    "conteudo":"sites. The extensive soft tissue calcification highly prevalent in MHD patients suggests that"
  },
  {
    "conteudo":"extraosseous sites seem to be the repository for this calcium.430"
  },
  {
    "conteudo":"Although calcium balance studies are demanding, they are essential to provide data to make"
  },
  {
    "conteudo":"conclusive recommendation for calcium intake from diet or supplements for patients on"
  },
  {
    "conteudo":"maintenance dialysis. Notably in KDIGO (CKD-MBD) 2009 and 2017 there is no"
  },
  {
    "conteudo":"recommendation regarding calcium intake for patients on maintenance dialysis or with kidney"
  },
  {
    "conteudo":"transplantation.333, 431"
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"Hypercalcemia is relatively common in patients on maintenance dialysis. Evidence has been"
  },
  {
    "conteudo":"accumulated linking higher serum calcium concentrations to increased nonfatal cardiovascular"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 172"
  },
  {
    "conteudo":"events432 and mortality.433-436 In the event of hypercalcemia the following adjustments are"
  },
  {
    "conteudo":"recommended:334"
  },
  {
    "conteudo":"● In patients taking calcium-based phosphate binders the dose should be reduced or"
  },
  {
    "conteudo":"therapy switched to a non-calcium phosphate binding."
  },
  {
    "conteudo":"● In patients taking active vitamin D analogs the dose should be reduced or therapy"
  },
  {
    "conteudo":"discontinued until serum concentration of calcium return to normal."
  },
  {
    "conteudo":"● If hypercalcemia persists, consider using low dialysate calcium (1.5 to 2.0 mEq\/L)."
  },
  {
    "conteudo":"This should be done with caution because observational studies have linked this"
  },
  {
    "conteudo":"approach with increased risk for arrhythmia and heart failure.437, 438"
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"Adequate dietary management of calcium can contribute in the control of mineral and bone-"
  },
  {
    "conteudo":"related complications in CKD. However, there is an urgent need of research to cover the"
  },
  {
    "conteudo":"existing gap in this area."
  },
  {
    "conteudo":"● Calcium balance studies are needed to provide data for recommendation of a safe"
  },
  {
    "conteudo":"calcium intake threshold for patients with CKD in the different stages of the disease"
  },
  {
    "conteudo":"including maintenance dialysis (MHD and PD) and kidney transplant."
  },
  {
    "conteudo":"● The effect different sources of calcium (dairy foods, fortified foods and calcium"
  },
  {
    "conteudo":"supplements) on serum calcium concentrations should be studied."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 173"
  },
  {
    "conteudo":"6.3 Statements on Phosphorus"
  },
  {
    "conteudo":"Dietary Phosphorus Amount"
  },
  {
    "conteudo":"6.3.1 In adults with CKD 3-5 and on MHD, we recommend adjusting dietary"
  },
  {
    "conteudo":"phosphorus intake to maintain serum phosphate levels in the normal range (1B)."
  },
  {
    "conteudo":"Dietary Phosphorus Source"
  },
  {
    "conteudo":"6.3.2 In adults with CKD 1-5D and post-transplant, it is reasonable when making"
  },
  {
    "conteudo":"decisions about phosphorus restriction treatment to consider the bioavailability of"
  },
  {
    "conteudo":"phosphorus sources (e.g. animal, vegetable, additives) (OPINION)."
  },
  {
    "conteudo":"Phosphorus Intake with Hypophosphatemia"
  },
  {
    "conteudo":"6.3.3 For adult kidney transplant recipients with hypophosphatemia, it is reasonable"
  },
  {
    "conteudo":"to consider prescribing high-phosphorus intake (diet or supplements) in order to replete"
  },
  {
    "conteudo":"serum phosphate (OPINION)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Phosphorus intake is necessary for bone growth and mineralization, as well as for regulation of"
  },
  {
    "conteudo":"acid-base homeostasis. Phosphorus is an essential nutrient, occurring in most foods both as a"
  },
  {
    "conteudo":"natural component and as an approved ingredient added during food processing. Because of"
  },
  {
    "conteudo":"difficulties of persons with CKD (CKD) to clear excess phosphorus, additional means of serum"
  },
  {
    "conteudo":"phosphate control is necessary to avoid hyperphosphatemia, which could lead to bone and"
  },
  {
    "conteudo":"mineral metabolism disorders of CKD."
  },
  {
    "conteudo":"There are physiologic adaptations in the early stages of CKD that prevent excessive"
  },
  {
    "conteudo":"phosphorus retention, so the inability to promote phosphorus excretion to avoid phosphorus"
  },
  {
    "conteudo":"accumulation and hyperphosphatemia is generally seen when estimated glomerular filtration"
  },
  {
    "conteudo":"rate (eGFR) level decreases below 45 mL\/min,439 being less common in earlier CKD stages. In"
  },
  {
    "conteudo":"the setting of anuria in patients on maintenance dialysis, hyperphosphatemia risks are"
  },
  {
    "conteudo":"particularly heightened,440 with a prevalence as high as 50%.441"
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"How much should dietary phosphorus\/phosphate be restricted in adult patients with CKD is not"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 174"
  },
  {
    "conteudo":"well established. Traditionally, CKD-specific recommendations suggest maintaining"
  },
  {
    "conteudo":"phosphorus intake between 800-1000 mg\/day in patients with CKD stages 3-5 and those in"
  },
  {
    "conteudo":"maintenance dialysis in order to maintain serum phosphate in the normal range.147, 333, 334, 442-"
  },
  {
    "conteudo":"444 The workgroup notes, however, that the efficacy of this recommendation has not been"
  },
  {
    "conteudo":"established. Further, such dietary phosphorus intake range is higher than current"
  },
  {
    "conteudo":"recommended dietary allowance for phosphorus in the adult general population (700 mg\/d).445"
  },
  {
    "conteudo":"While dietary intake influences serum phosphate in CKD patients, factors other than intestinal"
  },
  {
    "conteudo":"phosphorus\/phosphate absorption (namely exchange with bone and excretion by the kidneys in"
  },
  {
    "conteudo":"patients with residual renal function) may be major determinants of serum phosphate levels."
  },
  {
    "conteudo":"Thus, the workgroup prefers not suggesting specific dietary phosphate ranges, and instead"
  },
  {
    "conteudo":"emphasize on the need to individualize treatments based on patient needs and clinical"
  },
  {
    "conteudo":"judgment, taking into consideration natural sources of organic phosphorus (animal vs. vegetal"
  },
  {
    "conteudo":"protein-based dietary phosphorus), or the use of phosphorus additives in processed foods.446-448"
  },
  {
    "conteudo":"With the goal to better understand the effect of dietary phosphate control, the workgroup"
  },
  {
    "conteudo":"decided in this evidence analysis to focus on reports that addressed dietary phosphorus"
  },
  {
    "conteudo":"intake\/output\/balance. This resulted in the exclusion of studies reporting solely on serum"
  },
  {
    "conteudo":"phosphate levels."
  },
  {
    "conteudo":"Phosphorus Control"
  },
  {
    "conteudo":"Limiting dietary phosphorus intake (per se or in combination with dietary protein restriction-"
  },
  {
    "conteudo":"the major source of dietary phosphorus) may be recommended to prevent \/ treat complications"
  },
  {
    "conteudo":"related to high phosphate load patients with CKD stages 3-5 and maintenance dialysis. This"
  },
  {
    "conteudo":"can be achieved by intensified patient educational strategies or individualized dietary plans.449"
  },
  {
    "conteudo":"This evidence review included 5 short-term clinical trials that evaluated the effect of reduced"
  },
  {
    "conteudo":"dietary phosphorus on phosphorus intake, phosphate levels and urinary phosphorus excretion:"
  },
  {
    "conteudo":"Phosphate restriction regimes in non-dialysis CKD: Two RCTs144, 424 examined the effects of"
  },
  {
    "conteudo":"reduced dietary phosphorus in patients with CKD not undergoing dialysis. These studies"
  },
  {
    "conteudo":"evaluated the effect of a low phosphorus diet alone or in combination with a LPD,"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 175"
  },
  {
    "conteudo":"and observed significant reductions in serum phosphate, and urinary phosphorus excretion"
  },
  {
    "conteudo":"post-intervention."
  },
  {
    "conteudo":"Reducing phosphorus by limiting protein intake in non-dialysis CKD: Five RCTs in CKD"
  },
  {
    "conteudo":"patients not undergoing dialysis stages 4-5133, 134, 141, 154, 163 evaluated the effect of a low LPD"
  },
  {
    "conteudo":"or a VLPD supplemented with keto-analogs on serum phosphate levels. All five studies"
  },
  {
    "conteudo":"reported statistically significant134, 141, 154, 163 or borderline-significant133 reductions in serum"
  },
  {
    "conteudo":"phosphate levels at the end of intervention. The interested reader can find more information"
  },
  {
    "conteudo":"on this topic in the evidence analysis of dietary protein restriction in these guidelines."
  },
  {
    "conteudo":"Phosphate restriction regimes in maintenance dialysis: Two RCTs123, 450 examined the effects"
  },
  {
    "conteudo":"of limiting dietary phosphorus in patients with CKD undergoing MHD. Lou et al. tested the"
  },
  {
    "conteudo":"effect of 3-month intensified dietary counseling in order to achieve 800 – 900 mg\/d of dietary"
  },
  {
    "conteudo":"phosphorus and observed a greater decrease in serum phosphate concentration compared to"
  },
  {
    "conteudo":"standard care. 123 Sullivan et al. tested the effect of patient education on identifying foods with"
  },
  {
    "conteudo":"phosphorus additives and observed, compared to standard care, a significant reduction in serum"
  },
  {
    "conteudo":"phosphate levels after 3 months.450 No studies were identified that included PD patients."
  },
  {
    "conteudo":"Although dietary phosphorus restriction may be a valid stand-alone strategy in patients with"
  },
  {
    "conteudo":"CKD-stage 3-4, the working group notes that, collectively, the serum phosphate reductions"
  },
  {
    "conteudo":"achieved solely by limiting dietary intake are modest (especially for dialysis patients) and"
  },
  {
    "conteudo":"recommend this strategy as one in the armamentarium of interventions to maintain serum"
  },
  {
    "conteudo":"phosphate levels in the normal range. For other non-dietary phosphate management strategies,"
  },
  {
    "conteudo":"the interested reader can consult recent guidelines on the management of mineral and bone"
  },
  {
    "conteudo":"disorders of CKD.147, 333, 334, 442-444 Aligning with those guidelines, we recommend decisions to"
  },
  {
    "conteudo":"restrict dietary phosphorus be based on the presence of progressively or persistently elevated"
  },
  {
    "conteudo":"serum phosphate (that is, trends rather than a single laboratory value), and after consideration"
  },
  {
    "conteudo":"of concomitant calcium and PTH levels."
  },
  {
    "conteudo":"Clinical consequences of dietary phosphorus control"
  },
  {
    "conteudo":"Whereas many studies have explored the outcome associations with serum phosphate levels"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 176"
  },
  {
    "conteudo":"throughout the spectrum of CKD, the clinical consequences of restricting dietary phosphorus"
  },
  {
    "conteudo":"are not well studied."
  },
  {
    "conteudo":"CKD progression"
  },
  {
    "conteudo":"Three observational studies evaluated the effects of dietary phosphate restriction on CKD"
  },
  {
    "conteudo":"progression. Results were mixed and evidence was limited. Williams et al. studied impact of a"
  },
  {
    "conteudo":"dietary phosphorus restriction (alone or in combination with protein restriction) on creatinine"
  },
  {
    "conteudo":"clearance among 90 CKD patients of unreported etiology or CKD stage over a median"
  },
  {
    "conteudo":"intervention time of 19 months. 144 Compared to routine care, dietary protein and phosphate"
  },
  {
    "conteudo":"restriction or phosphate restriction only did not show any significant difference in the mean"
  },
  {
    "conteudo":"rate of fall of creatinine clearance. In an observational analysis from the Modification of Diet"
  },
  {
    "conteudo":"in Renal Disease (MDRD) study, greater 24-hr urinary phosphate excretion (taken in this study"
  },
  {
    "conteudo":"as an estimate of dietary phosphorus intake) was not associated with the future risk of"
  },
  {
    "conteudo":"ESRD.451 We note that in this study baseline phosphate levels were well controlled and normal"
  },
  {
    "conteudo":"on average, which may not be the case of real-world settings. A small retrospective"
  },
  {
    "conteudo":"observational analysis from Japan including CKD patients stages 2-5 observed that higher"
  },
  {
    "conteudo":"phosphorus excretion per creatinine clearance was associated with a higher 3-year risk of CKD"
  },
  {
    "conteudo":"progression (defined as the composite of ESKD or 50 % reduction of eGFR).452"
  },
  {
    "conteudo":"It has been proposed that hyperphosphatemia in non-dialysis patients stages 2-5 may reduce the"
  },
  {
    "conteudo":"antiproteinuric effect of ACE inhibition453 or of VLPDs.454 In a post hoc observational analysis"
  },
  {
    "conteudo":"from the Ramipril Efficacy In Nephropathy (REIN) trial, Zoccali et al. evaluated the"
  },
  {
    "conteudo":"relationships between serum phosphate concentration at baseline, disease progression, and"
  },
  {
    "conteudo":"response to ACE inhibition among 331 patients with proteinuric nephropathies.453 Independent"
  },
  {
    "conteudo":"of treatment, patients with higher phosphate progressed significantly faster either to ESRD or"
  },
  {
    "conteudo":"to a composite endpoint of doubling of serum creatinine or ESRD compared with patients with"
  },
  {
    "conteudo":"phosphate levels below the median, and the renoprotective effect of ramipril decreased as"
  },
  {
    "conteudo":"serum phosphate increased (P ≤ 0.008 for interaction). In another post hoc study from a non-"
  },
  {
    "conteudo":"randomized, study in which 99 proteinuric CKD patients who sequentially underwent low-"
  },
  {
    "conteudo":"protein diet (LPD; 0.6 g\/kg\/day) and VLPD (0.3 g\/kg\/day) supplemented with keto-analogues,"
  },
  {
    "conteudo":"each for periods longer than 1 year, Di Lorio et al. observed that 24-h proteinuria was reduced"
  },
  {
    "conteudo":"modestly in patients who maintained relatively higher serum phosphate levels or relatively"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 177"
  },
  {
    "conteudo":"higher phosphaturia to be maximal in those who achieved the lowest level of serum and urine"
  },
  {
    "conteudo":"phosphate.454"
  },
  {
    "conteudo":"Mortality"
  },
  {
    "conteudo":"In observational studies involving CKD patients, the associations of dietary phosphorus intake"
  },
  {
    "conteudo":"on mortality are mixed, impacted by residual confounding and probably pointing to a null"
  },
  {
    "conteudo":"association. Three studies evaluated the cross-sectional association between measures of"
  },
  {
    "conteudo":"dietary phosphorus and mortality in individuals with non-dialysis CKD.451, 455, 456 Murtaugh et"
  },
  {
    "conteudo":"al.455 evaluated the association between 24-h dietary recall estimation of phosphorus intake in"
  },
  {
    "conteudo":"participants with eGFR<60 ml\/min\/1.73m2 from the community-based U.S survey National"
  },
  {
    "conteudo":"Health and Nutrition Examination Survey III, and observed no association between dietary"
  },
  {
    "conteudo":"phosphorus and mortality. Palomino et al. examined myocardial infarction patients from the"
  },
  {
    "conteudo":"Heart and Soul Study, the majority of which with normal kidney function, and observed no"
  },
  {
    "conteudo":"association between higher urinary phosphorus excretion and mortality, but noted an"
  },
  {
    "conteudo":"association with CVD-related mortality (P-trend across tertiles =0.02).456 Selamet et al."
  },
  {
    "conteudo":"involved nephrology referred patients with CKD from the MDRD study and failed to observe"
  },
  {
    "conteudo":"an association between 24-hr urinary phosphorus excretion and mortality.451"
  },
  {
    "conteudo":"One study in MHD patients that examined the association between dietary phosphate (as"
  },
  {
    "conteudo":"estimated from 3-day food recalls) and mortality.457 Patients with higher dietary phosphorus"
  },
  {
    "conteudo":"intake were associated with greater 5-year mortality risk (p-trend across tertiles=0.04). Lynch"
  },
  {
    "conteudo":"et al.458 explored the between prescribed dietary phosphorus restriction and mortality in a post"
  },
  {
    "conteudo":"hoc analysis of the Hemodialysis (HEMO) study, which included 1751 MHD patients. The"
  },
  {
    "conteudo":"study exposure was ascertained by the serum phosphate targets that the dietitians from the"
  },
  {
    "conteudo":"clinical dialysis centers settled annually to prescribe their dietary recommendations. A more"
  },
  {
    "conteudo":"restrictive prescribed dietary phosphate was associated with poorer indices of nutritional status"
  },
  {
    "conteudo":"on baseline analyses and a persistently greater need for nutritional supplementation but not"
  },
  {
    "conteudo":"longitudinal changes in caloric or protein intake. There was a stepwise trend toward greater"
  },
  {
    "conteudo":"survival with more liberal phosphate prescription, which reached statistical significance among"
  },
  {
    "conteudo":"subjects prescribed 1001 to 2000 mg\/d and those with no specified phosphate restriction:"
  },
  {
    "conteudo":"hazard ratios (95% CIs) 0.73 (0.54 to 0.97) and 0.71 (0.55 to 0.92), respectively."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 178"
  },
  {
    "conteudo":"Special discussions"
  },
  {
    "conteudo":"Hypophosphatemia in kidney transplant patients: Hypophosphatemia is a relatively common"
  },
  {
    "conteudo":"complication after kidney transplantation, especially during the first months, and possibly"
  },
  {
    "conteudo":"leading to osteomalacia and osteodystrophy. Its pathogenesis has been attributed to increased"
  },
  {
    "conteudo":"renal phosphate excretion due to elevated levels of phosphaturic hormones, the effect of"
  },
  {
    "conteudo":"glucocorticoid, persistent elevated PTH levels, suboptimal recovery of vitamin D activation,"
  },
  {
    "conteudo":"and imbalance in fibroblast growth factor 23 (FGF23).459-461"
  },
  {
    "conteudo":"It has been proposed that dietary intensification of phosphorus can solve this complication; one"
  },
  {
    "conteudo":"small randomized controlled trial154 examined the effects of 12-week dietary phosphorus"
  },
  {
    "conteudo":"supplementation by means of a neutral phosphate salt (disodium phosphate) in patients with"
  },
  {
    "conteudo":"early post-transplantation hypophosphatemia. The authors observed that, compared to sodium"
  },
  {
    "conteudo":"chloride, supplementation of phosphorus improved hypophosphatemia as well as adenosine"
  },
  {
    "conteudo":"triphosphate in the muscles and the acid excretion capacity of the kidney. No adverse effects on"
  },
  {
    "conteudo":"serum calcium and PTH concentrations were noted during intervention."
  },
  {
    "conteudo":"The serum phosphate level at which supplementation should be considered in these patients or"
  },
  {
    "conteudo":"the dose of replacement to be given is, however, not well studied, and should be decided based"
  },
  {
    "conteudo":"on patient needs and clinical judgment."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"Recommendations to lower dietary phosphorus intake in patients with CKD have been met"
  },
  {
    "conteudo":"with concerns, often relating to the risk of limiting the intake of other nutrients, particularly"
  },
  {
    "conteudo":"protein, which is the main source of phosphate in the diet.458, 462, 463 These concerns are"
  },
  {
    "conteudo":"particularly relevant to patients treated with dialysis because of protein losses in dialysate and"
  },
  {
    "conteudo":"greater protein catabolism from hypermetabolic stress.205 Dietary counselling that includes"
  },
  {
    "conteudo":"information on not only the amount of phosphate but also on the source of protein from which"
  },
  {
    "conteudo":"the phosphate derives and suggestion on methods of cooking phosphate-rich foods can achieve"
  },
  {
    "conteudo":"phosphorus intake without compromising dietary quality or protein status.464"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 179"
  },
  {
    "conteudo":"• Advise choosing natural foods that are lower in bioavailable phosphorus. Animal-"
  },
  {
    "conteudo":"and plant-based foods contain the organic form of phosphate. While animal-based"
  },
  {
    "conteudo":"phosphate is absorbed in the GI tract by 40-60%, the absorption of plant-based"
  },
  {
    "conteudo":"phosphorus is lower (20-50%).465 In line with this, a small crossover trial including"
  },
  {
    "conteudo":"CKD patients’ stage 4 found that a 7-day vegetarian diet led to lower serum"
  },
  {
    "conteudo":"phosphate levels and decreased FGF23 levels than a 7-day meat-based diet.185"
  },
  {
    "conteudo":"Furthermore, foods with only organic phosphorus typically are more nutrient dense"
  },
  {
    "conteudo":"and have a higher nutritional value compared with processed foods containing"
  },
  {
    "conteudo":"phosphate additives, which tend to have a lower nutritional value, and are often"
  },
  {
    "conteudo":"paired with sodium and potassium additives.466"
  },
  {
    "conteudo":"• Advise choosing commercial food items prepared without phosphorus-containing"
  },
  {
    "conteudo":"food additives. Phosphorus additives are increasingly being added to processed and"
  },
  {
    "conteudo":"fast foods to preserve moisture or color, to emulsify ingredients and enhance flavor,"
  },
  {
    "conteudo":"and to stabilize foods. Phosphorus additives contain, however, inorganic"
  },
  {
    "conteudo":"phosphorus with a close to 100% intestinal absorption.464, 465 Meat and poultry"
  },
  {
    "conteudo":"products that report the use of additives have an average phosphate-protein ratio"
  },
  {
    "conteudo":"much higher than additive-free products.447, 448 The most-commonly used"
  },
  {
    "conteudo":"phosphorus additives in food industry can be found, for instance, in bakery products,"
  },
  {
    "conteudo":"enhanced meats, and processed cheeses.467"
  },
  {
    "conteudo":"• Advise choosing natural foods that have low amount of organic phosphorus versus"
  },
  {
    "conteudo":"high amount of protein. The content of organic phosphorus per gram of protein"
  },
  {
    "conteudo":"varies widely among foods. Nutrient composition tables reporting on"
  },
  {
    "conteudo":"phosphorus\/protein ratio content can be used to recommend food substitutions that"
  },
  {
    "conteudo":"can considerably reduce the daily intake of organic phosphorus while ensuring"
  },
  {
    "conteudo":"adequate dietary protein intake.465, 468-470"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 180"
  },
  {
    "conteudo":"• Advise preparing foods at home, using wet cooking methods such as boiling (and"
  },
  {
    "conteudo":"discard the water). These methods are able to remove about 50% of phosphorus"
  },
  {
    "conteudo":"content from foods.471, 472 Slicing the meat prior to boiling and the use of a pressure"
  },
  {
    "conteudo":"cooker has been shown more effective in terms of achieved protein to phosphorus"
  },
  {
    "conteudo":"content.471 At the same time, these methods may remove other minerals (e.g."
  },
  {
    "conteudo":"potassium) of concern for patients with CKD.473 Such practices, however, result in"
  },
  {
    "conteudo":"reduced palatability and texture of the food."
  },
  {
    "conteudo":"The work group emphasizes to individualize recommendations after appropriate evaluation of"
  },
  {
    "conteudo":"the patient daily intake. It requires nutrition expertise (preferably consultation with a renal"
  },
  {
    "conteudo":"dietitian) and should take into consideration culturally appropriate food substitutions."
  },
  {
    "conteudo":"Nutritional counselling sessions should evolve, from the simple concept of phosphate"
  },
  {
    "conteudo":"restriction to opportunities of educating the patient on differentiation between organic and"
  },
  {
    "conteudo":"inorganic sources of phosphate and avoidance of phosphate additives.124 Simple educational"
  },
  {
    "conteudo":"programs on how to read food labels and look for phosphate additives proved to be successful"
  },
  {
    "conteudo":"in helping dialysis patients reduce their serum phosphate levels.449, 450 A meta-analysis"
  },
  {
    "conteudo":"suggested that nutritional counselling based on a structured behavioral change are, in general,"
  },
  {
    "conteudo":"successful in controlling hyperphosphatemia in these patients.124 In this meta-analysis,"
  },
  {
    "conteudo":"however, only about half of the studies were randomized controlled interventions with a short"
  },
  {
    "conteudo":"duration ranging from 1 to 6 months, which calls for a need of more dedicated long-term"
  },
  {
    "conteudo":"interventional studies on this topic."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"Dietary management of phosphorus is an important strategy for serum phosphate control in"
  },
  {
    "conteudo":"CKD. However, as compared to the many studies exploring pharmacological management of"
  },
  {
    "conteudo":"this electrolyte disorder (e.g. use of phosphate binders), the amount of evidence on the"
  },
  {
    "conteudo":"effectiveness of dietary control is low. The workgroup recommends future studies to better"
  },
  {
    "conteudo":"define the effect of this simple and cost-effective strategy. Examples of still unanswered"
  },
  {
    "conteudo":"questions are:"
  },
  {
    "conteudo":"● Study if dietary phosphorus restriction is able to normalize serum phosphate levels in"
  },
  {
    "conteudo":"PD patients."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 181"
  },
  {
    "conteudo":"● Research if dietary phosphorus intake level is associated with worse clinical outcomes"
  },
  {
    "conteudo":"such as cardiovascular events, progression of kidney disease or mortality."
  },
  {
    "conteudo":"● Study the benefits and potential adverse nutritional and metabolic effects of restricting"
  },
  {
    "conteudo":"dietary phosphorus and\/or limiting the intake of phosphate additives in patients with"
  },
  {
    "conteudo":"non-dialysis CKD stage 3-5 and maintenance dialysis."
  },
  {
    "conteudo":"● Study the effects of nutritional counseling with focus on organic vs inorganic"
  },
  {
    "conteudo":"phosphorus sources on the diet quality and metabolic balance of maintenance dialysis"
  },
  {
    "conteudo":"patients beyond serum phosphate control."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 182"
  },
  {
    "conteudo":"6.4 Statement on Potassium"
  },
  {
    "conteudo":"Dietary Potassium Amount"
  },
  {
    "conteudo":"6.4.1 In adults with CKD 3-5D and post- transplant, it is reasonable to adjust dietary"
  },
  {
    "conteudo":"potassium intake to maintain serum potassium within the normal range (OPINION)."
  },
  {
    "conteudo":"Dietary Potassium in Hyperkalemia"
  },
  {
    "conteudo":"6.4.2 In adults with CKD 3-5D and post-transplant who exhibit hyperkalemia, it is"
  },
  {
    "conteudo":"reasonable to consider lowering dietary potassium intake as a therapeutic strategy"
  },
  {
    "conteudo":"(OPINION)."
  },
  {
    "conteudo":"Potassium Intake for Hyperkalemia or Hypokalemia"
  },
  {
    "conteudo":"6.4.3 In adults with CKD 3-5 on MHD (2D) and post-transplant (OPINION) with"
  },
  {
    "conteudo":"either hyperkalemia or hypokalemia, we suggest that dietary or supplemental potassium"
  },
  {
    "conteudo":"intake be based on a patient’s individual needs and clinician judgment."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"As the main intracellular cation potassium plays a major role mediating cellular"
  },
  {
    "conteudo":"electrophysiology, vascular function and BP, and neuromuscular function. High or low serum"
  },
  {
    "conteudo":"potassium levels have been associated with muscular weakness, hypertension, ventricular"
  },
  {
    "conteudo":"arrhythmias, and death. The influence of dietary potassium consumption on serum potassium"
  },
  {
    "conteudo":"content is therefore of great clinical relevance. Because the mechanisms involved in potassium"
  },
  {
    "conteudo":"homeostasis and excretion (i.e. adrenergic system, insulin, aldosterone, and urinary clearance)"
  },
  {
    "conteudo":"are commonly impaired in patients with CKD and ESRD hyperkalemia is an especially salient"
  },
  {
    "conteudo":"concern. Dietary potassium is the focus of these recommendations (potassium binders were"
  },
  {
    "conteudo":"outside the scope of the current guideline)."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"There is a scarcity of studies on this topic and we found no clinical trials on how modifying"
  },
  {
    "conteudo":"diet can influence serum potassium in patients with CKD. The work group emphasizes that"
  },
  {
    "conteudo":"factors other than dietary intake influence serum potassium levels. These include medications,"
  },
  {
    "conteudo":"kidney function, hydration status, acid-base status, glycemic control, adrenal function, a"
  },
  {
    "conteudo":"catabolic state, or gastrointestinal (GI) problems like vomiting, diarrhea, constipation and"
  },
  {
    "conteudo":"bleeding. All these factors should be considered when formulating a strategy to keep the serum"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 183"
  },
  {
    "conteudo":"potassium within the normal range."
  },
  {
    "conteudo":"The consequences of dietary potassium intake in patients with CKD are not known. Indeed, no"
  },
  {
    "conteudo":"clinical trials were identified that directly examined the relationship between dietary potassium"
  },
  {
    "conteudo":"consumption and either serum levels or clinical outcomes. However, several studies used urine"
  },
  {
    "conteudo":"potassium excretion or other surrogates for dietary intake to assess the following outcomes."
  },
  {
    "conteudo":"While we acknowledge that urine potassium excretion may not necessarily represent dietary"
  },
  {
    "conteudo":"potassium in these patients, the studies showed:"
  },
  {
    "conteudo":"Mortality"
  },
  {
    "conteudo":"Data on the association between dietary and urinary potassium excretion and mortality in"
  },
  {
    "conteudo":"adults with CKD were mixed. A study in MHD (stage 5), found that compared to the lowest"
  },
  {
    "conteudo":"quartile of dietary potassium intake (879 mg or 22.5 mEq\/24hr) as measured by the Block"
  },
  {
    "conteudo":"Food Frequency Questionnaire, higher quartiles of intake were associated with a stepwise"
  },
  {
    "conteudo":"increase in risk of 5-year mortality (p-trend=0.03).474 Another study in pre-dialysis (Stage 2-4)"
  },
  {
    "conteudo":"there was no significant association noted between quartiles of urinary potassium excretion and"
  },
  {
    "conteudo":"all-cause mortality.475 Compared to the highest quartile of urinary potassium excretion (mean"
  },
  {
    "conteudo":"3600 mg or 92.1 mEq\/24hr) persons in the three lowest quartiles had higher all-cause mortality"
  },
  {
    "conteudo":"(hazard ratio (95% CI) of 1.53 (1.15-2.02), 1.7 (1.25-2.31), 1.71 (1.23-2.38) for quartiles 3, 2,"
  },
  {
    "conteudo":"and 1, respectively). Results remained similar even after using time-updated average urine"
  },
  {
    "conteudo":"potassium excretion.476"
  },
  {
    "conteudo":"CKD Progression"
  },
  {
    "conteudo":"Data on the association between urinary potassium excretion and CKD progression in adults"
  },
  {
    "conteudo":"with CKD were mixed. In Stage 2-4; pre-dialysis urinary potassium excretion in the highest"
  },
  {
    "conteudo":"quartile (≥67.1 mmol or 2617 mg\/24 h) was significantly associated with CKD progression"
  },
  {
    "conteudo":"(defined as incident ESRD or halving of eGFR from baseline) (1.59, 95% CI: 1.25-2.03)"
  },
  {
    "conteudo":"compared to levels in the lowest quartile (<39.4 mmol or 1541 mg\/24 h).475 In another study in"
  },
  {
    "conteudo":"Stage 2-4; pre-dialysis, baseline urinary potassium excretion was not significantly associated"
  },
  {
    "conteudo":"with kidney failure (defined as dialysis therapy or transplantation) even when using time-"
  },
  {
    "conteudo":"updated average urine potassium.476"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 184"
  },
  {
    "conteudo":"Nerve Function"
  },
  {
    "conteudo":"One randomized study examined the effects of dietary potassium restriction on progression of"
  },
  {
    "conteudo":"peripheral neuropathy in CKD patients. In 42 patients randomized to either dietary potassium"
  },
  {
    "conteudo":"restriction vs. usual diet (change in dietary potassium -854 vs. -343, p=0.35), potassium"
  },
  {
    "conteudo":"restriction was associated with stabilization of a neuropathy score (difference 0.4 ± 2.2,"
  },
  {
    "conteudo":"p<0.01) and several other nerve-related or general health scores over 24 months.477"
  },
  {
    "conteudo":"Special Discussions"
  },
  {
    "conteudo":"Research on this topic is complicated by the fact that potassium handling by the kidney will"
  },
  {
    "conteudo":"vary by disease state and CKD stage. In patients with pre-dialysis CKD the acute and chronic"
  },
  {
    "conteudo":"effects of dietary potassium loading are not consistently reflected in serum potassium levels"
  },
  {
    "conteudo":"due to compensatory mechanisms that are triggered to maintain homeostasis.478-480 Research"
  },
  {
    "conteudo":"and evidence on this area is also limited because of difficulties in obtaining reliable data on"
  },
  {
    "conteudo":"dietary potassium intake and absorption."
  },
  {
    "conteudo":"Potassium binders bind potassium in the gut and prevent hyperkalemia. In theory, these"
  },
  {
    "conteudo":"medications could lead to a more liberalized diet in terms of potassium (i.e. fruits and"
  },
  {
    "conteudo":"vegetables). However, none of the pivotal trials examining potassium binders evaluated dietary"
  },
  {
    "conteudo":"potassium intake, and currently there is no known study that investigates how potassium intake"
  },
  {
    "conteudo":"should be modified when taking potassium binders. Since the focus of this guideline was dietary"
  },
  {
    "conteudo":"intake, rather than pharmacological treatments, potassium binders were outside the scope of this"
  },
  {
    "conteudo":"guideline."
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Potassium is widely distributed in foods, but the main sources are fruits, vegetables,"
  },
  {
    "conteudo":"legumes and nuts. As these foods are major sources of fiber, vitamins, minerals and other"
  },
  {
    "conteudo":"important nutrients, efforts should be made to avoid restricting dietary potassium. In"
  },
  {
    "conteudo":"particular reduced fiber can lead to constipation which could lower potassium excretion."
  },
  {
    "conteudo":"For these issues, consult the guideline statements on fiber and fruit\/vegetable intake."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 185"
  },
  {
    "conteudo":"● When treating hyperkalemia clinicians are advised to first try and identify contributing"
  },
  {
    "conteudo":"factors that can be corrected such as a hypoinsulinemic state or certain medications. This is"
  },
  {
    "conteudo":"true in light of the physiological benefits high potassium intake may confer, such as"
  },
  {
    "conteudo":"putative antihypertensive effects.481 If hyperkalemia cannot be reversed, the next step is to"
  },
  {
    "conteudo":"identify the most important dietary sources of potassium by interviewing the patient and"
  },
  {
    "conteudo":"dietary recalls. Clinicians preferably assisted by a renal dietitian should educate patients"
  },
  {
    "conteudo":"about hyperkalemia regarding fruits, vegetables, and other foods with low potassium"
  },
  {
    "conteudo":"content that ideally still contain higher levels of fiber and other micronutrients. Published"
  },
  {
    "conteudo":"food composition tables can be helpful in this regard.482 In addition, potassium content in"
  },
  {
    "conteudo":"vegetables can be lowered by boiling and reductions in food taste and palatability"
  },
  {
    "conteudo":"associated with this strategy can be partially improved with the use of aromatic herbs.409,410"
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"It will be necessary to approach pre-dialysis and dialysis populations separately in light of the"
  },
  {
    "conteudo":"great differences in potassium handling."
  },
  {
    "conteudo":"• There is a need for studies on what constitutes an optimal dietary potassium intake and"
  },
  {
    "conteudo":"how dietary potassium intake influences blood potassium content and clinical"
  },
  {
    "conteudo":"outcomes."
  },
  {
    "conteudo":"• There is a need for studies investigating optimal means of adjusting dietary potassium"
  },
  {
    "conteudo":"intake when taking potassium binders."
  },
  {
    "conteudo":"• In addition, in patients on MHD the effect of the potassium bath concentration on"
  },
  {
    "conteudo":"cardiovascular risk, mortality, and other outcomes needs further elucidation."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 186"
  },
  {
    "conteudo":"6.5 Statements on Sodium"
  },
  {
    "conteudo":"Sodium Intake and Blood Pressure"
  },
  {
    "conteudo":"6.5.1 In adults with CKD 3-5 (non-dialyzed) (1B), maintenance dialysis (1C),"
  },
  {
    "conteudo":"and post-transplant (1C), we recommend limiting sodium intake to less than 100"
  },
  {
    "conteudo":"mmol\/day (or <2.3 g\/day) to reduce blood pressure and improve volume control."
  },
  {
    "conteudo":"Sodium Intake and Proteinuria"
  },
  {
    "conteudo":"6.5.2 In adults with CKD 3-5 (non-dialyzed), we suggest that reduced sodium intake"
  },
  {
    "conteudo":"(100 mmol\/day or <2.3 g\/day) be prescribed to reduce proteinuria (2A)."
  },
  {
    "conteudo":"Sodium Intake and Dry Body Weight"
  },
  {
    "conteudo":"6.5.3 In adults with CKD 3-5D, we suggest reduced sodium intake as an"
  },
  {
    "conteudo":"adjunctive lifestyle modification strategy to achieve better volume control and a"
  },
  {
    "conteudo":"more desirable body weight (2B)."
  },
  {
    "conteudo":"Rationale\/Background"
  },
  {
    "conteudo":"Sodium is an extracellular cation responsible for fluid homeostasis in the body.483"
  },
  {
    "conteudo":"Normovolemia is maintained through the action of the renin-angiotensin aldosterone system."
  },
  {
    "conteudo":"This system acts to adjust the quantity of sodium excreted by the body, and thereby ECF"
  },
  {
    "conteudo":"volume and arterial BP. Excess sodium intake is excreted in the urine and serum levels are"
  },
  {
    "conteudo":"tightly controlled. requiring normal kidney and blood vessel function.484 However, this system"
  },
  {
    "conteudo":"may be compromised with excessive sodium intake, and\/or inadequate excretion, which may"
  },
  {
    "conteudo":"occur with chronic kidney disease."
  },
  {
    "conteudo":"Chronic high sodium intake may impact on a number of physiological functions relating to"
  },
  {
    "conteudo":"the vasculature, heart, kidneys and sympathetic nervous system.485 Excessive sodium intake"
  },
  {
    "conteudo":"is thought to exert toxic effects on blood vessels through mediating factors such as oxidative"
  },
  {
    "conteudo":"stress, inflammation and endothelial dysfunction.486 Of particular interest in CKD is the role"
  },
  {
    "conteudo":"of sodium reduction in improving the pharmacological effect of antihypertensive medication"
  },
  {
    "conteudo":"thereby controlling hypertension."
  },
  {
    "conteudo":"In the general population, short-term intervention studies show significant reductions in BP"
  },
  {
    "conteudo":"(hypertensive subgroup, reductions of 5.8 mmHg systolic BP and 2.82 mmHg diastolic BP)"
  },
  {
    "conteudo":"with 100mmol\/d reduction in sodium intake.487 Indications from a small number of long-"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 187"
  },
  {
    "conteudo":"term studies (>6 months) suggest a benefit for CV-morbidity and mortality, although the"
  },
  {
    "conteudo":"studies were underpowered to adequately examine these outcomes.488 The following will"
  },
  {
    "conteudo":"explore the evidence within CKD."
  },
  {
    "conteudo":"Detailed Justification"
  },
  {
    "conteudo":"Overall, the evidence for reducing sodium intake comes from randomized controlled trials of"
  },
  {
    "conteudo":"short duration and typically small sample size. As a result, there is a focus on clinical"
  },
  {
    "conteudo":"markers such as BP, inflammation, body weight, fluid and proteinuria. There is limited"
  },
  {
    "conteudo":"evaluation of hard outcomes, which thereby rely upon observational evidence. In addition,"
  },
  {
    "conteudo":"the certainty of evidence for sodium reduction is limited by imprecision and risk of bias,"
  },
  {
    "conteudo":"particularly selection, attribution and performance bias."
  },
  {
    "conteudo":"Five randomized controlled trials, 1 parallel489 and 4 cross-over studies490-493 examined the"
  },
  {
    "conteudo":"effects of reduced dietary sodium intake in CKD (Stage 2 to 5, non-dialysis). The cross-"
  },
  {
    "conteudo":"over studies utilized supplemental sodium491-493 or provided meals490 on the background of"
  },
  {
    "conteudo":"a low sodium diet to generate consistent intake in the high (180 mmol to 200mmol\/d, with"
  },
  {
    "conteudo":"~100-120mmol\/d supplemented) vs low sodium intake group (placebo, total 50 to 0 mmol"
  },
  {
    "conteudo":"sodium per day). The parallel RCT was the longest study duration (six months) conducted"
  },
  {
    "conteudo":"in a sample of Bangladeshi immigrants in the UK (n=48).489 Participants were randomized"
  },
  {
    "conteudo":"to a tailored intervention including cooking classes modifying traditional cultural recipes"
  },
  {
    "conteudo":"together with regular telephone calls with a dietitian. From a baseline sodium intake of"
  },
  {
    "conteudo":"approximately 260mmol, the intervention group achieved 138mmol\/day (a reduction of"
  },
  {
    "conteudo":"over 120mmol), whilst usual care stayed largely stable (to 247 mmol\/d)."
  },
  {
    "conteudo":"Two more recent studies build upon this evidence base and include a parallel494 and a"
  },
  {
    "conteudo":"crossover trial.495 Meuleman and colleagues conducted a 3 month open-label RCT, n=138"
  },
  {
    "conteudo":"adults with CKD, hypertension, and high urinary sodium excretion (≥120 mmol\/day).494 The"
  },
  {
    "conteudo":"intervention focused on self-management advice to reduce sodium (goal <100mmol\/day) and"
  },
  {
    "conteudo":"BP monitoring, or usual care. In the most recent cross-over trial, Saran et al. evaluated the"
  },
  {
    "conteudo":"effect of sodium restriction <2g\/day vs usual diet for 4 weeks (with a 2-week washout in-"
  },
  {
    "conteudo":"between) in Stage 3 and 4 CKD.495 This study improved upon previous cross-over trials as it"
  },
  {
    "conteudo":"used dietary counselling, rather than sodium supplementation, to achieve the difference"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 188"
  },
  {
    "conteudo":"between usual and sodium restricted intakes."
  },
  {
    "conteudo":"Four trials were conducted in the maintenance dialysis population. One RCT in peritoneal"
  },
  {
    "conteudo":"dialysis (PD),496 and two RCTs in MHD497, 498 and one non-randomized trial in both PD and"
  },
  {
    "conteudo":"MHD.499 In the MHD study, there was no significant reduction in BP.498 The difference with"
  },
  {
    "conteudo":"this study, compared to all others in dialysis, is that dietary prescription (rather than"
  },
  {
    "conteudo":"supplemental sodium) was used to achieve a modest reduction of intake (goal 34 mmol\/d"
  },
  {
    "conteudo":"lower than usual intake). This compares to the other interventions in maintenance dialysis"
  },
  {
    "conteudo":"using sodium supplementation, which achieved a much larger gradient of difference in"
  },
  {
    "conteudo":"sodium intake between low and high intake groups (100mmol.d or 2.3g sodium difference)."
  },
  {
    "conteudo":"One RCT was undertaken in patients post kidney transplantation.500 This was a parallel RCT"
  },
  {
    "conteudo":"of a 12-week intervention that included counselling by a dietitian for a target intake of 80-"
  },
  {
    "conteudo":"100mmol\/day compared with usual care. This trial demonstrated a significant reduction in"
  },
  {
    "conteudo":"sodium intake in the intervention group (from 190±75 mmol\/d to 106±48 mmol\/d) through"
  },
  {
    "conteudo":"dietary counselling, with no significant change in the usual care group (191±117 mmol\/d to"
  },
  {
    "conteudo":"237±113 mmol\/d)"
  },
  {
    "conteudo":"In the vast majority of trials, the target sodium restriction was 80-100 mmol\/day (or 2-"
  },
  {
    "conteudo":"2.3g\/day). However, there was a lack of consensus as to what constitutes a high sodium"
  },
  {
    "conteudo":"intake, which was either based on usual intake, or providing supplemental sodium to ensure a"
  },
  {
    "conteudo":"consistently high sodium intake, around 200mmol or 4g sodium per day."
  },
  {
    "conteudo":"Mortality, CKD Progression and Cardiovascular Events"
  },
  {
    "conteudo":"There is insufficient evidence to make a statement on reduced sodium intake and kidney"
  },
  {
    "conteudo":"disease progression, mortality and cardiovascular events. The evidence for clinical endpoints"
  },
  {
    "conteudo":"is derived from observational studies as there were no RCTs in sodium reduction in CKD that"
  },
  {
    "conteudo":"reported CKD progression cardiovascular events, mortality outcomes. This is attributable to"
  },
  {
    "conteudo":"the small sample sizes and the longest trial duration only six months.489"
  },
  {
    "conteudo":"The post-hoc analysis of two observational cohort studies showed mixed results investigating"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 189"
  },
  {
    "conteudo":"the association between sodium intake (measured by dietary recall) and subsequent mortality"
  },
  {
    "conteudo":"in MHD501 and PD patients.502 The retrospective cohort study in 303 PD patients in Japan"
  },
  {
    "conteudo":"indicated that low sodium intake was significantly associated with higher overall and"
  },
  {
    "conteudo":"cardiovascular mortality. However, this study was open to indication bias as sodium intake"
  },
  {
    "conteudo":"was also associated with higher LBM, younger age and higher BMI. In contrast, in a post-hoc"
  },
  {
    "conteudo":"analysis of a prospective cohort of 1770 MHD patients, McCausland et al. found higher"
  },
  {
    "conteudo":"dietary sodium intake associated with increased mortality.501"
  },
  {
    "conteudo":"More consistent results were demonstrated from a large high-quality prospective cohort"
  },
  {
    "conteudo":"(CRIC study) of predialysis Stage 2-4, using urinary sodium excretion. In He et al., 24-hour"
  },
  {
    "conteudo":"urinary sodium excretion was associated with greater all-cause mortality and CKD"
  },
  {
    "conteudo":"progression (defined as incident ESRD or halving of eGFR from baseline).475 Sodium"
  },
  {
    "conteudo":"excretion was also associated with composite CVD (heart failure, myocardial infarction,"
  },
  {
    "conteudo":"stroke).503"
  },
  {
    "conteudo":"Blood pressure"
  },
  {
    "conteudo":"Overall, sodium reduction probably reduces BP in kidney disease (moderate certainty"
  },
  {
    "conteudo":"evidence). This evidence review included 9 small (n=20 to n=52) randomized clinical trials"
  },
  {
    "conteudo":"(6 were cross-over trials) of short duration (1 week to 6 months), evaluating the effect on"
  },
  {
    "conteudo":"reducing sodium intake (typically to a level of <2g or 90mmol\/d) on BP. In fact, lower"
  },
  {
    "conteudo":"sodium intake significantly decreased systolic BP in all but one study,498 which reduced"
  },
  {
    "conteudo":"intake by only 34mmol\/d, compared with >90 mmol\/d from the other trials. However, the"
  },
  {
    "conteudo":"certainty of evidence was limited by risk of bias, particularly risk of selection, attribution and"
  },
  {
    "conteudo":"performance bias. When evaluating the evidence across stages of CKD, the vast amount of"
  },
  {
    "conteudo":"evidence exists in pre-dialysis CKD, however the BP benefits were also apparent in trials in"
  },
  {
    "conteudo":"dialysis496, 498, 499, 504and transplantation populations.500"
  },
  {
    "conteudo":"Although this review was unable to derive a summary estimate, a Cochrane review on"
  },
  {
    "conteudo":"this topic published in 2015 showed dietary sodium reduction (MD -105.9, 95% CI -"
  },
  {
    "conteudo":"119.2 to - 92.5mmol\/day) resulted in significant reduction in systolic BP (MD -8.76,"
  },
  {
    "conteudo":"95% CI -11.35 to - 3.80 mm Hg). These short-term studies showing clinically"
  },
  {
    "conteudo":"meaningful systolic BP reductions ranging from 2-12mmHg systolic BP and 1-8mmHg"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 190"
  },
  {
    "conteudo":"diastolic BP in trials one week to six months in duration.505"
  },
  {
    "conteudo":"Inflammatory Markers"
  },
  {
    "conteudo":"Sodium reduction may make little to no difference to inflammation (low certainty evidence)."
  },
  {
    "conteudo":"Two RCTs, a parallel RCT in MHD,498 and a crossover in Stage 3 and 4,491 investigated the"
  },
  {
    "conteudo":"impact of sodium restriction on inflammation, measured by CRP, IL-6, TNF-alpha. In the"
  },
  {
    "conteudo":"Telini study there was a significant reduction in all inflammatory markers within the"
  },
  {
    "conteudo":"intervention group, however not reported between group differences (and no difference"
  },
  {
    "conteudo":"within control group).498 The single crossover study in Stage 3-4 showed no difference in"
  },
  {
    "conteudo":"inflammation comparing high and low sodium intake.491"
  },
  {
    "conteudo":"Body weight and fluid"
  },
  {
    "conteudo":"Sodium restriction may slightly reduce body weight and total body fluid in non-dialysis"
  },
  {
    "conteudo":"CKD (low certainty evidence). However, it is uncertain whether sodium restriction reduces"
  },
  {
    "conteudo":"body weight and body water in dialysis. The evidence from non-dialysis CKD comes from"
  },
  {
    "conteudo":"two randomized-crossover trials, one using sodium supplementation to compare intake of"
  },
  {
    "conteudo":"60-80mmol\/d to 180-200mmol\/d for 2 weeks491 together with a more recent investigation"
  },
  {
    "conteudo":"by Saran et al. evaluating the effect of sodium restriction <2g\/day vs usual diet for 4 weeks"
  },
  {
    "conteudo":"(with a 2-week washout in-between).495 Both trials demonstrated a reduction in"
  },
  {
    "conteudo":"extracellular volume. Furthermore, in maintenance dialysis, two RCTS demonstrated no"
  },
  {
    "conteudo":"significant difference in body weight with salt restriction in peritoneal496 or both"
  },
  {
    "conteudo":"hemodialysis and peritoneal dialysis.506 In one non-randomized study in hemodialysis, the"
  },
  {
    "conteudo":"group advised to restrict sodium (<3 g \/day) and fluid (<1 L\/d) intake demonstrated within"
  },
  {
    "conteudo":"group decrease in interdialytic fluid gain, but there was no change in the control group, and"
  },
  {
    "conteudo":"between group difference was not significant.497"
  },
  {
    "conteudo":"Kidney function (including proteinuria)"
  },
  {
    "conteudo":"Restriction of sodium intake may slightly reduce kidney function markers of creatinine"
  },
  {
    "conteudo":"clearance490, 492, 493, 504 and eGFR507 demonstrated in short-term cross-over trials in the stage"
  },
  {
    "conteudo":"1-5 non-dialysis population (low certainty evidence). In the single parallel RCT over 6"
  },
  {
    "conteudo":"months of sodium restriction, deBrito-Ashurst found no difference in eGFR.489 The"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 191"
  },
  {
    "conteudo":"inconsistency in results may be due to the short-term cross-over trials demonstrating acute"
  },
  {
    "conteudo":"hyper filtration response to low sodium intake, compared with the longer-term parallel trial,"
  },
  {
    "conteudo":"reflecting a more clinically stable circumstance."
  },
  {
    "conteudo":"Restriction of sodium intake may reduce proteinuria as demonstrated in 3 randomized cross-"
  },
  {
    "conteudo":"over trials.491-493, 507 This evidence is supported by further parallel RCTs and observational"
  },
  {
    "conteudo":"studies. Meuleman et al. demonstrated a reduction in proteinuria over 3 months self-"
  },
  {
    "conteudo":"management intervention using a sodium intake <100mmol\/d that reversed to baseline"
  },
  {
    "conteudo":"proteinuria after cessation of the dietary sodium restriction.494 In addition, in a post-hoc"
  },
  {
    "conteudo":"analyses of clinical trials (REIN I & II) in proteinuric patients with established CKD have"
  },
  {
    "conteudo":"demonstrated participants consuming a higher sodium diet was associated with an increased"
  },
  {
    "conteudo":"risk of progressing to ESKD compared to a lower sodium diet <100mmol\/d.508"
  },
  {
    "conteudo":"Implementation considerations"
  },
  {
    "conteudo":"● Achieving a reduced sodium intake in CKD is recommended, however can be"
  },
  {
    "conteudo":"particularly challenging to achieve.509 This is a result of the need to navigate a"
  },
  {
    "conteudo":"complex interplay between individual food choice and food supply, together with a"
  },
  {
    "conteudo":"range of other dietary recommendations that come with CKD. As sodium is"
  },
  {
    "conteudo":"consumed largely from processed foods, the World Health Organization has"
  },
  {
    "conteudo":"initiatives for reducing sodium content in manufactured foods among the top"
  },
  {
    "conteudo":"priorities to combat non- communicable diseases.510Consuming a low sodium diet"
  },
  {
    "conteudo":"generally requires education and skill development (cooking, label reading) and"
  },
  {
    "conteudo":"explicit choice to consume a low sodium diet. Therefore, a concerted and multi-"
  },
  {
    "conteudo":"faceted intervention strategy is required to support achieving this intake in clinical"
  },
  {
    "conteudo":"practice. This includes targeting individual behavior change for dietary choices,"
  },
  {
    "conteudo":"together with a wider public health strategy to reduce availability of sodium in the"
  },
  {
    "conteudo":"food supply.510"
  },
  {
    "conteudo":"● The interventions undertaken in clinical trials of sodium reduction have limited"
  },
  {
    "conteudo":"applicability when translating into practice. Many trials to date have used sodium"
  },
  {
    "conteudo":"supplementation or provided foods to enhance adherence in short-term"
  },
  {
    "conteudo":"effectiveness studies.510 Investigations of efficacy and behavioral interventions to"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 192"
  },
  {
    "conteudo":"adopt low sodium intakes in real-life settings are limited in the literature. Of those"
  },
  {
    "conteudo":"that exist, the evidence is either short term (< 6 months) or demonstrate that"
  },
  {
    "conteudo":"achieving a reduced sodium intake is only apparent whilst receiving active"
  },
  {
    "conteudo":"intervention.494 The challenge for the future is to develop an evidence-base to"
  },
  {
    "conteudo":"inform successful strategies to support long-term adherence to dietary sodium"
  },
  {
    "conteudo":"reduction."
  },
  {
    "conteudo":"● Issues with sodium intake assessment: Measuring sodium intake and thereby"
  },
  {
    "conteudo":"accurately evaluating adherence to recommendations is extremely challenging in"
  },
  {
    "conteudo":"practice. Sodium intake can be measured in objective (urine collection over 24 hours"
  },
  {
    "conteudo":"or spot sample) and self-report (dietary recall) or a combination of methods. Urinary"
  },
  {
    "conteudo":"sodium excretion as a surrogate measure of intake assumes 1) a stable intake reflected"
  },
  {
    "conteudo":"in a single 24hour collection, 2) sodium excretion is a direct reflection of intake. It is"
  },
  {
    "conteudo":"this latter assumption which has been recently challenged by Titze and colleagues,"
  },
  {
    "conteudo":"who have identified a sodium storage pool in the skin and a wide disparity between"
  },
  {
    "conteudo":"sodium intake and excretion day to day.511 Increasing the number of 24-hour urinary"
  },
  {
    "conteudo":"collections may improve the accuracy to partially overcome these concerns, however"
  },
  {
    "conteudo":"it is not practical in clinical practice. Self-reported dietary assessment methods are"
  },
  {
    "conteudo":"prone to reporting bias and can be time consuming to collect and require technical"
  },
  {
    "conteudo":"expertise in the analysis. A panel of methods is therefore recommended, as no one"
  },
  {
    "conteudo":"method is ideal to adequately assess adherence.510"
  },
  {
    "conteudo":"● Sodium relative to potassium intake: Recent observational evidence suggests that the"
  },
  {
    "conteudo":"ratio of sodium-to-potassium intake may be as important, if not more important than"
  },
  {
    "conteudo":"lower sodium intake alone in CKD.475 This is the premise of the DASH- Sodium trial,"
  },
  {
    "conteudo":"and has demonstrated benefits in the general population, with sodium reduction"
  },
  {
    "conteudo":"providing additive benefit in BP reduction to the DASH diet.512 In hypertensive"
  },
  {
    "conteudo":"adults, post-hoc analysis of clinical trials indicate sodium-to-potassium ratio may be"
  },
  {
    "conteudo":"more effective in lowering BP than lowering sodium or increasing potassium as single"
  },
  {
    "conteudo":"interventions.513 However, there are unknown safety aspects in CKD, particularly with"
  },
  {
    "conteudo":"the risk of hyperkalemia. Investigating the relative benefit of sodium reduction"
  },
  {
    "conteudo":"compared to potassium intake is beyond the scope of the current guidelines however"
  },
  {
    "conteudo":"warrants further research. Evidence for Potassium recommendations is addressed"
  },
  {
    "conteudo":"within these guidelines."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 193"
  },
  {
    "conteudo":"• Currently, there is too much uncertainty in the evidence to advice on the effectiveness"
  },
  {
    "conteudo":"of sodium restriction based on specific thresholds of proteinuria. However, this"
  },
  {
    "conteudo":"intervention appears to be effective over a large range of proteinuria."
  },
  {
    "conteudo":"Future research"
  },
  {
    "conteudo":"● Clinical trials to investigate behavioral interventions, utilizing approaches that are"
  },
  {
    "conteudo":"patient-centered and support the adoption of long-term strategies for reducing sodium"
  },
  {
    "conteudo":"intake. In the design of behavioral interventions, incorporating less processed foods,"
  },
  {
    "conteudo":"including cooking skills, label reading, and provision of interventions which tailor to a"
  },
  {
    "conteudo":"range of literacy levels."
  },
  {
    "conteudo":"● Clinical trials investigating the safety and effectiveness of low sodium relative to"
  },
  {
    "conteudo":"increased potassium intake on CVD and CKD outcomes."
  },
  {
    "conteudo":"● Clinical trials to evaluate the long-term effectiveness of reduced sodium intake on hard"
  },
  {
    "conteudo":"outcomes."
  },
  {
    "conteudo":"● Enhance objective markers of intake, and\/or improve self-report options with"
  },
  {
    "conteudo":"technology advancement."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 194"
  },
  {
    "conteudo":"BIOGRAPHIC AND DISCLOSURE INFORMATION"
  },
  {
    "conteudo":"Jerrilynn D. Burrowes, PhD, RD, CDN, FNKF"
  },
  {
    "conteudo":"Dr. Burrowes is Professor of Nutrition and Chair of the Department of Nutrition at Long Island"
  },
  {
    "conteudo":"University (LIU) Post in Brookville, NY. Dr. Burrowes has dozens of publications in refereed"
  },
  {
    "conteudo":"journals and she has been an invited speaker at numerous professional meetings and"
  },
  {
    "conteudo":"conferences on nutrition in kidney disease. She is the co-editor of the 1st and 2nd editions of the"
  },
  {
    "conteudo":"textbook entitled, Nutrition in Kidney Disease, and a 3rd edition is currently being planned. Dr."
  },
  {
    "conteudo":"Burrowes has held many leadership and advisory roles in professional organizations and"
  },
  {
    "conteudo":"societies, and she has served on numerous association committees. She was recently elected"
  },
  {
    "conteudo":"Council Member to the ISRNM for the 2018-2020 term. For the past eight years, Dr."
  },
  {
    "conteudo":"Burrowes has served as the Editor-in-Chief for the Journal of Renal Nutrition (JRN). She"
  },
  {
    "conteudo":"received the Recognized Renal Dietitian Award and the Joel D. Kopple Award from the NKF"
  },
  {
    "conteudo":"Council on Renal Nutrition, and the Outstanding Service Award from the Renal Practice Group"
  },
  {
    "conteudo":"of the Academy of Nutrition & Dietetics. Dr. Burrowes has particular interest in the factors"
  },
  {
    "conteudo":"that influence appetite and their effect on health outcomes in dialysis patients; the influence of"
  },
  {
    "conteudo":"culture and ethnicity on dietary adherence in dialysis patients; and the use of complementary"
  },
  {
    "conteudo":"and alternative therapies for people with kidney failure. Dr. Burrowes earned her Bachelor’s"
  },
  {
    "conteudo":"degree in biology\/pre-medicine from Fisk University in Nashville, TN; her M.S. degree in"
  },
  {
    "conteudo":"foods, nutrition and dietetics from New York University; and her Ph.D. in nutrition from New"
  },
  {
    "conteudo":"York University."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Burrowes reports no relevant financial relationships."
  },
  {
    "conteudo":"Laura Byham-Gray, PhD, RDN, FNKF"
  },
  {
    "conteudo":"Dr. Byham-Gray is a Professor and Vice Chair for Research in the Department of Nutritional"
  },
  {
    "conteudo":"Sciences, School of Health Professions at Rutgers University. She has received several"
  },
  {
    "conteudo":"extramural research grants from the federal agencies to investigate energy expenditure and"
  },
  {
    "conteudo":"protein-energy wasting in patients on renal replacement therapies. Dr. Byham-Gray has held"
  },
  {
    "conteudo":"numerous elected and appointed positions at the national, state, and local levels of National"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 195"
  },
  {
    "conteudo":"Kidney Foundation, The American Society of Parenteral and Enteral Nutrition, and the"
  },
  {
    "conteudo":"Academy of Nutrition & Dietetics. She has also served as the associate editor for the National"
  },
  {
    "conteudo":"Kidney Foundation publication, the Journal of Renal Nutrition. Dr. Byham-Gray was the chief"
  },
  {
    "conteudo":"editor for two books: Nutrition in Kidney Disease (Springer Publications, 2014), and the A"
  },
  {
    "conteudo":"Clinical Guide to Nutrition Care in Kidney Disease (Academy of Nutrition and Dietetics,"
  },
  {
    "conteudo":"2013) and has over 100 peer-reviewed articles and presentations to her credit."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Byham-Gray has no relevant financial interests to disclose."
  },
  {
    "conteudo":"Katrina Campbell, PhD, RD"
  },
  {
    "conteudo":"Dr. Campbell is an Associate Professor at Bond University and Principal Research Fellow"
  },
  {
    "conteudo":"(Nutrition and Dietetics) at Princess Alexandra Hospital, Brisbane, Australia. As an academic"
  },
  {
    "conteudo":"dietitian with a career spanning clinical practice, teaching and research, Katrina has been"
  },
  {
    "conteudo":"dedicated to advancing the evidence base for the nutrition management in kidney disease. Her"
  },
  {
    "conteudo":"work includes lifestyle interventions in CKD, investigating the role of dietary patterns in the"
  },
  {
    "conteudo":"trajectory of CKD, nutrition status assessment and workforce issues, published in over 100"
  },
  {
    "conteudo":"peer-reviewed papers. In an effort to translate evidence to practice, Dr Campbell has authored"
  },
  {
    "conteudo":"numerous clinical guidelines and systematic reviews, evaluated the impact of research"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 196"
  },
  {
    "conteudo":"translation changing models of care, including co-design and evaluation for the delivery of"
  },
  {
    "conteudo":"lifestyle interventions using technology."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Campbell reports no relevant financial relationships."
  },
  {
    "conteudo":"Juan-Jesus Carrero, Pharm, PhD Pharm, PhD Med, MBA (section Chair)"
  },
  {
    "conteudo":"Dr. Carrero is a Professor of Renal Epidemiology at the Department of Medical Epidemiology"
  },
  {
    "conteudo":"and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Dr. Carrero is currently the co-"
  },
  {
    "conteudo":"director of education outreach program at the International Society of Renal Nutrition and"
  },
  {
    "conteudo":"Metabolism (ISRNM) and the chair of the European Renal Nutrition (ERN) working group at"
  },
  {
    "conteudo":"the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)."
  },
  {
    "conteudo":"In 2014 he received the Joel Kopple Award from the National Kidney Foundation for his work"
  },
  {
    "conteudo":"in Renal Nutrition Research. He has authored more than 350 peer-reviewed publications, and"
  },
  {
    "conteudo":"his research interests include chronic kidney disease epidemics, pharmacosafety and protein-"
  },
  {
    "conteudo":"energy wasting in chronic kidney disease, with special emphasis on the areas of body"
  },
  {
    "conteudo":"composition, diet quality and pro-catabolic endocrine disorders. He sits on the board of the"
  },
  {
    "conteudo":"Center for Gender Medicine at Karolinska Institutet and serves as associate editor for the"
  },
  {
    "conteudo":"Journal of Renal Nutrition, Journal of Nephrology and Nephrology-Dialysis and"
  },
  {
    "conteudo":"Transplantation."
  },
  {
    "conteudo":"Disclosures: Dr. Carrero reported no relevant financial disclosures."
  },
  {
    "conteudo":"Winnie Chan, PhD, RD, FNKF"
  },
  {
    "conteudo":"Dr. Chan is a Specialist Renal Dietician, a Dietetic Research and Postgraduate Education Lead,"
  },
  {
    "conteudo":"and a Dietician Representative of Non-Medical Clinical Academic Research Group at Queen"
  },
  {
    "conteudo":"Elizabeth Hospital Birmingham, United Kingdom. Dr Chan received her Bachelor’s Degree in"
  },
  {
    "conteudo":"Nutrition and Postgraduate Diploma in Dietetics from King’s College, University of London."
  },
  {
    "conteudo":"She obtained her PhD from the University of Birmingham, co-funded by a National Health"
  },
  {
    "conteudo":"Service West Midlands Strategic Health Authority PhD research training fellowship, and a"
  },
  {
    "conteudo":"research grant from the British Renal Society. She has fostered particular clinical and research"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 197"
  },
  {
    "conteudo":"interests in kidney transplantation. Her research work focused on investigating the role of"
  },
  {
    "conteudo":"nutritional factors and body composition on clinical and quality of life outcomes in kidney"
  },
  {
    "conteudo":"transplant recipients. In addition to publishing in well-respected journals, Dr Chan has"
  },
  {
    "conteudo":"authored the Practice-based Evidence in Nutrition (PEN) Knowledge Pathway in Intradialytic"
  },
  {
    "conteudo":"Parenteral Nutrition, The Global Resource for Nutrition Practice. She serves on the editorial"
  },
  {
    "conteudo":"board of Journal of Renal Nutrition. She has delivered numerous presentations and invited"
  },
  {
    "conteudo":"lectures in her areas of clinical and research expertise, including award-winning research at"
  },
  {
    "conteudo":"national and international conferences. She is an active research grant review panel member"
  },
  {
    "conteudo":"for Kidney Research UK and the British Renal Society. To date, she is serving as an Expert"
  },
  {
    "conteudo":"Advisor for the National Institute for Health and Care Excellence (NICE) Centre for"
  },
  {
    "conteudo":"Guidelines in Renal Disease."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Chan reports no relevant financial relationships."
  },
  {
    "conteudo":"Lilian Cuppari, PhD (Chair)"
  },
  {
    "conteudo":"Dr. Cuppari is a dietitian who completed a master’s degree in nutrition and PhD at Federal"
  },
  {
    "conteudo":"University of São Paulo, Brazil. She is currently affiliate professor in the Department of"
  },
  {
    "conteudo":"Medicine\/ Division of Nephrology at Federal University of São Paulo, and a supervisor of"
  },
  {
    "conteudo":"nutrition in the renal unit of Oswaldo Ramos Foundation- Kidney Hospital in São Paulo"
  },
  {
    "conteudo":"serving as the leader of the research and clinical practice group on nutrition and kidney disease."
  },
  {
    "conteudo":"She has published extensively in the field of nutrition and chronic kidney disease in the form of"
  },
  {
    "conteudo":"journal articles, books and book chapters. She is currently a member of the editorial board of"
  },
  {
    "conteudo":"Journal of Renal Nutrition."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Lilian Cuppari reports no relevant financial relationships"
  },
  {
    "conteudo":"Denis Fouque, MD, PhD"
  },
  {
    "conteudo":"Dr. Fouque is Professor of Nephrology at the University Claude Bernard Lyon1, and Chief of"
  },
  {
    "conteudo":"the Division of Nephrology at the Centre Hospitalier Lyon Sud in Lyon, France. He is the past"
  },
  {
    "conteudo":"Research Vice President (Health Affairs) at the Université Claude Bernard Lyon, the largest"
  },
  {
    "conteudo":"medical school in France (2012-2016). Dr Fouque has published 320 papers, including"
  },
  {
    "conteudo":"reviews, meta-analyses and 21 book chapters, among which 2 chapters in The Kidney, Brenner"
  },
  {
    "conteudo":"Page 199"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD"
  },
  {
    "conteudo":"and Rector, 2012 and 2015. His current h factor is 60. His research fields are in nutrition and"
  },
  {
    "conteudo":"metabolism in chronic kidney disease and dialysis. He is director of the adipocyte dysfunction"
  },
  {
    "conteudo":"research group in CARMEN at the University Claude Bernard Lyon1. Dr Fouque also got"
  },
  {
    "conteudo":"training in Evidence based Medicine by founding the Cochrane Collaboration Renal Group in"
  },
  {
    "conteudo":"1997 and being the Co-ordinating Editor until 2001. Dr Fouque was President of the"
  },
  {
    "conteudo":"International Society for Renal Nutrition and Metabolism (2004–2006), co-editor-in-Chief of"
  },
  {
    "conteudo":"the Journal of Renal Nutrition (2003-2011), chairman of the ERA-EDTA Nutrition Guideline"
  },
  {
    "conteudo":"(2007) and vice-chairman of the European Renal Best Practice group of ERA-EDTA until"
  },
  {
    "conteudo":"2017. He is the chairman of the European Nutrition working group of the ERA-EDTA, and the"
  },
  {
    "conteudo":"current Editor-in-chief of Nephrology Dialysis Transplantation journal."
  },
  {
    "conteudo":"Allon Friedman, MD"
  },
  {
    "conteudo":"Dr. Friedman is Associate Professor of Medicine at Indiana University School of Medicine in"
  },
  {
    "conteudo":"Indianapolis and director of one of its affiliated dialysis units. Dr. Friedman trained at Tufts"
  },
  {
    "conteudo":"University and the USDA Human Nutrition Research Center in Boston prior to joining the"
  },
  {
    "conteudo":"Indiana University nephrology faculty. Dr. Friedman has published dozens of articles,"
  },
  {
    "conteudo":"editorials, and book chapters on topics related to the overlap between nutrition and kidney"
  },
  {
    "conteudo":"disease and has received grant funding from the NIH, National Kidney Foundation, and other"
  },
  {
    "conteudo":"institutions. One current area of research interest involves the impact and treatment of obesity-"
  },
  {
    "conteudo":"related kidney disease. He has played a leadership role at the American Society of Nephrology"
  },
  {
    "conteudo":"and the American Association of Kidney Patients and is currently a council member of the"
  },
  {
    "conteudo":"International Society of Renal Nutrition and Metabolism."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Friedman reports no relevant financial relationships."
  },
  {
    "conteudo":"Sana Ghaddar, PhD, RDN"
  },
  {
    "conteudo":"Dr. Ghaddar is a renal dietitian at DaVita Health Care. She has over 22 years of experience in"
  },
  {
    "conteudo":"the renal and clinical dietetics field. Dr. Ghaddar taught at two private universities for over 15"
  },
  {
    "conteudo":"years and mentored several PhD students on their research studies. She served as a member of"
  },
  {
    "conteudo":"the K\/DOQI Anemia Workgroup Expert Panel. She has several publications in well-respected"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 200"
  },
  {
    "conteudo":"peer-reviewed journals, as well as editorials and book chapters. She has served as a member of"
  },
  {
    "conteudo":"the editorial board for Journal of Renal Nutrition and Archives of Clinical Nephrology, and a"
  },
  {
    "conteudo":"reviewer for several peer-reviewed journals. She presented at various national and international"
  },
  {
    "conteudo":"conferences, as an invited speaker. Dr. Ghaddar has a special interest in nutrition in CKD, fluid"
  },
  {
    "conteudo":"control and phosphorus balance, as well as in cognitive behavioral counseling to improve"
  },
  {
    "conteudo":"patient outcomes."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Ghaddar reports no relevant financial relationships."
  },
  {
    "conteudo":"D. Jordi Goldstein-Fuchs, DSc, APRN, NP-C, RD"
  },
  {
    "conteudo":"Dr. Goldstein-Fuchs is a nephrology nurse practitioner and kidney nutrition specialist with the"
  },
  {
    "conteudo":"Pediatric Nephrology Division at Lucile Packard Hospital Stanford. She has worked with"
  },
  {
    "conteudo":"adults within all stages of kidney disease and more recently has expanded her expertise to the"
  },
  {
    "conteudo":"realm of pediatric nephrology. Dr. Goldstein-Fuchs has been engaged in both basic and clinical"
  },
  {
    "conteudo":"research and has an active publication record pertaining to nutrition and metabolism in renal"
  },
  {
    "conteudo":"disease. She is Editor Emeritus of the Journal of Renal Nutrition, having served as Co-Editor-"
  },
  {
    "conteudo":"In Chief for 15 yrs. She has served on the Cardiovascular and Diabetes KDOQI Guideline"
  },
  {
    "conteudo":"committees and is a Fellow of the National Kidney Foundation."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Goldstein-Fuchs reports no relevant financial relationships."
  },
  {
    "conteudo":"T. Alp Ikizler, MD (Chair)"
  },
  {
    "conteudo":"Dr. Ikizler is the Director of Division of Nephrology and Professor of Medicine at the"
  },
  {
    "conteudo":"Vanderbilt University School of Medicine (VUSM) in Nashville, Tennessee. He also holds the"
  },
  {
    "conteudo":"Catherine McLaughlin Hakim Chair in Vascular Biology. He is a member of American Society"
  },
  {
    "conteudo":"of Clinical Investigation (ASCI), ASCI Advocacy Committee and FASEB Board of Directors"
  },
  {
    "conteudo":"as the ASCI representative since 2017. Dr. Ikizler’s clinical interests and expertise are focused"
  },
  {
    "conteudo":"on the care of the patients with CKD, end-stage renal disease on maintenance dialysis and"
  },
  {
    "conteudo":"acute kidney injury. He has significant research and clinical interest in nutritional and"
  },
  {
    "conteudo":"metabolic aspects of acute and chronic disease states. Dr. Ikizler was the Medical Director and"
  },
  {
    "conteudo":"CEO of the Vanderbilt University Medical Center Outpatient Dialysis unit between 2000 and"
  },
  {
    "conteudo":"2012. He is currently an Associate editor for Kidney International, and he was the Past"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 201"
  },
  {
    "conteudo":"President of International Society of Renal Nutrition and Metabolism 2010 – 2012, an"
  },
  {
    "conteudo":"Associate Editor of Journal of American Society of Nephrology 2006-2012, Director of the"
  },
  {
    "conteudo":"Master of Science in Clinical Investigation Program at VUSM 2005 - 2017 and member and"
  },
  {
    "conteudo":"Chair of American Board of Internal Medicine Nephrology Test Writing Committee 2008 -"
  },
  {
    "conteudo":"2018. He is the recipient of National Kidney Foundation Joel Kopple Award, International"
  },
  {
    "conteudo":"Society of Renal Nutrition and Metabolism Thomas Addis Award and VUSM Excellence in"
  },
  {
    "conteudo":"Mentoring Translational Scientist Award. As a clinical investigator focused on mechanisms of"
  },
  {
    "conteudo":"disease and patient related outcomes, he is the principal investigator of a number of ongoing"
  },
  {
    "conteudo":"studies aimed at improving the outcomes and quality of life in patient populations ranging from"
  },
  {
    "conteudo":"early kidney disease, patients on maintenance dialysis and patients with acute kidney injury."
  },
  {
    "conteudo":"He has published over 250 original articles, 50 editorial reviews and 20 book chapters. He is"
  },
  {
    "conteudo":"the co-editor of Handbook of Nutrition in Kidney Disease, 7th edition and Chronic Kidney"
  },
  {
    "conteudo":"Disease, Dialysis, and Transplantation, 4th edition."
  },
  {
    "conteudo":"George A. Kaysen, MD, PhD"
  },
  {
    "conteudo":"Dr. Kaysen is an emeritus professor of Medicine and Biochemistry and Molecular Medicine at"
  },
  {
    "conteudo":"the University of California Davis School of Medicine. He was Chief of the Nephrology"
  },
  {
    "conteudo":"Division for 23 years at UC Davis and Acting Chair of Biochemistry and Molecular Medicine"
  },
  {
    "conteudo":"for 6 years. He is still actively engaged in research and in-patient care. His research interests"
  },
  {
    "conteudo":"are in the relationships between inflammation and nutrition and cardiovascular and infectious"
  },
  {
    "conteudo":"outcomes and regulation of lipoprotein structure and function in both patients and experimental"
  },
  {
    "conteudo":"animals with chronic kidney disease and\/or proteinuria as well as regulation of albumin"
  },
  {
    "conteudo":"metabolism both in patients with CKD and with nephrotic range proteinuria. He received his"
  },
  {
    "conteudo":"MD and Ph.D at the Albert Einstein College of Medicine in the Bronx NY"
  },
  {
    "conteudo":"Joel D. Kopple, MD"
  },
  {
    "conteudo":"Dr. Kopple is a nephrologist who is Professor Emeritus of Medicine and Public Health at"
  },
  {
    "conteudo":"the David Geffen UCLA School of Medicine and UCLA Fielding School of Public Health. He"
  },
  {
    "conteudo":"served from 1982 to 2007 as the chief of the Division of Nephrology and Hypertension"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 202"
  },
  {
    "conteudo":"at Harbor-UCLA Medical Center. Kopple's research focus has been on amino acid and protein"
  },
  {
    "conteudo":"metabolism and nutritional and metabolic disorders and their management in kidney disease"
  },
  {
    "conteudo":"and kidney failure. He has authored or coauthored many hundreds of peer-reviewed"
  },
  {
    "conteudo":"manuscripts, invited papers and chapters. He is an editor of many proceedings and symposia"
  },
  {
    "conteudo":"and an editor of the textbook entitled, Nutritional Management of Renal Disease. He founded"
  },
  {
    "conteudo":"the International Society of Renal Nutrition and Metabolism, the International Federation of"
  },
  {
    "conteudo":"Kidney Foundations, and World Kidney Day, served a central role in founding other"
  },
  {
    "conteudo":"institutions, and served as president of the National Kidney Foundation, the American Society"
  },
  {
    "conteudo":"of Parenteral and Enteral Nutrition, and other professional and scientific societies. Dr. Kopple"
  },
  {
    "conteudo":"is a Fellow of the American Society for Nutrition, the American Society of Nephrology and the"
  },
  {
    "conteudo":"National Kidney Foundation. He has received many awards including the David M. Hume"
  },
  {
    "conteudo":"Memorial Award by the National Kidney Foundation, the Robert H. Herman Memorial Award"
  },
  {
    "conteudo":"and the E.V. McCollum Award from the American Society for Nutrition, and the Belding"
  },
  {
    "conteudo":"Scribner Award of the American Society of Nephrology. Dr. Kopple has received honorary"
  },
  {
    "conteudo":"doctorate degrees from the University of Pavol Jozef Šafárik, the University of Szeged, and the"
  },
  {
    "conteudo":"University d'Auvergne. The National Kidney Foundation and its Council on Renal Nutrition"
  },
  {
    "conteudo":"designated the 'Joel D Kopple Award ‘ in Renal Nutrition, which is annually granted to a"
  },
  {
    "conteudo":"distinguished individual for his\/her efforts to advance the field of renal nutrition. The"
  },
  {
    "conteudo":"International Federation of Kidney Foundations has created a separate Joel D. Kopple Award"
  },
  {
    "conteudo":"which is given to a person or group that has made a major contribution to the health or well-"
  },
  {
    "conteudo":"being of people with or at risk for kidney disease."
  },
  {
    "conteudo":"Angela Yee-Moon Wang, MD, PhD, FRCP"
  },
  {
    "conteudo":"Dr. Wang was graduated from the University of New South Wales, Australia and is Honorary"
  },
  {
    "conteudo":"Associate Professor, Associate Consultant at the University of Hong Kong, Queen Mary"
  },
  {
    "conteudo":"Hospital. She was the recipients of the NKF Joel D. Kopple Award 2018, John Maher Award"
  },
  {
    "conteudo":"of the ISPD 2006, and Travelling Lecturer Award of Asian and Pacific Federation of Clinical"
  },
  {
    "conteudo":"Biochemistry 2012. She is currently the President of the International Society of Renal"
  },
  {
    "conteudo":"Nutrition and Metabolism (ISRNM) and a Council member of the ISPD. She is a North and"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 203"
  },
  {
    "conteudo":"East Asia Regional Board member of the International Society of Nephrology (ISN),"
  },
  {
    "conteudo":"Committee Member of the ISN-Advancing Clinical Trial Core Group, and Executive"
  },
  {
    "conteudo":"Committee member of the Standardized Outcomes in Nephrology (SONG) Initiative,"
  },
  {
    "conteudo":"workgroup member of the SONG-PD and SONG-HD CVD. She was also an Executive"
  },
  {
    "conteudo":"Committee Member of KDIGO (Jan 2015 - Dec 2017). She is a workgroup member of the"
  },
  {
    "conteudo":"NKF KDOQI Nutrition Guidelines in CKD and the ISPD PD Adequacy Guideline update"
  },
  {
    "conteudo":"(2017-2019). She chaired the ISPD Adult Cardiovascular and Metabolic Guidelines (2012 –"
  },
  {
    "conteudo":"2015) and is a Subcommittee Chair of the ISPD PDOPPS. She was also a Core workgroup"
  },
  {
    "conteudo":"member of the first KDIGO – CKD-MBD guidelines (2007 – 2009). She also co-chaired the"
  },
  {
    "conteudo":"first KDIGO CKD-MBD Guideline Implementation Summit in Asia in 2018."
  },
  {
    "conteudo":"She is currently serving on the editorial board of JASN, CJASN, NDT (Editor of"
  },
  {
    "conteudo":"Cardiovascular Section), Am J Nephrol, Nephron Clin Pract (Associate Editor), European"
  },
  {
    "conteudo":"Medical Journal (EMJ)-Nephrology (Editor-in-Chief), Renal Replacement Therapy (Associate"
  },
  {
    "conteudo":"Editor), Nephrology (Subject Editor), J Ren Nutr, J Diabetes, Blood Purification, Biomedicine"
  },
  {
    "conteudo":"Hub, etc. She was previously an Associate Editor of AJKD and an International Editor of"
  },
  {
    "conteudo":"CJASN. Her main research interests are in CKD and dialysis complications, especially in the"
  },
  {
    "conteudo":"areas of cardiovascular disease, renal nutrition and metabolism."
  },
  {
    "conteudo":"Disclosures: Dr Wang reported no relevant financial disclosures."
  },
  {
    "conteudo":"Evidence Review Team"
  },
  {
    "conteudo":"Mary Rozga, PhD, RDN is a Nutrition Researcher for the Evidence Analysis Center at the"
  },
  {
    "conteudo":"Academy of Nutrition and Dietetics. In this role, she works as a systematic review and"
  },
  {
    "conteudo":"guideline methodologist and works with expert practitioners, researchers and patient advocates"
  },
  {
    "conteudo":"on a wide variety of nutrition topics to create evidence-based information for dietitians. Prior to"
  },
  {
    "conteudo":"this position, Dr. Rozga worked in the academic setting with a focus on breastfeeding research,"
  },
  {
    "conteudo":"including providing peer-counseling breastfeeding support to low income women in the"
  },
  {
    "conteudo":"community setting. She has served as an Assistant Professor at Bowling Green State"
  },
  {
    "conteudo":"University, where she created a master’s course on Environmental Nutrition. Dr. Rozga has"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 204"
  },
  {
    "conteudo":"published both primary and secondary research in peer-reviewed journals such as The Journal"
  },
  {
    "conteudo":"of the Academy of Nutrition and Dietetics, Public Health Nutrition, and the Maternal & Child"
  },
  {
    "conteudo":"Health Journal. Dr. Rozga received the 2015 Editorial Review Board Choice Research Article"
  },
  {
    "conteudo":"of the Year from the Journal of Human Lactation. Dr. Rozga earned a Bachelor’s degree in"
  },
  {
    "conteudo":"Dietetics from Central Michigan University, a Master’s degree in Nutrition Research from"
  },
  {
    "conteudo":"Bastyr University, and a PhD in Human Nutrition from Michigan State University, where she"
  },
  {
    "conteudo":"also completed her dietetic internship."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Rozga reports no relevant financial relationships."
  },
  {
    "conteudo":"Deepa Handu, PhD, serves as a Senior Scientific Director for the Academy of Nutrition and"
  },
  {
    "conteudo":"Dietetics Evidence Analysis Library. She has methodological expertise in conducting systematic"
  },
  {
    "conteudo":"reviews and quantitative analysis in the field of nutrition. In her position at the Academy, she"
  },
  {
    "conteudo":"has led the development of a number of systematic reviews and clinical practice guidelines, and"
  },
  {
    "conteudo":"conducted research to improve evidence-based methods for the EAL. Dr. Handu previously has"
  },
  {
    "conteudo":"served as the Dietetic Internship Director at Edward Hines Jr. VA Hospital, Director of the"
  },
  {
    "conteudo":"Master of Science in Nutrition and Wellness program at Benedictine University, and Assistant"
  },
  {
    "conteudo":"Clinical Professor at Loyola University. Dr. Handu’s research interests lie in the areas of"
  },
  {
    "conteudo":"evidence-based methods\/research methodology, public health nutrition, youth overweight"
  },
  {
    "conteudo":"prevalence and obesity risk, and diabetes. Her work has been published in refereed journals, she"
  },
  {
    "conteudo":"has published a book on Research Methodology, and she has delivered numerous professional"
  },
  {
    "conteudo":"presentations at the local, state, and national level. Dr. Handu earned her Ph.D. in Human"
  },
  {
    "conteudo":"Nutrition from Michigan State University."
  },
  {
    "conteudo":"Financial Disclosure: Dr. Handu reports no relevant financial relationships."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 205"
  },
  {
    "conteudo":"1. Workgroup G. GRADE Handbook. In: Schünemann HBJG, G; Oxman, A, ed2013."
  },
  {
    "conteudo":"2. Carrero JJ, Avesani CM. Pros and cons of body mass index as a nutritional and risk assessment"
  },
  {
    "conteudo":"tool in dialysis patients. Semin Dial. 2015;28(1): 48-58."
  },
  {
    "conteudo":"3. Chumlea WC CD, Dwyer JT, Han H, Kelly MP. Nutritional assessment in chronic kidney disease."
  },
  {
    "conteudo":"In: Byham-Gray LD BJ, Chertow GM, ed. Nutrition in kidney disease. Totowa, NJ: Humana"
  },
  {
    "conteudo":"Press; 2008:49–118."
  },
  {
    "conteudo":"4. Donadio C, Halim AB, Caprio F, Grassi G, Khedr B, Mazzantini M. Single- and multi-frequency"
  },
  {
    "conteudo":"bioelectrical impedance analyses to analyse body composition in maintenance haemodialysis"
  },
  {
    "conteudo":"patients: comparison with dual-energy x-ray absorptiometry. Physiol Meas. 2008;29(6): S517-"
  },
  {
    "conteudo":"524."
  },
  {
    "conteudo":"5. Furstenberg A, Davenport A. Comparison of multifrequency bioelectrical impedance analysis"
  },
  {
    "conteudo":"and dual-energy X-ray absorptiometry assessments in outpatient hemodialysis patients."
  },
  {
    "conteudo":"American journal of kidney diseases : the official journal of the National Kidney Foundation."
  },
  {
    "conteudo":"2011;57(1): 123-129."
  },
  {
    "conteudo":"6. Konings CJ, Kooman JP, Schonck M, et al. Influence of fluid status on techniques used to assess"
  },
  {
    "conteudo":"body composition in peritoneal dialysis patients. Perit Dial Int. 2003;23(2): 184-190."
  },
  {
    "conteudo":"7. Rigalleau V, Lasseur C, Chauveau P, et al. Body composition in diabetic subjects with chronic"
  },
  {
    "conteudo":"kidney disease: interest of bio-impedance analysis, and anthropometry. Ann Nutr Metab."
  },
  {
    "conteudo":"2004;48(6): 409-413."
  },
  {
    "conteudo":"8. Abad S, Sotomayor G, Vega A, et al. The phase angle of the electrical impedance is a predictor"
  },
  {
    "conteudo":"of long-term survival in dialysis patients. Nefrologia. 2011;31(6): 670-676."
  },
  {
    "conteudo":"9. Fiedler R, Jehle PM, Osten B, Dorligschaw O, Girndt M. Clinical nutrition scores are superior for"
  },
  {
    "conteudo":"the prognosis of haemodialysis patients compared to lab markers and bioelectrical"
  },
  {
    "conteudo":"impedance. Nephrol Dial Transplant. 2009;24(12): 3812-3817."
  },
  {
    "conteudo":"10. Rosenberger J, Kissova V, Majernikova M, Straussova Z, Boldizsar J. Body composition monitor"
  },
  {
    "conteudo":"assessing malnutrition in the hemodialysis population independently predicts mortality. J Ren"
  },
  {
    "conteudo":"Nutr. 2014;24(3): 172-176."
  },
  {
    "conteudo":"11. Cheng CH, Chen MY, Lee YJ, et al. Assessment of nutritional status in continuous ambulatory"
  },
  {
    "conteudo":"peritoneal dialysis patients: a comparison of bioelectric impedance and conventional"
  },
  {
    "conteudo":"methods. Zhonghua Yi Xue Za Zhi (Taipei). 2000;63(10): 758-764."
  },
  {
    "conteudo":"12. Mancini A, Grandaliano G, Magarelli P, Allegretti A. Nutritional status in hemodialysis patients"
  },
  {
    "conteudo":"and bioimpedance vector analysis. J Ren Nutr. 2003;13(3): 199-204."
  },
  {
    "conteudo":"13. Ohashi Y, Otani T, Tai R, Tanaka Y, Sakai K, Aikawa A. Assessment of body composition using"
  },
  {
    "conteudo":"dry mass index and ratio of total body water to estimated volume based on bioelectrical"
  },
  {
    "conteudo":"impedance analysis in chronic kidney disease patients. J Ren Nutr. 2013;23(1): 28-36."
  },
  {
    "conteudo":"14. Rodrigues NC, Sala PC, Horie LM, et al. Bioelectrical impedance analysis and skinfold thickness"
  },
  {
    "conteudo":"sum in assessing body fat mass of renal dialysis patients. J Ren Nutr. 2012;22(4): 409-415"
  },
  {
    "conteudo":"e402."
  },
  {
    "conteudo":"15. Nakao T, Kanazawa Y, Nagaoka Y, et al. Body protein index based on bioelectrical impedance"
  },
  {
    "conteudo":"analysis is a useful new marker assessing nutritional status: applications to patients with"
  },
  {
    "conteudo":"chronic renal failure on maintenance dialysis. Contrib Nephrol. 2007;155: 18-28."
  },
  {
    "conteudo":"16. Avesani CM, Draibe SA, Kamimura MA, et al. Assessment of body composition by dual energy"
  },
  {
    "conteudo":"X-ray absorptiometry, skinfold thickness and creatinine kinetics in chronic kidney disease"
  },
  {
    "conteudo":"patients. Nephrol Dial Transplant. 2004;19(9): 2289-2295."
  },
  {
    "conteudo":"17. Bross R, Chandramohan G, Kovesdy CP, et al. Comparing body composition assessment tests"
  },
  {
    "conteudo":"in long-term hemodialysis patients. American journal of kidney diseases : the official journal of"
  },
  {
    "conteudo":"the National Kidney Foundation. 2010;55(5): 885-896."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 206"
  },
  {
    "conteudo":"18. Kamimura MA, Avesani CM, Cendoroglo M, Canziani ME, Draibe SA, Cuppari L. Comparison of"
  },
  {
    "conteudo":"skinfold thicknesses and bioelectrical impedance analysis with dual-energy X-ray"
  },
  {
    "conteudo":"absorptiometry for the assessment of body fat in patients on long-term haemodialysis"
  },
  {
    "conteudo":"therapy. Nephrol Dial Transplant. 2003;18(1): 101-105."
  },
  {
    "conteudo":"19. Woodrow G, Oldroyd B, Smith MA, Turney JH. Measurement of body composition in chronic"
  },
  {
    "conteudo":"renal failure: comparison of skinfold anthropometry and bioelectrical impedance with dual"
  },
  {
    "conteudo":"energy X-ray absorptiometry. Eur J Clin Nutr. 1996;50(5): 295-301."
  },
  {
    "conteudo":"20. Araujo IC, Kamimura MA, Draibe SA, et al. Nutritional parameters and mortality in incident"
  },
  {
    "conteudo":"hemodialysis patients. J Ren Nutr. 2006;16(1): 27-35."
  },
  {
    "conteudo":"21. Aatif T, Hassani K, Alayoud A, et al. Parameters to assess nutritional status in a Moroccan"
  },
  {
    "conteudo":"hemodialysis cohort. Arab J Nephrol Transplant. 2013;6(2): 89-97."
  },
  {
    "conteudo":"22. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective"
  },
  {
    "conteudo":"global assessment of nutrition for dialysis patients. Nephrol Dial Transplant. 1999;14(7): 1732-"
  },
  {
    "conteudo":"1738."
  },
  {
    "conteudo":"23. Kamimura MA, Jose Dos Santos NS, Avesani CM, Fernandes Canziani ME, Draibe SA, Cuppari L."
  },
  {
    "conteudo":"Comparison of three methods for the determination of body fat in patients on long-term"
  },
  {
    "conteudo":"hemodialysis therapy. Journal of the American Dietetic Association. 2003;103(2): 195-199."
  },
  {
    "conteudo":"24. Oe B, de Fijter CW, Oe PL, Stevens P, de Vries PM. Four-site skinfold anthropometry (FSA)"
  },
  {
    "conteudo":"versus body impedance analysis (BIA) in assessing nutritional status of patients on"
  },
  {
    "conteudo":"maintenance hemodialysis: which method is to be preferred in routine patient care? Clin"
  },
  {
    "conteudo":"Nephrol. 1998;49(3): 180-185."
  },
  {
    "conteudo":"25. Stall SH, Ginsberg NS, DeVita MV, et al. Comparison of five body-composition methods in"
  },
  {
    "conteudo":"peritoneal dialysis patients. Am J Clin Nutr. 1996;64(2): 125-130."
  },
  {
    "conteudo":"26. Kaizu Y, Ohkawa S, Kumagai H. Muscle mass index in haemodialysis patients: a comparison of"
  },
  {
    "conteudo":"indices obtained by routine clinical examinations. Nephrol Dial Transplant. 2002;17(3): 442-"
  },
  {
    "conteudo":"448."
  },
  {
    "conteudo":"27. de Roij van Zuijdewijn CL, ter Wee PM, Chapdelaine I, et al. A Comparison of 8 Nutrition-"
  },
  {
    "conteudo":"Related Tests to Predict Mortality in Hemodialysis Patients. Journal of renal nutrition : the"
  },
  {
    "conteudo":"official journal of the Council on Renal Nutrition of the National Kidney Foundation."
  },
  {
    "conteudo":"2015;25(5): 412-419."
  },
  {
    "conteudo":"28. Walther CP, Carter CW, Low CL, et al. Interdialytic creatinine change versus predialysis"
  },
  {
    "conteudo":"creatinine as indicators of nutritional status in maintenance hemodialysis. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2012;27(2): 771-776."
  },
  {
    "conteudo":"29. Borovnicar DJ, Wong KC, Kerr PG, et al. Total body protein status assessed by different"
  },
  {
    "conteudo":"estimates of fat-free mass in adult peritoneal dialysis patients. Eur J Clin Nutr. 1996;50(9): 607-"
  },
  {
    "conteudo":"616."
  },
  {
    "conteudo":"30. Szeto CC, Kong J, Wu AK, Wong TY, Wang AY, Li PK. The role of lean body mass as a nutritional"
  },
  {
    "conteudo":"index in Chinese peritoneal dialysis patients--comparison of creatinine kinetics method and"
  },
  {
    "conteudo":"anthropometric method. Perit Dial Int. 2000;20(6): 708-714."
  },
  {
    "conteudo":"31. Churchill DT, W; Keshaviah,P. Adequacy of dialysis and nutrition in continuous peritoneal"
  },
  {
    "conteudo":"dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study"
  },
  {
    "conteudo":"Group. J Am Soc Nephrol. 1996;7(2): 198-207."
  },
  {
    "conteudo":"32. Bazanelli AP, Kamimura MA, Manfredi SR, Draibe SA, Cuppari L. Usefulness of waist"
  },
  {
    "conteudo":"circumference as a marker of abdominal adiposity in peritoneal dialysis: a cross-sectional and"
  },
  {
    "conteudo":"prospective analysis. Nephrol Dial Transplant. 2012;27(2): 790-795."
  },
  {
    "conteudo":"33. Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with"
  },
  {
    "conteudo":"increased inflammation, protein-energy wasting and worse outcome in patients undergoing"
  },
  {
    "conteudo":"haemodialysis. Nephrol Dial Transplant. 2010;25(2): 562-568."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 207"
  },
  {
    "conteudo":"34. Badve SV, Paul SK, Klein K, et al. The association between body mass index and mortality in"
  },
  {
    "conteudo":"incident dialysis patients. PLoS One. 2014;9(12): e114897."
  },
  {
    "conteudo":"35. Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D. Is there any survival"
  },
  {
    "conteudo":"advantage of obesity in Southern European haemodialysis patients? Nephrol Dial Transplant."
  },
  {
    "conteudo":"2009;24(9): 2871-2876."
  },
  {
    "conteudo":"36. Hanks LJ, Tanner RM, Muntner P, et al. Metabolic subtypes and risk of mortality in normal"
  },
  {
    "conteudo":"weight, overweight, and obese individuals with CKD. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2013;8(12): 2064-2071."
  },
  {
    "conteudo":"37. Hoogeveen EK, Halbesma N, Rothman KJ, et al. Obesity and mortality risk among younger"
  },
  {
    "conteudo":"dialysis patients. Clinical journal of the American Society of Nephrology : CJASN. 2012;7(2):"
  },
  {
    "conteudo":"280-288."
  },
  {
    "conteudo":"38. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight"
  },
  {
    "conteudo":"change over time with cardiovascular survival in hemodialysis population. American journal of"
  },
  {
    "conteudo":"kidney diseases : the official journal of the National Kidney Foundation. 2005;46(3): 489-500."
  },
  {
    "conteudo":"39. Kim YK, Kim SH, Kim HW, et al. The association between body mass index and mortality on"
  },
  {
    "conteudo":"peritoneal dialysis: a prospective cohort study. Perit Dial Int. 2014;34(4): 383-389."
  },
  {
    "conteudo":"40. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and"
  },
  {
    "conteudo":"mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the"
  },
  {
    "conteudo":"Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16(12):"
  },
  {
    "conteudo":"2386-2394."
  },
  {
    "conteudo":"41. Leinig C, Pecoits-Filho R, Nascimento MM, Goncalves S, Riella MC, Martins C. Association"
  },
  {
    "conteudo":"between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis,"
  },
  {
    "conteudo":"and peritoneal dialysis patients. J Ren Nutr. 2008;18(5): 424-429."
  },
  {
    "conteudo":"42. Lievense H, Kalantar-Zadeh K, Lukowsky LR, et al. Relationship of body size and initial dialysis"
  },
  {
    "conteudo":"modality on subsequent transplantation, mortality and weight gain of ESRD patients. Nephrol"
  },
  {
    "conteudo":"Dial Transplant. 2012;27(9): 3631-3638."
  },
  {
    "conteudo":"43. Madero M, Sarnak MJ, Wang X, et al. Body mass index and mortality in CKD. American journal"
  },
  {
    "conteudo":"of kidney diseases : the official journal of the National Kidney Foundation. 2007;50(3): 404-"
  },
  {
    "conteudo":"411."
  },
  {
    "conteudo":"44. Mathew S, Abraham G, Vijayan M, et al. Body composition monitoring and nutrition in"
  },
  {
    "conteudo":"maintenance hemodialysis and CAPD patients--a multicenter longitudinal study. Renal failure."
  },
  {
    "conteudo":"2015;37(1): 66-72."
  },
  {
    "conteudo":"45. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis"
  },
  {
    "conteudo":"outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol."
  },
  {
    "conteudo":"2003;14(11): 2894-2901."
  },
  {
    "conteudo":"46. Molnar MZ, Streja E, Kovesdy CP, et al. Associations of body mass index and weight loss with"
  },
  {
    "conteudo":"mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant."
  },
  {
    "conteudo":"2011;11(4): 725-736."
  },
  {
    "conteudo":"47. Wiesholzer M, Harm F, Schuster K, et al. Initial body mass indexes have contrary effects on"
  },
  {
    "conteudo":"change in body weight and mortality of patients on maintenance hemodialysis treatment. J"
  },
  {
    "conteudo":"Ren Nutr. 2003;13(3): 174-185."
  },
  {
    "conteudo":"48. Yen TH, Lin JL, Lin-Tan DT, Hsu CW. Association between body mass and mortality in"
  },
  {
    "conteudo":"maintenance hemodialysis patients. Ther Apher Dial. 2010;14(4): 400-408."
  },
  {
    "conteudo":"49. Beberashvili I, Sinuani I, Azar A, et al. Nutritional and inflammatory status of hemodialysis"
  },
  {
    "conteudo":"patients in relation to their body mass index. J Ren Nutr. 2009;19(3): 238-247."
  },
  {
    "conteudo":"50. Kadiri Mel M, Nechba RB, Oualim Z. Factors predicting malnutrition in hemodialysis patients."
  },
  {
    "conteudo":"Saudi J Kidney Dis Transpl. 2011;22(4): 695-704."
  },
  {
    "conteudo":"51. Kahraman S, Yilmaz R, Akinci D, et al. U-shaped association of body mass index with"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 208"
  },
  {
    "conteudo":"inflammation and atherosclerosis in hemodialysis patients. J Ren Nutr. 2005;15(4): 377-386."
  },
  {
    "conteudo":"52. Steiber A, Leon JB, Secker D, et al. Multicenter study of the validity and reliability of subjective"
  },
  {
    "conteudo":"global assessment in the hemodialysis population. Journal of renal nutrition : the official"
  },
  {
    "conteudo":"journal of the Council on Renal Nutrition of the National Kidney Foundation. 2007;17(5): 336-"
  },
  {
    "conteudo":"342."
  },
  {
    "conteudo":"53. Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Reliability of the 7-point"
  },
  {
    "conteudo":"subjective global assessment scale in assessing nutritional status of dialysis patients. Adv Perit"
  },
  {
    "conteudo":"Dial. 1999;15: 222-225."
  },
  {
    "conteudo":"54. Doshi M, Streja E, Rhee CM, et al. Examining the robustness of the obesity paradox in"
  },
  {
    "conteudo":"maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2016;31(8): 1310-1319."
  },
  {
    "conteudo":"55. Ricks J, Molnar MZ, Kovesdy CP, et al. Racial and ethnic differences in the association of body"
  },
  {
    "conteudo":"mass index and survival in maintenance hemodialysis patients. American journal of kidney"
  },
  {
    "conteudo":"diseases : the official journal of the National Kidney Foundation. 2011;58(4): 574-582."
  },
  {
    "conteudo":"56. Ahmadi SF, Zahmatkesh G, Streja E, et al. Association of Body Mass Index With Mortality in"
  },
  {
    "conteudo":"Peritoneal Dialysis Patients: A Systematic Review and Meta-Analysis. Perit Dial Int. 2016;36(3):"
  },
  {
    "conteudo":"315-325."
  },
  {
    "conteudo":"57. Ahmadi SF, Zahmatkesh G, Ahmadi E, et al. Association of Body Mass Index with Clinical"
  },
  {
    "conteudo":"Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-"
  },
  {
    "conteudo":"Analysis. Cardiorenal Med. 2015;6(1): 37-49."
  },
  {
    "conteudo":"58. Ahmadi SF, Zahmatkesh G, Streja E, et al. Body mass index and mortality in kidney transplant"
  },
  {
    "conteudo":"recipients: a systematic review and meta-analysis. Am J Nephrol. 2014;40(4): 315-324."
  },
  {
    "conteudo":"59. Campbell KL, MacLaughlin HL. Unintentional weight loss is an independent predictor of"
  },
  {
    "conteudo":"mortality in a hemodialysis population. J Ren Nutr. 2010;20(6): 414-418."
  },
  {
    "conteudo":"60. Jones CH, Akbani H, Croft DC, Worth DP. The relationship between serum albumin and"
  },
  {
    "conteudo":"hydration status in hemodialysis patients. J Ren Nutr. 2002;12(4): 209-212."
  },
  {
    "conteudo":"61. Malgorzewicz S, Debska-Slizien A, Rutkowski B, Lysiak-Szydlowska W. Serum concentration of"
  },
  {
    "conteudo":"amino acids versus nutritional status in hemodialysis patients. J Ren Nutr. 2008;18(2): 239-"
  },
  {
    "conteudo":"247."
  },
  {
    "conteudo":"62. Molfino A, Heymsfield SB, Zhu F, et al. Prealbumin is associated with visceral fat mass in"
  },
  {
    "conteudo":"patients receiving hemodialysis. J Ren Nutr. 2013;23(6): 406-410."
  },
  {
    "conteudo":"63. Yelken BM, Gorgulu N, Caliskan Y, et al. Comparison of nutritional status in hemodialysis"
  },
  {
    "conteudo":"patients with and without failed renal allografts. Clin Transplant. 2010;24(4): 481-487."
  },
  {
    "conteudo":"64. Gurreebun F, Hartley GH, Brown AL, Ward MC, Goodship TH. Nutritional screening in patients"
  },
  {
    "conteudo":"on hemodialysis: is subjective global assessment an appropriate tool? J Ren Nutr. 2007;17(2):"
  },
  {
    "conteudo":"114-117."
  },
  {
    "conteudo":"65. Leinig CE, Moraes T, Ribeiro S, et al. Predictive value of malnutrition markers for mortality in"
  },
  {
    "conteudo":"peritoneal dialysis patients. Journal of renal nutrition : the official journal of the Council on"
  },
  {
    "conteudo":"Renal Nutrition of the National Kidney Foundation. 2011;21(2): 176-183."
  },
  {
    "conteudo":"66. de Mutsert R, Grootendorst DC, Boeschoten EW, et al. Subjective global assessment of"
  },
  {
    "conteudo":"nutritional status is strongly associated with mortality in chronic dialysis patients. The"
  },
  {
    "conteudo":"American journal of clinical nutrition. 2009;89(3): 787-793."
  },
  {
    "conteudo":"67. Vannini FD, Antunes AA, Caramori JC, Martin LC, Barretti P. Associations between nutritional"
  },
  {
    "conteudo":"markers and inflammation in hemodialysis patients. Int Urol Nephrol. 2009;41(4): 1003-1009."
  },
  {
    "conteudo":"68. DiSilvestro RA, Blostein-Fujii A. Moderate zinc deficiency in rats enhances lipoprotein"
  },
  {
    "conteudo":"oxidation in vitro. Free Radic Biol Med. 1997;22(4): 739-742."
  },
  {
    "conteudo":"69. de Araujo Antunes A, Vannini FD, Martin LC, et al. Inflammation and overweight in peritoneal"
  },
  {
    "conteudo":"dialysis: is there an association? Renal failure. 2009;31(7): 549-554."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 209"
  },
  {
    "conteudo":"70. Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of muscle mass and"
  },
  {
    "conteudo":"muscle strength with mortality in dialysis patients. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2014;9(10): 1720-1728."
  },
  {
    "conteudo":"71. Molnar MZ, Keszei A, Czira ME, et al. Evaluation of the malnutrition-inflammation score in"
  },
  {
    "conteudo":"kidney transplant recipients. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2010;56(1): 102-111."
  },
  {
    "conteudo":"72. Cigarran S, Pousa M, Castro MJ, et al. Endogenous testosterone, muscle strength, and fat-free"
  },
  {
    "conteudo":"mass in men with chronic kidney disease. J Ren Nutr. 2013;23(5): e89-95."
  },
  {
    "conteudo":"73. Wing MR, Yang W, Teal V, et al. Race modifies the association between adiposity and"
  },
  {
    "conteudo":"inflammation in patients with chronic kidney disease: findings from the chronic renal"
  },
  {
    "conteudo":"insufficiency cohort study. Obesity (Silver Spring). 2014;22(5): 1359-1366."
  },
  {
    "conteudo":"74. Harty JC, Boulton H, Curwell J, et al. The normalized protein catabolic rate is a flawed marker"
  },
  {
    "conteudo":"of nutrition in CAPD patients. Kidney Int. 1994;45(1): 103-109."
  },
  {
    "conteudo":"75. Enia G, Sicuso C, Alati G, Zoccali C. Subjective global assessment of nutrition in dialysis"
  },
  {
    "conteudo":"patients. Nephrol Dial Transplant. 1993;8(10): 1094-1098."
  },
  {
    "conteudo":"76. Amparo FC, Cordeiro AC, Carrero JJ, et al. Malnutrition-inflammation score is associated with"
  },
  {
    "conteudo":"handgrip strength in nondialysis-dependent chronic kidney disease patients. Journal of renal"
  },
  {
    "conteudo":"nutrition : the official journal of the Council on Renal Nutrition of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2013;23(4): 283-287."
  },
  {
    "conteudo":"77. Hasheminejad N, Namdari M, Mahmoodi MR, Bahrampour A, Azmandian J. Association of"
  },
  {
    "conteudo":"Handgrip Strength With Malnutrition-Inflammation Score as an Assessment of Nutritional"
  },
  {
    "conteudo":"Status in Hemodialysis Patients. Iran J Kidney Dis. 2016;10(1): 30-35."
  },
  {
    "conteudo":"78. Silva LF, Matos CM, Lopes GB, et al. Handgrip strength as a simple indicator of possible"
  },
  {
    "conteudo":"malnutrition and inflammation in men and women on maintenance hemodialysis. Journal of"
  },
  {
    "conteudo":"renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2011;21(3): 235-245."
  },
  {
    "conteudo":"79. Gundmi S, Maiya AG, Bhat AK, Ravishankar N, Hande MH, Rajagopal KV. Hand dysfunction in"
  },
  {
    "conteudo":"type 2 diabetes mellitus: Systematic review with meta-analysis. Ann Phys Rehabil Med."
  },
  {
    "conteudo":"2018;61(2): 99-104."
  },
  {
    "conteudo":"80. Byham-Gray L, Parrott JS, Ho WY, Sundell MB, Ikizler TA. Development of a predictive energy"
  },
  {
    "conteudo":"equation for maintenance hemodialysis patients: a pilot study. J Ren Nutr. 2014;24(1): 32-41."
  },
  {
    "conteudo":"81. Dias Rodrigues JC, Lamarca F, Lacroix de Oliveira C, Cuppari L, Lourenço RA, Avesani CM."
  },
  {
    "conteudo":"Agreement between prediction equations and indirect calorimetry to estimate resting energy"
  },
  {
    "conteudo":"expenditure in elderly patients on hemodialysis. e-SPEN Journal. 2014;9(2): e91-e96."
  },
  {
    "conteudo":"82. Kamimura MA, Avesani CM, Bazanelli AP, Baria F, Draibe SA, Cuppari L. Are prediction"
  },
  {
    "conteudo":"equations reliable for estimating resting energy expenditure in chronic kidney disease"
  },
  {
    "conteudo":"patients? Nephrol Dial Transplant. 2011;26(2): 544-550."
  },
  {
    "conteudo":"83. Lee SW, Kim HJ, Kwon HK, Son SM, Song JH, Kim MJ. Agreements between indirect calorimetry"
  },
  {
    "conteudo":"and prediction equations of resting energy expenditure in end-stage renal disease patients on"
  },
  {
    "conteudo":"continuous ambulatory peritoneal dialysis. Yonsei Med J. 2008;49(2): 255-264."
  },
  {
    "conteudo":"84. Neyra R, Chen KY, Sun M, Shyr Y, Hakim RM, Ikizler TA. Increased resting energy expenditure"
  },
  {
    "conteudo":"in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr. 2003;27(1): 36-42."
  },
  {
    "conteudo":"85. Vilar E, Machado A, Garrett A, Kozarski R, Wellsted D, Farrington K. Disease-specific predictive"
  },
  {
    "conteudo":"formulas for energy expenditure in the dialysis population. J Ren Nutr. 2014;24(4): 243-251."
  },
  {
    "conteudo":"86. Beberashvili I, Azar A, Sinuani I, et al. Comparison analysis of nutritional scores for serial"
  },
  {
    "conteudo":"monitoring of nutritional status in hemodialysis patients. Clinical journal of the American"
  },
  {
    "conteudo":"Society of Nephrology : CJASN. 2013;8(3): 443-451."
  },
  {
    "conteudo":"87. Yamada M, Arai H, Nishiguchi S, et al. Chronic kidney disease (CKD) is an independent risk"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 210"
  },
  {
    "conteudo":"factor for long-term care insurance (LTCI) need certification among older Japanese adults: a"
  },
  {
    "conteudo":"two-year prospective cohort study. Arch Gerontol Geriatr. 2013;57(3): 328-332."
  },
  {
    "conteudo":"88. Lawson CS, Campbell KL, Dimakopoulos I, Dockrell ME. Assessing the validity and reliability of"
  },
  {
    "conteudo":"the MUST and MST nutrition screening tools in renal inpatients. Journal of renal nutrition : the"
  },
  {
    "conteudo":"official journal of the Council on Renal Nutrition of the National Kidney Foundation."
  },
  {
    "conteudo":"2012;22(5): 499-506."
  },
  {
    "conteudo":"89. Afsar B, Sezer S, Arat Z, Tutal E, Ozdemir FN, Haberal M. Reliability of mini nutritional"
  },
  {
    "conteudo":"assessment in hemodialysis compared with subjective global assessment. Journal of renal"
  },
  {
    "conteudo":"nutrition : the official journal of the Council on Renal Nutrition of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2006;16(3): 277-282."
  },
  {
    "conteudo":"90. Santin FG, Bigogno FG, Dias Rodrigues JC, Cuppari L, Avesani CM. Concurrent and Predictive"
  },
  {
    "conteudo":"Validity of Composite Methods to Assess Nutritional Status in Older Adults on Hemodialysis."
  },
  {
    "conteudo":"Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National"
  },
  {
    "conteudo":"Kidney Foundation. 2016;26(1): 18-25."
  },
  {
    "conteudo":"91. Erdogan E, Tutal E, Uyar ME, et al. Reliability of bioelectrical impedance analysis in the"
  },
  {
    "conteudo":"evaluation of the nutritional status of hemodialysis patients - a comparison with Mini"
  },
  {
    "conteudo":"Nutritional Assessment. Transplant Proc. 2013;45(10): 3485-3488."
  },
  {
    "conteudo":"92. Campbell KL, Bauer JD, Ikehiro A, Johnson DW. Role of nutrition impact symptoms in"
  },
  {
    "conteudo":"predicting nutritional status and clinical outcome in hemodialysis patients: a potential"
  },
  {
    "conteudo":"screening tool. Journal of renal nutrition : the official journal of the Council on Renal Nutrition"
  },
  {
    "conteudo":"of the National Kidney Foundation. 2013;23(4): 302-307."
  },
  {
    "conteudo":"93. Bennett PN, Breugelmans L, Meade A, Parkhurst D. A simple nutrition screening tool for"
  },
  {
    "conteudo":"hemodialysis nurses. Journal of renal nutrition : the official journal of the Council on Renal"
  },
  {
    "conteudo":"Nutrition of the National Kidney Foundation. 2006;16(1): 59-62."
  },
  {
    "conteudo":"94. Xia YA, Healy A, Kruger R. Developing and Validating a Renal Nutrition Screening Tool to"
  },
  {
    "conteudo":"Effectively Identify Undernutrition Risk Among Renal Inpatients. Journal of renal nutrition : the"
  },
  {
    "conteudo":"official journal of the Council on Renal Nutrition of the National Kidney Foundation."
  },
  {
    "conteudo":"2016;26(5): 299-307."
  },
  {
    "conteudo":"95. Moreau-Gaudry X, Jean G, Genet L, et al. A simple protein-energy wasting score predicts"
  },
  {
    "conteudo":"survival in maintenance hemodialysis patients. Journal of renal nutrition : the official journal of"
  },
  {
    "conteudo":"the Council on Renal Nutrition of the National Kidney Foundation. 2014;24(6): 395-400."
  },
  {
    "conteudo":"96. Jones CH, Wolfenden RC, Wells LM. Is subjective global assessment a reliable measure of"
  },
  {
    "conteudo":"nutritional status in hemodialysis? Journal of renal nutrition : the official journal of the Council"
  },
  {
    "conteudo":"on Renal Nutrition of the National Kidney Foundation. 2004;14(1): 26-30."
  },
  {
    "conteudo":"97. Perez Vogt B, Costa Teixeira Caramori J. Are Nutritional Composed Scoring Systems and"
  },
  {
    "conteudo":"Protein-Energy Wasting Score Associated With Mortality in Maintenance Hemodialysis"
  },
  {
    "conteudo":"Patients? Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2016;26(3): 183-189."
  },
  {
    "conteudo":"98. Tapiawala S, Vora H, Patel Z, Badve S, Shah B. Subjective global assessment of nutritional"
  },
  {
    "conteudo":"status of patients with chronic renal insufficiency and end stage renal disease on dialysis. J"
  },
  {
    "conteudo":"Assoc Physicians India. 2006;54: 923-926."
  },
  {
    "conteudo":"99. Garagarza C, Joao-Matias P, Sousa-Guerreiro C, et al. Nutritional status and overhydration: can"
  },
  {
    "conteudo":"bioimpedance spectroscopy be useful in haemodialysis patients? Nefrologia : publicacion"
  },
  {
    "conteudo":"oficial de la Sociedad Espanola Nefrologia. 2013;33(5): 667-674."
  },
  {
    "conteudo":"100. Passadakis P, Sud K, Dutta A, et al. Bioelectrical impedance analysis in the evaluation of the"
  },
  {
    "conteudo":"nutritional status of continuous ambulatory peritoneal dialysis patients. Adv Perit Dial."
  },
  {
    "conteudo":"1999;15: 147-152."
  },
  {
    "conteudo":"101. Hou Y, Li X, Hong D, et al. Comparison of different assessments for evaluating malnutrition in"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 211"
  },
  {
    "conteudo":"Chinese patients with end-stage renal disease with maintenance hemodialysis. Nutr Res."
  },
  {
    "conteudo":"2012;32(4): 266-271."
  },
  {
    "conteudo":"102. Chen KH, Wu CH, Hsu CW, et al. Protein nutrition index as a function of patient survival rate in"
  },
  {
    "conteudo":"peritoneal dialysis. Kidney Blood Press Res. 2010;33(3): 174-180."
  },
  {
    "conteudo":"103. Blumberg Benyamini S, Katzir Z, Biro A, et al. Nutrition assessment and risk prediction in"
  },
  {
    "conteudo":"dialysis patients-a new integrative score. Journal of renal nutrition : the official journal of the"
  },
  {
    "conteudo":"Council on Renal Nutrition of the National Kidney Foundation. 2014;24(6): 401-410."
  },
  {
    "conteudo":"104. Silva DA, Petroski EL, Peres MA. Accuracy and measures of association of anthropometric"
  },
  {
    "conteudo":"indexes of obesity to identify the presence of hypertension in adults: a population-based study"
  },
  {
    "conteudo":"in Southern Brazil. Eur J Nutr. 2013;52(1): 237-246."
  },
  {
    "conteudo":"105. Avesani CM, Kamimura MA, Draibe SA, Cuppari L. Is energy intake underestimated in"
  },
  {
    "conteudo":"nondialyzed chronic kidney disease patients? J Ren Nutr. 2005;15(1): 159-165."
  },
  {
    "conteudo":"106. Bazanelli AP, Kamimura MA, Vasselai P, Draibe SA, Cuppari L. Underreporting of energy intake"
  },
  {
    "conteudo":"in peritoneal dialysis patients. J Ren Nutr. 2010;20(4): 263-269."
  },
  {
    "conteudo":"107. Griffiths A, Russell L, Breslin M, Russell G, Davies S. A comparison of two methods of dietary"
  },
  {
    "conteudo":"assessment in peritoneal dialysis patients. J Ren Nutr. 1999;9(1): 26-31."
  },
  {
    "conteudo":"108. Kai H, Doi M, Okada M, et al. Evaluation of the Validity of a Novel CKD Assessment Checklist"
  },
  {
    "conteudo":"Used in the Frontier of Renal Outcome Modifications in Japan Study. J Ren Nutr. 2016;26(5):"
  },
  {
    "conteudo":"334-340."
  },
  {
    "conteudo":"109. Kloppenburg WD, Stegeman CA, de Jong PE, Huisman RM. Anthropometry-based equations"
  },
  {
    "conteudo":"overestimate the urea distribution volume in hemodialysis patients. Kidney Int. 2001;59(3):"
  },
  {
    "conteudo":"1165-1174."
  },
  {
    "conteudo":"110. Laxton JC, Harrison SP, Shaw AB. Assessment of protein intake in early progressive renal"
  },
  {
    "conteudo":"disease. Nephrol Dial Transplant. 1991;6(1): 17-20."
  },
  {
    "conteudo":"111. Shapiro BB, Bross R, Morrison G, Kalantar-Zadeh K, Kopple JD. Self-Reported Interview-"
  },
  {
    "conteudo":"Assisted Diet Records Underreport Energy Intake in Maintenance Hemodialysis Patients. J Ren"
  },
  {
    "conteudo":"Nutr. 2015;25(4): 357-363."
  },
  {
    "conteudo":"112. Delgado C, Ward P, Chertow GM, et al. Calibration of the brief food frequency questionnaire"
  },
  {
    "conteudo":"among patients on dialysis. J Ren Nutr. 2014;24(3): 151-156.e151."
  },
  {
    "conteudo":"113. Lorenzo V, de Bonis E, Rufino M, et al. Caloric rather than protein deficiency predominates in"
  },
  {
    "conteudo":"stable chronic haemodialysis patients. Nephrol Dial Transplant. 1995;10(10): 1885-1889."
  },
  {
    "conteudo":"114. Virga G, Viglino G, Gandolfo C, Aloi E, Cavalli PL. Normalization of protein equivalent of"
  },
  {
    "conteudo":"nitrogen appearance and dialytic adequacy in CAPD. Perit Dial Int. 1996;16 Suppl 1: S185-189."
  },
  {
    "conteudo":"115. Choose Your Foods: Food Lists for Weight Management: Academy of Nutrition and Dietetics"
  },
  {
    "conteudo":"and American Diabetes Association; 2014."
  },
  {
    "conteudo":"116. Campbell KL, Ash S, Davies PS, Bauer JD. Randomized controlled trial of nutritional counseling"
  },
  {
    "conteudo":"on body composition and dietary intake in severe CKD. American journal of kidney diseases :"
  },
  {
    "conteudo":"the official journal of the National Kidney Foundation. 2008;51(5): 748-758."
  },
  {
    "conteudo":"117. Howden EJ, Leano R, Petchey W, Coombes JS, Isbel NM, Marwick TH. Effects of exercise and"
  },
  {
    "conteudo":"lifestyle intervention on cardiovascular function in CKD. Clinical journal of the American"
  },
  {
    "conteudo":"Society of Nephrology : CJASN. 2013;8(9): 1494-1501."
  },
  {
    "conteudo":"118. Flesher M, Woo P, Chiu A, Charlebois A, Warburton DE, Leslie B. Self-management and"
  },
  {
    "conteudo":"biomedical outcomes of a cooking, and exercise program for patients with chronic kidney"
  },
  {
    "conteudo":"disease. J Ren Nutr. 2011;21(2): 188-195."
  },
  {
    "conteudo":"119. Paes-Barreto JG, Silva MI, Qureshi AR, et al. Can renal nutrition education improve adherence"
  },
  {
    "conteudo":"to a low-protein diet in patients with stages 3 to 5 chronic kidney disease? Journal of renal"
  },
  {
    "conteudo":"nutrition : the official journal of the Council on Renal Nutrition of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2013;23(3): 164-171."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 212"
  },
  {
    "conteudo":"120. Leon JB, Majerle AD, Soinski JA, Kushner I, Ohri-Vachaspati P, Sehgal AR. Can a nutrition"
  },
  {
    "conteudo":"intervention improve albumin levels among hemodialysis patients? A pilot study. J Ren Nutr."
  },
  {
    "conteudo":"2001;11(1): 9-15."
  },
  {
    "conteudo":"121. Orazio LK, Isbel NM, Armstrong KA, et al. Evaluation of dietetic advice for modification of"
  },
  {
    "conteudo":"cardiovascular disease risk factors in renal transplant recipients. J Ren Nutr. 2011;21(6): 462-"
  },
  {
    "conteudo":"471."
  },
  {
    "conteudo":"122. Ashurst Ide B, Dobbie H. A randomized controlled trial of an educational intervention to"
  },
  {
    "conteudo":"improve phosphate levels in hemodialysis patients. J Ren Nutr. 2003;13(4): 267-274."
  },
  {
    "conteudo":"123. Lou LM, Caverni A, Gimeno JA, et al. Dietary intervention focused on phosphate intake in"
  },
  {
    "conteudo":"hemodialysis patients with hyperphosphoremia. Clin Nephrol. 2012;77(6): 476-483."
  },
  {
    "conteudo":"124. Karavetian M, de Vries N, Rizk R, Elzein H. Dietary educational interventions for management"
  },
  {
    "conteudo":"of hyperphosphatemia in hemodialysis patients: a systematic review and meta-analysis. Nutr"
  },
  {
    "conteudo":"Rev. 2014;72(7): 471-482."
  },
  {
    "conteudo":"125. Morey B, Walker R, Davenport A. More dietetic time, better outcome? A randomized"
  },
  {
    "conteudo":"prospective study investigating the effect of more dietetic time on phosphate control in end-"
  },
  {
    "conteudo":"stage kidney failure haemodialysis patients. Nephron. Clinical practice. 2008;109(3): c173-180."
  },
  {
    "conteudo":"126. Hernandez Morante JJ, Sanchez-Villazala A, Cutillas RC, Fuentes MC. Effectiveness of a"
  },
  {
    "conteudo":"nutrition education program for the prevention and treatment of malnutrition in end-stage"
  },
  {
    "conteudo":"renal disease. J Ren Nutr. 2014;24(1): 42-49."
  },
  {
    "conteudo":"127. Reese PP, Mgbako O, Mussell A, et al. A Pilot Randomized Trial of Financial Incentives or"
  },
  {
    "conteudo":"Coaching to Lower Serum Phosphorus in Dialysis Patients. J Ren Nutr. 2015;25(6): 510-517."
  },
  {
    "conteudo":"128. Sutton D, Higgins B, Stevens JM. Continuous ambulatory peritoneal dialysis patients are"
  },
  {
    "conteudo":"unable to increase dietary intake to recommended levels. J Ren Nutr. 2007;17(5): 329-335."
  },
  {
    "conteudo":"129. Karavetian M, Ghaddar S. Nutritional education for the management of osteodystrophy"
  },
  {
    "conteudo":"(nemo) in patients on haemodialysis: a randomised controlled trial. Journal of renal care."
  },
  {
    "conteudo":"2013;39(1): 19-30."
  },
  {
    "conteudo":"130. Dietetics AoNa. Medical Nutrition Therapy Effectiveness (MNT) Systematic Review (2013-"
  },
  {
    "conteudo":"2015)2015."
  },
  {
    "conteudo":"131. Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J"
  },
  {
    "conteudo":"Med. 2017;377(18): 1765-1776."
  },
  {
    "conteudo":"132. Bellizzi V, Di Iorio BR, De Nicola L, et al. Very low protein diet supplemented with ketoanalogs"
  },
  {
    "conteudo":"improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71(3): 245-251."
  },
  {
    "conteudo":"133. Feiten SF, Draibe SA, Watanabe R, et al. Short-term effects of a very-low-protein diet"
  },
  {
    "conteudo":"supplemented with ketoacids in nondialyzed chronic kidney disease patients. Eur J Clin Nutr."
  },
  {
    "conteudo":"2005;59(1): 129-136."
  },
  {
    "conteudo":"134. Garneata L, Stancu A, Dragomir D, Stefan G, Mircescu G. Ketoanalogue-Supplemented"
  },
  {
    "conteudo":"Vegetarian Very Low-Protein Diet and CKD Progression. J Am Soc Nephrol. 2016;27(7): 2164-"
  },
  {
    "conteudo":"2176."
  },
  {
    "conteudo":"135. Herselman MG, Albertse EC, Lombard CJ, Swanepoel CR, Hough FS. Supplemented low-protein"
  },
  {
    "conteudo":"diets--are they superior in chronic renal failure? South African medical journal = Suid-"
  },
  {
    "conteudo":"Afrikaanse tydskrif vir geneeskunde. 1995;85(5): 361-365."
  },
  {
    "conteudo":"136. Kloppenburg WD, Stegeman CA, Hovinga TK, et al. Effect of prescribing a high protein diet and"
  },
  {
    "conteudo":"increasing the dose of dialysis on nutrition in stable chronic haemodialysis patients: a"
  },
  {
    "conteudo":"randomized, controlled trial. Nephrol Dial Transplant. 2004;19(5): 1212-1223."
  },
  {
    "conteudo":"137. Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status"
  },
  {
    "conteudo":"in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;52(3): 778-791."
  },
  {
    "conteudo":"138. Kuhlmann MK, Schmidt F, Kohler H. High protein\/energy vs. standard protein\/energy"
  },
  {
    "conteudo":"nutritional regimen in the treatment of malnourished hemodialysis patients. Mineral and"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 213"
  },
  {
    "conteudo":"electrolyte metabolism. 1999;25(4-6): 306-310."
  },
  {
    "conteudo":"139. Li H, Long Q, Shao C, et al. Effect of short-term low-protein diet supplemented with keto acids"
  },
  {
    "conteudo":"on hyperphosphatemia in maintenance hemodialysis patients. Blood Purif. 2011;31(1-3): 33-"
  },
  {
    "conteudo":"40."
  },
  {
    "conteudo":"140. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective,"
  },
  {
    "conteudo":"randomised, multicentre trial of effect of protein restriction on progression of chronic renal"
  },
  {
    "conteudo":"insufficiency. Northern Italian Cooperative Study Group. Lancet (London, England)."
  },
  {
    "conteudo":"1991;337(8753): 1299-1304."
  },
  {
    "conteudo":"141. Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in"
  },
  {
    "conteudo":"chronic kidney disease. J Ren Nutr. 2007;17(3): 179-188."
  },
  {
    "conteudo":"142. Prakash S, Pande DP, Sharma S, Sharma D, Bal CS, Kulkarni H. Randomized, double-blind,"
  },
  {
    "conteudo":"placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. J"
  },
  {
    "conteudo":"Ren Nutr. 2004;14(2): 89-96."
  },
  {
    "conteudo":"143. Sanchez C, Aranda P, Planells E, et al. Influence of low-protein dietetic foods consumption on"
  },
  {
    "conteudo":"quality of life and levels of B vitamins and homocysteine in patients with chronic renal failure."
  },
  {
    "conteudo":"Nutricion hospitalaria. 2010;25(2): 238-244."
  },
  {
    "conteudo":"144. Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein and phosphate"
  },
  {
    "conteudo":"restriction to retard the rate of progression of chronic renal failure: a prospective,"
  },
  {
    "conteudo":"randomized, controlled trial. Q J Med. 1991;81(294): 837-855."
  },
  {
    "conteudo":"145. Kopple JD, Shinaberger JH, Coburn JW, Sorensen MK, Rubini ME. Optimal dietary protein"
  },
  {
    "conteudo":"treatment during chronic hemodialysis. Trans Am Soc Artif Intern Organs. 1969;15: 302-308."
  },
  {
    "conteudo":"146. Slomowitz LA, Monteon FJ, Grosvenor M, Laidlaw SA, Kopple JD. Effect of energy intake on"
  },
  {
    "conteudo":"nutritional status in maintenance hemodialysis patients. Kidney Int. 1989;35(2): 704-711."
  },
  {
    "conteudo":"147. Fouque D, Vennegoor M, ter Wee P, et al. EBPG guideline on nutrition. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2007;22 Suppl 2: ii45-87."
  },
  {
    "conteudo":"148. Cianciaruso B, Pota A, Bellizzi V, et al. Effect of a low- versus moderate-protein diet on"
  },
  {
    "conteudo":"progression of CKD: follow-up of a randomized controlled trial. American journal of kidney"
  },
  {
    "conteudo":"diseases : the official journal of the National Kidney Foundation. 2009;54(6): 1052-1061."
  },
  {
    "conteudo":"149. Cianciaruso B, Pota A, Pisani A, et al. Metabolic effects of two low protein diets in chronic"
  },
  {
    "conteudo":"kidney disease stage 4-5--a randomized controlled trial. Nephrol Dial Transplant. 2008;23(2):"
  },
  {
    "conteudo":"636-644."
  },
  {
    "conteudo":"150. D'Amico G, Gentile MG, Fellin G, Manna G, Cofano F. Effect of dietary protein restriction on"
  },
  {
    "conteudo":"the progression of renal failure: a prospective randomized trial. Nephrol Dial Transplant."
  },
  {
    "conteudo":"1994;9(11): 1590-1594."
  },
  {
    "conteudo":"151. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on"
  },
  {
    "conteudo":"prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62(1): 220-228."
  },
  {
    "conteudo":"152. Jesudason DR, Pedersen E, Clifton PM. Weight-loss diets in people with type 2 diabetes and"
  },
  {
    "conteudo":"renal disease: a randomized controlled trial of the effect of different dietary protein amounts."
  },
  {
    "conteudo":"Am J Clin Nutr. 2013;98(2): 494-501."
  },
  {
    "conteudo":"153. Locatelli F. Controlled study of protein-restricted diet in chronic renal failure. Contrib Nephrol."
  },
  {
    "conteudo":"1989;75: 141-146."
  },
  {
    "conteudo":"154. Rosman JB, Langer K, Brandl M, et al. Protein-restricted diets in chronic renal failure: a four"
  },
  {
    "conteudo":"year follow-up shows limited indications. Kidney Int Suppl. 1989;27: S96-102."
  },
  {
    "conteudo":"155. Rosman JB, ter Wee PM, Piers-Becht GP, et al. Early protein restriction in chronic renal failure."
  },
  {
    "conteudo":"Proceedings of the European Dialysis and Transplant Association - European Renal Association."
  },
  {
    "conteudo":"European Dialysis and Transplant Association - European Renal Association. Congress."
  },
  {
    "conteudo":"1985;21: 567-573."
  },
  {
    "conteudo":"156. Rosman JBtW, P. M. Relationship between proteinuria and response to low protein diets early"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 214"
  },
  {
    "conteudo":"in chronic renal failure. Blood purification. 1989;7(1): 52-57."
  },
  {
    "conteudo":"157. Meloni C, Morosetti M, Suraci C, et al. Severe dietary protein restriction in overt diabetic"
  },
  {
    "conteudo":"nephropathy: benefits or risks? J Ren Nutr. 2002;12(2): 96-101."
  },
  {
    "conteudo":"158. Coggins CHD, J. T.; Greene, T.; Petot, G.; Snetselaar, L. G.; Van Lente, F. Serum lipid changes"
  },
  {
    "conteudo":"associated with modified protein diets: results from the feasibility phase of the Modification"
  },
  {
    "conteudo":"of Diet in Renal Disease Study. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 1994;23(4): 514-523."
  },
  {
    "conteudo":"159. Jiang N, Qian J, Sun W, et al. Better preservation of residual renal function in peritoneal"
  },
  {
    "conteudo":"dialysis patients treated with a low-protein diet supplemented with keto acids: a prospective,"
  },
  {
    "conteudo":"randomized trial. Nephrol Dial Transplant. 2009;24(8): 2551-2558."
  },
  {
    "conteudo":"160. Jungers P, Chauveau P, Ployard F, Lebkiri B, Ciancioni C, Man NK. Comparison of ketoacids and"
  },
  {
    "conteudo":"low protein diet on advanced chronic renal failure progression. Kidney Int Suppl. 1987;22: S67-"
  },
  {
    "conteudo":"71."
  },
  {
    "conteudo":"161. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure"
  },
  {
    "conteudo":"control on the progression of chronic renal disease. Modification of Diet in Renal Disease"
  },
  {
    "conteudo":"Study Group. N Engl J Med. 1994;330(13): 877-884."
  },
  {
    "conteudo":"162. Levey AS, Adler S, Caggiula AW, et al. Effects of dietary protein restriction on the progression"
  },
  {
    "conteudo":"of advanced renal disease in the Modification of Diet in Renal Disease Study. American journal"
  },
  {
    "conteudo":"of kidney diseases : the official journal of the National Kidney Foundation. 1996;27(5): 652-"
  },
  {
    "conteudo":"663."
  },
  {
    "conteudo":"163. Malvy D, Maingourd C, Pengloan J, Bagros P, Nivet H. Effects of severe protein restriction with"
  },
  {
    "conteudo":"ketoanalogues in advanced renal failure. J Am Coll Nutr. 1999;18(5): 481-486."
  },
  {
    "conteudo":"164. Menon VW, X.; Greene, T.; Beck, G. J.; Kusek, J. W.; Selhub, J.; Levey, A. S.; Sarnak, M. J."
  },
  {
    "conteudo":"Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B"
  },
  {
    "conteudo":"vitamins. Kidney international. 2005;67(4): 1539-1546."
  },
  {
    "conteudo":"165. Jiang Z, Tang Y, Yang L, Mi X, Qin W. Effect of restricted protein diet supplemented with keto"
  },
  {
    "conteudo":"analogues in end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol."
  },
  {
    "conteudo":"2018;50(4): 687-694."
  },
  {
    "conteudo":"166. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes"
  },
  {
    "conteudo":"and Chronic Kidney Disease. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2007;49(2 Suppl 2): S12-154."
  },
  {
    "conteudo":"167. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic"
  },
  {
    "conteudo":"Kidney Disease. Kidney Int Suppl. 2013;3(1): 1-150."
  },
  {
    "conteudo":"168. Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of"
  },
  {
    "conteudo":"protein-restricted diet on albuminuria and renal function in IDDM patients without clinical"
  },
  {
    "conteudo":"nephropathy and hypertension. Diabetes Care. 1993;16(2): 483-492."
  },
  {
    "conteudo":"169. Dussol B, Iovanna C, Raccah D, et al. A randomized trial of low-protein diet in type 1 and in"
  },
  {
    "conteudo":"type 2 diabetes mellitus patients with incipient and overt nephropathy. J Ren Nutr."
  },
  {
    "conteudo":"2005;15(4): 398-406."
  },
  {
    "conteudo":"170. Pijls LT, de Vries H, van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and"
  },
  {
    "conteudo":"albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr."
  },
  {
    "conteudo":"2002;56(12): 1200-1207."
  },
  {
    "conteudo":"171. Raal FJ, Kalk WJ, Lawson M, et al. Effect of moderate dietary protein restriction on the"
  },
  {
    "conteudo":"progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr."
  },
  {
    "conteudo":"1994;60(4): 579-585."
  },
  {
    "conteudo":"172. Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal"
  },
  {
    "conteudo":"failure in diabetic nephropathy. Lancet (London, England). 1989;2(8677): 1411-1415."
  },
  {
    "conteudo":"173. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 215"
  },
  {
    "conteudo":"the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J"
  },
  {
    "conteudo":"Med. 1991;324(2): 78-84."
  },
  {
    "conteudo":"174. Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on"
  },
  {
    "conteudo":"kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ"
  },
  {
    "conteudo":"Open. 2013;3(5)."
  },
  {
    "conteudo":"175. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane"
  },
  {
    "conteudo":"Database Syst Rev. 2007(4): CD002181."
  },
  {
    "conteudo":"176. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD. Normalized protein"
  },
  {
    "conteudo":"nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients"
  },
  {
    "conteudo":"with Kt\/V greater than 1.20. J Ren Nutr. 2003;13(1): 15-25."
  },
  {
    "conteudo":"177. Ravel VA, Molnar MZ, Streja E, et al. Low protein nitrogen appearance as a surrogate of low"
  },
  {
    "conteudo":"dietary protein intake is associated with higher all-cause mortality in maintenance"
  },
  {
    "conteudo":"hemodialysis patients. J Nutr. 2013;143(7): 1084-1092."
  },
  {
    "conteudo":"178. Ko GJ, Kalantar-Zadeh K, Goldstein-Fuchs J, Rhee CM. Dietary Approaches in the Management"
  },
  {
    "conteudo":"of Diabetic Patients with Kidney Disease. Nutrients. 2017;9(8)."
  },
  {
    "conteudo":"179. Chauveau P, Barthe N, Rigalleau V, et al. Outcome of nutritional status and body composition"
  },
  {
    "conteudo":"of uremic patients on a very low protein diet. American journal of kidney diseases : the official"
  },
  {
    "conteudo":"journal of the National Kidney Foundation. 1999;34(3): 500-507."
  },
  {
    "conteudo":"180. Neumann D, Lamprecht J, Robinski M, Mau W, Girndt M. Social relationships and their impact"
  },
  {
    "conteudo":"on health-related outcomes in peritoneal versus haemodialysis patients: a prospective cohort"
  },
  {
    "conteudo":"study. Nephrol Dial Transplant. 2018;33(7): 1235-1244."
  },
  {
    "conteudo":"181. Wada K, Nakamura K, Tamai Y, et al. Soy isoflavone intake and breast cancer risk in Japan:"
  },
  {
    "conteudo":"from the Takayama study. Int J Cancer. 2013;133(4): 952-960."
  },
  {
    "conteudo":"182. Jing Z, Wei-Jie Y. Effects of soy protein containing isoflavones in patients with chronic kidney"
  },
  {
    "conteudo":"disease: A systematic review and meta-analysis. Clin Nutr. 2016;35(1): 117-124."
  },
  {
    "conteudo":"183. Frigolet ME, Torres N, Tovar AR. Soya protein attenuates abnormalities of the renin-"
  },
  {
    "conteudo":"angiotensin system in adipose tissue from obese rats. Br J Nutr. 2012;107(1): 36-44."
  },
  {
    "conteudo":"184. Iwasaki K, Gleiser CA, Masoro EJ, McMahan CA, Seo EJ, Yu BP. The influence of dietary protein"
  },
  {
    "conteudo":"source on longevity and age-related disease processes of Fischer rats. J Gerontol. 1988;43(1):"
  },
  {
    "conteudo":"B5-12."
  },
  {
    "conteudo":"185. Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein"
  },
  {
    "conteudo":"source and phosphorus homeostasis in chronic kidney disease. Clinical journal of the American"
  },
  {
    "conteudo":"Society of Nephrology : CJASN. 2011;6(2): 257-264."
  },
  {
    "conteudo":"186. Soroka N, Silverberg DS, Greemland M, et al. Comparison of a vegetable-based (soya) and an"
  },
  {
    "conteudo":"animal-based low-protein diet in predialysis chronic renal failure patients. Nephron."
  },
  {
    "conteudo":"1998;79(2): 173-180."
  },
  {
    "conteudo":"187. Fanti P, Asmis R, Stephenson TJ, Sawaya BP, Franke AA. Positive effect of dietary soy in ESRD"
  },
  {
    "conteudo":"patients with systemic inflammation--correlation between blood levels of the soy isoflavones"
  },
  {
    "conteudo":"and the acute-phase reactants. Nephrol Dial Transplant. 2006;21(8): 2239-2246."
  },
  {
    "conteudo":"188. Tabibi H, Imani H, Hedayati M, Atabak S, Rahmani L. Effects of soy consumption on serum"
  },
  {
    "conteudo":"lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial. Perit Dial"
  },
  {
    "conteudo":"Int. 2010;30(6): 611-618."
  },
  {
    "conteudo":"189. Chen W, Liu Y, Yang Q, et al. The Effect of Protein-Enriched Meal Replacement on Waist"
  },
  {
    "conteudo":"Circumference Reduction among Overweight and Obese Chinese with Hyperlipidemia. J Am"
  },
  {
    "conteudo":"Coll Nutr. 2016;35(3): 236-244."
  },
  {
    "conteudo":"190. Leech RM, Worsley A, Timperio A, McNaughton SA. Understanding meal patterns: definitions,"
  },
  {
    "conteudo":"methodology and impact on nutrient intake and diet quality. Nutr Res Rev. 2015;28(1): 1-21."
  },
  {
    "conteudo":"191. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 216"
  },
  {
    "conteudo":"2002;13(1): 3-9."
  },
  {
    "conteudo":"192. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a"
  },
  {
    "conteudo":"Mediterranean diet. N Engl J Med. 2013;368(14): 1279-1290."
  },
  {
    "conteudo":"193. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to"
  },
  {
    "conteudo":"Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a"
  },
  {
    "conteudo":"systematic review and meta-analysis on observational prospective studies. Nutrition."
  },
  {
    "conteudo":"2013;29(4): 611-618."
  },
  {
    "conteudo":"194. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: an"
  },
  {
    "conteudo":"updated meta-analysis and a proposal for a literature-based adherence score. Public Health"
  },
  {
    "conteudo":"Nutr. 2014;17(12): 2769-2782."
  },
  {
    "conteudo":"195. Mekki K, Bouzidi-bekada N, Kaddous A, Bouchenak M. Mediterranean diet improves"
  },
  {
    "conteudo":"dyslipidemia and biomarkers in chronic renal failure patients. Food Funct. 2010;1(1): 110-115."
  },
  {
    "conteudo":"196. Di Daniele N, Di Renzo L, Noce A, et al. Effects of Italian Mediterranean organic diet vs. low-"
  },
  {
    "conteudo":"protein diet in nephropathic patients according to MTHFR genotypes. J Nephrol. 2014;27(5):"
  },
  {
    "conteudo":"529-536."
  },
  {
    "conteudo":"197. Stachowska E, Wesolowska T, Olszewska M, et al. Elements of Mediterranean diet improve"
  },
  {
    "conteudo":"oxidative status in blood of kidney graft recipients. Br J Nutr. 2005;93(3): 345-352."
  },
  {
    "conteudo":"198. Goraya N, Simoni J, Jo CH, Wesson DE. A comparison of treating metabolic acidosis in CKD"
  },
  {
    "conteudo":"stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clinical"
  },
  {
    "conteudo":"journal of the American Society of Nephrology : CJASN. 2013;8(3): 371-381."
  },
  {
    "conteudo":"199. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage"
  },
  {
    "conteudo":"3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine"
  },
  {
    "conteudo":"angiotensinogen and preserves glomerular filtration rate. Kidney international. 2014;86(5):"
  },
  {
    "conteudo":"1031-1038."
  },
  {
    "conteudo":"200. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with fruits and vegetables or"
  },
  {
    "conteudo":"bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular"
  },
  {
    "conteudo":"filtration rate due to hypertensive nephropathy. Kidney international. 2012;81(1): 86-93."
  },
  {
    "conteudo":"201. Kelly JT, Palmer SC, Wai SN, et al. Healthy Dietary Patterns and Risk of Mortality and ESRD in"
  },
  {
    "conteudo":"CKD: A Meta-Analysis of Cohort Studies. Clinical journal of the American Society of Nephrology"
  },
  {
    "conteudo":": CJASN. 2017;12(2): 272-279."
  },
  {
    "conteudo":"202. Palmer SC, Maggo JK, Campbell KL, et al. Dietary interventions for adults with chronic kidney"
  },
  {
    "conteudo":"disease. Cochrane Database Syst Rev. 2017;4: CD011998."
  },
  {
    "conteudo":"203. Joshi S, Shah S, Kalantar-Zadeh K. Adequacy of Plant-Based Proteins in Chronic Kidney Disease."
  },
  {
    "conteudo":"J Ren Nutr. 2019;29(2): 112-117."
  },
  {
    "conteudo":"204. Alp Ikizler T, Cano NJ, Franch H, et al. Prevention and treatment of protein energy wasting in"
  },
  {
    "conteudo":"chronic kidney disease patients: a consensus statement by the International Society of Renal"
  },
  {
    "conteudo":"Nutrition and Metabolism. Kidney International. 2013;84(6): 1096-1107."
  },
  {
    "conteudo":"205. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in"
  },
  {
    "conteudo":"chronic kidney disease: a consensus statement from the International Society of Renal"
  },
  {
    "conteudo":"Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23(2): 77-90."
  },
  {
    "conteudo":"206. Rocco MV, Paranandi L, Burrowes JD, et al. Nutritional status in the HEMO Study cohort at"
  },
  {
    "conteudo":"baseline. Hemodialysis. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2002;39(2): 245-256."
  },
  {
    "conteudo":"207. Allman MA, Stewart PM, Tiller DJ, Horvath JS, Duggin GG, Truswell AS. Energy"
  },
  {
    "conteudo":"supplementation and the nutritional status of hemodialysis patients. Am J Clin Nutr."
  },
  {
    "conteudo":"1990;51(4): 558-562."
  },
  {
    "conteudo":"208. Bolasco P, Caria S, Cupisti A, Secci R, Saverio Dioguardi F. A novel amino acids oral"
  },
  {
    "conteudo":"supplementation in hemodialysis patients: a pilot study. Renal failure. 2011;33(1): 1-5."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 217"
  },
  {
    "conteudo":"209. Calegari A, Barros EG, Veronese FV, Thome FS. Malnourished patients on hemodialysis"
  },
  {
    "conteudo":"improve after receiving a nutritional intervention. J Bras Nefrol. 2011;33(4): 394-401."
  },
  {
    "conteudo":"210. Fouque D, McKenzie J, de Mutsert R, et al. Use of a renal-specific oral supplement by"
  },
  {
    "conteudo":"haemodialysis patients with low protein intake does not increase the need for phosphate"
  },
  {
    "conteudo":"binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2008;23(9): 2902-2910."
  },
  {
    "conteudo":"211. Gonzalez-Espinoza L, Gutierrez-Chavez J, del Campo FM, et al. Randomized, open label,"
  },
  {
    "conteudo":"controlled clinical trial of oral administration of an egg albumin-based protein supplement to"
  },
  {
    "conteudo":"patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2005;25(2): 173-180."
  },
  {
    "conteudo":"212. Hung SC, Tarng DC. Adiposity and insulin resistance in nondiabetic hemodialysis patients:"
  },
  {
    "conteudo":"effects of high energy supplementation. Am J Clin Nutr. 2009;90(1): 64-69."
  },
  {
    "conteudo":"213. Moretti HD, Johnson AM, Keeling-Hathaway TJ. Effects of protein supplementation in chronic"
  },
  {
    "conteudo":"hemodialysis and peritoneal dialysis patients. J Ren Nutr. 2009;19(4): 298-303."
  },
  {
    "conteudo":"214. Teixido-Planas J, Ortiz A, Coronel F, et al. Oral protein-energy supplements in peritoneal"
  },
  {
    "conteudo":"dialysis: a multicenter study. Perit Dial Int. 2005;25(2): 163-172."
  },
  {
    "conteudo":"215. Tomayko EJ, Kistler BM, Fitschen PJ, Wilund KR. Intradialytic protein supplementation reduces"
  },
  {
    "conteudo":"inflammation and improves physical function in maintenance hemodialysis patients. J Ren"
  },
  {
    "conteudo":"Nutr. 2015;25(3): 276-283."
  },
  {
    "conteudo":"216. Wilson B, Fernandez-Madrid A, Hayes A, Hermann K, Smith J, Wassell A. Comparison of the"
  },
  {
    "conteudo":"effects of two early intervention strategies on the health outcomes of malnourished"
  },
  {
    "conteudo":"hemodialysis patients. J Ren Nutr. 2001;11(3): 166-171."
  },
  {
    "conteudo":"217. Wu HL, Sung JM, Kao MD, Wang MC, Tseng CC, Chen ST. Nonprotein calorie supplement"
  },
  {
    "conteudo":"improves adherence to low-protein diet and exerts beneficial responses on renal function in"
  },
  {
    "conteudo":"chronic kidney disease. J Ren Nutr. 2013;23(4): 271-276."
  },
  {
    "conteudo":"218. Cheu C, Pearson J, Dahlerus C, et al. Association between oral nutritional supplementation and"
  },
  {
    "conteudo":"clinical outcomes among patients with ESRD. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2013;8(1): 100-107."
  },
  {
    "conteudo":"219. Scott MK, Shah NA, Vilay AM, Thomas J, 3rd, Kraus MA, Mueller BA. Effects of peridialytic oral"
  },
  {
    "conteudo":"supplements on nutritional status and quality of life in chronic hemodialysis patients. J Ren"
  },
  {
    "conteudo":"Nutr. 2009;19(2): 145-152."
  },
  {
    "conteudo":"220. Sezer S, Bal Z, Tutal E, Uyar ME, Acar NO. Long-term oral nutrition supplementation improves"
  },
  {
    "conteudo":"outcomes in malnourished patients with chronic kidney disease on hemodialysis. JPEN J"
  },
  {
    "conteudo":"Parenter Enteral Nutr. 2014;38(8): 960-965."
  },
  {
    "conteudo":"221. Hiroshige K, Iwamoto M, Kabashima N, Mutoh Y, Yuu K, Ohtani A. Prolonged use of"
  },
  {
    "conteudo":"intradialysis parenteral nutrition in elderly malnourished chronic haemodialysis patients."
  },
  {
    "conteudo":"Nephrol Dial Transplant. 1998;13(8): 2081-2087."
  },
  {
    "conteudo":"222. Hiroshige K, Sonta T, Suda T, Kanegae K, Ohtani A. Oral supplementation of branched-chain"
  },
  {
    "conteudo":"amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol"
  },
  {
    "conteudo":"Dial Transplant. 2001;16(9): 1856-1862."
  },
  {
    "conteudo":"223. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in"
  },
  {
    "conteudo":"malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J"
  },
  {
    "conteudo":"Am Soc Nephrol. 2007;18(9): 2583-2591."
  },
  {
    "conteudo":"224. Toigo G, Situlin R, Tamaro G, et al. Effect of intravenous supplementation of a new essential"
  },
  {
    "conteudo":"amino acid formulation in hemodialysis patients. Kidney Int Suppl. 1989;27: S278-281."
  },
  {
    "conteudo":"225. Marsen TA, Beer J, Mann H. Intradialytic parenteral nutrition in maintenance hemodialysis"
  },
  {
    "conteudo":"patients suffering from protein-energy wasting. Results of a multicenter, open, prospective,"
  },
  {
    "conteudo":"randomized trial. Clin Nutr. 2017;36(1): 107-117."
  },
  {
    "conteudo":"226. Kalantar-Zadeh K, Ikizler TA. Let them eat during dialysis: an overlooked opportunity to"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 218"
  },
  {
    "conteudo":"improve outcomes in maintenance hemodialysis patients. J Ren Nutr. 2013;23(3): 157-163."
  },
  {
    "conteudo":"227. Akpele L, Bailey JL. Nutrition counseling impacts serum albumin levels. J Ren Nutr. 2004;14(3):"
  },
  {
    "conteudo":"143-148."
  },
  {
    "conteudo":"228. Park MS, Choi SR, Song YS, Yoon SY, Lee SY, Han DS. New insight of amino acid-based dialysis"
  },
  {
    "conteudo":"solutions. Kidney International. 2006;70: S110-S114."
  },
  {
    "conteudo":"229. Tjiong HL, Swart R, Van den Berg JW, Fieren MW. Dialysate as food as an option for automated"
  },
  {
    "conteudo":"peritoneal dialysis. NDT Plus. 2008;1(Suppl 4): iv36-iv40."
  },
  {
    "conteudo":"230. Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an"
  },
  {
    "conteudo":"amino acid based dialysate. Kidney Int. 1995;47(4): 1148-1157."
  },
  {
    "conteudo":"231. Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal"
  },
  {
    "conteudo":"dialysis solution: results of a multicenter outpatient study. American journal of kidney diseases"
  },
  {
    "conteudo":": the official journal of the National Kidney Foundation. 1998;32(5): 761-769."
  },
  {
    "conteudo":"232. Li FK, Chan LY, Woo JC, et al. A 3-year, prospective, randomized, controlled study on amino"
  },
  {
    "conteudo":"acid dialysate in patients on CAPD. American journal of kidney diseases : the official journal of"
  },
  {
    "conteudo":"the National Kidney Foundation. 2003;42(1): 173-183."
  },
  {
    "conteudo":"233. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown EA. Six-month prospective cross-"
  },
  {
    "conteudo":"over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in"
  },
  {
    "conteudo":"patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997;17(3): 279-286."
  },
  {
    "conteudo":"234. Friedman AN, Yu Z, Tabbey R, et al. Low blood levels of long-chain n-3 polyunsaturated fatty"
  },
  {
    "conteudo":"acids in US hemodialysis patients: clinical implications. Am J Nephrol. 2012;36(5): 451-458."
  },
  {
    "conteudo":"235. Lemos JR, Alencastro MG, Konrath AV, Cargnin M, Manfro RC. Flaxseed oil supplementation"
  },
  {
    "conteudo":"decreases C-reactive protein levels in chronic hemodialysis patients. Nutr Res. 2012;32(12):"
  },
  {
    "conteudo":"921-927."
  },
  {
    "conteudo":"236. Khalatbari Soltani S, Jamaluddin R, Tabibi H, et al. Effects of flaxseed consumption on systemic"
  },
  {
    "conteudo":"inflammation and serum lipid profile in hemodialysis patients with lipid abnormalities."
  },
  {
    "conteudo":"Hemodial Int. 2013;17(2): 275-281."
  },
  {
    "conteudo":"237. Svensson M, Schmidt EB, Jorgensen KA, Christensen JH. N-3 fatty acids as secondary"
  },
  {
    "conteudo":"prevention against cardiovascular events in patients who undergo chronic hemodialysis: a"
  },
  {
    "conteudo":"randomized, placebo-controlled intervention trial. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2006;1(4): 780-786."
  },
  {
    "conteudo":"238. Berthoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E. One-year randomized controlled"
  },
  {
    "conteudo":"trial with omega-3 fatty acid-fish oil in clinical renal transplantation. Transplant Proc."
  },
  {
    "conteudo":"1992;24(6): 2578-2582."
  },
  {
    "conteudo":"239. Maachi K, Berthoux P, Burgard G, Alamartine E, Berthoux F. Results of a 1-year randomized"
  },
  {
    "conteudo":"controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple"
  },
  {
    "conteudo":"immunosuppressive therapy. Transplant Proc. 1995;27(1): 846-849."
  },
  {
    "conteudo":"240. Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and"
  },
  {
    "conteudo":"cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a"
  },
  {
    "conteudo":"randomized controlled trial. JAMA. 2012;307(17): 1809-1816."
  },
  {
    "conteudo":"241. Bowden RG, Jitomir J, Wilson RL, Gentile M. Effects of omega-3 fatty acid supplementation on"
  },
  {
    "conteudo":"lipid levels in endstage renal disease patients. J Ren Nutr. 2009;19(4): 259-266."
  },
  {
    "conteudo":"242. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME. Prophylaxis of hemodialysis graft"
  },
  {
    "conteudo":"thrombosis with fish oil: double-blind, randomized, prospective trial. J Am Soc Nephrol."
  },
  {
    "conteudo":"2002;13(1): 184-190."
  },
  {
    "conteudo":"243. Irish AB, Viecelli AK, Hawley CM, et al. Effect of Fish Oil Supplementation and Aspirin Use on"
  },
  {
    "conteudo":"Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial."
  },
  {
    "conteudo":"JAMA Intern Med. 2017;177(2): 184-193."
  },
  {
    "conteudo":"244. Bennett WM, Carpenter CB, Shapiro ME, et al. Delayed omega-3 fatty acid supplements in"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 219"
  },
  {
    "conteudo":"renal transplantation. A double-blind, placebo-controlled study. Transplantation. 1995;59(3):"
  },
  {
    "conteudo":"352-356."
  },
  {
    "conteudo":"245. Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. Effects of omega-3"
  },
  {
    "conteudo":"polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients"
  },
  {
    "conteudo":"with dyslipidemia. J Ren Nutr. 2010;20(5): 321-328."
  },
  {
    "conteudo":"246. Guebre-Egziabher F, Debard C, Drai J, et al. Differential dose effect of fish oil on inflammation"
  },
  {
    "conteudo":"and adipose tissue gene expression in chronic kidney disease patients. Nutrition. 2013;29(5):"
  },
  {
    "conteudo":"730-736."
  },
  {
    "conteudo":"247. Mori TAB, V.; Puddey, I.; Irish, A.; Cowpl,; Ca,; Beilin, L.; Dogra, G.; Watts, G. F. The effects of"
  },
  {
    "conteudo":"[omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney"
  },
  {
    "conteudo":"disease: a randomized controlled trial. Journal of hypertension. 2009;27(9): 1863-1872."
  },
  {
    "conteudo":"248. Svensson M, Christensen JH, Solling J, Schmidt EB. The effect of n-3 fatty acids on plasma lipids"
  },
  {
    "conteudo":"and lipoproteins and blood pressure in patients with CRF. American journal of kidney diseases"
  },
  {
    "conteudo":": the official journal of the National Kidney Foundation. 2004;44(1): 77-83."
  },
  {
    "conteudo":"249. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J"
  },
  {
    "conteudo":"Ren Nutr. 2000;10(4): 191-195."
  },
  {
    "conteudo":"250. Guebre-Egziabher F, Bernhard J, Geelen G, Malvoisin E, Hadj-Aissa A, Fouque D. Leptin,"
  },
  {
    "conteudo":"adiponectin, and ghrelin dysregulation in chronic kidney disease. J Ren Nutr. 2005;15(1): 116-"
  },
  {
    "conteudo":"120."
  },
  {
    "conteudo":"251. Daud ZA, Tubie B, Adams J, et al. Effects of protein and omega-3 supplementation, provided"
  },
  {
    "conteudo":"during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis"
  },
  {
    "conteudo":"patients. Vascular health and risk management. 2012;8: 187-195."
  },
  {
    "conteudo":"252. Ewers B, Riserus U, Marckmann P. Effects of unsaturated fat dietary supplements on blood"
  },
  {
    "conteudo":"lipids, and on markers of malnutrition and inflammation in hemodialysis patients. J Ren Nutr."
  },
  {
    "conteudo":"2009;19(5): 401-411."
  },
  {
    "conteudo":"253. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand"
  },
  {
    "conteudo":"J Urol Nephrol. 2000;34(1): 62-66."
  },
  {
    "conteudo":"254. Kooshki A, Taleban FA, Tabibi H, Hedayati M. Effects of omega-3 fatty acids on serum lipids,"
  },
  {
    "conteudo":"lipoprotein (a), and hematologic factors in hemodialysis patients. Renal failure. 2011;33(9):"
  },
  {
    "conteudo":"892-898."
  },
  {
    "conteudo":"255. Poulia KA, Panagiotakos DB, Tourlede E, et al. Omega-3 fatty acids supplementation does not"
  },
  {
    "conteudo":"affect serum lipids in chronic hemodialysis patients. J Ren Nutr. 2011;21(6): 479-484."
  },
  {
    "conteudo":"256. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation"
  },
  {
    "conteudo":"raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot"
  },
  {
    "conteudo":"study. Nephrol Dial Transplant. 2007;22(12): 3561-3567."
  },
  {
    "conteudo":"257. Sorensen GV, Svensson M, Strandhave C, Schmidt EB, Jorgensen KA, Christensen JH. The Effect"
  },
  {
    "conteudo":"of n-3 Fatty Acids on Small Dense Low-Density Lipoproteins in Patients With End-Stage Renal"
  },
  {
    "conteudo":"Disease: A Randomized Placebo-Controlled Intervention Study. J Ren Nutr. 2015;25(4): 376-"
  },
  {
    "conteudo":"380."
  },
  {
    "conteudo":"258. Tayebi-Khosroshahi H, Dehgan R, Habibi Asl B, et al. Effect of omega-3 supplementation on"
  },
  {
    "conteudo":"serum level of homocysteine in hemodialysis patients. Iran J Kidney Dis. 2013;7(6): 479-484."
  },
  {
    "conteudo":"259. Taziki O, Lessan-Pezeshki M, Akha O, Vasheghani F. The effect of low dose omega-3 on plasma"
  },
  {
    "conteudo":"lipids in hemodialysis patients. Saudi J Kidney Dis Transpl. 2007;18(4): 571-576."
  },
  {
    "conteudo":"260. Ramezani M, Nazemian F, Shamsara J, Koohrokhi R, Mohammadpour AH. Effect of omega-3"
  },
  {
    "conteudo":"fatty acids on plasma level of 8-isoprostane in kidney transplant patients. J Ren Nutr."
  },
  {
    "conteudo":"2011;21(2): 196-199."
  },
  {
    "conteudo":"261. Madsen T, Schmidt EB, Christensen JH. The effect of n-3 fatty acids on C-reactive protein levels"
  },
  {
    "conteudo":"in patients with chronic renal failure. J Ren Nutr. 2007;17(4): 258-263."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 220"
  },
  {
    "conteudo":"262. Gharekhani A, Khatami MR, Dashti-Khavidaki S, et al. Effects of oral supplementation with"
  },
  {
    "conteudo":"omega-3 fatty acids on nutritional state and inflammatory markers in maintenance"
  },
  {
    "conteudo":"hemodialysis patients. J Ren Nutr. 2014;24(3): 177-185."
  },
  {
    "conteudo":"263. Harving F, Svensson M, Flyvbjerg A, et al. n-3 polyunsaturated fatty acids and adiponectin in"
  },
  {
    "conteudo":"patients with end-stage renal disease. Clin Nephrol. 2015;83(5): 279-285."
  },
  {
    "conteudo":"264. Hung AM, Booker C, Ellis CD, et al. Omega-3 fatty acids inhibit the up-regulation of endothelial"
  },
  {
    "conteudo":"chemokines in maintenance hemodialysis patients. Nephrol Dial Transplant. 2015;30(2): 266-"
  },
  {
    "conteudo":"274."
  },
  {
    "conteudo":"265. Deike E, Bowden RG, Moreillon JJ, et al. The effects of fish oil supplementation on markers of"
  },
  {
    "conteudo":"inflammation in chronic kidney disease patients. J Ren Nutr. 2012;22(6): 572-577."
  },
  {
    "conteudo":"266. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and"
  },
  {
    "conteudo":"docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr. 2007;17(5): 296-"
  },
  {
    "conteudo":"304."
  },
  {
    "conteudo":"267. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks"
  },
  {
    "conteudo":"and the benefits. JAMA. 2006;296(15): 1885-1899."
  },
  {
    "conteudo":"268. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition C. Fish"
  },
  {
    "conteudo":"consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation."
  },
  {
    "conteudo":"2002;106(21): 2747-2757."
  },
  {
    "conteudo":"269. Strobel C, Jahreis G, Kuhnt K. Survey of n-3 and n-6 polyunsaturated fatty acids in fish and fish"
  },
  {
    "conteudo":"products. Lipids Health Dis. 2012;11: 144."
  },
  {
    "conteudo":"270. Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA"
  },
  {
    "conteudo":"and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric."
  },
  {
    "conteudo":"2015;95(6): 1260-1267."
  },
  {
    "conteudo":"271. Omega-3 Fatty Acids: Fact Sheet for Health Professionals: National Institute of Health; 2018."
  },
  {
    "conteudo":"272. Lok CE. Protection against Incidences of Serious Cardiovascular Events Study (PISCES)2013."
  },
  {
    "conteudo":"273. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for"
  },
  {
    "conteudo":"Hypertriglyceridemia. N Engl J Med. 2019;380(1): 11-22."
  },
  {
    "conteudo":"274. Frank T, Czeche K, Bitsch R, Stein G. Assessment of thiamin status in chronic renal failure"
  },
  {
    "conteudo":"patients, transplant recipients and hemodialysis patients receiving a multivitamin"
  },
  {
    "conteudo":"supplementation. International journal for vitamin and nutrition research. Internationale"
  },
  {
    "conteudo":"Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de"
  },
  {
    "conteudo":"nutrition. 2000;70(4): 159-166."
  },
  {
    "conteudo":"275. Hung SC, Hung SH, Tarng DC, Yang WC, Chen TW, Huang TP. Thiamine deficiency and"
  },
  {
    "conteudo":"unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. American"
  },
  {
    "conteudo":"journal of kidney diseases : the official journal of the National Kidney Foundation. 2001;38(5):"
  },
  {
    "conteudo":"941-947."
  },
  {
    "conteudo":"276. Ihara M, Ito T, Yanagihara C, Nishimura Y. Wernicke's encephalopathy associated with"
  },
  {
    "conteudo":"hemodialysis: report of two cases and review of the literature. Clin Neurol Neurosurg."
  },
  {
    "conteudo":"1999;101(2): 118-121."
  },
  {
    "conteudo":"277. Porrini M, Simonetti P, Ciappellano S, et al. Thiamin, riboflavin and pyridoxine status in chronic"
  },
  {
    "conteudo":"renal insufficiency. International journal for vitamin and nutrition research. Internationale"
  },
  {
    "conteudo":"Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de"
  },
  {
    "conteudo":"nutrition. 1989;59(3): 304-308."
  },
  {
    "conteudo":"278. Corken M, Porter J. Is vitamin B(6) deficiency an under-recognized risk in patients receiving"
  },
  {
    "conteudo":"haemodialysis? A systematic review: 2000-2010. Nephrology (Carlton). 2011;16(7): 619-625."
  },
  {
    "conteudo":"279. Kalantar-Zadeh K, Kopple JD. Trace elements and vitamins in maintenance dialysis patients."
  },
  {
    "conteudo":"Adv Ren Replace Ther. 2003;10(3): 170-182."
  },
  {
    "conteudo":"280. Kopple JD, Mercurio K, Blumenkrantz MJ, et al. Daily requirement for pyridoxine supplements"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 221"
  },
  {
    "conteudo":"in chronic renal failure. Kidney Int. 1981;19(5): 694-704."
  },
  {
    "conteudo":"281. Singer R, Rhodes HC, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in"
  },
  {
    "conteudo":"an Australian peritoneal dialysis population. Nephrology (Carlton). 2008;13(1): 17-22."
  },
  {
    "conteudo":"282. Zhang K, Li Y, Cheng X, et al. Cross-over study of influence of oral vitamin C supplementation"
  },
  {
    "conteudo":"on inflammatory status in maintenance hemodialysis patients. BMC nephrology. 2013;14: 252."
  },
  {
    "conteudo":"283. Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2"
  },
  {
    "conteudo":"supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2014;29(7): 1385-1390."
  },
  {
    "conteudo":"284. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and D status in"
  },
  {
    "conteudo":"stages 3-5 chronic kidney disease. Clinical journal of the American Society of Nephrology :"
  },
  {
    "conteudo":"CJASN. 2010;5(4): 590-597."
  },
  {
    "conteudo":"285. Schlieper G, Westenfeld R, Kruger T, et al. Circulating nonphosphorylated carboxylated matrix"
  },
  {
    "conteudo":"gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011;22(2): 387-395."
  },
  {
    "conteudo":"286. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident"
  },
  {
    "conteudo":"hemodialysis patients. Kidney Int. 2007;72(8): 1004-1013."
  },
  {
    "conteudo":"287. Tucker BM, Safadi S, Friedman AN. Is routine multivitamin supplementation necessary in US"
  },
  {
    "conteudo":"chronic adult hemodialysis patients? A systematic review. J Ren Nutr. 2015;25(3): 257-264."
  },
  {
    "conteudo":"288. Jankowska M, Rutkowski B, Debska-Slizien A. Vitamins and Microelement Bioavailability in"
  },
  {
    "conteudo":"Different Stages of Chronic Kidney Disease. Nutrients. 2017;9(3)."
  },
  {
    "conteudo":"289. Kosmadakis G, Da Costa Correia E, Carceles O, Somda F, Aguilera D. Vitamins in dialysis: who,"
  },
  {
    "conteudo":"when and how much? Renal failure. 2014;36(4): 638-650."
  },
  {
    "conteudo":"290. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular"
  },
  {
    "conteudo":"disease outcomes in kidney transplant recipients: primary results from the Folic Acid for"
  },
  {
    "conteudo":"Vascular Outcome Reduction in Transplantation trial. Circulation. 2011;123(16): 1763-1770."
  },
  {
    "conteudo":"291. Heinz J, Kropf S, Domrose U, et al. B vitamins and the risk of total mortality and cardiovascular"
  },
  {
    "conteudo":"disease in end-stage renal disease: results of a randomized controlled trial. Circulation."
  },
  {
    "conteudo":"2010;121(12): 1432-1438."
  },
  {
    "conteudo":"292. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and"
  },
  {
    "conteudo":"vascular disease in advanced chronic kidney disease and end-stage renal disease: a"
  },
  {
    "conteudo":"randomized controlled trial. JAMA. 2007;298(10): 1163-1170."
  },
  {
    "conteudo":"293. Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins"
  },
  {
    "conteudo":"in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2008;23(2): 645-653."
  },
  {
    "conteudo":"294. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Does folic acid"
  },
  {
    "conteudo":"decrease plasma homocysteine and improve endothelial function in patients with predialysis"
  },
  {
    "conteudo":"renal failure? Circulation. 2000;102(8): 871-875."
  },
  {
    "conteudo":"295. van Guldener C, Janssen MJ, Lambert J, et al. No change in impaired endothelial function after"
  },
  {
    "conteudo":"long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol"
  },
  {
    "conteudo":"Dial Transplant. 1998;13(1): 106-112."
  },
  {
    "conteudo":"296. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels"
  },
  {
    "conteudo":"and vascular disease in hemodialysis patients. Med Sci Monit. 2003;9(4): PI19-24."
  },
  {
    "conteudo":"297. Vianna AC, Mocelin AJ, Matsuo T, et al. Uremic hyperhomocysteinemia: a randomized trial of"
  },
  {
    "conteudo":"folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007;11(2): 210-"
  },
  {
    "conteudo":"216."
  },
  {
    "conteudo":"298. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized"
  },
  {
    "conteudo":"trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc"
  },
  {
    "conteudo":"Nephrol. 2004;15(2): 420-426."
  },
  {
    "conteudo":"299. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 222"
  },
  {
    "conteudo":"Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a"
  },
  {
    "conteudo":"multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47(6): 1108-1116."
  },
  {
    "conteudo":"300. Chang TY, Chou KJ, Tseng CF, et al. Effects of folic acid and vitamin B complex on serum C-"
  },
  {
    "conteudo":"reactive protein and albumin levels in stable hemodialysis patients. Curr Med Res Opin."
  },
  {
    "conteudo":"2007;23(8): 1879-1886."
  },
  {
    "conteudo":"301. Tungkasereerak P, Ong-ajyooth L, Chaiyasoot W, et al. Effect of short-term folate and vitamin"
  },
  {
    "conteudo":"B supplementation on blood homocysteine level and carotid artery wall thickness in chronic"
  },
  {
    "conteudo":"hemodialysis patients. J Med Assoc Thai. 2006;89(8): 1187-1193."
  },
  {
    "conteudo":"302. Xu X, Qin X, Li Y, et al. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney"
  },
  {
    "conteudo":"Disease: The Renal Substudy of the China Stroke Primary Prevention Trial. JAMA Intern Med."
  },
  {
    "conteudo":"2016;176(10): 1443-1450."
  },
  {
    "conteudo":"303. Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T. Folic"
  },
  {
    "conteudo":"acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in"
  },
  {
    "conteudo":"hemodialysis patients. Nutrition. 2007;23(3): 242-247."
  },
  {
    "conteudo":"304. Bernasconi AR, Liste A, Del Pino N, Rosa Diez GJ, Heguilen RM. Folic acid 5 or 15 mg\/d similarly"
  },
  {
    "conteudo":"reduces plasma homocysteine in patients with moderate-advanced chronic renal failure."
  },
  {
    "conteudo":"Nephrology (Carlton). 2006;11(2): 137-141."
  },
  {
    "conteudo":"305. De Vecchi AF, Patrosso C, Novembrino C, et al. Folate supplementation in peritoneal dialysis"
  },
  {
    "conteudo":"patients with normal erythrocyte folate: effect on plasma homocysteine. Nephron. 2001;89(3):"
  },
  {
    "conteudo":"297-302."
  },
  {
    "conteudo":"306. McGregor D, Shand B, Lynn K. A controlled trial of the effect of folate supplements on"
  },
  {
    "conteudo":"homocysteine, lipids and hemorheology in end-stage renal disease. Nephron. 2000;85(3): 215-"
  },
  {
    "conteudo":"220."
  },
  {
    "conteudo":"307. Nafar M, Khatami F, Kardavani B, et al. Role of folic acid in atherosclerosis after kidney"
  },
  {
    "conteudo":"transplant: a double-blind, randomized, placebo-controlled clinical trial. Exp Clin Transplant."
  },
  {
    "conteudo":"2009;7(1): 33-39."
  },
  {
    "conteudo":"308. Ossareh S, Shayan-Moghaddam H, Salimi A, Asgari M, Farrokhi F. Different doses of oral folic"
  },
  {
    "conteudo":"acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled"
  },
  {
    "conteudo":"trial. Iran J Kidney Dis. 2009;3(4): 227-233."
  },
  {
    "conteudo":"309. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on"
  },
  {
    "conteudo":"hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am"
  },
  {
    "conteudo":"Soc Nephrol. 2000;11(6): 1106-1116."
  },
  {
    "conteudo":"310. Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH. Efficacy of folate and"
  },
  {
    "conteudo":"vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Saudi J Kidney"
  },
  {
    "conteudo":"Dis Transpl. 2009;20(5): 779-788."
  },
  {
    "conteudo":"311. Bostom AG, Shemin D, Nadeau MR, et al. Short term betaine therapy fails to lower elevated"
  },
  {
    "conteudo":"fasting total plasma homocysteine concentrations in hemodialysis patients maintained on"
  },
  {
    "conteudo":"chronic folic acid supplementation. Atherosclerosis. 1995;113(1): 129-132."
  },
  {
    "conteudo":"312. Chiu YW, Chang JM, Hwang SJ, Tsai JC, Chen HC. Pharmacological dose of vitamin B12 is as"
  },
  {
    "conteudo":"effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis"
  },
  {
    "conteudo":"patients. Renal failure. 2009;31(4): 278-283."
  },
  {
    "conteudo":"313. Gonin JM, Nguyen H, Gonin R, et al. Controlled trials of very high dose folic acid, vitamins B12"
  },
  {
    "conteudo":"and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J"
  },
  {
    "conteudo":"Nephrol. 2003;16(4): 522-534."
  },
  {
    "conteudo":"314. Nakhoul F, Abassi Z, Plawner M, et al. Comparative study of response to treatment with"
  },
  {
    "conteudo":"supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients. Isr Med"
  },
  {
    "conteudo":"Assoc J. 2004;6(4): 213-217."
  },
  {
    "conteudo":"315. Tamadon MR, Jamshidi L, Soliemani A, Ghorbani R, Malek F, Malek M. Effect of different doses"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 223"
  },
  {
    "conteudo":"of folic acid on serum homocysteine level in patients on hemodialysis. Iran J Kidney Dis."
  },
  {
    "conteudo":"2011;5(2): 93-96."
  },
  {
    "conteudo":"316. Trimarchi H, Schiel A, Freixas E, Diaz M. Randomized trial of methylcobalamin and folate"
  },
  {
    "conteudo":"effects on homocysteine in hemodialysis patients. Nephron. 2002;91(1): 58-63."
  },
  {
    "conteudo":"317. Abdollahzad H, Eghtesadi S, Nourmohammadi I, Khadem-Ansari M, Nejad-Gashti H,"
  },
  {
    "conteudo":"Esmaillzadeh A. Effect of vitamin C supplementation on oxidative stress and lipid profiles in"
  },
  {
    "conteudo":"hemodialysis patients. International journal for vitamin and nutrition research. Internationale"
  },
  {
    "conteudo":"Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de"
  },
  {
    "conteudo":"nutrition. 2009;79(5-6): 281-287."
  },
  {
    "conteudo":"318. Biniaz V, Tayebi A, Ebadi A, Sadeghi Shermeh M, Einollahi B. Effect of vitamin C"
  },
  {
    "conteudo":"supplementation on serum uric acid in patients undergoing hemodialysis: a randomized"
  },
  {
    "conteudo":"controlled trial. Iran J Kidney Dis. 2014;8(5): 401-407."
  },
  {
    "conteudo":"319. Fumeron C, Nguyen-Khoa T, Saltiel C, et al. Effects of oral vitamin C supplementation on"
  },
  {
    "conteudo":"oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant."
  },
  {
    "conteudo":"2005;20(9): 1874-1879."
  },
  {
    "conteudo":"320. Khajehdehi P, Mojerlou M, Behzadi S, Rais-Jalali GA. A randomized, double-blind, placebo-"
  },
  {
    "conteudo":"controlled trial of supplementary vitamins E, C and their combination for treatment of"
  },
  {
    "conteudo":"haemodialysis cramps. Nephrol Dial Transplant. 2001;16(7): 1448-1451."
  },
  {
    "conteudo":"321. Singer RF. Vitamin C supplementation in kidney failure: effect on uraemic symptoms. Nephrol"
  },
  {
    "conteudo":"Dial Transplant. 2011;26(2): 614-620."
  },
  {
    "conteudo":"322. De Vriese AS, Borrey D, Mahieu E, et al. Oral vitamin C administration increases lipid"
  },
  {
    "conteudo":"peroxidation in hemodialysis patients. Nephron. Clinical practice. 2008;108(1): c28-34."
  },
  {
    "conteudo":"323. Ono K. The effect of vitamin C supplementation and withdrawal on the mortality and"
  },
  {
    "conteudo":"morbidity of regular hemodialysis patients. Clin Nephrol. 1989;31(1): 31-34."
  },
  {
    "conteudo":"324. IOM. Food and Nutrition Board. Dietary Reference Intakes: Vitamin C, Vitamin E, Selenium and"
  },
  {
    "conteudo":"Carotenoids. Washington, DC: National Academy Press; 2000."
  },
  {
    "conteudo":"325. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3): 266-281."
  },
  {
    "conteudo":"326. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-"
  },
  {
    "conteudo":"sectional study across latitudes in the United States. American journal of kidney diseases : the"
  },
  {
    "conteudo":"official journal of the National Kidney Foundation. 2005;45(6): 1026-1033."
  },
  {
    "conteudo":"327. Taskapan H, Ersoy FF, Passadakis PS, et al. Severe vitamin D deficiency in chronic renal failure"
  },
  {
    "conteudo":"patients on peritoneal dialysis. Clin Nephrol. 2006;66(4): 247-255."
  },
  {
    "conteudo":"328. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of"
  },
  {
    "conteudo":"vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab."
  },
  {
    "conteudo":"2011;96(7): 1911-1930."
  },
  {
    "conteudo":"329. Barreto Silva MI, Cavalieri VV, Lemos CC, Klein MR, Bregman R. Body adiposity predictors of"
  },
  {
    "conteudo":"vitamin D status in nondialyzed patients with chronic kidney disease: A cross-sectional analysis"
  },
  {
    "conteudo":"in a tropical climate city. Nutrition. 2017;33: 240-247."
  },
  {
    "conteudo":"330. Caravaca-Fontan F, Gonzales-Candia B, Luna E, Caravaca F. Relative importance of the"
  },
  {
    "conteudo":"determinants of serum levels of 25-hydroxy vitamin D in patients with chronic kidney disease."
  },
  {
    "conteudo":"Nefrologia. 2016;36(5): 510-516."
  },
  {
    "conteudo":"331. Cuppari L, Carvalho AB, Draibe SA. Vitamin D status of chronic kidney disease patients living in"
  },
  {
    "conteudo":"a sunny country. J Ren Nutr. 2008;18(5): 408-414."
  },
  {
    "conteudo":"332. Takemoto F, Shinki T, Yokoyama K, et al. Gene expression of vitamin D hydroxylase and"
  },
  {
    "conteudo":"megalin in the remnant kidney of nephrectomized rats. Kidney Int. 2003;64(2): 414-420."
  },
  {
    "conteudo":"333. KDIGO. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation,"
  },
  {
    "conteudo":"Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)."
  },
  {
    "conteudo":"Kidney International Supplements. 2017;7: 1-59."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 224"
  },
  {
    "conteudo":"334. KDOQI. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney"
  },
  {
    "conteudo":"disease. American journal of kidney diseases : the official journal of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2003;42(4 Suppl 3): S1-201."
  },
  {
    "conteudo":"335. Bhan I, Dobens D, Tamez H, et al. Nutritional vitamin D supplementation in dialysis: a"
  },
  {
    "conteudo":"randomized trial. Clinical journal of the American Society of Nephrology : CJASN. 2015;10(4):"
  },
  {
    "conteudo":"611-619."
  },
  {
    "conteudo":"336. Miskulin DC, Majchrzak K, Tighiouart H, et al. Ergocalciferol Supplementation in Hemodialysis"
  },
  {
    "conteudo":"Patients With Vitamin D Deficiency: A Randomized Clinical Trial. J Am Soc Nephrol. 2016;27(6):"
  },
  {
    "conteudo":"1801-1810."
  },
  {
    "conteudo":"337. Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in"
  },
  {
    "conteudo":"patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-"
  },
  {
    "conteudo":"controlled trial. Am J Clin Nutr. 2012;96(3): 672-679."
  },
  {
    "conteudo":"338. Alvarez JA, Zughaier SM, Law J, et al. Effects of high-dose cholecalciferol on serum markers of"
  },
  {
    "conteudo":"inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr."
  },
  {
    "conteudo":"2013;67(3): 264-269."
  },
  {
    "conteudo":"339. Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R. 25-Hydroxyvitamin D response to"
  },
  {
    "conteudo":"cholecalciferol supplementation in hemodialysis. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2012;7(9): 1428-1434."
  },
  {
    "conteudo":"340. Chandra P, Binongo JN, Ziegler TR, et al. Cholecalciferol (vitamin D3) therapy and vitamin D"
  },
  {
    "conteudo":"insufficiency in patients with chronic kidney disease: a randomized controlled pilot study."
  },
  {
    "conteudo":"Endocr Pract. 2008;14(1): 10-17."
  },
  {
    "conteudo":"341. Delanaye P, Weekers L, Warling X, et al. Cholecalciferol in haemodialysis patients: a"
  },
  {
    "conteudo":"randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant."
  },
  {
    "conteudo":"2013;28(7): 1779-1786."
  },
  {
    "conteudo":"342. Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ. Effects of cholecalciferol on functional,"
  },
  {
    "conteudo":"biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clinical journal of"
  },
  {
    "conteudo":"the American Society of Nephrology : CJASN. 2013;8(7): 1143-1149."
  },
  {
    "conteudo":"343. Mager DR, Jackson ST, Hoffmann MR, Jindal K, Senior PA. Vitamin D3 supplementation, bone"
  },
  {
    "conteudo":"health and quality of life in adults with diabetes and chronic kidney disease: Results of an"
  },
  {
    "conteudo":"open label randomized clinical trial. Clin Nutr. 2017;36(3): 686-696."
  },
  {
    "conteudo":"344. Marckmann P, Agerskov H, Thineshkumar S, et al. Randomized controlled trial of"
  },
  {
    "conteudo":"cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D."
  },
  {
    "conteudo":"Nephrol Dial Transplant. 2012;27(9): 3523-3531."
  },
  {
    "conteudo":"345. Massart A, Debelle FD, Racape J, et al. Biochemical parameters after cholecalciferol repletion"
  },
  {
    "conteudo":"in hemodialysis: results From the VitaDial randomized trial. American journal of kidney"
  },
  {
    "conteudo":"diseases : the official journal of the National Kidney Foundation. 2014;64(5): 696-705."
  },
  {
    "conteudo":"346. Meireles MS, Kamimura MA, Dalboni MA, Giffoni de Carvalho JT, Aoike DT, Cuppari L. Effect of"
  },
  {
    "conteudo":"cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in"
  },
  {
    "conteudo":"dialysis patients: A randomized controlled trial. Clin Nutr. 2016;35(6): 1251-1258."
  },
  {
    "conteudo":"347. Seibert E, Lehmann U, Riedel A, et al. Vitamin D3 supplementation does not modify"
  },
  {
    "conteudo":"cardiovascular risk profile of adults with inadequate vitamin D status. Eur J Nutr. 2017;56(2):"
  },
  {
    "conteudo":"621-634."
  },
  {
    "conteudo":"348. Tokmak F, Quack I, Schieren G, et al. High-dose cholecalciferol to correct vitamin D deficiency"
  },
  {
    "conteudo":"in haemodialysis patients. Nephrol Dial Transplant. 2008;23(12): 4016-4020."
  },
  {
    "conteudo":"349. Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D"
  },
  {
    "conteudo":"supplementation in chronic kidney disease: a systematic review and meta-analysis of"
  },
  {
    "conteudo":"observational studies and randomized controlled trials. Clinical journal of the American Society"
  },
  {
    "conteudo":"of Nephrology : CJASN. 2011;6(1): 50-62."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 225"
  },
  {
    "conteudo":"350. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and"
  },
  {
    "conteudo":"albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)."
  },
  {
    "conteudo":"American journal of kidney diseases : the official journal of the National Kidney Foundation."
  },
  {
    "conteudo":"2007;50(1): 69-77."
  },
  {
    "conteudo":"351. Damasiewicz MJ, Magliano DJ, Daly RM, et al. Serum 25-hydroxyvitamin D deficiency and the"
  },
  {
    "conteudo":"5-year incidence of CKD. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2013;62(1): 58-66."
  },
  {
    "conteudo":"352. Levin A, Tang M, Perry T, et al. Randomized Controlled Trial for the Effect of Vitamin D"
  },
  {
    "conteudo":"Supplementation on Vascular Stiffness in CKD. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2017;12(9): 1447-1460."
  },
  {
    "conteudo":"353. Susantitaphong P, Nakwan S, Peerapornratana S, et al. A double-blind, randomized, placebo-"
  },
  {
    "conteudo":"controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic"
  },
  {
    "conteudo":"kidney disease with proteinuria. BMC nephrology. 2017;18(1): 19."
  },
  {
    "conteudo":"354. Foundation NK. Evaluation and Treatment of Chronic Kidney Disease-Mineral and Bone"
  },
  {
    "conteudo":"Disorder (CKD-MBD)2010."
  },
  {
    "conteudo":"355. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3"
  },
  {
    "conteudo":"supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-"
  },
  {
    "conteudo":"analysis. Am J Clin Nutr. 2012;95(6): 1357-1364."
  },
  {
    "conteudo":"356. (IOM) IoM. Dietary Reference Intakes for Calcium and Vitamin D, Institute of Medicine (US)"
  },
  {
    "conteudo":"Committee to Review Dietary Reference Intakes for Vitamin D and Calcium: National"
  },
  {
    "conteudo":"Academies Press; 2011."
  },
  {
    "conteudo":"357. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis:"
  },
  {
    "conteudo":"high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med."
  },
  {
    "conteudo":"2005;142(1): 37-46."
  },
  {
    "conteudo":"358. Takouli L, Hadjiyannakos D, Metaxaki P, et al. Vitamin E-coated cellulose acetate dialysis"
  },
  {
    "conteudo":"membrane: long-term effect on inflammation and oxidative stress. Renal failure. 2010;32(3):"
  },
  {
    "conteudo":"287-293."
  },
  {
    "conteudo":"359. Zweiger C NM, Storr M et al. Chapter 2: Progress in the development of membranes for kidney"
  },
  {
    "conteudo":"-replacement therapy. In: Drioli E GL, ed. Comprehensive Membrane Science and Engineering."
  },
  {
    "conteudo":"United Kingdom: Elsevier; 2013:351-387."
  },
  {
    "conteudo":"360. Huang J, Yi B, Li AM, Zhang H. Effects of vitamin E-coated dialysis membranes on anemia,"
  },
  {
    "conteudo":"nutrition and dyslipidemia status in hemodialysis patients: a meta-analysis. Renal failure."
  },
  {
    "conteudo":"2015;37(3): 398-407."
  },
  {
    "conteudo":"361. Ahmadi A, Mazooji N, Roozbeh J, Mazloom Z, Hasanzade J. Effect of alpha-lipoic acid and"
  },
  {
    "conteudo":"vitamin E supplementation on oxidative stress, inflammation, and malnutrition in"
  },
  {
    "conteudo":"hemodialysis patients. Iran J Kidney Dis. 2013;7(6): 461-467."
  },
  {
    "conteudo":"362. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of"
  },
  {
    "conteudo":"cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial."
  },
  {
    "conteudo":"Lancet (London, England). 2000;356(9237): 1213-1218."
  },
  {
    "conteudo":"363. Daud ZA, Tubie B, Sheyman M, et al. Vitamin E tocotrienol supplementation improves lipid"
  },
  {
    "conteudo":"profiles in chronic hemodialysis patients. Vascular health and risk management. 2013;9: 747-"
  },
  {
    "conteudo":"761."
  },
  {
    "conteudo":"364. Himmelfarb J, Ikizler TA, Ellis C, et al. Provision of antioxidant therapy in hemodialysis (PATH):"
  },
  {
    "conteudo":"a randomized clinical trial. J Am Soc Nephrol. 2014;25(3): 623-633."
  },
  {
    "conteudo":"365. Hodkova M, Dusilova-Sulkova S, Kalousova M, et al. Influence of oral vitamin E therapy on"
  },
  {
    "conteudo":"micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients."
  },
  {
    "conteudo":"Renal failure. 2006;28(5): 395-399."
  },
  {
    "conteudo":"366. Mann JF, Lonn EM, Yi Q, et al. Effects of vitamin E on cardiovascular outcomes in people with"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 226"
  },
  {
    "conteudo":"mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int. 2004;65(4): 1375-"
  },
  {
    "conteudo":"1380."
  },
  {
    "conteudo":"367. Ramos LF, Kane J, McMonagle E, et al. Effects of combination tocopherols and alpha lipoic acid"
  },
  {
    "conteudo":"therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Ren"
  },
  {
    "conteudo":"Nutr. 2011;21(3): 211-218."
  },
  {
    "conteudo":"368. Harshman SG, Saltzman E, Booth SL. Vitamin K: dietary intake and requirements in different"
  },
  {
    "conteudo":"clinical conditions. Curr Opin Clin Nutr Metab Care. 2014;17(6): 531-538."
  },
  {
    "conteudo":"369. Card DJ, Gorska R, Cutler J, Harrington DJ. Vitamin K metabolism: current knowledge and"
  },
  {
    "conteudo":"future research. Mol Nutr Food Res. 2014;58(8): 1590-1600."
  },
  {
    "conteudo":"370. . Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper,"
  },
  {
    "conteudo":"Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington"
  },
  {
    "conteudo":"(DC)2001."
  },
  {
    "conteudo":"371. Shearer MJ, Newman P. Recent trends in the metabolism and cell biology of vitamin K with"
  },
  {
    "conteudo":"special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 2014;55(3): 345-362."
  },
  {
    "conteudo":"372. Fusaro M, D'Alessandro C, Noale M, et al. Low vitamin K1 intake in haemodialysis patients."
  },
  {
    "conteudo":"Clinical nutrition. 2017;36(2): 601-607."
  },
  {
    "conteudo":"373. Pineo GF, Gallus AS, Hirsh J. Unexpected vitamin K deficiency in hospitalized patients. Can Med"
  },
  {
    "conteudo":"Assoc J. 1973;109(9): 880-883."
  },
  {
    "conteudo":"374. Williams KJ, Bax RP, Brown H, Machin SJ. Antibiotic treatment and associated prolonged"
  },
  {
    "conteudo":"prothrombin time. J Clin Pathol. 1991;44(9): 738-741."
  },
  {
    "conteudo":"375. Cheung CL, Sahni S, Cheung BM, Sing CW, Wong IC. Vitamin K intake and mortality in people"
  },
  {
    "conteudo":"with chronic kidney disease from NHANES III. Clinical nutrition. 2015;34(2): 235-240."
  },
  {
    "conteudo":"376. Thamratnopkoon S, Susantitaphong P, Tumkosit M, et al. Correlations of Plasma"
  },
  {
    "conteudo":"Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and"
  },
  {
    "conteudo":"Vascular Stiffness in Chronic Kidney Disease. Nephron. 2017;135(3): 167-172."
  },
  {
    "conteudo":"377. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional"
  },
  {
    "conteudo":"vitamin K deficiency in hemodialysis patients: a randomized trial. American journal of kidney"
  },
  {
    "conteudo":"diseases : the official journal of the National Kidney Foundation. 2012;59(2): 186-195."
  },
  {
    "conteudo":"378. Holden RM, Booth SL, Day AG, et al. Inhibiting the progression of arterial calcification with"
  },
  {
    "conteudo":"vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a"
  },
  {
    "conteudo":"randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health"
  },
  {
    "conteudo":"Dis. 2015;2: 17."
  },
  {
    "conteudo":"379. Krueger T, Schlieper G, Schurgers L, et al. Vitamin K1 to slow vascular calcification in"
  },
  {
    "conteudo":"haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2014;29(9): 1633-1638."
  },
  {
    "conteudo":"380. Chen B, Lamberts LV, Behets GJ, et al. Selenium, lead, and cadmium levels in renal failure"
  },
  {
    "conteudo":"patients in China. Biol Trace Elem Res. 2009;131(1): 1-12."
  },
  {
    "conteudo":"381. Chen J, Peng H, Zhang K, et al. The insufficiency intake of dietary micronutrients associated"
  },
  {
    "conteudo":"with malnutrition-inflammation score in hemodialysis population. PLoS One. 2013;8(6):"
  },
  {
    "conteudo":"e66841."
  },
  {
    "conteudo":"382. Fujishima Y, Ohsawa M, Itai K, et al. Serum selenium levels are inversely associated with death"
  },
  {
    "conteudo":"risk among hemodialysis patients. Nephrol Dial Transplant. 2011;26(10): 3331-3338."
  },
  {
    "conteudo":"383. Marti del Moral L, Agil A, Navarro-Alarcon M, Lopez-Ga de la Serrana H, Palomares-Bayo M,"
  },
  {
    "conteudo":"Oliveras-Lopez MJ. Altered serum selenium and uric acid levels and dyslipidemia in"
  },
  {
    "conteudo":"hemodialysis patients could be associated with enhanced cardiovascular risk. Biol Trace Elem"
  },
  {
    "conteudo":"Res. 2011;144(1-3): 496-503."
  },
  {
    "conteudo":"384. Prasad AS. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp"
  },
  {
    "conteudo":"Gerontol. 2008;43(5): 370-377."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 227"
  },
  {
    "conteudo":"385. Foster M, Samman S. Zinc and regulation of inflammatory cytokines: implications for"
  },
  {
    "conteudo":"cardiometabolic disease. Nutrients. 2012;4(7): 676-694."
  },
  {
    "conteudo":"386. Prasad AS. Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health."
  },
  {
    "conteudo":"Front Nutr. 2014;1: 14."
  },
  {
    "conteudo":"387. Shen H, Oesterling E, Stromberg A, Toborek M, MacDonald R, Hennig B. Zinc deficiency"
  },
  {
    "conteudo":"induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling."
  },
  {
    "conteudo":"J Am Coll Nutr. 2008;27(5): 577-587."
  },
  {
    "conteudo":"388. Cooper-Capetini V, de Vasconcelos DAA, Martins AR, et al. Zinc Supplementation Improves"
  },
  {
    "conteudo":"Glucose Homeostasis in High Fat-Fed Mice by Enhancing Pancreatic beta-Cell Function."
  },
  {
    "conteudo":"Nutrients. 2017;9(10)."
  },
  {
    "conteudo":"389. Ott ES, Shay NF. Zinc deficiency reduces leptin gene expression and leptin secretion in rat"
  },
  {
    "conteudo":"adipocytes. Exp Biol Med (Maywood). 2001;226(9): 841-846."
  },
  {
    "conteudo":"390. Bozalioglu S, Ozkan Y, Turan M, Simsek B. Prevalence of zinc deficiency and immune response"
  },
  {
    "conteudo":"in short-term hemodialysis. J Trace Elem Med Biol. 2005;18(3): 243-249."
  },
  {
    "conteudo":"391. Hsieh YY, Shen WS, Lee LY, Wu TL, Ning HC, Sun CF. Long-term changes in trace elements in"
  },
  {
    "conteudo":"patients undergoing chronic hemodialysis. Biol Trace Elem Res. 2006;109(2): 115-121."
  },
  {
    "conteudo":"392. Kiziltas H, Ekin S, Erkoc R. Trace element status of chronic renal patients undergoing"
  },
  {
    "conteudo":"hemodialysis. Biol Trace Elem Res. 2008;124(2): 103-109."
  },
  {
    "conteudo":"393. Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W. Antioxidant status in patients on"
  },
  {
    "conteudo":"chronic hemodialysis therapy: impact of parenteral selenium supplementation. Wien Klin"
  },
  {
    "conteudo":"Wochenschr. 1997;109(1): 13-19."
  },
  {
    "conteudo":"394. Stockler-Pinto MB, Lobo J, Moraes C, et al. Effect of Brazil nut supplementation on plasma"
  },
  {
    "conteudo":"levels of selenium in hemodialysis patients: 12 months of follow-up. J Ren Nutr. 2012;22(4):"
  },
  {
    "conteudo":"434-439."
  },
  {
    "conteudo":"395. Temple KA, Smith AM, Cockram DB. Selenate-supplemented nutritional formula increases"
  },
  {
    "conteudo":"plasma selenium in hemodialysis patients. J Ren Nutr. 2000;10(1): 16-23."
  },
  {
    "conteudo":"396. Tonelli M, Wiebe N, Thompson S, et al. Trace element supplementation in hemodialysis"
  },
  {
    "conteudo":"patients: a randomized controlled trial. BMC nephrology. 2015;16: 52."
  },
  {
    "conteudo":"397. Salehi M, Sohrabi Z, Ekramzadeh M, et al. Selenium supplementation improves the nutritional"
  },
  {
    "conteudo":"status of hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Nephrol"
  },
  {
    "conteudo":"Dial Transplant. 2013;28(3): 716-723."
  },
  {
    "conteudo":"398. Adamowicz A, Trafikowska U, Trafikowska A, Zachara B, Manitius J. Effect of erythropoietin"
  },
  {
    "conteudo":"therapy and selenium supplementation on selected antioxidant parameters in blood of uremic"
  },
  {
    "conteudo":"patients on long-term hemodialysis. Med Sci Monit. 2002;8(3): CR202-205."
  },
  {
    "conteudo":"399. Argani H, Mahdavi R, Ghorbani-haghjo A, Razzaghi R, Nikniaz L, Gaemmaghami SJ. Effects of"
  },
  {
    "conteudo":"zinc supplementation on serum zinc and leptin levels, BMI, and body composition in"
  },
  {
    "conteudo":"hemodialysis patients. J Trace Elem Med Biol. 2014;28(1): 35-38."
  },
  {
    "conteudo":"400. Guo CH, Chen PC, Hsu GS, Wang CL. Zinc supplementation alters plasma aluminum and"
  },
  {
    "conteudo":"selenium status of patients undergoing dialysis: a pilot study. Nutrients. 2013;5(4): 1456-1470."
  },
  {
    "conteudo":"401. Jern NA, VanBeber AD, Gorman MA, Weber CG, Liepa GU, Cochran CC. The effects of zinc"
  },
  {
    "conteudo":"supplementation on serum zinc concentration and protein catabolic rate in hemodialysis"
  },
  {
    "conteudo":"patients. J Ren Nutr. 2000;10(3): 148-153."
  },
  {
    "conteudo":"402. Chevalier CA, Liepa G, Murphy MD, et al. The effects of zinc supplementation on serum zinc"
  },
  {
    "conteudo":"and cholesterol concentrations in hemodialysis patients. J Ren Nutr. 2002;12(3): 183-189."
  },
  {
    "conteudo":"403. Rahimi-Ardabili B, Argani H, Ghorbanihaghjo A, et al. Paraoxonase enzyme activity is enhanced"
  },
  {
    "conteudo":"by zinc supplementation in hemodialysis patients. Renal failure. 2012;34(9): 1123-1128."
  },
  {
    "conteudo":"404. Roozbeh J, Hedayati P, Sagheb MM, et al. Effect of zinc supplementation on triglyceride,"
  },
  {
    "conteudo":"cholesterol, LDL, and HDL levels in zinc-deficient hemodialysis patients. Renal failure."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 228"
  },
  {
    "conteudo":"2009;31(9): 798-801."
  },
  {
    "conteudo":"405. Pakfetrat M, Malekmakan L, Hasheminasab M. Diminished selenium levels in hemodialysis and"
  },
  {
    "conteudo":"continuous ambulatory peritoneal dialysis patients. Biol Trace Elem Res. 2010;137(3): 335-339."
  },
  {
    "conteudo":"406. Guo CH, Wang CL. Effects of zinc supplementation on plasma copper\/zinc ratios, oxidative"
  },
  {
    "conteudo":"stress, and immunological status in hemodialysis patients. Int J Med Sci. 2013;10(1): 79-89."
  },
  {
    "conteudo":"407. Mazani M, Argani H, Rashtchizadeh N, et al. Effects of zinc supplementation on antioxidant"
  },
  {
    "conteudo":"status and lipid peroxidation in hemodialysis patients. J Ren Nutr. 2013;23(3): 180-184."
  },
  {
    "conteudo":"408. Zachara BA, Adamowicz A, Trafikowska U, Trafikowska A, Manitius J, Nartowicz E. Selenium"
  },
  {
    "conteudo":"and glutathione levels, and glutathione peroxidase activities in blood components of uremic"
  },
  {
    "conteudo":"patients on hemodialysis supplemented with selenium and treated with erythropoietin. J"
  },
  {
    "conteudo":"Trace Elem Med Biol. 2001;15(4): 201-208."
  },
  {
    "conteudo":"409. Nagraj SK, Naresh S, Srinivas K, et al. Interventions for the management of taste disturbances."
  },
  {
    "conteudo":"Cochrane Database Syst Rev. 2014(11): CD010470."
  },
  {
    "conteudo":"410. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation"
  },
  {
    "conteudo":"slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9): 2075-"
  },
  {
    "conteudo":"2084."
  },
  {
    "conteudo":"411. Szeto CC, Wong TY, Chow KM, Leung CB, Li PK. Oral sodium bicarbonate for the treatment of"
  },
  {
    "conteudo":"metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. J Am Soc"
  },
  {
    "conteudo":"Nephrol. 2003;14(8): 2119-2126."
  },
  {
    "conteudo":"412. Kooman JP, Deutz NE, Zijlmans P, et al. The influence of bicarbonate supplementation on"
  },
  {
    "conteudo":"plasma levels of branched-chain amino acids in haemodialysis patients with metabolic"
  },
  {
    "conteudo":"acidosis. Nephrol Dial Transplant. 1997;12(11): 2397-2401."
  },
  {
    "conteudo":"413. Movilli E, Zani R, Carli O, et al. Correction of metabolic acidosis increases serum albumin"
  },
  {
    "conteudo":"concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: a"
  },
  {
    "conteudo":"prospective study. Nephrol Dial Transplant. 1998;13(7): 1719-1722."
  },
  {
    "conteudo":"414. Verove C, Maisonneuve N, El Azouzi A, Boldron A, Azar R. Effect of the correction of metabolic"
  },
  {
    "conteudo":"acidosis on nutritional status in elderly patients with chronic renal failure. Journal of renal"
  },
  {
    "conteudo":"nutrition : the official journal of the Council on Renal Nutrition of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2002;12(4): 224-228."
  },
  {
    "conteudo":"415. Banerjee T, Crews DC, Wesson DE, et al. High Dietary Acid Load Predicts ESRD among Adults"
  },
  {
    "conteudo":"with CKD. J Am Soc Nephrol. 2015;26(7): 1693-1700."
  },
  {
    "conteudo":"416. Scialla JJ, Appel LJ, Astor BC, et al. Net endogenous acid production is associated with a faster"
  },
  {
    "conteudo":"decline in GFR in African Americans. Kidney international. 2012;82(1): 106-112."
  },
  {
    "conteudo":"417. Kanda E, Ai M, Kuriyama R, Yoshida M, Shiigai T. Dietary acid intake and kidney disease"
  },
  {
    "conteudo":"progression in the elderly. American journal of nephrology. 2014;39(2): 145-152."
  },
  {
    "conteudo":"418. Yamamoto T, Shoji S, Yamakawa T, et al. Predialysis and Postdialysis pH and Bicarbonate and"
  },
  {
    "conteudo":"Risk of All-Cause and Cardiovascular Mortality in Long-term Hemodialysis Patients. American"
  },
  {
    "conteudo":"journal of kidney diseases : the official journal of the National Kidney Foundation. 2015;66(3):"
  },
  {
    "conteudo":"469-478."
  },
  {
    "conteudo":"419. Bommer J, Locatelli F, Satayathum S, et al. Association of predialysis serum bicarbonate levels"
  },
  {
    "conteudo":"with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study"
  },
  {
    "conteudo":"(DOPPS). American journal of kidney diseases : the official journal of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2004;44(4): 661-671."
  },
  {
    "conteudo":"420. Gennari FJ, Hood VL, Greene T, Wang X, Levey AS. Effect of dietary protein intake on serum"
  },
  {
    "conteudo":"total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study"
  },
  {
    "conteudo":"findings. Clinical journal of the American Society of Nephrology : CJASN. 2006;1(1): 52-57."
  },
  {
    "conteudo":"421. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium,"
  },
  {
    "conteudo":"and phosphorus in patients with chronic kidney disease: results of the study to evaluate early"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 229"
  },
  {
    "conteudo":"kidney disease. Kidney Int. 2007;71(1): 31-38."
  },
  {
    "conteudo":"422. Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is"
  },
  {
    "conteudo":"associated with arterial stiffening and increased mortality in patients with stages 4 and 5"
  },
  {
    "conteudo":"chronic kidney disease. Clinical journal of the American Society of Nephrology : CJASN."
  },
  {
    "conteudo":"2007;2(6): 1241-1248."
  },
  {
    "conteudo":"423. Hirukawa T, Kakuta T, Nakamura M, Fukagawa M. Mineral and bone disorders in kidney"
  },
  {
    "conteudo":"transplant recipients: reversible, irreversible, and de novo abnormalities. Clin Exp Nephrol."
  },
  {
    "conteudo":"2015;19(4): 543-555."
  },
  {
    "conteudo":"424. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and"
  },
  {
    "conteudo":"phosphorous in the secondary hyperparathyroidism of patients with early renal failure."
  },
  {
    "conteudo":"American journal of kidney diseases : the official journal of the National Kidney Foundation."
  },
  {
    "conteudo":"1997;29(4): 496-502."
  },
  {
    "conteudo":"425. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney"
  },
  {
    "conteudo":"disease on low- and high-calcium diets. Kidney Int. 2012;81(11): 1116-1122."
  },
  {
    "conteudo":"426. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not"
  },
  {
    "conteudo":"phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83(5): 959-966."
  },
  {
    "conteudo":"427. Dietary Reference Intake. Calcium and Vitamin D: Institute of Medicine; 2011."
  },
  {
    "conteudo":"428. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid"
  },
  {
    "conteudo":"calcium content. Clinical journal of the American Society of Nephrology : CJASN. 2010;5 Suppl"
  },
  {
    "conteudo":"1: S12-22."
  },
  {
    "conteudo":"429. Gotch F, Levin NW, Kotanko P. Calcium balance in dialysis is best managed by adjusting"
  },
  {
    "conteudo":"dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake,"
  },
  {
    "conteudo":"dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010;29(2):"
  },
  {
    "conteudo":"163-176."
  },
  {
    "conteudo":"430. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification"
  },
  {
    "conteudo":"in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial"
  },
  {
    "conteudo":"Transplant. 2003;18(9): 1731-1740."
  },
  {
    "conteudo":"431. KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and"
  },
  {
    "conteudo":"treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl."
  },
  {
    "conteudo":"2009(113): S1-130."
  },
  {
    "conteudo":"432. Gallieni M, Caputo F, Filippini A, et al. Prevalence and progression of cardiovascular"
  },
  {
    "conteudo":"calcifications in peritoneal dialysis patients: A prospective study. Bone. 2012;51(3): 332-337."
  },
  {
    "conteudo":"433. Coen G, Pierantozzi A, Spizzichino D, et al. Risk factors of one year increment of coronary"
  },
  {
    "conteudo":"calcifications and survival in hemodialysis patients. BMC nephrology. 2010;11: 10."
  },
  {
    "conteudo":"434. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in"
  },
  {
    "conteudo":"a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6): 1948-1955."
  },
  {
    "conteudo":"435. Fukagawa M, Kido R, Komaba H, et al. Abnormal mineral metabolism and mortality in"
  },
  {
    "conteudo":"hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural"
  },
  {
    "conteudo":"models used to adjust for time-dependent confounding. American journal of kidney diseases :"
  },
  {
    "conteudo":"the official journal of the National Kidney Foundation. 2014;63(6): 979-987."
  },
  {
    "conteudo":"436. Markaki A, Kyriazis J, Stylianou K, et al. The role of serum magnesium and calcium on the"
  },
  {
    "conteudo":"association between adiponectin levels and all-cause mortality in end-stage renal disease"
  },
  {
    "conteudo":"patients. PLoS One. 2012;7(12): e52350."
  },
  {
    "conteudo":"437. Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility Dialysate Calcium Practices and"
  },
  {
    "conteudo":"Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational"
  },
  {
    "conteudo":"Study. American journal of kidney diseases : the official journal of the National Kidney"
  },
  {
    "conteudo":"Foundation. 2015;66(4): 655-665."
  },
  {
    "conteudo":"438. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 230"
  },
  {
    "conteudo":"cardiac arrest in hemodialysis patients. Clinical journal of the American Society of Nephrology :"
  },
  {
    "conteudo":"CJASN. 2013;8(5): 797-803."
  },
  {
    "conteudo":"439. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic"
  },
  {
    "conteudo":"complications. J Am Soc Nephrol. 2009;20(1): 164-171."
  },
  {
    "conteudo":"440. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and"
  },
  {
    "conteudo":"calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national"
  },
  {
    "conteudo":"study. American journal of kidney diseases : the official journal of the National Kidney"
  },
  {
    "conteudo":"Foundation. 1998;31(4): 607-617."
  },
  {
    "conteudo":"441. Blayney MJ, Tentori F. Trends and consequences of mineral bone disorder in haemodialysis"
  },
  {
    "conteudo":"patients: lessons from The Dialysis Outcomes and Practice Patterns Study (DOPPS). Journal of"
  },
  {
    "conteudo":"renal care. 2009;35 Suppl 1: 7-13."
  },
  {
    "conteudo":"442. KDOQI. Clinical practice guidelines for nutrition in chronic renal failure. K\/DOQI, National"
  },
  {
    "conteudo":"Kidney Foundation. American journal of kidney diseases : the official journal of the National"
  },
  {
    "conteudo":"Kidney Foundation. 2000;35(6 Suppl 2): S1-140."
  },
  {
    "conteudo":"443. Isakova T, Nickolas TL, Denburg M, et al. KDOQI US Commentary on the 2017 KDIGO Clinical"
  },
  {
    "conteudo":"Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic"
  },
  {
    "conteudo":"Kidney Disease-Mineral and Bone Disorder (CKD-MBD). American journal of kidney diseases :"
  },
  {
    "conteudo":"the official journal of the National Kidney Foundation. 2017;70(6): 737-751."
  },
  {
    "conteudo":"444. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic"
  },
  {
    "conteudo":"Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and"
  },
  {
    "conteudo":"why it matters. Kidney Int. 2017;92(1): 26-36."
  },
  {
    "conteudo":"445. Intakes IoMUSCotSEoDR. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium,"
  },
  {
    "conteudo":"Vitamin D, and Fluoride. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium,"
  },
  {
    "conteudo":"Vitamin D, and Fluoride. Washington (DC): National Acedemies Press; 1997."
  },
  {
    "conteudo":"446. Benini O, D'Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in"
  },
  {
    "conteudo":"commonly eaten foods: a real and insidious danger for renal patients. J Ren Nutr. 2011;21(4):"
  },
  {
    "conteudo":"303-308."
  },
  {
    "conteudo":"447. Parpia AS, L'Abbe M, Goldstein M, Arcand J, Magnuson B, Darling P. The Impact of Additives"
  },
  {
    "conteudo":"on the Phosphorus, Potassium, and Sodium Content of Commonly Consumed Meat, Poultry,"
  },
  {
    "conteudo":"and Fish Products Among Patients With Chronic Kidney Disease. J Ren Nutr. 2017."
  },
  {
    "conteudo":"448. Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry"
  },
  {
    "conteudo":"products: implications for patients who receive dialysis. Clinical journal of the American"
  },
  {
    "conteudo":"Society of Nephrology : CJASN. 2009;4(8): 1370-1373."
  },
  {
    "conteudo":"449. Caldeira D, Amaral T, David C, Sampaio C. Educational strategies to reduce serum phosphorus"
  },
  {
    "conteudo":"in hyperphosphatemic patients with chronic kidney disease: systematic review with meta-"
  },
  {
    "conteudo":"analysis. J Ren Nutr. 2011;21(4): 285-294."
  },
  {
    "conteudo":"450. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among"
  },
  {
    "conteudo":"patients with end-stage renal disease: a randomized controlled trial. Jama. 2009;301(6): 629-"
  },
  {
    "conteudo":"635."
  },
  {
    "conteudo":"451. Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of"
  },
  {
    "conteudo":"end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification"
  },
  {
    "conteudo":"of Diet in Renal Disease Study. Kidney Int. 2016;89(1): 176-184."
  },
  {
    "conteudo":"452. Kawasaki T, Maeda Y, Matsuki H, Matsumoto Y, Akazawa M, Kuyama T. Urinary phosphorus"
  },
  {
    "conteudo":"excretion per creatinine clearance as a prognostic marker for progression of chronic kidney"
  },
  {
    "conteudo":"disease: a retrospective cohort study. BMC nephrology. 2015;16: 116."
  },
  {
    "conteudo":"453. Zoccali C, Ruggenenti P, Perna A, et al. Phosphate may promote CKD progression and"
  },
  {
    "conteudo":"attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011;22(10): 1923-1930."
  },
  {
    "conteudo":"454. Di Iorio BR, Bellizzi V, Bellasi A, et al. Phosphate attenuates the anti-proteinuric effect of very"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 231"
  },
  {
    "conteudo":"low-protein diet in CKD patients. Nephrol Dial Transplant. 2013;28(3): 632-640."
  },
  {
    "conteudo":"455. Murtaugh MA, Filipowicz R, Baird BC, Wei G, Greene T, Beddhu S. Dietary phosphorus intake"
  },
  {
    "conteudo":"and mortality in moderate chronic kidney disease: NHANES III. Nephrol Dial Transplant."
  },
  {
    "conteudo":"2012;27(3): 990-996."
  },
  {
    "conteudo":"456. Palomino HL, Rifkin DE, Anderson C, Criqui MH, Whooley MA, Ix JH. 24-hour urine phosphorus"
  },
  {
    "conteudo":"excretion and mortality and cardiovascular events. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2013;8(7): 1202-1210."
  },
  {
    "conteudo":"457. Noori N, Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D, Kopple JD. Association of dietary"
  },
  {
    "conteudo":"phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients."
  },
  {
    "conteudo":"Clinical journal of the American Society of Nephrology : CJASN. 2010;5(4): 683-692."
  },
  {
    "conteudo":"458. Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and"
  },
  {
    "conteudo":"survival among hemodialysis patients. Clinical journal of the American Society of Nephrology :"
  },
  {
    "conteudo":"CJASN. 2011;6(3): 620-629."
  },
  {
    "conteudo":"459. Sakhaee K. Post-renal transplantation hypophosphatemia. Pediatr Nephrol. 2010;25(2): 213-"
  },
  {
    "conteudo":"220."
  },
  {
    "conteudo":"460. Tomida K, Hamano T, Ichimaru N, et al. Dialysis vintage and parathyroid hormone level, not"
  },
  {
    "conteudo":"fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal"
  },
  {
    "conteudo":"transplantation. Bone. 2012;51(4): 729-736."
  },
  {
    "conteudo":"461. Trombetti A, Richert L, Hadaya K, et al. Early post-transplantation hypophosphatemia is"
  },
  {
    "conteudo":"associated with elevated FGF-23 levels. Eur J Endocrinol. 2011;164(5): 839-847."
  },
  {
    "conteudo":"462. Rufino M, de Bonis E, Martin M, et al. Is it possible to control hyperphosphataemia with diet,"
  },
  {
    "conteudo":"without inducing protein malnutrition? Nephrol Dial Transplant. 1998;13 Suppl 3: 65-67."
  },
  {
    "conteudo":"463. Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary"
  },
  {
    "conteudo":"protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr."
  },
  {
    "conteudo":"2008;88(6): 1511-1518."
  },
  {
    "conteudo":"464. St-Jules DE, Woolf K, Pompeii ML, Kalantar-Zadeh K, Sevick MA. Reexamining the Phosphorus-"
  },
  {
    "conteudo":"Protein Dilemma: Does Phosphorus Restriction Compromise Protein Status? J Ren Nutr."
  },
  {
    "conteudo":"2016;26(3): 136-140."
  },
  {
    "conteudo":"465. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary"
  },
  {
    "conteudo":"phosphorus in the treatment of patients with chronic kidney disease. Clinical journal of the"
  },
  {
    "conteudo":"American Society of Nephrology : CJASN. 2010;5(3): 519-530."
  },
  {
    "conteudo":"466. Gutierrez OM. Sodium- and phosphorus-based food additives: persistent but surmountable"
  },
  {
    "conteudo":"hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis."
  },
  {
    "conteudo":"2013;20(2): 150-156."
  },
  {
    "conteudo":"467. Karalis M, Murphy-Gutekunst L. Patient education. Enhanced foods: hidden phosphorus and"
  },
  {
    "conteudo":"sodium in foods commonly eaten. J Ren Nutr. 2006;16(1): 79-81."
  },
  {
    "conteudo":"468. Barril-Cuadrado G, Puchulu MB, Sanchez-Tomero JA. Table showing dietary"
  },
  {
    "conteudo":"phosphorus\/protein ratio for the Spanish population. Usefulness in chronic kidney disease."
  },
  {
    "conteudo":"Nefrologia. 2013;33(3): 362-371."
  },
  {
    "conteudo":"469. Cupisti A, Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in"
  },
  {
    "conteudo":"kidney disease. Semin Nephrol. 2013;33(2): 180-190."
  },
  {
    "conteudo":"470. Cupisti A, Morelli E, D'Alessandro C, Lupetti S, Barsotti G. Phosphate control in chronic uremia:"
  },
  {
    "conteudo":"don't forget diet. J Nephrol. 2003;16(1): 29-33."
  },
  {
    "conteudo":"471. Ando S, Sakuma M, Morimoto Y, Arai H. The Effect of Various Boiling Conditions on Reduction"
  },
  {
    "conteudo":"of Phosphorus and Protein in Meat. J Ren Nutr. 2015;25(6): 504-509."
  },
  {
    "conteudo":"472. Cupisti A, Comar F, Benini O, et al. Effect of boiling on dietary phosphate and nitrogen intake. J"
  },
  {
    "conteudo":"Ren Nutr. 2006;16(1): 36-40."
  },
  {
    "conteudo":"473. Bethke PC, Jansky SH. The effects of boiling and leaching on the content of potassium and"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 232"
  },
  {
    "conteudo":"other minerals in potatoes. J Food Sci. 2008;73(5): H80-85."
  },
  {
    "conteudo":"474. Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-"
  },
  {
    "conteudo":"term hemodialysis patients. American journal of kidney diseases : the official journal of the"
  },
  {
    "conteudo":"National Kidney Foundation. 2010;56(2): 338-347."
  },
  {
    "conteudo":"475. He J, Mills KT, Appel LJ, et al. Urinary Sodium and Potassium Excretion and CKD Progression. J"
  },
  {
    "conteudo":"Am Soc Nephrol. 2016;27(4): 1202-1212."
  },
  {
    "conteudo":"476. Leonberg-Yoo AK, Tighiouart H, Levey AS, Beck GJ, Sarnak MJ. Urine Potassium Excretion,"
  },
  {
    "conteudo":"Kidney Failure, and Mortality in CKD. American journal of kidney diseases : the official journal"
  },
  {
    "conteudo":"of the National Kidney Foundation. 2017;69(3): 341-349."
  },
  {
    "conteudo":"477. Arnold R, Pianta TJ, Pussell BA, et al. Randomized, Controlled Trial of the Effect of Dietary"
  },
  {
    "conteudo":"Potassium Restriction on Nerve Function in CKD. Clinical journal of the American Society of"
  },
  {
    "conteudo":"Nephrology : CJASN. 2017;12(10): 1569-1577."
  },
  {
    "conteudo":"478. Alvestrand A, Wahren J, Smith D, DeFronzo RA. Insulin-mediated potassium uptake is normal"
  },
  {
    "conteudo":"in uremic and healthy subjects. Am J Physiol. 1984;246(2 Pt 1): E174-180."
  },
  {
    "conteudo":"479. Hayes CP, Jr., McLeod ME, Robinson RR. An extravenal mechanism for the maintenance of"
  },
  {
    "conteudo":"potassium balance in severe chronic renal failure. Trans Assoc Am Physicians. 1967;80: 207-"
  },
  {
    "conteudo":"216."
  },
  {
    "conteudo":"480. Sterns RH, Feig PU, Pring M, Guzzo J, Singer I. Disposition of intravenous potassium in anuric"
  },
  {
    "conteudo":"man: a kinetic analysis. Kidney Int. 1979;15(6): 651-660."
  },
  {
    "conteudo":"481. Adrogue HJ, Madias NE. Sodium surfeit and potassium deficit: keys to the pathogenesis of"
  },
  {
    "conteudo":"hypertension. J Am Soc Hypertens. 2014;8(3): 203-213."
  },
  {
    "conteudo":"482. Cupisti A, Kovesdy CP, D'Alessandro C, Kalantar-Zadeh K. Dietary Approach to Recurrent or"
  },
  {
    "conteudo":"Chronic Hyperkalaemia in Patients with Decreased Kidney Function. Nutrients. 2018;10(3)."
  },
  {
    "conteudo":"483. Geerling JC, Loewy AD. Central regulation of sodium appetite. Exp Physiol. 2008;93(2): 177-"
  },
  {
    "conteudo":"209."
  },
  {
    "conteudo":"484. Schweda F. Salt feedback on the renin-angiotensin-aldosterone system. Pflugers Arch."
  },
  {
    "conteudo":"2015;467(3): 565-576."
  },
  {
    "conteudo":"485. Kotchen TA, Cowley AW, Jr., Frohlich ED. Salt in health and disease--a delicate balance. The"
  },
  {
    "conteudo":"New England journal of medicine. 2013;368(13): 1229-1237."
  },
  {
    "conteudo":"486. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress,"
  },
  {
    "conteudo":"and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014: 406960."
  },
  {
    "conteudo":"487. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure."
  },
  {
    "conteudo":"Cochrane Database Syst Rev. 2013(4): CD004937."
  },
  {
    "conteudo":"488. Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S. Reduced dietary salt for the"
  },
  {
    "conteudo":"prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014(12): CD009217."
  },
  {
    "conteudo":"489. de Brito-Ashurst I, Perry L, Sanders TA, et al. The role of salt intake and salt sensitivity in the"
  },
  {
    "conteudo":"management of hypertension in South Asian people with chronic kidney disease: a"
  },
  {
    "conteudo":"randomised controlled trial. Heart. 2013;99(17): 1256-1260."
  },
  {
    "conteudo":"490. Konishi Y, Okada N, Okamura M, et al. Sodium sensitivity of blood pressure appearing before"
  },
  {
    "conteudo":"hypertension and related to histological damage in immunoglobulin a nephropathy."
  },
  {
    "conteudo":"Hypertension. 2001;38(1): 81-85."
  },
  {
    "conteudo":"491. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in"
  },
  {
    "conteudo":"CKD. J Am Soc Nephrol. 2013;24(12): 2096-2103."
  },
  {
    "conteudo":"492. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added"
  },
  {
    "conteudo":"to angiotensin converting enzyme inhibition compared with dual blockade in lowering"
  },
  {
    "conteudo":"proteinuria and blood pressure: randomised controlled trial. Bmj. 2011;343: d4366."
  },
  {
    "conteudo":"493. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and"
  },
  {
    "conteudo":"hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):"
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 233"
  },
  {
    "conteudo":"999-1007."
  },
  {
    "conteudo":"494. Meuleman Y, Hoekstra T, Dekker FW, et al. Sodium Restriction in Patients With CKD: A"
  },
  {
    "conteudo":"Randomized Controlled Trial of Self-management Support. American journal of kidney"
  },
  {
    "conteudo":"diseases : the official journal of the National Kidney Foundation. 2017;69(5): 576-586."
  },
  {
    "conteudo":"495. Saran R, Padilla RL, Gillespie BW, et al. A Randomized Crossover Trial of Dietary Sodium"
  },
  {
    "conteudo":"Restriction in Stage 3-4 CKD. Clinical journal of the American Society of Nephrology : CJASN."
  },
  {
    "conteudo":"2017;12(3): 399-407."
  },
  {
    "conteudo":"496. Fine A, Fontaine B, Ma M. Commonly prescribed salt intake in continuous ambulatory"
  },
  {
    "conteudo":"peritoneal dialysis patients is too restrictive: results of a double-blind crossover study. J Am"
  },
  {
    "conteudo":"Soc Nephrol. 1997;8(8): 1311-1314."
  },
  {
    "conteudo":"497. Liang X, Wang W, Li H. Water and sodium restriction on cardiovascular disease in young"
  },
  {
    "conteudo":"chronic hemodialysis patients. Chin Med J (Engl). 2013;126(9): 1667-1672."
  },
  {
    "conteudo":"498. Rodrigues Telini LS, de Carvalho Beduschi G, Caramori JC, Castro JH, Martin LC, Barretti P."
  },
  {
    "conteudo":"Effect of dietary sodium restriction on body water, blood pressure, and inflammation in"
  },
  {
    "conteudo":"hemodialysis patients: a prospective randomized controlled study. Int Urol Nephrol."
  },
  {
    "conteudo":"2014;46(1): 91-97."
  },
  {
    "conteudo":"499. Magden K, Hur E, Yildiz G, et al. The effects of strict salt control on blood pressure and cardiac"
  },
  {
    "conteudo":"condition in end-stage renal disease: prospective-study. Renal failure. 2013;35(10): 1344-"
  },
  {
    "conteudo":"1347."
  },
  {
    "conteudo":"500. Keven K, Yalcin S, Canbakan B, et al. The impact of daily sodium intake on posttransplant"
  },
  {
    "conteudo":"hypertension in kidney allograft recipients. Transplant Proc. 2006;38(5): 1323-1326."
  },
  {
    "conteudo":"501. Mc Causland FR, Waikar SS, Brunelli SM. Increased dietary sodium is independently associated"
  },
  {
    "conteudo":"with greater mortality among prevalent hemodialysis patients. Kidney Int. 2012;82(2): 204-"
  },
  {
    "conteudo":"211."
  },
  {
    "conteudo":"502. Dong J, Li Y, Yang Z, Luo J. Low dietary sodium intake increases the death risk in peritoneal"
  },
  {
    "conteudo":"dialysis. Clinical journal of the American Society of Nephrology : CJASN. 2010;5(2): 240-247."
  },
  {
    "conteudo":"503. Mills KT, Chen J, Yang W, et al. Sodium Excretion and the Risk of Cardiovascular Disease in"
  },
  {
    "conteudo":"Patients With Chronic Kidney Disease. Jama. 2016;315(20): 2200-2210."
  },
  {
    "conteudo":"504. Koomans HA, Roos JC, Dorhout Mees EJ, Delawi IM. Sodium balance in renal failure. A"
  },
  {
    "conteudo":"comparison of patients with normal subjects under extremes of sodium intake. Hypertension."
  },
  {
    "conteudo":"1985;7(5): 714-721."
  },
  {
    "conteudo":"505. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with"
  },
  {
    "conteudo":"chronic kidney disease. Cochrane Database Syst Rev. 2015(2): CD010070."
  },
  {
    "conteudo":"506. Sevick MA, Piraino BM, St-Jules DE, et al. No Difference in Average Interdialytic Weight Gain"
  },
  {
    "conteudo":"Observed in a Randomized Trial With a Technology-Supported Behavioral Intervention to"
  },
  {
    "conteudo":"Reduce Dietary Sodium Intake in Adults Undergoing Maintenance Hemodialysis in the United"
  },
  {
    "conteudo":"States: Primary Outcomes of the BalanceWise Study. J Ren Nutr. 2016;26(3): 149-158."
  },
  {
    "conteudo":"507. Campbell KL, Johnson DW, Bauer JD, et al. A randomized trial of sodium-restriction on kidney"
  },
  {
    "conteudo":"function, fluid volume and adipokines in CKD patients. BMC nephrology. 2014;15: 57-57."
  },
  {
    "conteudo":"508. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE"
  },
  {
    "conteudo":"inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23(1): 165-173."
  },
  {
    "conteudo":"509. Meuleman Y, Hoekstra T, Dekker FW, van der Boog PJM, van Dijk S. Perceived Sodium"
  },
  {
    "conteudo":"Reduction Barriers Among Patients with Chronic Kidney Disease: Which Barriers Are Important"
  },
  {
    "conteudo":"and Which Patients Experience Barriers? Int J Behav Med. 2018;25(1): 93-102."
  },
  {
    "conteudo":"510. McMahon EJ, Campbell KL, Mudge DW, Bauer JD. Achieving salt restriction in chronic kidney"
  },
  {
    "conteudo":"disease. Int J Nephrol. 2012;2012: 720429."
  },
  {
    "conteudo":"511. Titze J. Sodium balance is not just a renal affair. Curr Opin Nephrol Hypertens. 2014;23(2): 101-"
  },
  {
    "conteudo":"105."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 234"
  },
  {
    "conteudo":"512. Juraschek SP, Miller ER, 3rd, Weaver CM, Appel LJ. Effects of Sodium Reduction and the DASH"
  },
  {
    "conteudo":"Diet in Relation to Baseline Blood Pressure. J Am Coll Cardiol. 2017;70(23): 2841-2848."
  },
  {
    "conteudo":"513. Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and"
  },
  {
    "conteudo":"disease: a review of the evidence. Mayo Clin Proc. 2013;88(9): 987-995."
  },
  {
    "conteudo":"Guideline on Nutrition in CKD Page 235"
  }
]